Protein citrullination by Porphyromonas gingivalis and its implications for autoimmunity in rheumatoid arthritis by Wegner, Natalia & Wegner, Natalia
  
                                                                                  
                                                                     
 
Protein citrullination by Porphyromonas 
gingivalis and its implications for 
autoimmunity in rheumatoid arthritis 
 
 
 
 
Natalia Wegner 
 
 
 
Imperial College London 
Faculty of Medicine 
Kennedy Institute of Rheumatology Division 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
March 2011 
 
 
 
 2 
Abstract 
 
Autoantibodies to citrullinated proteins are characteristic for rheumatoid arthritis (RA). RA 
has been associated with periodontitis in epidemiologic studies. Chronic periodontal infection 
with Porphyromonas gingivalis (P. gingivalis) is a possible risk factor for developing RA, as 
this bacterium expresses a peptidylarginine deiminase enzyme (PPAD) which could generate 
antigenic citrullinated proteins within an infectious context. The aim of this project was to 
investigate protein citrullination by P. gingivalis and its potential for breaking tolerance to 
citrullinated proteins in RA. 
 
Endogenous citrullinated proteins were abundant in cell extracts of P. gingivalis but lacking 
in other tested oral bacteria. Deletion of the PPAD gene resulted in abrogation of protein 
citrullination. Inactivation of arginine-gingipains but not lysine-gingipains, the major 
proteolytic virulence factors, led to decreased citrullination. Incubation of wildtype P. 
gingivalis with fibrinogen or α-enolase caused degradation of the proteins by bacterial 
proteinases and peptidases and citrullination of the resulting peptides at carboxy-terminal 
arginine residues. No statistically significant antibody reactivity was found in RA serum with 
two of these peptides tested. The PPAD enzyme was cloned and expressed in E. coli in an 
enzymatically active form and used for in vitro enzymatic assays to confirm substrate 
specificity for carboxy-terminal arginine residues and demonstrate inhibition by 2-
chloroacetamidine, but not by conventional RA drugs. Site-directed mutagenesis identified 
five amino acids crucial for catalysis. A polyclonal antibody was developed and 
demonstrated that PPAD is localised in the bacterial outer membrane. 
 
The results demonstrate that P. gingivalis generates citrullinated endogenous and host 
peptides by proteolytic cleavage at arginine-X peptide bonds by arginine-gingipains followed 
by citrullination of carboxy-terminal arginines by PPAD. Mutagenesis and inhibition studies 
point to a critical cysteine (Cys-351) in the catalytic centre. The work provides the basis for 
future studies of the role of PPAD in bacterial virulence and tolerance breakdown in RA. 
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Chapter 1          Introduction 
 
This project investigates the mechanism of protein citrullination by the oral bacterium 
Porphyromonas gingivalis (P. gingivalis) and evaluates its potential to prime or perpetuate 
the autoimmune response to citrullinated proteins in rheumatoid arthritis. 
 
Rheumatoid arthritis and autoimmunity to citrullinated proteins 
Rheumatoid arthritis - classification, aetiology, pathophysiology and current treatment 
Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown aetiology, affecting 
0.5-1.0% of the adult population (Symmons et al., 2002; Helmick et al., 2008). It is a 
complex, heterogenous disease in which chronic inflammation of synovial joints and erosion 
of bone result in joint destruction, pain, disability, and premature mortality (reviewed by 
Firestein 2003).  
 
Classification 
To aid uniform classification of RA, the American College of Rheumatology (ACR) 
published the former „ACR 1987 classification criteria for rheumatoid arthritis‟ (Arnett et al. 
1988) (Table 1.1). 
 
Table 1.1     1987 ACR criteria for the classification of rheumatoid arthritis 
1 Morning stiffness in and around joints lasting at least 1 hour before maximal 
improvement 
2 Soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician 
3 Swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or wrist 
joints 
4 Symmetric swelling (arthritis) 
5 Rheumatoid nodules 
6 The presence of rheumatoid factor 
7 Radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints 
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Criteria 1 to 4 were required to have been present for at least 6 weeks, and RA was defined 
by the presence of 4 or more criteria. These criteria demonstrated 91-94% sensitivity and 89% 
specificity for RA when compared with non-RA rheumatic disease control subjects. However, 
over time, they proved insufficient to discriminate early RA from self-limiting or other 
inflammatory arthritides, and therefore to identify those patients who would benefit from 
early treatment. Further, the emerging findings of the importance of antibodies to citrullinated 
proteins in patients with early and established RA as a predictive marker for disease 
progression and severe disease triggered a concerted effort towards defining updated 
classification criteria, which were published recently as the „2010 ACR/EULAR (European 
League Against Rheumatism) classification criteria for RA‟ (Aletaha et al., 2010).  
 
Table 1.2     2010 ACR/EULAR criteria for the classification of RA 
Criteria can be applied to individuals who have at least one joint with synovitis which is not 
better explained by another disease. RF = rheumatoid factor; ACPA = anti-citrullinated 
protein antibodies; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate. 
Definitions and detailed explanations for fulfilment of each of the features can be found in 
(Aletaha et al., 2010). 
 
Category Variables Score 
Joint involvement 1 large joint 0 
 2-10 large joints 1 
 1-3 small joints (with or without large joints) 2 
 4-10 small joints (with or without large joints) 3 
 >10 joints (at least 1 small joint) 5 
Serology (at least 1 test) Negative RF and negative ACPA 0 
 Low-positive RF or low-positive ACPA 2 
 High-positive RF or high-positive ACPA 3 
Acute-phase reactants  Normal CPR and normal ESR 0 
(at least 1 measure) Abnormal CPR or abnormal ESR 1 
Duration of symptoms <6 weeks 0 
 ≥6 weeks 1 
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According to these new criteria, „definite RA‟ is classified based on synovitis in at least 1 
joint, no alternative diagnosis that better explains the synovitis, and a total score of at least 6 
out of 10, added up from 4 categories (Table 1.2). Additionaly, patients can be classified as 
having „definite RA‟ if they present with obvious erosions typical for RA or a longstanding 
disease history where they have previously fulfilled the criteria. Additionaly, patients with 
early disease that are being treated might not fulfil the criteria at initial presentation but at a 
later stage as the condition evolves.  
 
These new criteria allow a standardised identification of patients who first present with an 
undifferentiated inflammatory synovitis and are at a sufficiently high risk of developing RA 
to be considered for therapeutic intervention. In turn, this means that the RA literature to date 
has to be viewed under the aspect of the old classification criteria, where subjects with early 
RA would not had been routinely included in studies. This applies in particular to clinical 
trials, genetic association and serological studies. 
 
In light of the work presented in this thesis, the inclusion of anti-citrullinated protein antibody 
status into the classification criteria is particularly welcomed, as it formally underscores the 
importance of these autoantibodies in a large group of patients with RA. 
 
Aetiology 
Despite the heterogeneity of RA, it is generally considered an autoimmune disease. Evidence 
of autoimmunity includes the presence of autoantibodies, the composition of the cellular 
infiltrate in the inflamed joint featuring activated B cells, the linkage of RA to certain MHC 
class II alleles and the benefits of B-cell depleting therapy. 
 
Genetic influences are estimated to be responsible for around 50% of the risk of developing 
RA (MacGregor et al., 2000; van der Woude et al., 2009) with hormonal, environmental, and 
other factors (epigenetics, post-translational modification, stochastics) explaining the 
remaining risk. 
 
Amongst the major and best studied genetic risk factors identified so far is a group of MHC 
class II gene variants collectively called the „shared epitope‟ (SE). MHC class II molecules 
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are glycoproteins expressed on the surface B cells, dendritic cells, macrophages and other 
cells and are involved in the presentation of peptide antigens to T cells. Each molecule 
consists of a noncovalent complex of two chains, α and β, each of which is made up of two 
domains (Figure 1.1).  
 
 
Figure 1.1 Schematic structure of an MHC class II molecule. The MHC class II molecule is composed 
of two transmembrane glycoprotein chains (α and β). Each chain consistes of two domains (1 and 2). Domains 
β1 and α1 form the peptide-binding cleft, which binds peptides (green) for presentation to T cells. The β1 domain 
(outlined in red) is the source of the majority of genetic polymorphism in the rheumatoid arhtitis-relevant HLA-
DR subtypes of the MHC class II molecules. This figure was generated by myself using Microsoft Powerpoint. 
 
The α1 and β1 domains form the walls of a cleft on the surface of the molecule (peptide-
binding cleft) to which peptides bind for presentation and interaction with T cells. This is also 
the site of major polymorphism, allowing the binding of a wide range of peptides. There are 
three pairs of MHC class II α- and β-chain genes: HLA-DP, -DQ, and –DR. In HLA-DR, the 
β-chain is encoded by four different loci (HLA-DRB1, -DRB3, -DRB4, -DRB5), which show 
considerable polymorphism. In total, more than 400 different alleles are known for the genes 
encoding the HLA-DR β-chain (indicated by a star [*] followed by four digits). The shared 
epitope is made up of the alleles DRB1*0401, *0404, *0408, *0405, *0101, *0102, *1001 
and *1402, which are expressed in the serotypes HLA-DR4, -DR1 and -DR10 (Zanelli et al. 
2000b). All alleles share variants of the Q/R-K/R-R-A-A amino acid motif present in the 
peptide-binding cleft of the MHC class II β chain (Gregersen et al. 1987). There is much 
speculation in the literature regarding the underlying mechanism of SE-RA association. 
Hypotheses range from a direct role of the SE on increased affinity and presentation of 
autoantigenic peptides and activation of self-reactive T cells (Holoshitz 2010), to a decreased 
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activation of regulatory T cells (Zanelli et al. 2000a), an influence on thymic T cell repertoire 
selection (Bhayani et al. 1991), to a role of the SE as an innate immune system activator 
(Ling et al., 2007; De Almeida et al., 2010).  
 
Women are three times as likely as men to develop RA (Pritchard 1992). The mechanism 
underlying this observation has been under intensive research and findings are controversial, 
but most studies show an increased risk of RA associated with pregnancy and breastfeeding 
and a decreased risk associated with the prolonged use of oral contraceptives (≥7 years) 
(Berglin et al. 2010). 
 
Environmental factors are considered to contribute to the onset of RA in a genetically 
predisposed individual. Evidence mainly stems from the low disease concordance rate (15%) 
in monozygotic twins (Silman et al. 1993) and the declining incidence of RA in genetically 
predisposed populations such as the Pima Indians (Jacobsson et al., 1994; Ferucci et al., 
2005). The best-studied environmental factors to date are smoking and infections.  
 
Infection as a contributory or even sole aetiological factor in RA has been suggested and 
discussed for decades, but no convincing data has been produced pinpointing any specific 
organism (discussed by Carty et al. 2004). No major viable organism could be isolated 
specifically from the rheumatoid joint to date. However, the relationship between a 
microorganism and RA might be more complex and subtle, and trigger or contribute to the 
disease by one of its products rather than cause it directly by residing at the diseased site, the 
joint. Temporal aspects might also play a role, such as a time lag between the microbial 
triggering event(s) and the onset of RA, which would be difficult to account for in studies. 
Findings supporting a role of microorganisms in RA also come from arthritis animal models, 
where bacterial components, on their own (Kim et al. 2009) or combined with protein antigen 
such as collagen type II (Luross et al. 2001), are routinely used to induce or exacerbate 
arthritis (reviewed by Asquith et al. 2009).  In view of the combined data, a direct, causal role 
between a specific microorganism and RA still seems unlikely, but a more indirect 
contributory/triggering function leading to RA in a subset of predisposed individuals appears 
possible and is explored in depth in this thesis, focussing on the possible role of the bacterium 
P. gingivalis. 
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Cigarette smoking is today the best-known environmental risk factor for the development of 
RA. The link to smoking was first recognized in 1987 (Vessey et al. 1987) as an unexpected 
finding in a study investigating the association between RA and the use of oral contraceptive, 
and later confirmed in a number of case-control and cohort studies (reviewed by Sugiyama et 
al. 2010). The most striking results were presented from the Arthritis and Rheumatism 
Council Twin Study, where 13 pairs of monozygotic twins, discordant for RA and smoking, 
were identified, and in 12 out of 13 cases the RA patient was also the smoker (Silman et al. 
1996). It is currently unknown how smoking may contribute to the development of RA. 
Cigarette smoke contains thousands of toxic compounds (Pryor et al. 1993) which may cause 
tissue damage and inflammation and modulate the immune cell function and cytokine 
production (Costenbader et al., 2006; Baka et al., 2009). However, it is important to bear in 
mind that in vitro smoking studies use different compounds, cells, and experimental 
conditions to mimic smoking, and therefore afford only a limited reproducibility of the true 
short- and long-term physiological events accompanying tobacco smoking.
1
 
 
Pathophysiology 
The classic characteristic of RA is the chronically inflamed synovial joint. Experimental 
evidence to date suggests the following key players in mediating the pathology: 
Autoantibodies and cytokines, degradative enzymes, T and B cells, macrophage-like and 
fibroblast-like synovial cells, macrophages, dendritic cells, neutrophils, osteoclasts and 
chondrocytes, with both the innate and adaptive immune system playing a role (reviewed by 
Firestein 2003; Sidiropoulos et al. 2008). These components presumably interact in a highly 
complex system, with substantial variations between individuals.  
 
Cytokines have been in the centre of interest lately due to the success of anti-tumour necrosis 
factor (TNF)-α therapy in RA. Besides TNF-α, several other cytokines are believed to play a 
role in pathophysiology, such as IL-1, IL-6, IL-15, IL-17, IL-18, IL-32, and IL-33, leading to 
activation and recruitment of inflammatory cells (reviewed in McInnes et al. 2007).  
 
                                                 
1
 This paragraph was originally published in Wegner, N., K. Lundberg, A. Kinloch, B. Fisher, V. Malmstrom, M. 
Feldmann and P. J. Venables (2010a). "Autoimmunity to specific citrullinated proteins gives the first clues to 
the etiology of rheumatoid arthritis." Immunol Rev 233(1): 34-54. 
 22 
T cells can be found in large numbers in the rheumatoid joint. Their definite role is unclear 
and seems to differ between animal models and human disease, but involves cytokine 
secretion and effector and regulatory function (reviewed by Lundy et al. 2007).  
B cells moved back into the centre of RA research recently because of the advent of B cell-
depleting therapeutics such as the CD20-specific monoclonal antibody rituximab, which 
depletes all B cell subsets except plasma cells. In addition to autoantibody production and 
immune complex formation, B cells are considered to contribute to RA pathology through the 
production of cytokines and chemokines, antigen presentation and by exerting regulatory 
effects on lymphoid neogenesis, follicular dendritic cells and T cell-macrophage and T cell-B 
cell interactions (reviewed by Mauri et al. 2007). The role of autoantibodies in RA pathology 
will be discussed separately.  
 
In addition to these classical mediators of adaptive immunity, several other cell types have 
recently attracted interest in rheumatology research: macrophage-like and fibroblast-like 
synoviocytes are believed to be potent producers of pro-inflammatory cytokines and to 
invade cartilage, respectively (reviewed by Muller-Ladner et al. 2007). Activated osteaclasts 
contribute to bone erosion (reviewed by Schett 2007). Neutrophils synthesise a wide variety 
of cytokines and release chemokines, prostaglandins, reactive oxygen and nitrogen species 
and were therefore suggested to contribute to the inflammatory and hypoxic milieu in the RA 
joint (reviewed by Cascao et al. 2010). Macrophages are believed to mediate and amplify 
tissue distruction by chemokine-mediated recruitment of pro-inflammatory and antigen-
presenting cells, cytokine-mediated activation of inflammatory cells and secretion of matrix-
degrading enzymes (reviewed by Kinne et al. 2007). Dendritic cells‟ major role most likely 
lies in antigen presentation and MHC-restricted autoimmune response priming, and the 
production of innate immune inflammatory mediators (reviewed by Lutzky et al. 2007). Data 
on a direct involvement of chondrocytes in RA are sparse but suggest that chondrocytes 
secrete pro-inflammatory cytokines and release degradative enzymes, participating in the 
distruction of the cartilage matrix (reviewed by Otero et al. 2007). 
 
Current treatment 
The aim of current treatment is to achieve disease remission or a low state of disease activity 
and prevent long-term disabilities. Traditional drugs are nonsteroidal anti-inflammatory drugs 
(NSAIDs), corticosteroids and disease-modifying anti-rheumatic drugs (DMARDs) 
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(reviewed by O'Dell 2004; and Scott et al. 2010), and, more recently, biological agents were 
included in the spectrum. 
NSAIDs were traditionally used in the first few weeks of symptoms for pain relief and to 
reduce stiffness until a definitive diagnosis of RA has been made. In the long-term, however, 
they do not slow progression of disease and may result in many adverse effects, such as 
gastrointestinal ulcer, perforation, haemorrhage and cardiovascular disease. At present, the 
use of NSAIDS as „first line therapy‟ has been replaced by the early use of DMARDS and 
and corticosteroids. Corticosteroids are potent suppressors of inflammation and are given to 
reduce synovitis in the short-term and to decrease joint damage in the long-term. However, 
they come with a range of severe adverse effects such as infections, thinning of the skin, 
osteoporosis, hypertension, cataracts, and hyperlipidemia. DMARDs are a heterogenous 
group of drugs grouped together by use and convention. They reduce joint swelling and pain, 
decrease acute-phase markers, limit progressive joint damage and improve function. Their 
mechanisms of action are believed to be diverse and are incompletely understood. The major 
DMARDs are methotrexate, sulfasalazine, leflunomide, hydroxychloroquine and chloroquine. 
Gold and cyclosporine are additional DMARDs but their use is limited by toxic effects. 
Adverse effects include nausea and hepatotoxicity, blood dyscrasias (abnormal constitution 
of blood) and interstitial lung disease. Methotrexate is usually the first DMARD administered 
to people with RA and is often combined with other DMARDs, corticosteroids or biological 
agents to increase efficacy. 
 
Biological agents are antibody-based drugs such as TNF-α inhibitors (etanercept, infliximab, 
adalimumab, certolizumab, golimumab), T cell co-stimulation blockers targeting the B7 
receptor (abatacept), B cell depletors targeting CD20 (rituximab), and IL-6 inhibitors 
(tocilizumab). The discovery of TNF-α inhibitors, the first biological agents, as a highly 
effective treatment for RA at this institution (Elliott et al. 1993; reviewed by Feldmann 2002), 
has revolutionised RA treatment due to the halting and even repair of joint destruction 
(Lipsky et al. 2000). However, adverse effects exist, such as reactions and infections at drug 
infusion and injection sites and an increased risk of tuberculosis.  
 
Despite these advances, not every patient can be treated successfully; life-long ongoing 
treatment is often required and complete remission is rare. Further, the overall treatment and 
societal cost is substantial. Therefore, focus is now shifting towards strategies to prevent the 
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disease by identifying people with a high risk of developing it on the basis of genetic and 
serological markers, and to cure the disease by treating patients with very early signs of 
arthritis intensively (discussed by Machold 2010). The strategy of prevention is particularly 
relevant to this project and will be discussed accordingly.  
 
Protein citrullination - mechanism and its role in health and disease 
 
Citrulline, in the context of a peptide backbone, is a non-standard amino acid that results 
from posttranslational modification of arginine residues. In humans it is catalysed by the 
peptidylarginine deiminase (PAD) family of enzymes in the presence of sufficient 
concentrations of Ca
2+
. This conversion, termed citrullination or deimination, reduces the net 
charge of the protein by the loss of a positive charge per citrulline residue (Figure 1.2).  
 
 
 
Figure 1.2 Enzymatic conversion of peptidylarginine into peptidylcitrulline, catalysed by the family 
of peptidylarginine deiminase enzymes. The positively charged arginine guanidino group is converted into the 
neutral citrulline ureido group in the presence of water, yielding ammonia and a hydrogen ion as by-products. 
The possible consequences on the three-dimensional protein structure are shown schematically. The red dotted 
line represents hydrogen bonds (with the protein backbone or with polar amino acid side chains) or ionic 
interactions (with negatively charged amino acid side chains). This figure was originally published in (Wegner 
et al. 2010a). 
 
Arginine residues within polypeptides often play a central role in the structural integrity of a 
protein, due to their ability to participate in ionic interactions with negatively charged amino 
acid side chains, substrates and cofactors, and to form multiple hydrogen bonds to both the 
peptide backbone and other amino acid side chains (Borders et al. 1994). Arginine has got the 
most polar of all the common amino acid side chains and is therefore the amino acid that is 
most likely to be found on the surface of proteins in an aqueous environment. Citrullination 
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would be expected to destroy the ionic interactions, interfere with hydrogen bonds, and create 
new interactions. In fact, the unfolding of certain proteins upon citrullination was reported to 
be similar to that observed in the presence of high concentrations of urea (>4.5 M) (Tarcsa et 
al. 1996). Hence, the conversion of arginine into citrulline may result in an altered three-
dimensional structure and function of a protein.
2
 
 
Human peptidylarginine deiminases (PADs): Enzymes that catalyse protein citrullination  
PAD enzymes are activated by higher Ca
2+
 concentrations than that present in intact cells. 
The Ca
2+ 
concentration threshold for PAD activity is >10
-6
 M, but this varies with the source 
of PAD enzyme and in vitro substrate used (Inagaki et al. 1989; Nakayama-Hamada et al. 
2005). The estimates for the intracellular Ca
2+
 concentration range from 10
-9
 to 10
-7
 (Orlov et 
al. 2003). Five members of the PAD family (PAD1, -2, -3, -4, -6) have been found in humans, 
sharing 50-55% sequence identity overall. They have different tissue distribution, subcellular 
localisation and substrates (reviewed by Vossenaar et al. 2003b). Of particular relevance to 
RA are PAD2 and PAD4.  PAD2 is distributed widely in various tissues, and is especially 
abundant in musle and brain. PAD4 is mainly located in bloodstream granulocytes. However, 
both their expression has been demonstrated in rheumatoid synovial membrane (Chang et al. 
2005; De Rycke et al. 2005; Nakayama-Hamada et al. 2005; Foulquier et al. 2007), synovial 
fluid cells (Vossenaar et al. 2004b), and extracellularly in synovial fluid (Kinloch et al. 
2008).
2
 
 
Structure and classification of human PAD4 
Human PAD4 is the only protein of the PAD family for which the three-dimensional 
structure has been solved (Arita et al. 2003). Based on X-ray crystallographic data, it 
provided an insight into the catalytic residues of PAD4 and its structural basis for Ca
2+
 
dependency (Arita et al. 2004) and preference for arginine residues in certain amino acid 
contexts (Arita et al. 2006).  
PAD4 is organised into two domains: The N-terminal domain (Met1-Pro300) consists of two 
immunoglobulin-like subdomains and the nuclear localisation signal (NLS), the C-terminal 
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domain (Asn301-Pro663) is folded into an α/β propeller (five ββαβ modules arranged 
circularly in a pseudo-five fold symmetric structure), containing the active site (Figure 1.3).  
  
 
  
 
 
 
  
 
Figure 1.3     Ribbon representation of the structure of Ca
2+
-bound PAD4 in complex with a histone 
peptide. Ca
2+
 ions are shown as yellow balls, the histone peptide is shown as a green stick model. Carboxy- and 
amino-termini are indicated (C and N, respectively). NLS: nuclear localisation sequence. Figure adapted from 
(Arita et al. 2006). 
 
PAD4 exists as a dimer in the protein crystal and in solution, formed by head-to-tail contact 
between the N-terminal domain of one molecule and the C-terminal domain of the other. 
Each PAD4 monomer binds five Ca
2+
 ions, three in the N-terminal domain and two in the C-
terminal active site domain. The Ca
2+
 ions in both domains induce a conformational change, 
but only the two Ca
2+
 ions in the active site domain are essential for recognition of substrate 
and catalysis by stabilising disordered regions around the active site cleft and organising it. 
The active site residues were studied by site-directed mutagenesis and were identified to be 
cysteine-645, histidine-471, aspartic acid-350 and -473. Cysteine and histidine are involved 
in catalysis, whereas the two aspartic acid residues are crucial for substrate binding and 
orientation by hydrogen bonding of the arginine side chain nitrogen atoms. Mutation of any 
of these residues to alanine abolished enzymatic activity (Arita et al. 2004). 
 
The C-terminal domain of human PAD4, in its active Ca
2+
-bound state, is structurally similar 
to other arginine-processing enzymes which are calcium-independent, such as 
α/β propeller 
(catalytic domain) 
Ig-like domain 1 
Ig-like domain 2 
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amidinotransferase (AT), dimethyl-L-arginine deiminase (DDAH), arginine deiminase (ADI) 
and P. gingivalis PAD (PPAD). Despite no overall sequence similarity between these 
enzymes, their (proposed) catalytic residues overlap (Arita et al. 2004; Shirai et al. 2006). 
Based on these findings, the enzymes have been assigned to a new superfamily, called the 
guanidino-group modifying enzymes (GME) (Shirai et al. 2006). 
 
Substrate specificity and enzymatic mechanism of human PAD4 
The following catalytic mechanism was proposed: Side chain carboxyl groups of Asp-350 
and Asp-473 form hydrogen bonds and a salt bridge with the substrate peptidyl-L-arginine. A 
nucleophilic attack by the thiol group of Cys-645 on the Cδ atom of peptidyl-L-arginine 
cleaves the bond between this carbon atom and nitrogen ε2, generating ammonia. A water 
molecule, activated by His-471, forms a second nucleophilic attack on Cδ, and hydrolysis 
yields peptidyl-L-citrulline (Arita et al. 2004).  
 
Building up on this work, Arita et al. studied the interaction between PAD4 and peptide 
substrates from the N-terminal tail of histones H3 and H4 (Arita et al. 2006). They reported 
that PAD4 recognises five successive residues of the peptide substrate via hydrogen bonds to 
the backbone of the peptide. It was suggested that the substrate specificity is fairly broad, 
with the only restriction being at the N-2 position (two amino acids before arginine), where 
amino acids with small side-chains are favoured. The five residues were further observed to 
form a bent conformation within the active site cleft, and therefore flexible, unstructured, 
surface-exposed peptide regions in substrates might be favoured by PAD4, which is in line 
with experimental results (Takahara et al. 1985; Kurokawa et al. 1987; Tarcsa et al. 1996).  
 
Human PAD4 does not catalyse conversion of free L-arginine to L-citrulline. This was 
suggested to be due to essential hydrogen bond interaction between PAD4 (via Arg-372, Arg-
374, Arg-639) and atoms of the peptide bond formed between arginine and the preceding 
amino acid, which are absent in free L-arginine, but required for recognition of substrate 
(Arita et al. 2004). Early in vitro studies using rabbit PAD2 further showed that highest 
activity is observed towards substrates where both the amino- and carboxyl-groups of 
arginine are substituted with a peptide or ester bond, equivalent to internal rather than C- or 
N-terminal peptidylarginine (Sugawara et al. 1982). 
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Significance of citrullination in healthy physiology
3
 
In healthy physiology, citrullinated proteins are present in a variety of cells and tissues. An 
overview of the type of citrullinated proteins, localisation, function and relevant references is 
given in Table 1.3. Citrullinated proteins play a major role in the generation of structural 
tissue, the proper functioning of the central nervous system, in transcriptional regulation and 
in cytoskeletal stability. Recently, a direct role for protein citrullination in immune system 
regulation has been suggested by demonstrating that stimulation of peripheral blood 
mononuclear cells with IFN-γ and dsRNA caused citrullination of the chemokines CXCL8 
and CXCL10 with fundamental effects on their receptor usage, proteolytic processing and 
biological activities. In innate immunity, histone citrullination has been shown to result in the 
decondensation of chromatin and formation of neutrophil extracellular traps (NETs) as an 
innate response to infectious and inflammatory stimuli. In vitro experiments have 
demonstrated that fibrinogen can be citrullinated, resulting in defective thrombin-catalysed 
polymerisation, but the physiological role of this is unclear.  
 
 
Table 1.3 Citrullinated proteins in healthy human physiology 
 
Citrullinated 
protein 
Localisation Function References 
Keratin, Filaggrin Epidermis Cornification of 
epidermins, skin 
moisturisation 
(Steinert et al. 1979)  
(Tarcsa et al. 1996) 
Trichohyalin Hair follicle Mechanical 
strengthening of the 
hair follicle 
(Tarcsa et al. 1997) 
(Steinert et al. 2003) 
S100A3 Hair cuticle Maturation of hair 
cuticle cells 
(Kizawa et al. 2008) 
Myelin basic protein CNS (myelin 
sheaths) 
CNS development and 
function 
(Pritzker et al. 2000) 
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Citrullinated 
protein 
Localisation Function References 
Histones H2A, H3, 
H4 
Various cells Transcriptional 
regulation, formation 
of neutrophil 
extracellular traps 
(Wang et al. 2004) 
(Cuthbert et al. 2004) 
(Hagiwara et al. 2005) 
(Yao et al. 2008) 
(Li et al. 2008) 
(Neeli et al. 2008) 
(Li et al. 2010a) 
(Li et al. 2010b) 
 
Vimentin Monocytes, 
Macrophages 
? Apoptosis  
(In vitro: Unfolding of 
citrullinated proteins, 
diminished 
cytoskeletal stability) 
(Inagaki et al. 1989) 
(Vossenaar et al. 2004b) 
Chemokines  
(CXCL-8, -10) 
Peripheral 
blood 
mononuclear 
cells 
? Immune regulation 
(In vitro: citrullinated 
chemokines show 
altered receptor usage, 
proteolytic processing 
and biological 
activities) 
(Proost et al. 2008)  
(Loos et al. 2008) 
Fibrin(ogen) Peripheral 
blood, tissue 
deposits 
? Anti-inflammatory 
mechanism 
(In vitro: Inhibition of 
thrombin-catalysed 
fibrinogen 
polymerisation) 
(Okumura et al. 2009) 
(Nakayama-Hamada et al. 
2008) 
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Citrullinated proteins in disease
4
 
A dysregulation of protein citrullination at the site of disease has been associated with 
inflammation and tissue injury in general, not just in RA but also in other forms of 
inflammatory arthritis, multiple sclerosis, glaucoma, psoriasis, myositis, Alzheimer‟s disease, 
and most recently in sporadic Creutzfeldt-Jakob disease (Table 1.4). It is unknown what 
causes the aberrant protein citrullination in these diseases. In inflammatory arthritis, 
including RA, it is assumed that inflammation and the resulting release of pro-inflammatory 
stimuli and increased cell death activates PAD in a calcium rich environment, which might 
account for the accumulation of citrullinated proteins seen at diseased sites. However, 
intracellular citrullinated proteins in inflammatory arthritides were also observed by a number 
of investigators (Baeten et al. 2001; Cantaert et al. 2005; De Rycke et al. 2005) and might 
result from a controlled increase of intracellular Ca
2+
 concentrations, for example in response 
to activation by chemokines. 
 
Table 1.4 Citrullinated proteins in diseased human physiology 
 
Disease Citrullinated 
proteins confirmed 
at diseased site 
Localisation of 
citrullinated 
proteins 
References 
Rheumatoid arthritis 
and other 
inflammatory 
arthritides 
Fibrin(ogen), 
vimentin, collagen 
type II, α-enolase, 
fibronectin 
Synovial joint 
 
(Vossenaar et al. 2004c) 
(Makrygiannakis et al. 
2006) 
(Chapuy-Regaud et al. 
2005) 
(Chang et al. 2005)  
(Nakayama-Hamada et al. 
2005) 
(De Rycke et al. 2005) 
(Foulquier et al. 2007) 
(Van Steendam et al. 2010) 
Multiple sclerosis Myelin basic protein Brain (Moscarello et al. 1994) 
Glaucoma Myelin basic protein Optic nerve (Bhattacharya et al. 2006) 
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Disease Citrullinated 
proteins confirmed 
at diseased site 
Localisation of 
citrullinated 
proteins 
References 
Psoriasis Keratin (decreased 
levels of 
citrullination)  
Epidermis 
(keratinocytes) 
(Ishida-Yamamoto et al. 
2000) 
Myositis ? Muscle (Makrygiannakis et al. 
2006) 
Cancer 
(Adenocarcinoma) 
Cytokeratin Various  (Chang et al. 2006) 
Alzheimer‟s Vimentin, glial 
fibrillary acidic 
protein 
Brain 
(hippocampus) 
(Ishigami et al. 2005) 
Creutzfeldt-Jakob 
disease 
Vimentin, glial 
fibrillary acidic 
protein, enolase, 
aldolase A, myelin 
basic protein, 
phosphoglycerate 
kinase, cyclophilin A 
Brain (frontal 
cortex) 
(Jang et al. 2010) 
 
Autoimmunity to citrullinated proteins in rheumatoid arthritis
5
 
 
Since accumulation of citrullinated proteins occurs in a variety of conditions, it is now 
accepted that it is the autoantibody response rather than the presence of the citrullinated 
antigen that characterises RA. These autoantibodies are therefore most likely the result of an 
abnormal immune response to particular citrullinated proteins, where additional short- and 
long-term factors, such as the genetic background and environment, are required to induce 
and/or sustain antibody formation (Figure 1.4). This triad of factors - autoantibodies, genes 
and environment - is of course a gross simplification of the diverse and complex pathways 
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that underlie the clinical manifestations seen in RA. Nevertheless, it serves as a useful 
template for addressing a fundamental issue; namely, what actually causes the disease.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The gene/environment/autoimmunity triad.  Schematic representation of the hypothesis for 
the involvement of genes and environment in the development of specific and pathogenic autoantibodies in 
chronic autoimmune diseases. 
 
Rheumatoid factor 
Historically, rheumatoid factor (RF), an antibody reactive with the Fc portion of IgG and 
elevated in up to 80% of patients with RA, has been the main serological marker for the 
diagnosis of RA, and is still used as one of the criteria for the classification of the disease 
(Table 1.2). However, RFs also occur in other autoimmune diseases, infections and in 5% of 
the healthy population, and thus may simply be a consequence of polyclonal B cell activation 
(Sutton et al. 2000). 
 
Anti-citrullinated protein antibodies: Historical development
6
 
Antibodies to citrullinated proteins as a more specific marker of RA were described over 40 
years ago as the anti-perinuclear factor test; though at the time it was not known that it was 
detecting anti-citrullinated protein antibodies. In this test, human buccal mucosa cells were 
used as the substrate and antibodies reactive with granular structures around the nucleus were  
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detected by indirect immunofluorescence (Nienhuis et al. 1964). The assay had a high 
diagnostic specificity for RA but with variable sensitivity. This, combined with the 
cumbersome nature of the assay, precluded its use for routine diagnosis. An antibody reactive 
with the keratinised layer of rat oesophagus was subsequently reported as the so-called „anti-
keratin antibody‟ (Young et al. 1979) and correlated strongly with the anti-perinuclear factor. 
More recently, it was shown that both anti-perinuclear and anti-keratin antibodies reacted 
with mature filaggrin (Hoet et al. 1991; Simon et al. 1993; Sebbag et al. 1995), and a crucial 
discovery was that this reactivity was citrulline-specific (Schellekens et al. 1998; Girbal-
Neuhauser et al. 1999).  
 
Detection of anti-citrullinated protein antibodies for RA diagnostics today 
Nowadays, enzymatic assays using cyclic citrullinated peptides (CCP) as surrogate target 
antigens are routinely used in the diagnosis of RA and form part of the revised RA 
classification criteria (Table 1.2). The first generation of CCP assay (CCP1) was based on 
citrulline-containing peptides from the arginine-rich filaggrin sequence, and had a diagnostic 
sensitivity of approximately 70% with a disease-specificity of 96% (Schellekens et al. 2000). 
Because filaggrin, a protein which is involved in epidermal differentiation and hydration, is 
found only in epithelial cells but not in the joint, it was concluded that citrullinated filaggrin 
acted as a surrogate antigen and that other citrullinated proteins were more likely to be 
driving the autoimmune response in RA. In order to improve the diagnostic sensitivity and 
specificity of the CCP1 test, the CCP2 assay was developed and is now widely used in 
diagnostic laboratories. The substrates for this test were selected from a large panel of 
randomly generated citrulline-containing peptides which were tested against RA and control 
serum, with the sequences giving the best discrimination in diagnostic sensitivity and 
specificity being adopted for a commercial assay. Using an enzyme-linked immunosorbent 
assay (ELISA), CCP2 antibodies have a diagnostic sensitivity that is at least equivalent to 
that of RF (up to 82%) and a specificity that is much higher (98%) (van Venrooij et al. 2008). 
CCP antibodies have been detected prior to the development of clinically apparent RA 
(Rantapaa-Dahlqvist et al. 2003) and are associated with more severe and erosive disease 
(reviewed by Zendman et al. 2006). There is also increasing evidence that anti-citrullinated 
protein antibodies contribute to RA pathogenesis, possibly by formation of immune 
complexes resulting in production of proinflammatory molecules, perpetuating the 
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inflammatory process and leading to tissue injury and erosion in humans (Clavel et al. 2008) 
and mice (Kuhn et al. 2006; Petkova et al. 2006) (also see Figure 1.5).  
 
In spite of being a powerful diagnostic tool, the cyclic citrullinated peptides used in the CCP2 
are of limited use for understanding the disease aetiology and pathogenesis of RA as they do 
not correspond to in vivo generated citrullinated proteins. However, four citrullinated proteins 
that are targeted by anti-citrullinated protein antibodies, and are present in the joint, are now 
well established: citrullinated fibrinogen/fibrin (Masson-Bessiere et al. 2001), vimentin 
(Vossenaar et al. 2004a), collagen type II (Burkhardt et al. 2005), and α-enolase (Kinloch et 
al. 2005), with further awaiting identification and characterisation (reviewed by Wegner et al. 
2010a). Of particular relevance to this project are citrullinated fibrin(ogen) and α-enolase.  
 
Citrullinated fibrin(ogen) as a target of anti-citrullinated protein antibodies 
Fibrinogen is the precursor of fibrin, and citrullinated fibrin(ogen) is one of the best-
established specific autoantigens in RA. Citrullinated fibrin(ogen) is abundantly expressed in 
inflammatory joints of humans (Masson-Bessiere et al. 2001; Vossenaar et al. 2004c; 
Chapuy-Regaud et al. 2005; Tilleman et al. 2005; Matsuo et al. 2006) and experimental 
animals (Vossenaar et al. 2003a). It was originally identified by its cross-reaction with anti-
citrullinated filaggrin antibodies, which were affinity-purified from RA serum. By 
immunoblotting, these antibodies reacted mainly with the α- and β-chains of fibrin (Masson-
Bessiere et al. 2001). Antibodies to whole citrullinated fibrinogen are equal, in terms of 
diagnostic sensitivity and specificity, to the CCP-assay (vander Cruyssen 2006). Fibrinogen-
containing immune complexes were found in serum samples from about 50% of anti-CCP-
positive RA patients and immunohistochemical staining demonstrated co-localisation of 
fibrinogen, immunoglobulin and complement component 3 (C3) in the pannus tissue. 
Evidence for citrullination of fibrinogen contained in immune complexes and pannus tissue 
was also shown (Zhao et al. 2008). The expression of citrullinated fibrin(ogen) in the joint, 
and the detection of disease-specific antibodies in the serum, makes immune complexes 
containing citrullinated fibrin(ogen) an attractive mechanism for mediating some of the 
immunopathology of RA. This was recently explored in in vitro model systems. Clavel et al. 
found that human monocyte-derived macrophages produced large amounts of TNF-α when 
incubated with immobilised immune complexes containing citrullinated fibrinogen, and that 
the effect was mediated by Fcγ receptor IIa  (Clavel et al. 2008). These results were 
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supported and extended by Sokolove et al. (Sokolove et al. 2011), showing that immune 
complexes containing citrullinated fibrinogen induce TNF-α secretion by macrophages via 
dual engagement of Fcγ receptors and the innate immune toll-like receptor (TLR) 4, a well-
known ligand for fibrinogen (Smiley et al. 2001; Kuhns et al. 2007). The levels of secreted 
TNF-α were significantly higher when citrullinated fibrinogen immune complexes were used, 
as compared to citrullinated or native fibrinogen alone, anti-fibrinogen antibody alone, or 
native fibrinogen-containing immune complexes, suggesting that the presence of anti-
citrullinated fibrinogen antibodies mediates the pro-inflammatory response and that this is 
influenced by the specific antigen incorporated in the immune complex. The combined 
findings highlight how immune complexes, containing citrullinated fibrinogen, might be 
important in the pathogenesis of RA by driving inflammation via Fcγ, toll-like and 
complement receptors, resulting in inflammatory cytokine release (Figure 1.5). 
 
Figure 1.5 Schematic representation of potential pathways contributing to the pathogenic role of 
immune complexes containing citrullinated fibrinogen in the arthritic joint of RA patients. Antibodies 
specific for citrullinated fibrin(ogen) form immune complexes with citrullinated fibrin(ogen) deposits in the 
joint tissue. The immune complexes activate pro-inflammatory effector mechanisms by activating macrophages 
via Fcγ receptor (FcγR) II and toll-like receptor (TLR) 4, leading to the secretion of tumour necrosis factor-α 
(TNF-α). The immune complexes can also bind complement component 1 (C1), which eventually results in the 
release of C3a, C5a and C4a, leading to the recruitment and activation of neutrophils, macrophages and other 
pro-inflammatory components, and secretion of the cytokine TNF-α, amongst others, by these cells. The 
combined activity of all pathways results in cell lysis, tissue damage, and amplification of the inflammatory 
process. This figure was generated by myself using Microsoft Powerpoint. 
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Citrullinated α-enolase as a target of anti-citrullinated protein antibodies 
Alpha-enolase was first described by Saulot and colleagues as a candidate autoantigen 
reactive with 25% of early RA sera, using human placenta and epithelial cell line extracts 
(Saulot et al. 2002). However, using recombinant α-enolase as the substrate, only eight of the 
36 previously positive samples showed reactivity, strongly suggesting the presence of post-
translational modifications in α-enolase from the placental/cell line tissue extracts. Work in 
our laboratory described the citrullinated form of -enolase as a polypeptide in deiminated 
lysates of HL-60 cells reactive with serum from patients with RA (Kinloch et al. 2005). 
lpha-enolase was found to be abundantly expressed in RA synovial membrane and 
antibodies reacting only with the citrullinated form of the molecule were specific for RA 
(sensitivity approximately 40%), compared to healthy serum. More recently, using cyclic 
citrullinated -enolase peptides covering 15 out of 17 arginine residues present in human α-
enolase, our laboratory identified a peptide containing the immunodominant B cell epitope 
(Lundberg et al. 2008). This region comprised amino acids 5-21 of α-enolase, with arginine-9 
and arginine-15 replaced by citrulline (
5
KIHAcitEIFDScitGNPTVE
21
). Carboxy- and amino-
terminal cysteine residues were added to enable the peptide to adopt a cyclic conformation, 
which increases antibody reactivity. The resultant peptide is referred to as citrullinated α-
enolase peptide-1 (CEP-1). Using mass spectrometry, it had already been confirmed that both 
arginine-9 and arginine-15 can be citrullinated in vitro (Kinloch et al. 2005). A three-
dimensional representation of the human α-enolase protein shows that the CEP-1 peptide is 
present near the amino-terminus on a pole of the molecule, comprising the first and part of 
the second beta strand, and is surface-accessible (Figure 1.6). Arginine-15, which is the 
crucial amino acid in CEP-1, is located in the loop region between the first and the second 
beta strand. Taken together, this could explain why CEP-1 might be a dominant epitope and 
why a cyclic version of the peptide may be required for the detection of antibodies. In our 
studies of over 300 serum samples, antibodies to CEP-1 were found in 37% of RA patients, 3% 
of disease controls and 2% of healthy controls (Lundberg et al. 2008). Similar frequencies of 
anti-CEP-1 antibodies (41%) were found in a large cohort of Swedish patients with RA (Snir 
et al. 2009). Approximately half of the anti-CCP-positive patients with RA also have 
antibodies to CEP-1 (Lundberg et al. 2008).  
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Figure 1.6 Molecular representation of the human α-enolase dimer (A, B) and monomer (C). A: 
Ribbon diagramm. The immunodominant B cell epitope (CEP-1) is highlighted in red. Secondary structure 
elements (helices, light blue; strands, dark blue; loops, grey) are labelled. B: Molecular surface model. The 
CEP-1 epitope in the dimeric molecule is highlighted in red, with the two arginines in orange. C: Molecular 
surface model of the monomer, looking onto the dimer interface. Colour coding as in B. This figure was 
generated by myself using the software DeepView v4.0 (http://spdbv.vital-it.ch/) and is based on the X-ray 
crystal structure published by Kang and co-workers (Kang et al. 2008). This figure was published in (Wegner et 
al. 2010a). 
 
Similar to anti-CCP antibodies, expression of anti-CEP-1 antibodies precedes the onset of 
clinical RA by several years. In a study of 15 pre-RA serum samples selected on the basis of 
HLA-DRB1 SE alleles and anti-CCP antibodies being present, antibodies to a range of 
citrullinated enolase peptides were detected in 9 samples, 5 of which were directed 
specifically towards CEP-1 (Lundberg 2009). This finding suggests that the initial breakdown 
of immunological tolerance to citrullinated proteins, including α-enolase, might occur as a 
consequence of an inflammatory event outside the joint. Furthermore, the presence of IgA 
anti-CCP (73.9%) (dos Anjos et al. 2009) and IgA anti-CEP-1 (16%) (Snir et al. 2009) 
indicates the involvement of mucosal surfaces.  
 
Similar to other established antigens in human autoimmune diseases, enolase is a highly 
conserved and ubiquitous protein (reviewed by Wegner et al. 2009). Mammals express three 
enolase isotypes (α, β and γ), which form homodimers or heterodimers. Alpha-enolase is the 
most ubiquitous isotype and is expressed in a variety of tissues, while β-enolase is 
exclusively found in muscle tissues and γ-enolase in neuronal and neuroendocrine tissues. 
Enolase is a multifunctional protein: it catalyses the penultimate step in glycolysis, but also 
plays a role in various processes, such as hypoxia tolerance, growth control, and in 
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fibrinolysis, extracellular matrix remodelling and cell migration. This is due to its ability to 
bind plasminogen on the cell surface of various eukaryotic cells (Miles et al. 1991; Redlitz et 
al. 1995; Lopez-Alemany et al. 2003; Wygrecka et al. 2009) and a number of bacteria 
(Pancholi et al. 1998; Bergmann et al. 2001; Ge et al. 2004; Yavlovich et al. 2007), fungi 
(Fox et al. 2001), and parasites (Jolodar et al. 2003; Vanegas et al. 2007; Mundodi et al. 
2008). Using human cell lines and a monoclonal antibody directed towards the plasminogen-
binding region of -enolase, Lopez-Alemany et al. showed that α-enolase, despite being 
responsible for only around 15-20% of the total plasminogen binding, accounts for up to 90% 
of plasminogen‟s activation activity on the cell surface (Lopez-Alemany et al. 2003). It was 
also reported that plasminogen upregulates -enolase gene expression in fibroblasts and 
peripheral blood mononuclear cells (Sousa et al. 2005), supporting an important 
physiological role of -enolase in the plasminogen system. A recent study by Wygrecka and 
colleagues demonstrated a role for cell-surface -enolase in inflammatory cell recruitment. 
They showed that cell-surface expression of -enolase is upregulated in monocytes upon LPS 
stimulation and enhances plasmin generation, monocyte cell migration and matrix invasion in 
inflamed lungs (Wygrecka et al. 2009). 
 
Previous work in the laboratory demonstrated increased expression of -enolase in synovial 
membrane from patients with RA compared to osteoarthritis (OA) (Kinloch et al. 2005), and 
upregulation of extracellular -enolase in cell-free synovial fluid in inflammatory arthritis 
compared to controls (Kinloch et al. 2008). In a synovial fluid sample from a patient with RA, 
citrullination of α-enolase was indirectly demonstrated through a shift of the molecule (using 
an antibody raised against CEP-1) towards a more acidic isoelectric point (pI) in the two-
dimensional electrophoretic migration (Kinloch et al. 2008). This relative „acidic shift‟ 
towards the anode is a characteristic of protein citrullination due to the resulting decreased 
net positive charge. These data provide some evidence that citrullinated -enolase is involved 
in the pathogenesis of RA, and an animal model is currently under investigation. 
 
Risk factors for developing anti-citrullinated protein antibodies 
It is now beginning to emerge that two of the best described and strongest risk factors for RA, 
smoking and the presence of shared epitope alleles, are in fact specifically associated with 
CCP-positive RA (van der Helm-van Mil et al. 2006; Michou et al. 2008; reviewed by Baka 
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et al. 2009), suggesting a biological gene-environment interaction. More recently, a case–
control analysis of 1,000 patients with RA and 872 healthy controls from the Karolinska 
Institute, Stockholm, and our laboratory found that smoking and the shared epitope is 
primarily associated with the anti-CEP-1 positive subset of CCP-positive RA. The subset of 
patients that (i) smoked, (ii) expressed shared epitope alleles and (iii) the susceptibility allele 
of 620W PTPN22 (a gene encoding a tyrosine phosphatase involved in T and B cell signaling 
(Kallberg et al. 2007)) and (iv) had antibodies to both CCP and CEP-1, demonstrated an OR 
of 39.0 (95% CI 15.6–98.0) for the development of RA, compared to an odds ratio (OR) of 
4.3 (95% CI 2.2–8.6) in the corresponding subset that was negative for anti-CEP-1 (Mahdi et 
al. 2009). These data strongly suggest that CEP-1 is a peptide from a specific autoantigen 
which links smoking to the shared epitope in the development of RA. 
 
Of further relevance is the finding that polymorphisms in the human PADI4 gene have been 
associated with RA in Asian populations (Suzuki et al. 2003; Ikari et al. 2005; Kang et al. 
2006; Takata et al. 2008; Bang et al. 2010), and weakly in some Caucasian cohorts (Plenge et 
al. 2005; Iwamoto et al. 2006; Lee et al. 2007; Gandjbakhch et al. 2009; Hoppe et al. 2009), 
but not in most other Caucasian cohorts (Barton et al. 2004; Caponi et al. 2005; Harney et al. 
2005; Martinez et al. 2005; Burr et al. 2009). In the original study using a Japanese cohort, 
four single nucleotide polymorphisms (SNPs) (padi4_89: Serine-55 to Glycine; padi4_90: 
Alanine-82 to Valine; padi4_92: Alanine-112 to Glycine; padi4_104: Leucine-117, no amino 
acid residue replacement) were described to be associated with RA (OR 1.97 over the entire 
gene), and individuals harbouring these haplotypes showed higher anti-CCP antibody levels 
than controls (p = 0.038) (Suzuki et al. 2003). A large Korean case control study (1,313 
patients and 1,004 controls) confirmed that these SNPs are associated with RA susceptibility, 
however regardless of anti-CCP status (Bang et al. 2010). Further experiments using RNA 
containing the two most common haplotypes of RA-susceptible SNPs showed that it is 
degraded more slowly by HL-60 cell supernatants, compared to non-susceptible RNA, 
suggesting that these nucleotide substitutions make PAD4 mRNA more resistant to 
degradation, possibly resulting in increased levels of PAD4 enzyme and thereby citrullination 
(Suzuki et al. 2003). On the protein level, the resulting amino acid replacements are located 
in the N-terminal domain far from the active site and are therefore unlikely to affect catalytic 
activity directly, but might influence interaction with other proteins. A recent study 
determined the crystallographic structure of the mutant PAD4 enzyme harbouring all three 
amino acid replacement, confirming that the structure of the catalytic domain is identical to 
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that of the wildtype enzyme, and that the enzymatic activity is not affected by the mutations 
(Horikoshi et al. 2011).  
Inhibition of protein citrullination as a possible therapeutical strategy in RA 
Blockade of human PADs has been suggested by several investigators as a powerful novel 
therapy by inhibiting the generation of the antigens that sustain autoimmunity in RA. The 
approach employed for developing potential PAD inhibitors by most investigators is targeting 
the crucial cysteine (cysteine-645 in PAD4) in the active site (Arita et al. 2004). 
 
Stone and colleagues investigated 2-chloroacetamidine as a potential inhibitor (Stone et al. 
2005). 2-chloroacetamidine was found to inhibit both human PAD4 and dimethylarginase 
(also called dimethylarginine dimethylaminohydrolase; DDAH) from Pseudomonas 
aeruginosa. DDAH hydrolyses methylated arginines into citrulline and the corresponding 
alkylamine. In humans, DDAH enzymes regulate nitric oxide production by hydrolysing the 
endogenous inhibitors of nitric oxide synthase, L-NMMA (N
G
-monomethyl-L-arginine) and 
ADMA (asymmetric dimethylarginine) (Vallance et al. 2002). Both DDAH and PAD4 
belong to the GME superfamily and share a similar catalytic mechanism involving an active-
site Cys residue (Shirai et al. 2006). 2-chloroacetamidine (Figure 1.7) consists of an 
amidinium group similar to the natural substrates of PAD, but also a chloromethylene moiety, 
proposed to bind covalently to the active site cysteine. 
 
  
 
Figure 1.7     Chemical structure of 2-chloroacetamidine (IUPAC name: 2-chloroethanimidamide) 
 
The reported Ki (inhibitor dissociation constant) was relatively high at 20 mM for PAD4, and 
3.1 mM for DDAH, indicating weaker inhibitor potency of 2-chloroacetamidine with PAD4 
compared to DDAH. Addition of excess substrate (BAEE, 10 mM) to the enzyme-inhibitor 
mix decreased the inactivation rate, indicating that 2-chloroacetamidine acts at the active site. 
Using DDAH as a model, the authors showed by employing mass spectrometry that the 
inhibitor binds covalently to a peptide containing the active site cysteine, and suggested that 
it inhibits PAD4 via a similar mechanism due to the analogous active site residues. The 
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authors concluded that 2-chloroacetamidine should be used as a chemical scaffold to develop 
bioavailable inhibitors with higher affinity and selectivity. Two such compounds were shown 
to be F-amidine [N-α-benzoyl- N5-(2-fluoro-1-iminoethyl)-l-ornithine amide] and Cl-amidine 
[N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-l-ornithine amide], which inhibit PAD with an 
IC50
7
 of 21.6 μM (F-amidine) (Luo et al. 2006b) and 5.9 μM (Cl-amidine) (Luo et al. 2006a). 
Both molecules combine the basic structure of natural PAD substrates (peptidylarginine side 
chain), combined with a haloacetamidine warhead that is also found in 2-chloroacetamidine, 
and a benzoyl moiety (Figure 1.8). They act as irreversible inactivators of PAD4 by 
covalently modifying the active-site cysteine (Knuckley et al. 2010b). Their increased 
potency over 2-chloroacetamidine is likely to be due to their closer similarity of natural and 
synthetic PAD substrates such benzoyl-arginine ethylester (BAA) (Figure 1.8), targeting the 
compounds to the active site. 
 
 
                BAA                                    Cl-amidine 
 
Figure 1.8     Chemical structures of the synthetic peptidylarginine deiminase substrate BAA (benzoyl-arginine 
ethylester) and the inhibitor Cl-amidine (N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-l-ornithine amide) 
 
Inactivation by F-amidine and Cl-amidine is calcium-dependent. Both compounds 
preferentially inactivate the calcium-bound form >10-fold (Luo et al. 2006a; Luo et al. 
2006b). In vitro studies with PAD4 have shown that calcium binding leads to a 
conformational change that moves Cys-645 and His-471 into a position that is competent for 
catalysis (Arita et al. 2004), and presumably reactive with F-amidine and Cl-amidine. This is 
of therapeutic importance as these compounds would be expected to inhibit PAD4 in its 
activated state only at sites of inflammatory activity such as the synovium and not the 
inactive enzyme at other sites in the body, limiting toxicity. Ex vivo studies with F-amidine 
and Cl-amidine, using a cell line and an assay measuring PAD4-mediated citrullination of a 
                                                 
7
 IC50 represents the concentration of an agent required to inhibit a reaction by 50%. 
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nuclear protein and the resulting enhancement in binding to another protein, indicated that 
these inhibitors can be taken up by cells (Luo et al. 2006a; Luo et al. 2006b). Another study 
investigating PAD4 inhibition in cancer therapy showed that treatment of osteosarcoma 
U2OS cells with 200 μM Cl-amidine for 3 days halted cell proliferation and lowered levels of 
citrullinated histone H3 citrullination by ~50%, compared to untreated cells (Li et al. 2008; 
Li et al. 2010b). Van Willis and colleagues published a paper demonstrating the potential of 
these agents as useful therapeutic inhibitors in a mouse model of arthritis (Willis et al. 2011). 
Cl-amidine treatment in the CIA mouse model of arthritis (daily treatment on days 0-35 after 
immunisation with collagen II) significantly reduced clinical disease activity scores by 55%, 
53%, and 42% in the 50, 10, and 1 mg/kg per day groups, respectively. Histological severity 
scores, serum and synovial citrullination levels and C3 deposition in synovial tissue and 
cartilage paralleled the decrease in disease activity. In addition, mice receiving Cl-amidine 
(50 mg/kg) showed a reduced autoantibody response to native synovial antigens and 
citrullinated filaggrin peptides. In summary, in this model of arthritis, treatment with a PAD 
inhibitor does not prevent but at least ameliorates disease activity and synovial inflammation, 
probably through limiting the generation of anti-citrullinated protein and other autoantibodies, 
which in turn reduces pro-inflammatory effector mechanisms and thereby disease severity. A 
more indirect effect on inflammatory signalling cannot be excluded however, for example 
through the inhibition of chemokine citrullination.  
 
The combined data suggest that Cl-amidine and related compounds may indeed represent a 
novel class of RA therapeutics that specifically target citrullination. A challenge will be to 
define not only PAD-specific but further isozyme-specific inhibitors, as the inhibition of all 
PAD activity with equal efficiency in the long-term might lead to severe side effects 
associated with disturbed skin and hair follicle cell differentiation, apoptosis, antimicrobial 
response etc. The study described above did not mention any side effects of Cl-amidine 
treatment on mice despite the fact that Cl-amidine is an unselective inhibitor of PADs, 
although the potential long-term effects cannot be deducted. A recent study determined the 
IC50 levels of Cl-and F-amidine for PAD1 and 3 as 0.8 μM (Cl-amidine+PAD1), 6.2 μM (Cl-
amidine+PAD3), 29.5 μM (F-amidine+PAD1), and ~350 μM (F-amidine+PAD3) (Knuckley 
et al. 2010a). Comparing these to the IC50 values for PAD4 described earlier (21.6 μM with 
F-amidine and 5.9 μM for Cl-amidine), it becomes apparent that neither compound is 
isozyme-specific; Cl-amidine would inhibit PAD1, 3, and 4 while Fl-amidine would show a 
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preference for PAD1 and 4, if all enzymes were available at the site of inhibition at the same 
concentration. 
 
On the basis of the therapeutic use of DMARDs and antibiotics (O'Dell et al. 1999) in RA, 
Knuckley and colleagues screened a range of DMARDs (5-aminosalicylic acid, leflunomide, 
methotrexate), tetracycline derivatives (minocycline, doxycycline, tetracycline, 
chlortetracycline), and other antibiotics (streptomycin, clindamycin, sulfamethoxazole, 
trimethoprim, sulfapyridine, azithromycin) for their potential to inhibit PAD4 activity 
(Knuckley et al. 2008). Chlortetracycline was identified as the most potent inhibitor (IC50 100 
μM) and was suggested to bind to a region distal from the active site (Knuckley et al. 2008). 
Minocycline, tetracycline and doxycycline demonstrated IC50 values of 620, 780 and 860 μM, 
respectively. Streptomycin, an aminoglycoside antibiotic, was tested because of its two 
guanidinium groups that could act as substrate inhibitors of PAD4. Streptomycin was not 
citrullinated, but found to inhibit PAD4, though with a lower potency (IC50 = approximately 
1.8 mM) compared to tetracyclines, and was suggested to bind within or in close proximity to 
the active site. All other compounds were ineffective or only weakly inhibitory (IC50 between 
2.4 and >10 mM). The data suggest that tetracyclines are indeed PAD4 inhibitors, but their 
relatively weak inhibitory potency suggests that the efficacy in RA is probably not only due 
to PAD inhibition mainly to other mechanism, such as inhibition of metalloproteinases, as 
has been demonstrated for a range of tetracyclines (Sorsa et al. 1998). Nevertheless, they 
could provide a valuable scaffold for engineering inhibitors with greater potency and 
selectivity. 
 
Paclitaxel, a chemotherapeutic agent that interferes with microtubule function in cell mitosis, 
migration, chemotaxis, and intracellular transport, was shown to weakly inhibit PAD from 
bovine brain in the millimolar range (IC50 ~5 mM) (Pritzker et al. 1998). It prevented the 
induction of collagen-induced arthritis (CIA) and caused significant regression of existing 
CIA (Brahn et al. 1994), although it was not investigated what mediated this effect. An open-
label multicenter phase II study of paclitaxel in patients with RA was completed in July 2008, 
although results of this are still pending
8
. 
 
  
                                                 
8
 http://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT00055133) 
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Porphyromonas gingivalis, periodontitis and rheumatoid arthritis 
 
Summary of previous work and state of knowledge leading to this project 
 
The identification of citrullinated human α-enolase, and specifically the CEP-1 epitope within 
it, as a major target for autoantibodies to citrullinated proteins in RA, raised the question as to 
which factors trigger this specific response. As enolase is an evolutionary highly conserved 
enzyme and present in all domains of life, including bacteria, the investigation of the epitope 
mimicry hypothesis was prompted. According to the epitope mimicry hypothesis as it is 
commonly interpreted, an autoimmune response is induced by an infectious agent and 
initially directed against its microbial antigens. Owing to the structural resemblance between 
microbial and particular host antigens, the autoimmune response not only attacks the 
invading pathogen but also host tissue, which, in susceptible individuals, may tip the balance 
of immunological response versus immune tolerance and subsequently lead to autoimmune 
disease (discussed by Davies 1997; Oldstone 1998).  
 
P. gingivalis, a major causative agent in periodontitis (PD), seemed a promising candidate as 
it was reported to expresses a unique bacterial PAD-like enzyme (McGraw et al. 1999), and 
because PD had been associated with RA in a number of epidemiologic studies (reviewed by 
de Pablo et al. 2009). Further, an amino acid sequence alignment revealed that full-length 
human α-enolase and P. gingivalis enolase are 50.9% identical overall (Figure 1.9), and share 
82% sequence identity at the region corresponding to CEP-1 (highlighted in Figure 1.9). In 
addition, the nine amino acids at positions 13–21, which surround the crucial citrulline 
residue at position 15 in terms of antibody reactivity (Lundberg et al. 2008), are 100% 
identical. The role of enolase-specific autoimmunity in RA, evolutionary conservation of 
enolase and presence of a PAD-like enzyme in P. gingivalis therefore led to the initial 
hypothesis that P. gingivalis is involved in the aetiology of RA via citrullination of P. 
gingivalis enolase by the bacterial PAD enzyme, the triggering of antibodies to bacterial 
citrullinated enolase, which then cross-react with citrullinated human α-enolase in the joint. 
Of note, the citrullination link between RA and P. gingivalis had also previously been 
suggested in an opinion article by Rosenstein (Rosenstein et al. 2004), however without a 
focus on specific mediating molecules. 
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ENOA_HUMAN.        1 MSILKIHAREIFDSRGNPTVEVDLFTSKGLF-RAAVPSGASTGIYEALEL     49 
                     |.|.||..|||.|||||||||||:..:.|:. |||||||||||..||:|| 
ENO_PORGI.         1 MEIAKIIGREILDSRGNPTVEVDVHLACGIIGRAAVPSGASTGENEAIEL     50 
 
ENOA_HUMAN.       50 RDNDKTRYMGKGVSKAVEHINKTIAPALVSKKLNVTEQEKIDKLMIEMDG     99 
                     ||.||.||.||||.|||:::|:.|.|||..  ::|.||..||:.:||:|| 
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                      |. :|.|||||||||.:...::.:|.:..|:..|||.  ..:.|.||.| 
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                     :||||:.|.|| ..|:......|.|. :|:|.| ...:..||:.||||.. 
ENO_PORGI.       244 SSEFFKDGIYDYTKFEGEKGKKRSID-EQVAYL-TELVGKYPIDSIEDGM    291 
 
ENOA_HUMAN.      297 DQDDWGAWQKFTASAG--IQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKV    344 
                     .::||..|:|.|.:.|  :|:|||||.|||.:.:.:.:.||..|.:|:|| 
ENO_PORGI.       292 SENDWEGWKKLTVALGDKVQLVGDDLFVTNVEFLRRGIAEKCGNSILIKV    341 
 
ENOA_HUMAN.      345 NQIGSVTESLQACKLAQANGWGVMVSHRSGETEDTFIADLVVGLCTGQIK    394 
                     ||||::||:|.|.::|..:|:..:.||||||||||.|||:.|...:|||| 
ENO_PORGI.       342 NQIGTLTETLNAIEMAHRHGFTSVTSHRSGETEDTTIADIAVATNSGQIK    391 
 
ENOA_HUMAN.      395 TGAPCRSERLAKYNQLLRIEEELGSKAKFAGRNFRNPLAK    434 
                     ||:..|::|:||||||||||||||..|.:..:..       
ENO_PORGI.       392 TGSLSRTDRMAKYNQLLRIEEELGPCAVYGYKKV------    425 
 
 
Figure 1.9     Amino acid sequence alignment of human α-enolase (ENOA_HUMAN, SwissProt ID P06733) 
and P. gingivalis enolase (ENO_PORGI, SwissProt ID Q7MTV8). Identical amino acids are indicated by 
vertical lines, similar amino acids are indicated by colons and dots. The CEP-1 sequence is highlighted in colour. 
Identical amino acids are blue, non-identical amino acids are red. The two arginine residues (Arg-9 and Arg-15) 
which are substituted by citrulline in CEP-1 are underlined. The alignment was created using the EMBOSS 
program
9
 (Matrix: Blosom62, Gap penalty 10.0, Extend penalty 0.5).  
 
 
This initial hypothesis was investigated in our laboratory prior to the start of this project: the 
antibody response in RA patients to the P. gingivalis version of the CEP-1 peptide was 
measured by ELISA, and demonstrated to correlate strongly with that to human CEP-1 (r
2
 = 
0.8, P <0.0001) (Lundberg et al. 2008). Antibody cross-reactivity between whole citrullinated 
P. gingivalis enolase and citrullinated human α-enolase was then tested by immunoblot using 
CEP-1-affinity-purified antibodies from a patient with RA, which cross-reacted with 
citrullinated P. gingivalis enolase (Lundberg et al. 2008). 
 
  
                                                 
9
 http://www.ebi.ac.uk/Tools/emboss/align/ 
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The hypothesis that evolved from these initial experiments and formed the basis for this 
project was that infection with P. gingivalis reduces tolerance to citrullinated antigens, and 
that one antigen in particular, citrullinated α-enolase, is central to the initiation of the 
pathogenic pathway leading to RA (Figure 1.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10     Schematic illustration of the aetiological hypothesis for P. gingivalis involvement in RA. a) 
Infection by P. gingivalis leads to citrullination of bacterial proteins (i.e. P. gingivalis enolase) by PPAD in the 
gingiva. In the presence of danger signals, such as LPS and DNA, pathogenic T cells are activated by APCs, 
which present citrullinated antigen in the context of the HLA-DRB1 shared epitope. T cell-mediated activation 
of pathogenic B cells results in the production of antibodies specific for citrullinated proteins generated in the 
gingiva. b) A second inflammatory event occurs in the joint, leading to citrullination of joint proteins (i.e. 
human α-enolase) by human PADs. Anti-citrullinated protein antibodies initially formed as a result of gingival 
infection and citrullination cross-react with citrullinated joint antigens, through molecular mimicry and epitope 
spreading, resulting in the formation of immune complexes in the joint and activation of pro-inflammatory 
effector mechanisms. The perpetuation of the inflammatory process eventually causes chronic RA. 
Abbreviations: ACPA, anti-citrullinated protein/peptide antibody; APC, antigen presenting cell; LPS, 
lipopolysaccharide; P. gingivalis, Porphyromonas gingivalis; PAD, peptidylarginine deiminases; PPAD, P. 
gingivalis PAD; RA, rheumatoid arthritis; SE, shared epitope. Figure was published in a review co-authored by 
myself (Lundberg et al. 2010). 
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Porphyromonas gingivalis - the organism and its role in human disease 
 
P. gingivalis is an interesting organism that has been linked to RA not only through the 
expression of its bacterial PAD-like enzyme but also through epidemiological and serological 
studies and shared risk factors. In the following sections, the relevant literature is summarised 
to highlight its basic characteristics, role in periodontitis and links to RA. 
 
Characteristics of Porphyromonas gingivalis 
P. gingivalis is a gram-negative, anaerobic bacterium. It grows on blood-containing culture 
medium forming small glossy colonies of 1-2 mm diameter, with a varying degree of 
darkening because of the production of a heme-derived pigment (Figure 1.11). 
 
 
 
 
 
 
Figure 1.11     P. gingivalis colonies (strain W83) growing on sheep blood agar. Picture courtesy of 
Katarzyna Maresz, Jagiellonian University, Krakow, Poland. 
The organism is present, together with other oral bacteria, as a biofilm in the gingival crevice 
and intracellularly in oral epithelial cells (Rudney et al. 2001; Colombo et al. 2007). 
Colonisation of the subgingival region is facilitated by the ability of P. gingivalis to adhere to 
available substrates such as adsorbed salivary molecules, matrix proteins, epithelial cells, and 
bacteria that are already established as a biofilm on tooth and epithelial surfaces (Lamont et 
al. 2000). P. gingivalis produces an array of virulence factors with the capacity to colonise 
the host, obtain nutrients from the host, perturb host defence mechanisms and disintegrate 
periodontal tissue and bone. These include in particular extracellular cysteine proteases called 
gingipains, a unique lipopolysaccharide (LPS), and adhesins such as fimbriae and 
hemagglutinins (Holt et al. 1999).  
20 mm 
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Gingipains are of particular relevance to this project, as at the start of this work it was known 
that they share physical properties with PPAD (they were repeatedly co-purified from P. 
gingivalis cell extracts) (Hayashi et al. 1993; McGraw et al. 1999), that they are active under 
the same conditions as PPAD (citrullinating activity was detected by coincidence when 
assaying for gingipain activity) (Hayashi et al. 1993; McGraw et al. 1999) and that they 
target arginine residues, raising the possibility of concerted activity. Gingipains are major 
contributors to the pathogenic potential of P. gingivalis, playing a role in all stages of 
destructive periodontitis: adherence and colonisation, nutrient acquisition, neutralisation of 
host defences, manipulation of the inflammatory response, tissue destruction, invasion and 
dissemination (reviewed by Curtis et al. 2001; Guo et al. 2010). They are potent proteases 
and cleave various proteins/peptides after either arginine residues (i.e., arginine gingipain A 
and B [RgpA and RgpB]) or lysine residues (i.e., lysine gingipain [Kgp] (Curtis et al. 1999)), 
resulting in peptides with carboxy-terminal arginines or lysines. All gingipains have a 
catalytic protease domain and an immunoglobulin-like domain. RgpA and Kgp further 
contain several hemagglutinin-adhesin domains. Gingipains are subjected to extensive post-
translational proteolytic processing and glycosylation on their way to the cell surface, where 
they are attached to the outer membrane via sugar links or are secreted (reviewed by Potempa 
et al. 2003).  
 
Periodontitis - classification and pathogenesis 
 
The prevalence of severe generalised PD ranges between 4-15% (AAOP 1996; Borrell et al. 
2005), although this varies depending on the definition criteria of PD and the applied 
examination protocol. Currently, two broad types of PD are distinguished: aggressive and 
chronic PD (Armitage 1999). Unlike aggressive PD, chronic PD is traditionally considered a 
slowly progressing disease; however some patients may also have short periods of rapid 
progression. Both chronic and aggressive PD can be further subclassified based on extent and 
severity. The extent is defined by the percentage of potential sites involved, resulting in 
localised (≤30% of sites involved) or generalised (>30% of sites involved) PD. The severity 
is characterised on the basis of the clinical attachment loss (CAL), which is a cumulative 
measure of the destruction of the tooth-supporting connective tissue and alveolar bone, 
measured as the distance between the cement-enamel junction and the bottom of the 
periodontal pocket. Slight PD is defined as 1-2 mm CAL, moderate PD as 3-4 mm CAL, and 
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severe PD as ≥5 mm CAL. Not all studies adhere to these classification guidelines though, 
often using other or additional measures such as gingival bleeding on probing, periodontal 
pocket probing depth, periodontal bone loss and tooth mobility, all of which are increased in 
PD. Confusingly, in the older literature various types of PD are treated as separate diseases 
that are now known as subcategories of chronic or aggressive PD, or both. For example, 
chronic PD now includes the old terms „adult‟ and sometimes „generalised juvenile‟ or 
„rapidly progressing PD‟. Aggressive PD may include „early-onset‟, „juvenile‟, and also 
„rapidly progressing‟ PD (Armitage 1999). 
 
PD is characterised by inflammation of the gums, connective tissue breakdown and alveolar 
bone destruction. The initial periodontal lesion usually begins with a self-sustaining 
inflammation of the periodontium as a result of plaque accumulation, genetic and 
environmental risk factors, and then progresses into a destructive disease, accompanied by 
the release or activation of complement, TNF-, IL1-β, IL-6, IL-8, IL-17, prostaglandins E2, 
and metalloproteinases (Gemmell et al. 1997). Persistent, uncontrolled inflammation leads to 
an accumulation of lymphocytes and monocytes and release of more degradative and 
proinflammatory molecules, resulting in soft tissue degradation and erosion of adjacent teeth 
and bone, and eventually in loss of teeth, if left untreated (Ohlrich et al. 2009).  
 
The role of Porphyromonas gingivalis in periodontitis 
 
P. gingivalis is a major aetiological agent in the initiation and progression of PD (Lamont et 
al. 1998). P. gingivalis is directly associated with PD: Higher numbers of P. gingivalis are 
found in subgingival plaque taken from diseased sites than those from healthy sites (Dzink et 
al. 1988), and P. gingivalis is prevalent more often in PD patients than in controls (OR 12.3) 
(van Winkelhoff et al. 2002). Using a PCR-based protocol, P. gingivalis could be detected in 
80-95% of periodontitis patients and only 10-30% of healthy subjects (Griffen et al. 1998; 
Takeuchi et al. 2001; Yang et al. 2004). Implantation of P. gingivalis into the periodontal 
tissue of monkeys produced symptoms similar to human periodontitis (Holt et al. 1988). 
Other organisms often associated with periodontitis but with a less evident or unclear 
aetiological role are Tannerella forsythensis, Aggregatibacter actinomycetemcomitans, 
Fusobacterium nucleatum, Prevotella intermedia, Treponema dendicola, Campylobacter 
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rectus, Eubacterium nodatum, Peptostreptococcus micros, and Staphylococcus intermedius 
(reviewed by Lovegrove 2004).  
 
In recent years it has emerged that PD is a complex disease, with a combination of individual 
susceptibility factors and the microbial ecosystem contributing to the occurrence and severity 
of disease. Genetic influences account for around 50% of the total risk for developing chronic 
periodontitis (Michalowicz et al. 2000). Gene polymorphisms associated with periodontitis 
were reported for a number of genes encoding cytokines, Fc receptors, MHC class II alleles, 
each of which confers a relatively small risk, and no consensus has been reached to date 
(reviewed by Kinane et al. 2005; and Yoshie et al. 2007). 
 
Smoking has also been linked to PD with an odds ratio in the order of 2 to 6 (reviewed in 
Kinane et al. 2000). There is a dose-response relationship between the number of cigarettes 
smoked per day and the odds of developing disease (Tomar et al. 2000). Smokers have more 
severe PD, as measured by the degree of alveolar bone erosion and/or loss. In a large study of 
1,361 subjects, smokers were at greater risk for severe bone loss than non-smokers, with odds 
ratios of 3.25 and 7.28 for light and heavy smokers, respectively (Grossi et al. 1995). Levels 
of cotinine, the principle metabolite of nicotine, have been shown to correlate directly with 
periodontal destruction (Yamamoto et al. 2005). The mechanistic role of smoking in the 
pathogenesis of periodontitis is uncertain, but studies have shown increased levels of TNF-α 
in gingival crevicular fluid of smoking as compared to non-smoking periodontitis patients 
(Bostrom et al. 1999). 
 
Antibody response to Porphyromonas gingivalis in periodontitis 
The oral cavity is a complex and diverse ecological reservoir for a large number of species, 
with more than 500 estimated species colonising the gingivae, teeth, tongue and cheek (Paster 
et al. 2001). A change in periodontal status is reflected by shifts in the subgingival oral 
community (Kumar et al. 2006). It remains unclear how the immune system differentiates 
between commensal and pathogenic species, but it is known that an immune response is 
mounted primarily against the major bacteria commonly associated with periodontal disease, 
such as P. gingivalis. A recent study investigated serum antibody levels against a number of 
pathogenic and commensal species in patients with periodontal destruction and healthy 
controls, showing that antibody levels to pathogenic species, in particular P. gingivalis, are 
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evelated in periodontal disease, whereas antibody levels to commensals are comparable 
between diseased subjects and controls. B cells and plasma cells are predominant in the 
periodontal lesion, representing about 68% of cells (Berglundh et al. 2005). The presence and 
levels of antibodies in periodontitis against pathogenic species seems to dependent on the 
combination of factors, such as the type of PD, smoking, gender, hygiene measurements and 
race/ethnicity (reviewed by Schenkein et al. 2007). For example, out of 18 different bacterial 
species tested using radioimmunoassay, only serum antibody levels to P. gingivalis were 
predictive for PD (Gunsolley et al. 1990). A more recent study of >5,000 dentate adults using 
checkerboard immunoblotting found similar results; out of 19 bacterial species tested, high 
serum IgG levels to P. gingivalis were most strongly associated with PD (OR ~2). All 
reviewed studies focussed on IgG responses; a few studies compared Ig subclasses and found 
that in general IgA are lower than IgG responses and that IgM responses do not discriminate 
between PD and healthy subjects (for example, Naito et al. 1987; De Nardin et al. 1991).  
 
Most assays to measure antibody responses to P. gingivalis use whole cell bacterial lysates or 
whole formalin-fixed bacteria as antigen. So far, efforts to identify one or more dominant 
antigens (fimbrial proteins, LPS, gingipains, heat-shock proteins, mix of outer membrane 
proteins) were of limited success (reviewed by Kinane et al. 1999). This may be due to the 
loss of avidity when considering only one or a few antigens, variations in the makeup of the 
predominant antigens between different strains and different major autoantigens between 
individuals. For example, one study showed that six different P. gingivalis strains were 
required to adequately document the serum IgG response, and using a single or only a few 
strains missed a significant number of responses (Califano et al. 1999). Another study 
showed that the response to three different strains of P. gingivalis varies considerably 
between individuals with periodontal disease (De Nardin et al. 1991). 
 
A number of studies reported a protective effect of higher serum antibody levels to whole cell 
extracts of P. gingivalis on periodontal disease severity (as measured by degree of bone loss) 
(Gunsolley et al. 1990; Rams et al. 2006), although other studies contradict this finding 
(reviewed by Kinane et al. 1999). Smoking seems to influence antibody levels depending on 
the context in which PD is presented (type of PD, race). Generally, lower IgG levels were 
reported in smokers compared to healthy controls (Quinn et al. 1998; Mooney et al. 2001). 
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The sum of these findings raises the question as to why the antibody response elicited by oral 
pathogenic bacteria, and in particular by P. gingivalis, does not clear the infection. Several 
mechanism are probably at play that allow bacterial immune evasion: the formation of 
biofilms in subgingival plaque acts as a physical barrier, potent proteases and peptidases (e.g. 
gingipains from P. gingivalis) inactivate immune mediators, for example by degrading 
antibodies and complement components, and a number of studies have suggested that the 
immune response against oral pathogens is immature in many patients, with a low antibody 
avidity and lowered protective capacity (Mooney et al. 1993; Benjamin et al. 1997). 
 
Porphyromonas gingivalis PAD and citrullination 
The most striking feature of this bacterium in the context of autoimmunity in RA is that P. 
gingivalis is the only prokaryote described to express a functional PAD enzyme (McGraw et 
al. 1999). The authors purified the enzymatically active form from the culture supernatant of 
P. gingivalis HG66. This strain is a mutant that arose naturally after repeated passage of the 
wildtype H66 strain. HG66 is characterised by spontaneous secretion of most of its cell-
surface attached proteins, including PPAD, into the culture medium, and was therefore 
chosen for the comparably easy purification of cell-surface proteins from the culture 
supernatant (Jan Potempa, personal communication). The discovery of a peptidylarginine 
deiminase activity in P. gingivalis was a by-product of the initial aim to characterise peptide 
cleavage products using a gingipain preparation. Further fractionation of the gingipain 
preparation revealed an additional protein matching to a previously unassigned hypothetical 
protein in the P. gingivalis W83 genome, however starting at amino acid 44 (alanine) of the 
full-length hypothetical protein. This protein migrated as a single band with a molecular mass 
of 47 kDa, whereas the theoretical mass of the protein is 62 kDa, suggesting a truncated 
protein. The pH optimum was found at pH 9.3. Addition of flavin nucleotides appeared to 
increase the enzymatic activity, whereas Ca
2+
, which is indispensable for the activity of 
human PAD enzymes, was not required for the activity of PPAD. Enzyme activity assays 
were performed using free L-arginine, several synthetic arginine derivates (such as benzoyl-
L-arginine-ethylester), short peptidylarginine derivates (such as benzoyl-glycyl-L-arginine) 
and the short peptide bradykinin (contains nine amino acids, two of which are arginine: one 
on the amino-terminal and one on the carboxy-terminal end). The results showed that PPAD 
citrullinates free L-arginine, synthetic arginine derivatives, and bradykinin. Further analysis 
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revealed that bradykinin was citrullinated at the carboxy-terminal arginine, but not the amino-
terminal arginine, suggesting a preference of PPAD towards arginine residues in a certain 
environment. Further, inhibition experiments using reagents that interfere with sulfhydryl 
groups (such as thiocitrulline, leupeptin and 4,4‟-dithiopyridine) indicated the presence of a 
crucial cysteine residue in or near the active site of PPAD.  
 
In retrospect, indications for the presence of a citrullinating enzyme can be found in a 
preceding publication (Hayashi et al. 1993). Insulin chain B was incubated with a semi-
purified gingipain preparation (referred to as „hemagglutinin with trypsin-like activity‟) and 
amino acid analysis of the resulting peptides by hydrolysis and thin-layer chromatography 
revealed that one peptide species contained a citrulline residue. This peptide species 
corresponded in molecular mass and remaining amino acid content to another peptide species 
harbouring one arginine, at its C-terminus. The arginine-containing peptide inhibited 
hemagglutination of red blood cells, whereas the citrulline-containing counterpart did not. To 
prove that the citrulline residue resulted from enzymatic conversion of arginine, free L-
arginine was incubated with the gingipain preparation and the products analysed. 10-25% of 
the added L-arginine was recovered as L-citrulline, depending on incubation time, and no 
significant activity was detected using a boiled gingipain preparation. The authors therefore 
concluded in a side sentence that the gingipain preparation most likely contained an “arginine 
deiminase-like activity” and that this should be investigated further as a factor that plays a 
role in the hemagglutination by P. gingivalis. 
 
Using a bioinformatics approach, two subsequent publications by Shirai et al. investigated the 
evolutionary relationship amongst a number of enzymes that catalyse the modification of 
arginine or arginine-derivatives. Based on the low level of amino acid sequence similarity 
between PPAD and human PADs, it was argued that these enzymes are not evolutionary 
related (Shirai et al. 2001). The crystal structure of PPAD has not yet been determined but 
structural prediction by Shirai et al. suggested an α/β propeller domain at its N-terminus and 
an immunoglobulin-like β sandwich domain at its C-terminus. Based on these structural 
similarities to human PAD4 (Figure 1.3), but also on the similar enzymatic function and 
(proposed) conserved catalytic residues (Figure 1.12), Shirai et al. concluded that human 
PADs, PPAD and five other guanidino group modifying enzyme families [arginine deiminase 
(ADI), aminotransferases (AT), dimethylarginine dimethylamino hydrolases (DDAH), 
agmatine iminohydrolase (AIH), and succinylarginine dihydrolase (AstB)] are actually 
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members of a novel superfamily, the guanidino group modifying enzymes (GME) (Shirai et 
al. 2006). In fact, on the amino acid sequence level PPAD is connected to the AIH family 
(Figure 1.12). AIHs deiminate agmatine (decarboxylated arginine) to N-carbamoylputrescine 
and ammonia but are often annotated in both genomic and structural databases as 
'Porphyromonas-type peptidyl-arginine deiminases' or „putative peptidyl-arginine 
deiminases‟. Several studies have now confirmed however that these enzymes are indeed 
AIHs and not PPADs (Nakada et al. 2003; Jones et al. 2010a; Jones et al. 2010b). 
 
It is unknown what role protein citrullination might play in P. gingivalis and the pathogenesis 
of periodontitis. It was speculated that production of ammonia during PPAD-mediated 
deimination enhances the survival of P. gingivalis within the periodontal pocket (McGraw et 
al. 1999). Indeed, ADI- and AIH-catalysed ammonium production among oral bacterial 
species is known to act as a virulence factor, promoting the survival of microbial pathogens 
in the host environment (Takahashi et al. 1997). Ammonia neutralises acidic environments 
and might thereby optimise gingipain and PPAD function, and further has negative effects on 
neutrophil function by inhibiting phagocytosis, degranulation and oxygen metabolism 
(Niederman et al. 1990).  
 
Additionally, based on the findings by Hayashi et al. described above, it can be speculated 
that PPAD acts as a virulence factor by generating citrullinated peptides which may assist the 
bacterium in spreading and circumventing the humoral immune response, for example by 
citrullinating peptides with naturally occurring C-terminal peptidylarginines or after 
gingipain-mediated protein cleavage, which can be efficient inhibitors of hemagglutination or 
unwelcome mediators of the host immune system (e.g. C5a). 
 
A role for PPAD as a virulence factor is also supported by an in vivo study using the chamber 
model. In this model, a small metal coil (the chamber) is implanted subcutaneously into mice 
and inoculated with live P. gingivalis. Six hours after inoculation, the chamber fluid was 
removed and subjected to proteomic analysis. It was found that PPAD and 13 other proteins 
were upregulated, compared to the proteome of P. gingivalis grown in culture (Yoshimura et 
al. 2008). 
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Figure 1.12     Amino acid sequence alignment of the catalytic domains of PPAD (residues 86-363), AIH 
from Dyadobacter fermentans DSM 18053 (locus Dfer_2630, residues 60-352), and human PAD4 (residues 
306-556).  Residues identical in PPAD and AIH and/or PAD4 are highlighted. Guanidino-binding (#) and 
catalytic residues (*) which are conserved in all families of the guanidino-group modifying enzyme superfamily 
are indicated. The amino-terminal sequence of each enzyme is unique and not shown here. In PAD4 the amino-
terminal portion is folded into two consecutive Ig-like β-sandwich domains preceding the catalytic domain 
harbouring the α/β-propeller fold (Arita et al. 2004).  A long 200-residue carboxy-terminal extension of PPAD 
is predicted to adopt a Ig-like β-sandwich structure (Shirai et al. 2006). This figure was previously published in 
a review co-authored by myself (Mangat et al. 2010). PPAD: P. gingivalis peptidylarginine deiminase; AIH: 
agmatine iminohydrolase; PAD4: peptidylarginine deiminase 4. 
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Studies on the links between periodontitis and RA   
 
Several studies, reviews and opinion articles have been published on possible associations 
between RA and PD or P. gingivalis, many of which are hampered by small study size, crude 
assays and/or uncritical evaluation. A critical summary shall be provided here  
 
Epidemiological association between RA and PD 
A number of studies have reported a significant association between RA and PD and/or tooth 
loss. The results are difficult to compare because widely heterogenous disease classification 
criteria for RA and PD were used, some even relying on self-reported health questionnaires, 
and only a few studies appropriately adjusted their results for important confounding factors 
such as smoking and age. Despite these limitations, it can be concluded that a trend emerges 
indicating that RA is more prevalent in individuals with periodontitis and vice versa in 
comparison to the general population. The most recent studies are summarised here (also see 
Table 1.5): 
 
Mercado et al. studied 1,412 individuals attending a dental clinic in Brisbane, Australia 
(Mercado et al. 2000). Subjects were divided into two groups: those that were referred for 
periodontal treatment (defined as the PD group, n=809) and those that attended the clinic for 
other treatment (defined as the general group, n=603). Severity of periodontal bone loss (no, 
mild, moderate, severe) was further assessed in the PD group using dental X-rays. RA was 
assessed based on a self-reported health questionnaire and the self-reported prescription of 
drugs consistent with RA (e.g. NSAIDs, methotrexate). Based on these criteria, the 
prevalence of RA in the PD group was 32 out of 809 subjects (3.95%), compared to 4 out of 
603 (0.66%) in the general group (p<0.05). Within the PD group, patients with RA were 
more likely to have moderate-to-severe PD (62.5% of all RA patients) than patients without 
RA (43.8%) (p<0.05). Obvious limitations to this study are the reliance on self-reported RA, 
the definition of PD using a non-validated parameter (i.e. referral), the failure to document 
and adjust for smoking, and the lack of a limiting time period between clinic attendance and 
self-reporting in the health questionnaire.  
 
The authors therefore conducted a subsequent study (Mercado et al. 2001) involving 65 
consecutive patients attending a tertiary referral rheumatology clinic in Brisbane. All subjects 
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fulfilled the ACR 1987 criteria for classification of RA and were clinically examined for their 
periodontal health. The control group consisted of an undisclosed number of age-, sex- and 
smoking status-matched individuals without RA that were selected from a pool of patients 
who presented at a general dental clinic in Brisbane and were examined for periodontal health 
in the same way as the RA patients. In comparing the RA with the non-RA group, statistically 
significant associations (p<0.05) were an increased number of missing teeth (11.6 in RA vs. 
6.7 in non-RA), a higher percentage of subjects with deeper (>6.2 mm) pocketing  (44.6 vs. 
24.6%), and a higher percentage of subjects with moderate to severe bone loss (69.2% vs. 
33.8%). The values for the latter parameter compare well with the previous study on self-
reported RA (62.5% vs. 43.8%, see above).  
 
Another study on data from 4,461 subjects from the American NHANES III (National Health 
and Nutrition Examination Survey) investigated the associations between RA and periodontal 
measures (de Pablo et al. 2008). All subjects were aged ≥60 years, as musculoskeletal 
examination had been carried out in this age group only in the initial investigation. RA was 
defined based on the presence of only 3 out of 7 ACR 1987 criteria (normally 4 are required) 
because radiographic data were not available. PD was defined on the basis of clinical 
parameters. 2.3% of all subjects were defined as having RA, which is considerably higher 
than the average (0.5-1%) and might result from the looser classification criteria for RA used 
in this study. This is in line with the finding that only 29% of RA subjects were positive for 
rheumatoid factor, indicating that a proportion of patients defined as having RA in fact had 
other rheumatic diseases. Compared with non-RA subjects, participants with RA had a higher 
prevalence of PD (16% vs 10%), edentulism (56% vs. 34%), and a higher number of missing 
teeth (20 vs. 16, p=0.0001). Across all subjects, participants with RA were more likely than 
individuals without RA to be edentulous (OR 2.27, 95% CI 1.56-3.31). Among dentate 
subjects, participants with RA were more likely to have PD, independent of age, sex, 
ethnicity and smoking habits (OR 1.82, 95% CI 1.04-3.20). Recognising the weaknesses of 
the study as a result of using 3 instead of 4 classification criteria for RA, the authors 
conducted a sensitivity analysis based on the presence of 4 criteria for the definition of RA. 
The results showed a stronger association between RA and endentulism (OR 3.34, 95% CI 
1.16-9.64), and RA and PD (OR 4.13, 95% CI 1.30-13.15), independent of age, sex, 
race/ethnicity, and smoking. 
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The methodologically soundest study investigated 57 Caucasian subjects with RA and 52 
non-RA controls (Pischon et al. 2008). RA subjects were recruited from a rheumatology 
clinic in Berlin, Germany, and RA was classified according to standard ARC 1987 criteria. 
Control subjects were recruited from a general dental clinic in Berlin, and were matched for 
age and sex. The exclusion criterion for both groups was a history of periodontal therapy. All 
subjects were clinically assessed for periodontal disease, which was defined as a mean CAL > 
4 mm (moderate-to-severe PD). Questionnaires assessed smoking status (never, former, 
current), education, alcohol consumption and BMI. Statistical analysis showed an increased 
risk of PD in subjects with RA compared to controls (OR 8.05, 95% CI 2.93-22.09), 
independent of smoking, gender, education, alcohol consumption and BMI, and adjusted for 
age. When further adjusted for oral hygiene measures (plaque, gingival bleeding), the OR for 
the association of RA with PD was 6.09 (95% CI 1.72-21.58). Weaknesses of this study are 
the control population which is not representative of the general population and the relatively 
small sample size in both populations. However, the detailed documentation of smoking 
status, appropriate statististical adjustment and disease classification for both RA and PD are 
considerable strengths of this study. 
 
The most recent study (Nesse et al. 2010) studied a large number of subjects (n=1,208), 
failed however on appropriate classification of PD and RA, and the sufficient documentation 
of smoking and the relevant statistical adjustment. The 1,208 subjects who met inclusion 
criteria had been randomly selected from dental records of patients attending a dental or 
periodontal clinic. Data on prevalence of RA, other autoimmune diseases and cardiovascular 
disease was obtained from a health questionaire within 1 year of date of periodontal screening. 
Sex, age, and smoking habits (currently yes or no) were determined from dental records; 
smoking status was available for only 50% of subjects, however. PD was defined based on a 
probing depth ≥ 4 mm. Probing depth is defined as the distance from the free gingival margin 
to the bottom of the periodontal pocket, and is therefore a fraction of CAL, the official 
measure. A probing depth of ≥ 4 mm therefore corresponds to a CAL of at least 4 mm (more 
likely ≥ 5 mm), which is defined as severe PD according to the official criteria (Armitage 
1999). The control group consisted of patients attending the dental clinic without a diagnosis 
of PD (n=320). The PD group included subjects attending the dental or periontal clinic with a 
diagnosis of PD (n=888). In uncontrolled analysis, the prevalence of RA was significantly 
increased in PD patients [1 control (0.3%) had RA, and 26 PD subjects (2.9%) had RA]. The 
nature of the observed association between PD and RA remained unclear however because of 
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the low prevalence of RA (n=27) and the lack of smoking data for half of these subjects, 
reducing statistical power. 
 
Table 1.5 Summary of epidemiological studies on the association between 
rheumatoid arthritis and periodontitis. 
 
Cases Controls Adjustment 
for smoking 
Reported 
associations 
Limitations Reference 
809 subjects 
with PD  
 
PD 
definition: 
referred for 
periodontal 
treatment. 
Severity of 
PD assessed 
using dental 
X-rays 
 
RA 
definition: 
self-reported 
health 
questionnaire 
603 non-PD 
subjects, 
unmatched 
 
Non-PD 
definition: 
subjects 
attending a 
clinic for 
treatment 
other than 
periodontitis 
 
RA 
definition: 
self-reported 
health 
questionnaire 
No adjustment PD vs non-
PD: RA 
present in 
3.95% of PD 
group and 
0.66% of 
control group 
(p<0.05) 
 
Within PD 
group, 
moderate-to-
severe PD 
present in 
62.5% of all 
RA patients 
and 43.8% of 
non-RA 
patients 
(p<0.05) 
Self-reported 
RA 
 
Definition of 
PD using non-
validated 
parameter 
(referral) 
 
No 
documentation 
of time period 
between PD 
assessment 
and RA self-
reporting 
(Mercado 
et al. 2000) 
65 subjects 
with RA 
 
RA 
definition: 
fulfilment of 
at least 4 out 
of 7 ACR 
1987 criteria 
 
PD 
definition: 
clinical 
examination 
n = ? non-
RA subjects, 
matched for 
age, sex and 
smoking 
status  
 
Non-RA 
definition: 
no fulfilment 
of at least 4 
out of 7 
ACR 1987 
criteria 
 
PD 
definition: 
clinical 
examination  
Cases and 
controls 
matched for 
smoking 
RA versus 
non-RA: 
More missing 
teeth (11.6 vs. 
6.7); higher % 
of subjects 
with deep 
pockets (44.6 
vs. 24.6%); 
higher % of 
subjects with 
moderate-to-
severe bone 
loss (69.2 vs. 
33.8%) 
(p<0.05 for 
all 
associations) 
Cases and 
controls were 
matched for 
smoking but it 
is not clear 
according to 
which 
parameters 
this was done 
(ever/never/ 
current 
smoker, 
extend of 
smoking etc.) 
 
Small sample 
size 
(Mercado 
et al. 2001) 
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Cases Controls Adjustment 
for smoking 
Reported 
associations 
Limitations Reference 
103 subjects 
with RA  
 
RA 
definition: 
fulfilment of 
at least 3 out 
of 7 ACR 
1987 criteria 
 
PD 
definition: 
clinical 
examination 
 
 
4,358 non-
RA subjects 
 
Non-RA 
definition: 
no fulfilment 
of at least 3 
out of 7 
ACR 1987 
criteria 
 
PD 
definition: 
clinical 
examination 
 
Statistical 
adjustment 
based on 
questionnaire 
(never, 
former, 
current, 
number of 
cigarettes per 
day for 
current 
smokers) 
RA vs. non-
RA: more 
likely to have 
PD 
independent 
of age, sex, 
ethnicity and 
smoking 
habits (OR 
1.82, 95% CI 
1.04-3.20) 
Adjustment 
for smoking 
based on 
simple 
questionnaire 
(de Pablo 
et al. 2008) 
57 subjects 
with RA 
 
RA 
definition: 
fulfilment of 
at least 4 out 
of 7 ACR 
1987 criteria 
 
PD 
definition: 
clinical 
examination 
 
 
 
52 non-RA 
subjects 
 
non-RA 
definition: 
no fulfilment 
of at least 4 
out of 7 
ACR 1987 
criteria 
 
PD 
definition: 
clinical 
examination 
 
Statistical 
adjustment 
based on 
questionnaire 
(never, 
former, 
current) 
RA vs. non-
RA: increased 
risk of PD 
when adjusted 
for smoking, 
gender, 
education, 
alcohol 
consumption, 
BMI, age and 
oral hygiene 
(OR 6.09, 
95% CI 1.72-
21.58) 
Small sample 
size 
 
Adjustment 
for smoking 
based on 
simple 
questionnaire 
(Pischon et 
al. 2008) 
888 subjects 
with PD 
 
PD 
definition: 
clinical 
examination 
 
RA 
definition: 
health 
questionnaire 
 
 
320 non- PD 
subjects 
 
Non-PD 
definition: 
no diagnosis 
of PD after 
clinical 
examination 
 
RA 
definition: 
health 
questionnaire 
 
No adjustment PD versus 
non-PD: 
Prevalence of 
RA increased 
(2.9% vs. 
0.3%, p<0.05) 
No adjustment 
for smoking 
 
RA defined by 
health 
questionnaire 
 
 
(Nesse et 
al. 2010) 
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Common risk factors: Shared epitope and smoking 
As cigarette smoking is a risk factor common to both RA and periodontitis, it also is an 
important confounding factor for epidemiological studies on the association between 
periodontitis and RA, as summarised in the previous section. Some recent studies (Mercado 
et al. 2001; de Pablo et al. 2008; Pischon et al. 2008) included adjustment for smoking in 
their analysis, showing that the association between RA and periodontitis is independent of 
smoking; however, the evaluation of smoking was based on questionnaires, sometimes 
containing a grossly simplified documentation of smoking variables (yes/no) (Mercado et al. 
2001), resulting in the potential to inflate the incidence of RA in individuals with 
periodontitis in these particular studies (discussed by Hujoel et al. 2002).  
 
Studies evaluating the „shared epitope‟ as a risk factor for the development of PD are small in 
scale and heterogenous disease classification and patient/control selection criteria were used. 
Further, patients were often recruited from different ethnical backgrounds, and a varying 
number of HLA antigens was included in each study, making it difficult to interpret the 
results and to draw a conclusion. The relevant studies are summarised here: 
 
The first study to report an association between HLA-DR4 and periodontitis was published in 
1987 on 10 Caucasian patients with “rapidly progressing periodontitis” and 120 blood donor 
controls with unknown periodontal status (Katz et al. 1987). All subjects were typed for 
HLA-A, -B, -C, and -D. The only significant association was established for HLA-DR4, 
which was present in 80% of PD patients and in 38.3% of controls. Drawbacks to this study 
are the small number of sampled cases and the unknown periodontal status of the control 
group. 
 
Alley et al. studied 15 Caucasian subjects with moderate to severe chronic PD and 15 healthy 
controls (no PD) by determining their HLA-D phenotype. HLA-DR4 was highly associated 
with PD (p<0.001) compared to healthy controls (Alley et al. 1993). The small sample size of 
both cases and controls makes this study less conclusive. The same results were published a 
second time in another paper, including an additional analysis on IgG serum responses to 
Capnocytophaga (Dyer et al. 1997), and is therefore not considered an independent study for 
this purpose. 
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Firatli et al. determined HLA-A, -B, -C, and -DR phenotypes in 30 Caucasian patients with 
“juvenile periodontitis”, and 30 Caucasian patients with “rapidly progressive periodontitis” 
patients. Controls were 3,731 subjects of the general population (periodontal status unknown). 
In both forms of PD, DR4 was found “at a significantly higher level than the control group” 
(Firatli et al. 1996), although the detailed statistical values are not revealed, making an 
interpretation difficult, in addition to the small number of cases.  
 
The study most often cited in this context was published by Bonfil et al., who studied 48 
cases with “severe periodontitis”, and a subgroup of 12 patients characterised by extremely 
severe disease who met the criteria as applied in the study by Katz et al., 1987 (see above). 
Control subjects (n = 55) were free of periodontal disease. DR4 alleles and subtypes were 
detected for all subjects and the results adjusted for ethno-geographic origin, as the study 
population was of mixed ethnic backgrounds. A trend, but not a significant association was 
found between the presence of the DR4 serotype and periodontitis (16% of controls were 
positive compared to 23% of severe PD and 42% of extremely severe PD). A statistically 
significant association was found between the presence of either of the subtypes *0401, 
*0404, *0405 and *0408 and extremely severe periodontitis (p=0.08) (Bonfil et al. 1999). 
The drawbacks to this study are a mixed population, although this was adjusted for 
statistically, and small number of cases. Although the same disease classification criteria 
were used to classify extremely severe PD by this study (n=12) and by Katz et al. (n=10) the 
DR4 frequency differs considerably. Katz et al. found that 80% of patients and 38.3% of 
controls were positive, while Bonfil et al. detected DR4 in 42% of patients and 16% of 
controls. The variations might stem from the small study sizes.   
 
Marotte et al. investigated the link between RA, PD, and the „shared epitope‟ by genotyping 
147 patients with RA and assessing them for wrist and periodontal bone destruction using X-
rays; no healthy controls were enrolled. Based on dental X-ray data, 56.5% of RA patients 
had periodontal bone destruction. Significant associations were found between the presence 
of the „shared epitope‟ and wrist bone destruction, compared to the absence of the „shared 
epitope‟ (OR 2.5, 95% CI 1.16 - 5.42, p<0.05); and further between the presence of the 
„shared epitope‟ and periodontal bone destruction (OR 2.2, 95% CI 1.04 - 4.84, p<0.05). A 
stronger correlation was observed between patients with destruction at both sites and the 
presence of the „shared epitope‟, compared to patients without any destructions (OR 3.9, 95% 
CI 1.53 - 9.96, p<0.001) (Marotte et al. 2006). However, on detailed analysis of the method 
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to determine the presence of the „shared epitope‟ alleles, it becomes apparent that in fact only 
one primer pair was used, complementary to HLA-DRB4 (BLASTN analysis). While the 
DRB4 locus is linked to the DRB1 locus, which encodes the „shared epitope‟ alleles, this is a 
rather confusing and indirect way of assessing the presence of the shared epitope. 
 
Stein et al. performed a meta-analysis of case-control studies involving Caucasian subjects 
that were typed for HLA-A, -B, -Cw and DR and/or –DQ; where cases were defined as 
having aggressive (early-onset/rapidly progressive/localised/generalised juvenile) PD or 
chronic (adult) PD; where controls were defined as free of periodontal disease in the case of 
chronic PD (for aggressive PD blood donors were accepted as controls because aggressive 
PD is rare in the general population); and with consistent and reproducible data presentation. 
12 studies fulfilled these criteria, including Katz et al. and Alley et al. The other 10 studies 
included however did not find a significant association between periodontitis and DR4 or 
specific „shared epitope‟ alleles, so that the DR4 association lost its significance when all 
studies were combined. The only significant association in this meta-analysis was established 
between PD and the MHC class I antigens HLA-A9 and -B15 (Stein et al. 2008). 
 
Shared antibody profiles 
A recent study (Havemose-Poulsen et al. 2006) measured serum anti-CCP IgG levels in the 
serum of 23 patients with RA (no PD), 45 patients with generalised and localised aggressive 
periodontitis (no RA) and 25 healthy controls (no PD/RA). Periodontitis and RA was 
diagnosed after clinical examination and classified according to generally accepted criteria 
(ACR 1987 criteria for RA; American Academy of Periodontology classification criteria for 
PD). A somewhat higher than expected frequency of anti-CCP antibodies in patients with 
generalized aggressive periodontitis (7.4%; 2 out of 27) was found when compared with 
controls, though the difference was not statistically significant. Drawbacks to this study are 
the small sample size and the sampling of relatively young patients only (all subjects were 
≤35 years old). Noticeable is also the fact that only 35% of RA patients had anti-CCP 
antibodies. 
 
Another study measured anti-CCP antibodies in the serum of 33 individuals who developed 
RA up to 8 years after their serum was collected and their periodontal status assessed 
(Molitor et al. 2009). Patients were selected based on hospitalisation discharge codes of 5,413 
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participants in the Atherosclerosis Risk in Communities study. After adjustment for age, sex, 
and race, the hazard ratio (HR) of developing RA in subjects with moderate-to-severe PD 
(n=27) was 2.6 (95% CI 1.0-6.4), compared to those with no or mild PD (n=6). Among life-
time non-smokers, the HR rose to 8.8 (95% CI 1.1-68.9). Anti-CCP levels were significantly 
higher (p=0.04) in patients with moderate-to-severe PD (225.5 U) than in those with no or 
mild PD (8.4 U). As these data are presented in the form of a conference abstract, a more 
detailed interpretation is not possible. 
 
The study by Pischon et al., presented in detail on p. 58, also measured anti-CCP antibodies 
in 57 subjects with RA and 52 non-RA controls that were clinically examined for periodontal 
disease. The mean anti-CCP levels did not differ significantly in RA subjects with or without 
PD (Pischon et al. 2008). Another study measuring anti-CCP antibody in serum from 22 
patients with chronic periodontitis reported that only one patient was borderline positive 
(22.2 U/ml, cut-off is 20 U/ml), whereas Hendler et al. found anti-CCP antibodies in patients 
with aggressive periodontitis but not in patients with chronic periodontitis or gingivitis 
(Hendler et al. 2010).  
 
Mikuls et al. studied serum of 78 RA patients (classified according to ACR 1987 criteria) 
with unknown periodontal status, 39 non-RA patients with moderate to severe PD and 40 
healthy controls (Mikuls et al. 2009). Smoking status was recorded as either current smoker 
or not. Subjects were ≥19 years old. Antibody levels to whole cell extracts of P. gingivalis 
were measured by ELISA in all three groups, and anti-CCP was measured in PD and RA 
subjects. Antibody levels to P. gingivalis showed statistically significant differences between 
groups, with 40% of controls, 67% of RA, and 77% of PD being positive (p = 0.002). Further, 
91% of RA subjects but only 5% of PD subjects (2 out of 39) were positive for anti-CCP 
antibodies. Antibody levels to P. gingivalis were correlated to clinical parameters in RA 
subjects, showing  that total anti-CCP or RF did not correlate, but certain anti-CCP IgG 
subtypes did (IgG2, p = 0.01; IgM, p = 0.02), as did CRP (p = 0.003). The anti-P. gingivalis 
assay, which used a crude lysate of bacterial cells, could be criticised for a lack of specificity. 
Nevertheless, the test can differentiate between individuals infected with P. gingivalis and 
those who are not (Ebersole et al. 1987). The results are supported by a more recent study, 
where 82 patients with RA and 47 non-RA controls, all from a Native North American 
population genetically predisposed for RA, were assessed for antibody levels to P. gingivalis 
LPS and CCP, showing that anti-P. gingivalis antibody levels are higher in patients with RA 
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than controls (p=0.005) and associated with anti-CCP antibody positivity (p=0.04), but not 
rheumatoid factor-positivity (Hitchon et al. 2010). 
 
Another commonly cited publication (Moen et al. 2003) investigated antibody responses to P. 
gingivalis, P. intermedia, T. forsythensis, and Candida albicans, in 116 RA serum, 52 non-
matching RA synovial fluid, 43 non-RA (various arthritides) synovial fluid, 9 osteoarthritis 
synovial fluid and 100 blood donor (no history of RA; PD status unknown) samples. 
Antibody levels were measured by ELISA, however whole formalin-fixed cells instead of 
cell lysates were used. Further, the P. gingivalis strain used was different to the one used in 
Mikuls et al. The authors discuss various differences in antibody levels between groups and 
strain, for example that levels to P. gingivalis are comparable between all groups and that 
antibody levels to T. forsythensis are higher in synovial fluid of RA and non-RA compared to 
OA patients, but lower in the serum of RA patients compared to blood donor controls. 
Especially the latter is surprising, indicating inappropriate choice of study and control 
populations (non-matched serum/synovial fluid and unknown periodontal status of controls). 
 
Finally, Ogrendik studied serum from 30 RA patients and 20 healthy blood-donor controls 
(Ogrendik et al. 2005). All subjects were free of periodontal disease. Antibody levels to P. 
gingivalis (same strain as Mikuls et al.), Prevotella melaninogenica, T. forsythensis, P. 
intermedia, and A. actinomycetemcomitans were measured by ELISA using whole bacteria. It 
is assumed here that the bacteria were formalin-fixed and not alive, although this is not 
explicitly stated in the paper. The results showed that IgG levels were significantly higher in 
RA patients compared to controls for all bacteria except A. actinomycetemcomitans (P. 
gingivalis, p<0.001; P. intermedia, p< 0.001; P. melaninogenica, p<0.01; T. forsythensis, 
p<0.05). Further, a positive correlation between antibody levels to P. gingivalis and serum 
CRP in RA patients was found (r=0.809). Although an interesting result, it is unclear what 
the cause of the increased antibody levels in RA patients is, as they were defined as free of 
current periodontal disease. Possible explanations is humoral immunity resulting from 
previous periodontal conditions or increased total serum IgG levels, which was not adjusted 
for in this study. 
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Presence of P. gingivalis DNA in serum or synovial fluid from RA patients 
Moen et al. investigated serum and synovial fluid from 16 patients with RA, 14 with 
spondyloarthropathies, and 9 with osteoarthritis for P. gingivalis DNA (Moen et al. 2006). 
Total DNA was extracted and submitted to checkerboard DNA-DNA-hybridisation using 16S 
rRNA-based oligonucleotide probes for identification of 40 different oral bacteria species. 
The authors reported higher numbers of different bacterial species in the serum of RA 
(average of 6.2 different bacterial species) and spondyloarthropathies patients (5.4) over 
osteoarthritis patients (2.7). Higher numbers were also found in synovial fluid of RA (14.0) 
and spondyloarthropathies (19.4) over osteoarthritis (4.0) patients. P. gingivalis was detected 
in RA and spondyloarthropathies serum/synovial fluid but not in osteoarthritis patients. 
Unfortunately, as any technique based on affinity and avidity, checkerboard DNA-DNA-
hybridisation, when used with DNA samples containing only a minimal fraction of bacterial 
DNA compared to human DNA, is prone to false positives and cross-reaction. If the results 
are to be trusted however, they indicate that synovial inflammation, which is characteristic 
for RA and spondyloarthropathies but generally not for osteoarthritis, traps oral bacterial 
DNA, possibly in leukocytes in the form of engulfed bacteria or bacterial products. However, 
it does not indicate that live bacteria in the joint are directly responsible for disease. A more 
recent study aimed at identifying periodontal bacterial DNA in subgingival plaque, serum, 
synovial fluid and leukocytes from 19 patients with both RA and periodontitis failed to 
support this view (Martinez-Martinez et al. 2009). DNA was extracted and subjected to PCR 
with species-specific primers to P. gingivalis and five other periodontal pathogens. DNA 
from at least one bacterium was detected in 100% of subgingival plaque samples, 100% of 
synovial fluid samples, and 83.5% of serum, but in none of the DNA samples extracted from 
blood leukocytes. No bacterial species could be grown on agar plates under aerobic or 
unaerobic conditions from any of the synovial fluid samples. The authors conclude that the 
most likely mode of transport of bacterial DNA from the mouth to the joints is in its free 
form.Unfortunately, the original PCR agarose gels are not shown to convince the reader of 
the specificity of the primers. If the results can be replicated, they would imply that free 
bacterial DNA may trigger inflammatory pathways in the joint. 
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Similar pathobiology 
PD and RA are characterised by similar pathogenic findings and mechanisms: both diseases 
are characterised by destruction of tissue and erosion of periarticular bone and periodontal 
bone, respectively, as a result of persistent inflammation. In both diseases the pathogenesis 
includes B cells and proinflammatory cells, release or activation of proinflammatory 
mediators, notably TNF-α, antibody production and upregulation of matrix 
metalloproteinases (reviewed by Mercado et al. 2003; Bartold et al. 2005; de Pablo et al. 
2009). 
 
Common treatment effects 
Another commonly cited link is a beneficiary effect on RA of treatment with certain 
antibiotics and of mechanical periodontal treatment.  
 
Ogrendik evaluated the efficacy of ornidazole (Ogrendik et al. 2006), clarithromycin 
(Ogrendik 2007a), and levofloxacin in combination with methotrexate (Ogrendik 2007b) in 
RA. Ornidazole is a nitroimidazole antiprotozoal drug which also has antibacterial activity 
against anaerobes and is therefore used in periodontal therapy (Kamma et al. 2000); 
levofloxacin is a  fluoroquinolone antibiotic used in periodontal therapy (Kleinfelder et al. 
2000); clarithromycine is a macrolide antibiotic that is best known for its efficacy against 
Helicobacter pylori, but is also used in periodontal treatment (Burrell et al. 2008). All studies 
were randomised and placebo-controlled, enrolling 76-160 patients, with patients having RA 
(ornidazole), persistently active RA despite at least 6 months methotrexate therapy 
(levofloxacin), or early RA (clarithromycin). Studies ran for 3 months (ornidazole) or 6 
months (levofloxacin, clarithromycin). Efficacy measures were the percentage of subjects 
showing an ACR 20/50/70 response, which requires a subject to have a 20/50/70% reduction 
in the number of swollen and tender joints, and a reduction of 20/50/70% in three of the 
following five parameters: physician global assessment of disease, patient global assessment 
of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, 
and degree of disability in Health Assessment Questionnaire (HAQ) score. It is reported in all 
three studies that the treatment group showed statistically significant (p<0.001) levels of 
ACR 20, 50 and 70 improvements, compared to placebo control, with ARC 20 being 50-62% 
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in cases and 18-33% in controls, ACR 50 34-38% in cases and 8-11% in controls, and ACR 
70 18-20% in cases and 1-3% in controls for all drugs. 
 
It is not clear which mechanisms lead to the observed efficacy of these antibiotics in RA. 
Although they are used to treat periodontal disease, these studies have not investigated 
whether efficacy mirrors improvement in periodontal health status. Additionally, other, non-
antibiotic mechanisms might mediate their efficacy. This has been shown for example for 
minocycline, a tetracycline derivative antibiotic which shows efficacy in early rheumatoid 
factor-positive RA (O'Dell et al. 2001). Minocycline has been shown to have anti-
inflammatory, immunomodulatory, and chondroprotective effects: it inhibits phospholipase 
A2 (Pruzanski et al. 1992) and metalloproteinases (Golub et al. 1998) activity, nitric oxide 
synthetase expression (Amin et al. 1996), and suppresses leukocyte-associated tissue damage 
(Gabler et al. 1991). 
The benefit of mechanical periodontal therapy on RA disease activity, measured by the 
disease activity score (DAS) 28 or the HAQ Disability Index (HAQ-DI) score, was assesed in 
three studies. DAS28 is a numeric index and calculated using number of tender joints, 
swollen joints, patients‟ general assessment of their condition, and ESR. The HAQ-DI 
assesses a patient's level of functional ability and includes questions of fine movements of the 
upper extremity, locomotor activities of the lower extremity, and activities that involve both 
upper and lower extremities.  
Al-Katma et al. enrolled 29 subjects with RA (classified using ACR 1987 criteria; DAS28 ≥ 
2.5) and generalised mild-to-moderate chronic PD (≥3 years duration) (Al-Katma et al. 2007). 
All subjects were recruited from a rheumatology clinic in Cleveland, USA, were ≥30 years 
old, non-smokers and non-diabetic. 17 subjects received detailed oral hygiene instructions 
and periodontal treatment by full-mouth scaling and root planning (SRP), which is a cleaning 
of the root surfaces below the gum line. The other 12 subjects received neither treatment nor 
instructions. DAS28 and periodontal parameters were recorded at baseline and after 8 weeks. 
13 out 17 subjects (76%) in the treatment group showed improvement in DAS28, compared 
to 2 out of 12 (17%) in the untreated group. A statistically significant difference was found 
between DAS28 and ESR between the treatment and control group. Further, all periodontal 
parameters were significantly correlated with improvement of DAS28 and ESR. 
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Similar results were obtained in another study in the same center (Ortiz et al. 2009). 40 
subjects with RA and generalised severe chronic PD were enrolled. Subjects were ≥30 years 
old, non-smokers and non-diabetics. 20 subjects were randomly assigned to periodontal 
therapy (SRP) and oral hygiene instructions, the other 20 received neither therapy nor 
instructions. At baseline and after 6 weeks, periodontal clinical parameters, DAS28, ESR, 
and TNF-α levels in peripheral blood were measured. Patients receiving treatment showed a 
significant decrease in mean DAS28, ESR, periodontal clinical parameters and serum TNF-α 
at 6 weeks after treatment. No significant decrease was seen in subjects without periodontal 
treatment.  
 
A third study (Ribeiro et al. 2005) enrolled 42 consecutive patients attending a rheumatology 
clinic in Brazil with RA (classified according to ACR 1987 criteria) and severe PD (clinical 
assessment). Patients were ≥40 years old and non-smokers. RA severity was determined 
based on the HAQ-DI, ESR, and serum IgM-RF. Subjects were divided into 2 groups, 
matched for age and gender. Group 1 (n=16) received oral hygiene instructions and 
professional supragingival tooth cleaning, whereas goup 2 (n=26) additionally submitted to 
SRP. Periodontal and laboratory measurements were taken 3 months after periodontal 
treatment. Group 2 showed significant improvement on periodontal clinical parameters; some 
improvement was recorded for group 1. No significant association between these periodontal 
clinical parameters and the HAQ-DI score was measured between groups and before and 
after therapy. RF levels were reduced for both groups but this was not statistically significant. 
However, the ESR was significantly reduced for group 2. 
 
It becomes apparent that all three studies demonstrated a siginificant reduction in the ESR, 
which is a component of the DAS28 but not the HAQ score. This most likely reflects the 
reduction in periodontal inflammation as a result of periodontal treatment, and therefore 
lower levels of systemic inflammatory markers such as TNF-α. The time period between 
periodontal treatment and assessment for RA activity is relatively short in all three studies (6-
12 weeks). An improvement in HAQ score might become apparent over a longer period of 
continous improved periodontal health, especially as this seems to result in significantly 
decreased systemic TNF-α levels.  
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Aims of this study  
The aim of this project was to investigate the molecular basis of protein citrullination by P. 
gingivalis and the potential of this to contribute to the development of anti-citrullinated 
protein antibodies in RA.  
 
This involved five major steps: 
  
1. Examination of the presence of endogenous citrullinated proteins in P. gingivalis and 
other periodontopathogenic bacteria (Chapter 3). 
 
2. Determination of the potential of P. gingivalis to citrullinate human proteins, in 
particular known RA autoantigens such as α-enolase and fibrinogen (Chapter 3). 
 
3. Analysis of the antibody responses to P. gingivalis-generated citrullinated peptides in 
patients with RA (Chapter 3). 
 
4. Cloning and expression of P. gingivalis PAD in an active form and investigation of its 
functional properties, activity towards human proteins, and its inhibition by candidate 
compounds (Chapter 4). 
 
5. Generation of a polyclonal antibody to P. gingivalis PAD; examination of the native 
form and subcellular localisation of the enzyme in bacterial lysates; investigation of 
periodontal tissue for the presence of citrullinated proteins and P. gingivalis PAD 
(Chapter 5). 
  
 71 
Chapter 2          Materials and Methods 
List of materials and reagents 
 
Reagent/Material Supplier Storage and Notes 
Agar BD Difco™, granulated 
RT 
Agarose, UltraPure™ Invitrogen RT 
Albumin Sigma From bovine serum 
4˚C 
2-Amino-2-methyl-1,3-
propanediol (AMPD) 
Sigma-Aldrich  RT 
Ammonium ferric sulphate 
Dodecahydrate 
Fluka Protect from light 
RT 
Ampicillin Sigma RT 
Antarctic phosphatase NEB 5,000 U/ml 
-20˚C 
Anti-CEP-1 antibody (Lundberg et al. 
2008) 
Rabbit polyclonal antibody 
Raised against the CEP-1 peptide from human 
α-enolase (CKIHA-Cit-EIFDS-Cit-
GNPTVEC) 
-20˚C 
Anti-citrulline (modified) 
detection kit 
Upstate/Millipore -20˚C 
Anti-enolase (H-300) 
antibody 
Santa-Cruz 
Biotechnology 
Rabbit polyclonal antibody 
Raised against amino acids 1-300 mapping at 
the N-terminus of human α-enolase. Detects α-, 
β- and γ-enolase.  
4˚C 
Anti-fibrinogen α (C-20) 
antibody 
Santa-Cruz 
Biotechnology 
sc-18026 
Goat polyclonal antibody 
Raised against a peptide mapping near the C-
terminus of human fibrinogen-α. 
4˚C 
Anti-fibrinogen β (I-18) 
antibody 
Santa-Cruz 
Biotechnology 
sc-18027 
Goat polyclonal antibody 
Raised against a peptide mapping within an 
internal region of human fibrinogen-β 
4˚C 
Anti-fibrinogen γ (C-20) 
antibody 
Santa-Cruz 
Biotechnology 
sc-18032 
Goat polyclonal antibody 
Raised against a peptide mapping at the C-
terminus of human fibrinogen-γ 
4˚C 
Anti-his antibody Novagen #70796-3 
Mouse monoclonal antibody 
Anti-goat Ig antibody, HRP-
conjugated 
DAKO #P0449 
Raised in rabbit 
4˚C 
Anti-GST antibody, HRP-
conjugated 
GE Healthcare #27-4577-01 
Goat polyclonal antibody 
4˚C 
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Anti-mouse Ig antibody, 
HRP-conjugated 
DAKO #P0260 
Raised in rabbit 
Dilution for WB: 1:5000 
4˚C 
Anti-rabbit Ig antibody, HRP-
conjugate 
DAKO #P0448 
Raised in goat 
Dilution for WB: 1:5000 
4°C 
   
BCA Protein Assay Kit Pierce RT 
Benzonase Nuclease Novagen 250 U/μl, purity >99% 
-20˚C 
Biotaq DNA Polymerase Bioline -20˚C 
BL21 (DE3) chemically 
competent cells 
Merck -80˚C 
Bpu10I NEB 5,000 U/ml (R0649S) 
Bradford Coomassie Plus 
Assay Reagent 
Pierce/Thermo 
Scientific 
RT 
Bromophenol Blue Sigma RT 
BugBuster Protein Extraction 
Reagent 
Novagen RT 
2,3-Butanedione oxime Fluka RT 
   
C41 (DE3) OverExpress 
competent cells 
Lucigen 
Corporation 
-80˚C 
C41 (DE3) pLysS 
OverExpress competent cells 
Lucigen 
Corporation 
-80˚C 
C43 (DE3) OverExpress 
competent cells 
Lucigen 
Corporation 
-80˚C 
C41 (DE3) pLysS 
OverExpress competent cells 
Lucigen 
Corporation 
-80˚C 
Calcium chloride Riedel-de Haёn 97% powder, pure 
RT  
Chloroacetamidine 
hydrochloride 
Alfa Aesar 4˚C 
2-(Cyclohexylamino) 
ethanesulfonic acid (CHES) 
Sigma RT 
   
DC Protein Assay Bio-Rad RT 
dNTP solution mix NEB 10 mM each nucleotide 
avoid repeated freeze/thaw 
-20˚C 
Doxycycline hyclate VWR/Applichem 4˚C 
   
ECL blocking agent Amersham/GE 
Healthcare 
4˚C 
ECL and ECL PLUS Western 
blotting detection reagents 
Amersham/GE 
Healthcare 
4˚C 
EDTA disodium salt VWR/BDH AnalaR NORMAPUR 
   
Full-range rainbow molecular Amersham/GE -20˚C 
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weight markers Healthcare 
   
Glutathione Sepharose 4B GE Healthcare 4˚C 
Glycerol BDH/VWR AnalaR Normapur, bidistilled, 99.5 % 
RT 
GoTaq Hot Start Polymerase Promega 5 U/μl 
-20˚C 
   
High-range rainbow 
molecular weight markers 
Amersham/GE 
Healthcare 
-20˚C 
HRV 3C protease Novagen/Merck 2000 U/ml 
-20˚C 
Hyperladder I Bioline 4˚C 
   
Imidazole, 99% pure Sigma-Aldrich RT 
Instant Blue Novexin/Triple 
Red 
4˚C 
IPTG, Dioxane-Free, High 
Purity 
Calbiochem 2-8˚C 
protect from light 
   
Kanamycin monosulfate Sigma from Streptomyces kanamyceticus 
RT 
KOD Hot Start DNA 
polymerase 
Novagen/Merck 1 U/μl 
-20˚C 
KpnI NEB 10,000 U/ml (R0142S) 
-20˚C 
   
L-Arginine Fluka >99.0% 
RT 
LB agar (Lennox) Invitrogen RT 
LB broth (Miller) Merck/VWR RT 
L-Citrulline Fluka >99.0% 
RT 
L-Cysteine hydrochloride 
monohydrate 
Sigma-Aldrich 4˚C 
Low-range rainbow molecular 
weight markers 
GE Healthcare -20˚C 
   
meta-Phosphoric acid Sigma 33.5-36.5% 
RT 
Methotrexate VWR/Applichem 4˚C 
Minocycline hydrochloride VWR/Calbiochem 4˚C 
   
NdeI NEB 20,000 U/ml (R0111S) 
NEB 5-alpha F’Iq chemically 
competent E. coli 
NEB -80˚C 
Nitrocelllose membrane 1) GE Healthcare 
2) Whatman 
1) Hybond-ECL, 0.45 μm, 6 x 8 cm, 50 sheets 
2) Protran, 0.1 μm, 30 cm x 3 m 
NovaBlue Singles chemically 
competent cells 
Merck -80˚C 
Novex Tricine Gels Invitrogen RT or 4˚C 
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NuPAGE Novex Bis-Tris 
Gels 
Invitrogen RT or 4˚C 
   
PAD from rabbit skeletal 
muscle 
Sigma P1584 
-80˚C 
pGEM
®
-T Easy Vector 
System I 
Promega -20˚C 
pET-49b(+) DNA Novagen -20˚C 
pGEX-6P-3 vector DNA GE Healthcare -20˚C 
P. gingivalis genomic DNA 
from strain W83  
LGC Promochem #ATCC BAA-308D-5 
Lot Number 4726393 
Phusion High-Fidelity DNA 
Polymerase 
Finnzymes -20˚C 
 
Phusion Hot Start High-
Fidelity DNA Polymerase 
Finnzymes -20˚C 
 
PreScission Protease GE Healthcare -20˚C 
PVDF Membrane Invitrogen 0.2 μm 
RT 
   
RC DC Protein Assay Bio-Rad RT 
rLysozyme solution  Novagen -20˚C 
Rosetta Competent Cells Novagen -80˚C 
   
SacI NEB 20,000 U/ml (R0156S) 
SnakeSkin Pleated Dialysis 
Tubing 
Thermo Scientific 10,000 molecular weight cut off 
22 mm x 35 feet dry diameter 
Sodium chloride BDH/VWR RT 
Sodium dihydrogen 
orthophosphate 1-hydrate 
(NaH2PO4 . H20) 
BDH/VWR RT 
Sodium hydrogen sulfite 
(sodium bisulfite) 
Sigma RT 
StyI NEB 10,000 U/ml (R0500S) 
-20˚C 
Sucrose BDH/VWR RT 
Sulfasalazine VWR/Calbiochem 4˚C 
swine anti-rabbit 
immunoglobulins, HRP-
conjugated 
DAKO Dilution: 1:5000 
4˚C 
   
T4 DNA ligase NEB 400,000 U/ml (M0202S) 
-20˚C 
Talon Metal Affinity Resin Clontech 4°C 
Taq DNA Polymerase NEB 5,000 U/ml (M0273G) 
-20˚C 
Tergitol NP-40 Sigma-Aldrich 70% solution 
Tetracycline hydrochlorid VWR/AppliChem RT 
Thiosemicarbazide Fluka Store in poisons cabinet 
RT 
TMB KPL 4˚C 
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Tris-HCl (Trizma 
hydrochloride) 
Sigma Reagent grade 
RT 
Tryptone Fisher Scientific large granules 
RT 
   
Urea VWR/BDH AnalaR 
   
Quick Ligation kit NEB -20˚C 
QIAprep spin miniprep kit Qiagen RT 
QIAquick gel extraction kit Qiagen RT 
QIAquick PCR purification 
kit 
Qiagen RT 
   
Virkon Tablets Du Pont Rely+On 
RT 
   
X-Ray Film Fuji/GRI Ltd SuperRX, 100NIF, 18x24 
   
Yeast Extract Fisher Scientific RT 
  
 
Solutions and Buffers 
 
Common molecular biology solutions and buffers 
 
Tris-HCl, 1M 
To make 50 ml of a 1 M stock solution, 7.88 g Tris-HCl (157.60 g/mol) were dissolved in 
double deionised water, pH adjusted to the desired value (7.0-9.2), and filter-sterilised using a 
0.2 μm membrane. Store at RT or 4˚C. 
 
1x PBS 
1x PBS was made up from a commercially available 10x PBS stock by diluting the required 
volume with ddH2O. 
 
1x PBS-T 
1x PBS-T was made up from a commercially available 10x PBS stock by diluting the 
required volume with ddH2O and adding 500 μl Tween-20. Store at 4˚C. 
 
1x TBS 
50 mM Tris-HCl 
150 mM NaCl 
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For 1 L of 1x TBS, 7.88 g of Tris-HCl and 8.77 g of NaCl were combined in 800 mL ddH2O. 
pH was adjusted to 7.6 with HCl and volume was adjusted to 1L with ddH2O. 
 
1x TBS-T 
50 mM Tris-HCl 
150 mM NaCl 
0.05% Tween-20 
For 1 L of 1x TBS, 7.88 g of Tris-HCl and 8.77 g of NaCl were combined in 800 mL ddH2O. 
pH was adjusted to 7.6 with HCl and volume was adjusted to 1L with ddH2O. 500 μl Tween-
20 were added. Store at 4˚C. 
 
25x TAE 
For a 25x stock of TAE buffer, 242 g of Tris base were dissolved in 500 ml of ddH2O, 57.1 
ml of glacial acetic acid and 100 ml of 0.5 M EDTA (pH 8.0) were added and the volume 
was adjusted to 1 L with ddH2O. For electrophoresis, 1x TAE buffer was prepared by dilution 
in ddH2O. Store at RT. 
 
TE buffer 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA, pH 8.0 
For 50 ml TE buffer, 500 μl of 1 M Tris-HCl, pH 8.0, and 100 μl 0.5 M EDTA, pH 8.0 were 
added to 49.4 ml ddH2O. The solution was filter-sterilised and stored at RT. 
 
IPTG, 1M 
To make 100 ml of a 1 M stock solution, 23.8 g IPTG (238.3 g/mol) were dissolved in double 
deionised water, sterile-filtered using a 0.2 μm membrane and aliquoted à 1 ml. Store at -
20˚C. 
 
DTT, 1M 
To make 10 ml of a 1 M stock solution, 1.54 g DTT (154.25 g/mol) were dissolved in double 
deionised water, filter-sterilised using a 0.2 μm membrane and aliquoted à 0.5 ml. Store at -
20˚C. 
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EDTA, 0.5 M 
To make 100 ml, 18.61 g EDTA disodium salt were dissolved in 80 ml ddH2O and the pH 
adjusted to ~8.0 with sodium hydroxid, until the solution cleared. The final volume was 
adjusted to 100 ml with ddH2O. Store at RT. 
 
LB agar, Lennox 
For 250 mL of LB agar, sufficient for approximately 20 plates, 8 g of commercially available 
pre-mixed LB agar Lennox powder were dissolved in 250 mL ddH2O and autoclaved. 
Antibiotics were added after the solution was allowed to cool down to <50˚C. Ampicillin was 
used at 100 µg/mL,kanamycin at15 µg/mL and chloramphenicol was used at 34 µg/mL.  
 
LB broth, Miller 
For 1 L of LB broth, 20g of commercially available pre-mixed LB broth granules were 
dissolved in 1L ddH2O and autoclaved. Ampicillin was used at 100 µg/mL, kanamycin was 
used at 15 µg/mL and chloramphenicol was used at 34 µg/mL. 
 
6x DNA loading dye  
0.1% (w/v)  Bromophenol Blue   
40% (w/v) Sucrose 
For 10 ml, 10 mg bromophenol blue was added to 4 g sucrose and the volume adjusted to 10 
ml with double deionised water. Store at 4˚C. 
 
Sample buffer for SDS-PAGE 
4x LDS sample buffer and 2x Tricine sample buffer were purchased from Invitrogen and 
used according to the manufacturer‟s recommendations. 
 
 
Buffers for purification of GST-enolase (human and P. gingivalis) 
 
Lysis Buffer 
50 mM Tris-HCl, pH 7.6 
150 mM NaCl 
5 mM MgCl2 
25 U/mL Benzonase 
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1 kU/mL rLysozyme 
For 100 ml, mix 5 ml of a 1 M stock of Tris-HCl, pH 7.6, 15 ml of a 1 M stock of NaCl, and 
500 μl of a 1 M stock of MgCl2. Add 10 µl Benzonase (250 U/µl stock) and 3.3 µl 
rLysozyme (30 kU/µl stock). Add ddH2O to 100 ml and filter-sterilise. Store at 4˚C. 
 
Binding/Wash Buffer 
50 mM Tris-HCl, pH 7.6 
150 mM NaCl 
5 mM MgCl2 
For 100 ml, mix 5 ml of a 1 M stock of Tris-HCl, pH 7.6, 15 ml of a 1 M stock of NaCl, and 
500 μl of a 1 M stock of MgCl2. Add ddH2O to 100 ml and filter-sterilise. Store at 4˚C. 
 
Glutathione elution buffer 
50 mM Tris-HCl  
10 mM reduced Glutathione  
pH 8.0 
For 100 ml, dissolve 0.78 g Tris-HCl and 0.31 g reduced Glutathione in 80 ml ddH2O, set pH 
to 8.0 using sodium hydroxid, and adjust to a final volume of 100 ml with ddH2O. Filter-
sterilise and aliquot. Store at -20˚C. 
 
PreScission protease buffer 
50 mM Tris-HCl pH 7.6  
150 mM NaCl    
1 mM EDTA    
1 mM DTT    
For 50 ml, mix 2.5 ml of 1 M Tris-HCl, pH 7.6, 7.5 ml of 1 M NaCl, 100 μl of 0.5 M EDTA, 
and50 μl of 1 M DTT. Add ddH2O to 50 ml and filter-sterilise. 
 
Buffers for purification of GST-PPAD 
 
Lysis Buffer 
90% (v/v) BugBuster 
10% (v/v) Glycerol 
25 U/ml Benzonase 
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1 kU/ml rLysozyme 
For 100 mL, mix 90 mL BugBuster and 10 mL glycerol. Add 10 µl Benzonase (250 U/µl 
stock) and 3.3 µl rLysozyme (30 kU/µl stock). Add ddH2O to 100 ml. Store at 4ºC. 
 
Binding/Wash Buffer 
50 mM Tris-HCl, pH 7.6 
150 mM NaCl 
For 100 ml, mix 5 ml of a 1 M stock of Tris-HCl, pH 7.6 and 15 ml of a 1 M stock of NaCl. 
Add ddH2O to 100 ml and filter-sterilise. Store at 4˚C. 
 
Glutathione elution buffer 
see “Buffers for purification of GST-enolase” 
 
PreScission protease buffer 
see “Buffers for purification of GST-enolase” 
 
Buffers for purification of His-PPAD and Trx-His-PPAD 
 
Lysis Buffer 
see “Buffers for purification of GST-PPAD” 
 
Binding/Wash Buffer 
50 mM NaH2PO4 · H20  
300 mM NaCl    
10 mM Imidazole   
pH 8.0  
For 250 ml, dissolve 1.73 g NaH2PO4 · H20, 4.39 g NaCl and 0.17 g imidazole in 230 ml 
ddH2O, adjust pH to 8.0 using hydrochloric acid and add double deionised water to a final 
volume of 250 ml. Keep at 4˚C. 
 
Elution Buffer 
50 mM NaH2PO4 · H20  
300 mM NaCl     
250 mM imidazole    
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pH 7.0 
For 100 ml, dissolve 0.7 g NaH2PO4 . H20, 1.75 g NaCl and 1.7 g imidazole in 90 ml double 
deionised water, adjust pH to 7.0 using hydrochloric acid and add double deionised water to a 
final volume of 100 ml. Keep at 4˚C. 
 
HRV 3C protease buffer 
50 mM Tris-HCl pH 7.6  
150 mM NaCl      
For 50 ml, mix 2.5 ml of 1 M Tris-HCl, pH 7.6 and 7.5 ml of 1 M NaCl. Add ddH2O to 50 ml 
and filter-sterilise. 
 
50% Glutathione slurry (for purification of GST- and GST-His-proteins) 
The slurry is provided as 75% (v/v) slurry. The “bed volume” equals the volume of 100% 
(v/v) slurry. 1 ml bed volume holds 5-8 mg protein. The working concentration for pull-down 
of GST-tag proteins is 50% (v/v) slurry in binding/wash buffer. Typically, for a 3-L culture, 
0.5-1ml bed volume (=1-2 ml 50% slurry) was used. To make up 1 ml of 50% slurry, 0.665 
ml of 75% slurry were used. To make up the working solution of slurry, the bottle was 
inverted a few times and the required volume transferred to a 15-ml Falcon using a wide-bore 
tip (1-ml tip with the lower third cut off). Binding/wash buffer was added to the tube and the 
tube inverted a few times until the slurry was resuspended. The slurry was then allowed to set 
on the bench top (10-15 min) or centrifuged at 500 g for 5 min at RT. The supernatant was 
decanted and the wash repeated three times. After the final wash, the required volume of 
binding/wash buffer for a 50% slurry was added and kept on ice until use. Prolonged storage 
should be avoided due to microbial growth. 
 
50% Talon slurry (for purification of His- and Trx-His-proteins) 
Talon slurry is provided as 50% (v/v) slurry. 1 ml bed volume holds 5-8 mg protein. The 
working concentration for pull-down of His-tag proteins is 50% (v/v) slurry in binding/wash 
buffer. Based on the expected amount of target protein present in the cell lysate, the required 
volume of well resuspended slurry was transferred to a 15-ml Falcon using a wide-bore tip. 
To remove ethanol, the slurry was washed four times in binding/wash buffer as described 
above for glutathione slurry. 
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PPAD activity buffer (for P. gingivalis PAD) 
50 mM CHES, pH 9.5 
10 mM DTT 
For 100 ml, dissolve 1.04 g CHES in 90 ml double deionised water, adjust pH to 9.5 using 
sodium hydroxid and add double deionised water to a final volume of 100 ml. Keep at 4˚C. 
Add DTT to a final concentration of 10 mM from a 1M stock (1:100 dilution) just before use. 
 
2x PAD activity buffer (for rabbit PAD) 
200 mM Tris-HCl, pH 7.4 
20 mM CaCl2      
10 mM DTT 
For 100 ml, add 20 ml of a 1 M Tris-HCl, pH 7.4, stock solution to 80 ml double deionised 
water, dissolve 0.22 g CaCl2, add double deionised water to a final volume of 100 ml. Keep 
at 4˚C. Add DTT to a final concentration of 10 mM from a 1M stock (1:100 dilution) just 
before use. 
 
Reagents for colorimetric quantification of citrulline 
Colour developing reagent (CDR), the working reagent, is assembled from 1 volume of 
solution A and 3 volumes of solution B just before use. It should be stored at 4˚C in the dark 
for no more than 1 hour. 
Solution A 
80 mM 2,3-Butanedione oxime (DAMO) 
2 mM Thiosemicarbazide (TSC) 
For 200 ml, dissolve 1.62 g DAMO and 36 mg TSC in 200 ml of double deionised water and 
aliquot à 1-5 ml. Store at -20˚C. Keep at 4˚C for no more than 1 month. 
Solution B 
3 M 85% H3PO4 
6 M 96-98% H2SO4  
2 mM NH4Fe(SO4)2·12H2O (Ammonium ferric sulphate Dodecahydrate) 
For 200 ml, pour 90 ml double deionised water into a 250-mL glas bottle on ice, slowly add 
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40 ml H3PO4 under gentle stirring, then slowly add 66 ml H2SO4. Leave on ice for a few 
minutes to cool down and then dissolve 150 mg NH4Fe(SO4)2·12H2O. Upon cooling to RT, 
adjust volume to 250 mL with double deionised water. 
 
Buffers for ELISA analysis 
Coating buffer (50 mM carbonate buffer, pH 9.5) 
To make 1 L, combine 1.59 g Na2CO3, 2.93 g NaHCO3 and 2 ml of a 10% NaN3 stock. 
Adjust to 1 L with ddH2O. 
 
RIA buffer 
1% (w/v) BSA 
350 mM NaCl 
10 mM Tris-HCl (pH 7.6) 
1% (v/v) Triton X-100 
0.5% (w/v) Na-deoxycholate 
0.1% (W/v) SDS 
To make 1 L, combine 10g BSA, 20.4 g NaCl, 10 ml of 1 M Tris-HCl (pH 7.6), 10 ml Triton-
X-100, 5 g Na-deoxycholate, 10 ml of 10% SDS and ddH2O to 1L. 
 
DNA cloning and mutagenesis 
Primer synthesis and DNA sequencing 
DNA oligonucleotide primer synthesis and DNA sequencing was carried out by Eurofins 
MWG Operon (Ebersberg, Germany). The chosen purification procedure was HPSF (high 
purity salt free), unless otherwise stated. Primer melting temperatures (Tm, defined as the 
temperature at which half of all double-stranded DNA is present in a dissociated, single-
stranded form) were determined with according to modified Breslauer‟s thermodynamics 
(Breslauer et al. 1986). An online calculator using this algorithm can be found on the 
Finnzymes website
10
. Non-matching primer bases (restriction sites, mutations) were excluded 
from the Tm calculation. Lyophilised primers were reconstituted with TE buffer or ddH2O to 
a final concentration of 100 pmol/µL (=100 µM) and a small aliquot further diluted to give a 
                                                 
10
 https://www.finnzymes.fi/tm_determination.html 
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working concentration of 10 µM. Reconstituted primers were stored at -20°C. Repeated 
freeze-thaw cycles were avoided as this resulted in primer degradation and unsuccessful PCR 
reactions. 
Agarose gel electrophoresis 
Agarose gel electrophoresis was used for separation of DNA fragments. Typically, a 1% (w/v) 
agarose gel was prepared (separation range: 0.5 – 8 kb). The desired amount of agarose was 
added to 40-100 ml of water, depending on gel size, and heated in a glas bottle with the lid 
off in a microwave, until the agarose had fully melted. After cooling to a safe temperature for 
handling, ethidium bromide (final concentration: 0.5 μg/ml, from a 10 mg/ml stock) were 
added. The solution was then poured into a gel chamber, a plastic comb inserted, and left to 
solidify. The gel was then immersed in 1x TAE buffer in the gel chamber. DNA samples 
were mixed with 6x DNA loading dye and loaded into the gel wells, along with a suitable 
DNA ladder (Hyperladder I-V). The DNA was separated under constant voltage (80-130V, 
depending on gel size). 
 
Preparation of glycerol stocks 
For long-term storage of E. coli cells, 150 μl of autoclaved, sterile glycerol (100%) were 
added to 850 μl of a logarithmic-phase E.coli culture (OD600 0.6-0.8). The vial was then 
vortexed vigorously to ensure even mixing of the glycerol and the bacterial culture and frozen 
in liquid nitrogen for storage at -80˚C. A small scraping from the surface of the frozen cells 
was later used to inoculate liquid medium and the vial returned to the freezer immediately to 
maintain viability of bacteria. 
 
Quantification of DNA using NanoDrop 
To measure the DNA concentration in samples containing purified DNA in buffer, 1 µl of the 
sample was used on the Nano-Drop Spectrophotometer (ND-1000, Thermo Fisher Scientific) 
according to the manufacturer‟s instructions. The ratio of absorbance at 260 nm (proteins) 
and 280 nm (nucleic acids) was recorded and used as an indicator for the purity of the sample. 
A value around 1.8 is generally considered as „pure‟ for DNA. Lower values indicate protein 
contamination. 
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Polymerase chain reaction (PCR) 
PCR reactions were performed using Taq Polymerase, KOD Polymerase, Phusion High-
Fidelity Polymerase, or Phusion Hot Start High-Fidelity Polymerase, depending on amount of 
available template DNA and complexity of the amplification reaction. The reactions were set 
up according to the manufacturer‟s instructions. Parameters for individual reactions can be 
found in the respective sections. Thin-walled tubes and PCR thermal cyclers with heated lids 
were used for all reactions.  
 
Purification of PCR product reactions 
Following PCR, a small amount of the reaction product (1-5 µl) was analysed by agarose gel 
electrophoresis to assess the efficiency and specificity of amplification and confirm the size 
of the DNA product amplified. When only one product was present, the remaining volume 
was purified using the QIAquick PCR purification kit to remove DNA polymerase, primers, 
nucleotides, and salt. When more than one product was present, the complete reaction was 
loaded onto an agarose gel and, after electrophoresis, the desired product was cut out and gel-
purified using the QIAquick gel extraction kit. 
 
Restriction enzyme digestion of DNA 
In order to insert a gene of interest into vector DNA, all DNA was digested using appropriate 
restriction endonuclease enzymes, generating compatible ends on gene inserts and vector 
DNA. In a typical reaction, between 1 and 5 µg of insert and vector DNA were combined 
with 1 µl of each restriction enzyme, 10% (v/v) of supplied BSA solution, the supplied buffer, 
and ddH2O to 50 µl. Double digests were routinely perfomed, allowing directional insertion 
of the insert DNA. The reactions were mixed thoroughly and incubated at 37˚C for 3 hours. 
Vector DNA was also treated with Antarctic Phosphatase to remove the 5‟ phosphate group, 
thus preventing self-ligation. 5 units of Antarctic Phosphatase and 10x buffer (1/10 of the 
reaction volume) were added after 2.5 hr of the incubation period and the reaction then 
allowed to proceed at 37˚C for a further 30 min. The total reaction volume was then loaded 
onto an agarose gel and the desired DNA fragments gel-purified following electrophoresis.  
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Purification of DNA from agarose gels 
The desired DNA fragments were excised from the gel in a slice using a clean scalpel and 
purified using the QIAquick Gel Extraction Kit, following the manufacturer‟s instructions. 
DNA was eluted using 30 μl buffer EB or nuclease-free water. To evaluate the purification 
and estimate the DNA concentration for ligation, 2 μl of the eluted DNA was analysed on an 
agarose gel.  
 
Ligation of insert into linearised vector DNA 
Constructs were generated by the ligation of purified insert and linearised vector DNA. This 
was done using either NEB T4 Ligase pr NEB Quick Ligase, following the manufacturer‟s 
instructions. It was important to mix all buffers thoroughly prior to use. Typically, in a total 
reaction volume of 20 μl, 50 ng vector DNA was mixed with the insert DNA in a molar 
vector-to-insert ratio of 1:3. The amount of required insert DNA was calculated using the 
following formula: 
 
              
                            
            
                     
 
As a negative control, water instead of insert DNA was added. After careful mixing the 
reactions were incubated overnight at 16˚C (T4 ligase) or 10 min - 2 hours at RT (Quick 
Ligase). The ligation reactions were used immediately for transformation or stored at -20˚C. 
 
Ligation PCR 
In cases where ligation proved a challenging step and several conditions had to be tested, 
PCR was used to evaluate the ligation reaction. For this, 1 μl of a 1:10 dilution of the ligation 
reaction was mixed with 10 μl 5x Phusion HF buffer, 5 μl 2 mM dNTPs, 2.5 μl each of 10 
μM primers complementary to the vector DNA upstream and downstream of the insert, 0.5 μl 
Phusion High-Fidelity Polymerase and nuclease-free water to a total volume of 50 μl. The 
cycling conditions were adjusted to the particular template and primers and are specified in 
the relevant sections. The total volume of the PCR reaction was loaded onto an agarose gel. 
Successful ligation was indicated by the presence of a band corresponding to the expected 
combined size of insert and vector DNA located between the chosen primers and the absence 
of such band in the control ligation lacking insert DNA. 
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Transformation of competent E. coli cells with ligated DNA and evaluation 
Chemically competent E. coli cells (prepared in our laboratory or commercially available 
cells) were transformed with ligated DNA with the aim of selecting E. coli clones harbouring 
the final DNA construct. Pre-chilled 14-ml BD Falcon polypropylene round-bottom tubes 
were used thoughout the procedure. Typically, 1-2 μl of the ligation reaction was used to 
transform 20-100 μl of cells, depending on transformation efficiency of the cells.  
 
Specifically, the following protocols were employed: 
 
Self-prepared NovaBlue cells: 2 μl ligation reaction was mixed with 100 μl cells and 
incubated on ice for 30 min. Heat-shock was carried out at 42˚C for 45 seconds. Cells were 
recovered on ice for 2 min. 900 μl SOC was added and the mixture incubated at 37˚C and 
220 rpm for 1 hour. 100 μl were spread onto LB-agar plates containing the appropriate 
antibiotics for selection of cells containing the construct. 
 
Commercial NovaBlue: 1 μl ligation reaction was mixed with 20 μl cells and incubated on ice 
for 15 min. Heat-shock was carried out at 42˚C for 30 seconds. Cells were recovered on ice 
for 2 min. 80 μl SOC was added and the mixture incubated at 37˚C and 220 rpm for 1 hour. 
10 μl were spread in a pool of 90 μl LB medium onto LB-agar plates containing the 
appropriate antibiotics for selection of cells containing the construct. 
 
Commercial NEB 5-alpha F’Iq cells: 2 μl ligation reaction was mixed with 50 μl cells and 
incubated on ice for 30 min. Heat-shock was carried out at 42˚C for 30 seconds. Cells were 
recovered on ice for 5 min. 950 μl SOC was added and the mixture incubated at 37˚C and 
220 rpm for 1 hour. 100 μl were spread onto LB-agar plates containing the appropriate 
antibiotics for selection of cells containing the construct. 
 
The plates were incubated overnight at 37˚C. The next morning, plates were examined and 
the number of colonies was estimated and compared to the control plate (E. coli cells 
transformed with vector DNA alone).  
 
Confirmation of successful ligation by plasmid miniprep and analytical digestion 
4-12 single clones were picked and used to inoculate 5 ml of LB medium containing the 
appropriate antibiotics. Cultures were grown at 37˚C and 220 rpm overnight. Cells were then 
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harvested by centrifugation at 3000 g for 3 min at RT. The supernatant was discarded and the 
plasmid DNA isolated from the cells using the QIAprep Spin Miniprep Kit in accordance 
with the manufacturer‟s instructions. Purified plasmid DNA was eluted in 50 μl EB or 
nuclease-free water.  
 
To confirm correct ligation and transformation, an analytical digest was performed using 
restriction enzymes that would generate fragments of known size. To this end, 5 μl of 
miniprep DNA was mixed with 0.5 μl of each restriction enzyme and the appropriate buffer 
and incubated for 1 hour at 37˚C, in a total volume of 10 μl. The reaction was then loaded 
onto an agarose gel and the number and size of the generated DNA fragments was compared 
with the number and size of the hypothetical fragments for a successful ligation.  
 
To unambiguously verify the identity of the construct and exclude the occurrence of 
mutations, the constructs were sequenced by a commercial service using primers 
complementary to the vector DNA ~50 nucleotides upstream and downstream of the insert. 
 
An alternative method to confirm successful transformation of clones was colony PCR, as 
described in the protocol below. 
 
Confirmation of successful ligation by colony PCR 
PCR with primers complementary to the vector DNA upstream and downstream of the insert 
was performed directly with the colonies of transformed E. coli cells to determine which 
clones contain the insert. To do this, 4-12 colonies were picked from the plate using a sterile 
pipette tip, making sure to collect as many cells as possible, touched briefly onto a numbered 
grid on a fresh agar plate (to cultivate a reference colony for plasmid isolation later on), 
before transferring each colony to a tube containing 50 μl sterile water. The tube was 
vigorously vortexted and then placed in a heat block at ~99˚C for 5 min to lyse the cells and 
denature DNAse enzymes. The cell debris was pelleted at 12,000g for 2 min. 10 μl of the 
supernatant was transferred to a PCR tube and placed on ice. The remaining components 
were added to the PCR tube according to the recommendations for the DNA polymerase used, 
resulting in a total volume of 50 μl. As a positive control, 10 ng of uncut vector DNA was 
used instead of the cell lysates. The cycling conditions were adjusted to the primers and were 
in accordance with the recommendations for the DNA polymerase used. 
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After PCR, 15 μl were loaded onto an agarose gel. The presence of the desired construct 
DNA in a clone was indicated by the presence of a band corresponding to the expected 
combined size of insert and vector DNA located between the chosen primers. The positive 
clones were picked from the reference plate and used to inoculate 5 ml of LB medium 
containing the appropriate antibiotics. Cultures were grown at 37˚C and 220 rpm overnight. 
Cells were then harvested by centrifugation at 3000 g for 3 min at RT. The supernatant was 
discarded and the plasmid DNA isolated from the cells using the QIAprep Spin Miniprep Kit 
in accordance with the manufacturer‟s instructions. Purified plasmid DNA was eluted in 50 
μl EB or nuclease-free water.  
 
Transformation of competent E. coli cells with plasmid DNA 
In order to amplify previously generated constructs for maintainance and further experiments, 
chemically competent E. coli cells were transformed with plasmid DNA according to the 
protocols described above, except that 10 ng plasmid DNA were used (1 μl of a 10 ng/μl 
diluted in nuclease-free water). Plasmid DNA was isolated from overnight cultures using the 
QIAprep Spin Miniprep Kit as described above. 
 
Construction of recombinant expression vectors 
This section describes protocols and procedures specific for the respective constructs. If not 
otherwise mentioned, the standard procedures as described above were followed. All 
expression constructs and the encoded recombinant proteins generated in this study are listed 
in Table 2.1. 
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Table 2.1 Expression constructs generated in this study. Pg = Porphyromonas gingivalis  
Construct Vector Insert Restriction 
sites 
Fusion Protein 
(tag-linker-protein) 
Peno/pGex pGEX 6P-3 Pg enolase BamHI/XhoI GST-peno 
2
SILKI...NPLAK
434
 
PPAD/pET48 pET-48b(+) Pg PAD KpnI/SacI Thioredoxin-His-PPAD 
2
KKLLQ...MKILK
556
 
mPPAD/pET48 pET-48b(+) Pg PAD 
(truncated) 
KpnI/SacI Thioredoxin-His-mPPAD 
44
AFQET...MKILK
556
 
PPAD/pET47 pET-47b(+) Pg PAD KpnI/SacI His-PPAD 
2
KKLLQ...MKILK
556
 
PPAD/pET49 pET-49b(+) Pg PAD KpnI/SacI GST-His-PPAD 
2
KKLLQ...MKILK
556
 
D130A/pET48 pET-48b(+) Pg PAD with 
Asp-130 
replaced by 
Ala 
KpnI/SacI Thioredoxin-His-PPAD 
2
KKLLQ...
130A…MKILK556 
H236A/pET48 pET-48b(+) Pg PAD with 
His-236 
replaced by 
Ala 
KpnI/SacI Thioredoxin-His-PPAD 
2
KKLLQ...
238A…MKILK556 
D238A/pET48 pET-48b(+) Pg PAD with 
Asp-351 
replaced by 
Ala 
KpnI/SacI Thioredoxin-His-PPAD 
2
KKLLQ...
238A…MKILK556 
N297A/pET48 pET-48b(+) Pg PAD with 
Asn-297 
replaced by 
Ala 
KpnI/SacI Thioredoxin-His-PPAD 
2
KKLLQ...
297A…MKILK556 
C351A/pET48 pET-48b(+) Pg PAD with 
Cys-351 
replaced by 
Ala 
KpnI/SacI Thioredoxin-His-PPAD 
2
KKLLQ...
351A…MKILK556 
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P. gingivalis enolase in pGEX 6P-3 
 
Primer design and PCR 
P. gingivalis genomic DNA from strain W83 was purchased in a dried form and rehydrated 
overnight at 4˚C with deionised, autoclaved and sterile-filtered water, resulting in a final 
concentration of 0.1 g/l. Primers were designed to add a BamHI restriction site at the 5‟ 
end and a XhoI restriction site at the 3‟ end of the PCR amplified full-length nucleotide 
sequence (coding for residues 
2
SILKI...NPLAK
434
 of P. gingivalis enolase, referring to 
SwissProt entry Q7MTV8) for insertion into the pGEX 6P-3 expression vector, which 
contains a coding sequence for an amino-terminal GST tag. The expected PCR product size 
was 1.3 kilobases. 
 
 
Forward primer (pg-eno_for)  5’ AGTT-GGATCC-GAAATTGCAAAGATTATTGGCAG 
Tm 63C 
 
Reverse primer (pg-eno_rev)  5’ ATC-CTCGAG-TTACACTTTCTTGTAGCCGTATAC 
Tm 58C 
 
P. gingivalis enolase nucleotide sequence (GeneID: 2551984)
11
 
 
ATGGAAATTGCAAAGATTATTGGCAGGGAGATCCTCGATTCCAGAGGCAATCCGACGGTTGAGGTAGATGTACACCTGGCCTG
TGGCATAATAGGACGCGCGGCTGTACCCAGCGGAGCTTCCACCGGTGAGAATGAGGCTATCGAGCTTCGCGATCAGGATAAGG
CTCGCTACTGTGGCAAAGGTGTCCTCAAGGCTGTGAAGAACGTAAATGAAGTGATAGATCCCGCACTCTGCGGAATGTCTGTA
TTGGAACAAACAGCTATTGACCGCAAGCTCATCGAATTGGATGGCACCAAAACGAAAAGCAACCTCGGAGCAAATGCCATGCT
GGGCGTATCACTGGCCGTAGCCAAAGCAGCTGCAGCTTATTTGGATATTCCTCTCTACCGATATATCGGCGGTTCGAACACCT
ATGTCCTGCCTGTTCCTATGATGAATATCATCAACGGCGGTTCTCACTCGGACGCTCCTATCGCATTCCAGGAGTTCATGATC
CGCCCTGTGGGAGCATGCTGCTTCCGTGAGGGCTTGCGCATGGGTGCCGAAGTTTTCCATGCACTCAAAAAGGTGCTTCACGA
TCGTGGTCTGAGTACTGCAGTCGGGGATGAAGGAGGTTTTGCTCCTGCCCTGAATGGTACGGAAGATGCTATCGAATCAATCC
TCAAGGCTGTGGAAGCTGCCGGATACGTGCCCGGTAAGGATATTACCATCGCAATGGACTGCGCCTCTTCCGAGTTCTTCAAG
GATGGTATTTACGACTACACTAAGTTCGAAGGCGAAAAGGGCAAGAAACGCTCTATCGATGAGCAGGTGGCTTATCTGACCGA
ACTGGTTGGCAAGTATCCCATCGATTCTATCGAAGACGGTATGAGCGAAAATGACTGGGAAGGATGGAAGAAGCTGACCGTAG
CTTTGGGAGATAAGGTTCAGCTCGTCGGCGACGATCTCTTCGTTACCAACGTGGAATTCCTTCGCCGTGGTATCGCCGAGAAG
TGCGGCAACTCCATCCTTATCAAGGTAAACCAGATTGGTACGCTCACAGAGACCCTGAATGCCATCGAGATGGCACACCGTCA
CGGCTTTACCAGCGTTACTTCGCACCGCTCCGGAGAGACAGAAGACACCACTATCGCAGACATTGCTGTAGCAACCAACTCGG
GACAGATCAAGACGGGATCGCTCAGTCGTACCGACCGTATGGCTAAGTACAACCAACTGCTCCGCATCGAAGAGGAGTTAGGC
CCTTGCGCTGTATACGGCTACAAGAAAGTGTAA 
 
 
 
 
                                                 
11
 http://www.ncbi.nlm.nih.gov/gene/2551984 
BamHI 
XhoI 
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P. gingivalis enolase amino acid sequence (SwissProt: Q7MTV8)
12
 (ProteinID: 
AAQ66821.1)
13
 
 
MEIAKIIGREILDSRGNPTVEVDVHLACGIIGRAAVPSGASTGENEAIELRDQDKARYCGKGVLKAVKNVNEVIDPALCGMSV
LEQTAIDRKLIELDGTKTKSNLGANAMLGVSLAVAKAAAAYLDIPLYRYIGGSNTYVLPVPMMNIINGGSHSDAPIAFQEFMI
RPVGACCFREGLRMGAEVFHALKKVLHDRGLSTAVGDEGGFAPALNGTEDAIESILKAVEAAGYVPGKDITIAMDCASSEFFK
DGIYDYTKFEGEKGKKRSIDEQVAYLTELVGKYPIDSIEDGMSENDWEGWKKLTVALGDKVQLVGDDLFVTNVEFLRRGIAEK
CGNSILIKVNQIGTLTETLNAIEMAHRHGFTSVTSHRSGETEDTTIADIAVATNSGQIKTGSLSRTDRMAKYNQLLRIEEELG
PCAVYGYKKV 
 
  
PCR was performed in a total reaction volume of 50 l. The components were assembled on 
ice in this order: 10x NEB Taq Buffer (final concentration: 1x), ddH2O, 0.2 μM of each 
primer, 200 M of each deoxynucleotide (dATP, dGTP, dTTP, dCTP), 50 ng template DNA 
(1 g/ml final concentration), 2.5 U of NEB Taq Polymerase (50 U/ml final concentration). 
Three different annealing temperatures were used: 55˚C, 59˚C, and 65˚C.  
 
The cycling parameters were: 
1 x 94˚C for  2 min 
25 x   94˚C for  30 seconds 
  55/59/65 ˚C  1 minute 
  72˚C  2 minutes 
1 x 72˚C  5 minutes 
1 x 4˚C  ∞ 
 
Ligation of PCR product into pGEM
®
-T Easy Vector 
The purified PCR product was inserted via its single 5‟-A overhangs into a TA-vector 
(pGEM
®
-T Easy Vector) containing complementary single 3‟-T overhangs. In a total volume 
of 10 μl, 50 ng of the vector were mixed with 65 ng of the PCR product (desired molar ratio 
of vector:insert was 1:3), 3 U of the provided T4 ligase, 2x Rapid Ligation buffer (final 
concentration: 1x) and ddH2O to 10 μl. After careful mixing the reaction was incubated 
overnight at 4˚C. 
 
Transformation of competent E. coli cells with the enolase-pGEM construct 
4 μl of ligation mix was added to 100 μl chemically competent DH5α E. coli cells in pre-
chilled 14-ml Falcon round-bottom tubes. The tubes were incubated for 25 min on ice, then 
                                                 
12
 http://www.uniprot.org/uniprot/Q7MTV8 
13
 http://www.ncbi.nlm.nih.gov/protein/AAQ66821.1 
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for 45 seconds in a 42˚C waterbath, and again on ice for 2 min. 900 μl of LB medium was 
added and incubated for 1 hour at 37˚C in a shaking incubator at 220 rpm. 150 μl were then 
plated on LB-Ampicillin plates and incubated overnight at 37˚C. 
 
Isolation of plasmid DNA from transformed E. coli cells 
6 colonies were picked from the plate and used to inoculate 5 ml of LB-Ampicillin medium 
each. After overnight incubation at 37˚C, 220 rpm, plasmid DNA was isolated from the 
cultures using the QIAprep spin miniprep kit according to the manufactorer‟s instructions. 
 
Analytical restriction digest of isolated enolase-pGEM construct 
To confirm successful insertion of the enolase PCR product into the pGEM vector, a small-
scale restriction digest and subsequent agarose gel electrophoresis were performed. 5 μl of 
miniprep DNA was mixed with 1 μl NEB3 buffer, 1 μl BSA (final concentration: 1 μg/ml), 1 
μl NotI and 2 μl ddH2O, in a total volume of 10 μl. The reaction was incubated for 3 hours at 
37˚C. 2 μl 6x DNA sample buffer were added to the reaction and visualized on a 0.8% 
agarose gel with ethidium bromide. Positive clones were sequenced to confirm the correct 
nucleotide sequence and reading frame. Sequencing primers were standard T7 forward (5‟-
TAATACGACTCACTATAGGG) and SP6 reverse (5‟-CATTTAGGTGACACTATAG) 
primers. 
 
Subcloning into the pGEX-6P-3 expression vector 
1.5 μg of enolase-pGEM construct and 1.5 μg of pGEX-6P-3 DNA were digested separately 
with the restriction enzymes XhoI and BamHI according to the standard protocol described 
above.  
 
All further procedures leading to the generation of the final expression constructs were 
carried out according to the standard protocols described above. 
 
Constructs were sent for nucleotide sequencing using pGEX forward and reverse sequencing 
primers (standard primers provided by sequencing service; “pGex for”: 
ATAGCATGGCCTTTGCAGG and “pGex rev”: GAGCTGCATGTGTCAGAGG) to 
confirm correct amplification and insertion of the full-length enolase sequence.  
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Human α-enolase in pGEX 6P-3 
 
A pGEX-6P3 expression construct containing the full nucleotide sequence for human α-
enolase (GeneID: 2023)
14
, inserted between the BamHI and XhoI restriction sites, was 
constructed by Dr. Andrew Kinloch (The Kennedy Institute of Rheumatology) and the 
experimental procedures have been published (Kinloch et al. 2008) (co-authored paper in 
Appendix). 
 
Full and mature P. gingivalis PAD in pET-48b(+) 
 
Primer design and PCR 
Primers were designed to add a KpnI restriction site at the 5‟ end and a SacI restriction site at 
the 3‟ end of the PCR amplified full-length nucleotide sequence (coding for residues 
2
KKLLQ...MKILK
556
 of P. gingivalis PAD, referring to SwissProt entry Q9RQJ2), for 
insertion into the pET-48b(+) expression vector coding for an amino-terminal thioredoxin 
and His tag. The expected PCR product size was 1.7 kilobases. 
 
Forward primer (PAD_full_F):   
 
5’ CATATC-GGTACC-TGAAAAAGCTTTTACAGGCTAAAGCCTTGATTC 
Tm 72C  
 
Reverse primer (PAD_full_R):   
 
5’ TCAAATAA-GAGCTC-TTATTTGAGAATTTTCATTGTCTCACGGATTC 
Tm 70C 
 
For amplification of the hypothesised “mature” form of P. gingivalis PAD (residues 
44
AFQET...MKILK
556
), the following forward primer was used, along with the same reverse 
primer as above (PAD_full_R):  
 
Forward primer (PAD_mat_F):   5’ GAAGAGA-GGTACC-TGGCATTCCAGGAAACGAATC 
 Tm 70C 
 
                                                 
14
 http://www.ncbi.nlm.nih.gov/gene/2023 
KpnI 
SacI 
KpnI 
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P. gingivalis PAD nucleotide sequence (GeneID: 2552184)
15
 
 
ATGAAAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATCGCCCAAACGCAAATGCA
AGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGC
GTGCTATCGCTGAGTACGAACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAGCTG
GCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTTATAACCCAGTACACCCAAAGCGGTGT
GAATCTCTCTAATTGCGATTTCATCATTGCGAAAACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACG
ATACGAACAAAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAATACGAAGCACAA
TATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGCAACTACATGACGGACGGATATGGATCCGCTGTGCA
GTCACATATCGCATATACGGAGAACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC
ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAGTATTTGGCACCGAACAAAATC
CTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGC
ATGGGGAACGAAGTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAACAACAGGG
TATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACGTCTATAAGACGGCAATGCCCGGTTACGAAATT
ATAGGTGTCAAAGGGGCTTCAGGAACACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGG
CTATCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAAGCAGATGTCGTCTCATGCG
CCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATCAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAA
TCAACAGGTCACTATACTTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGACAATAG
TGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACGTGTATGAACGAAACCAATACATGTACTG
TGACCGGAGCTGCCAAAGCTCTTCGTGCATGGTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCC
GGCACATATCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTAGCAGGGACGAGTGT
CTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTGGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAA
TTCTCAAATAA 
 
P. gingivalis PAD amino acid sequence (Protein ID: NP_905579.1)
16
 (SwissProt: Q9RQJ2)
17
 
 
MKKLLQAKALILALGLFQLPAIAQTQMQADRTNGQFATEEMQRAFQETNPPAGPVRAIAEYERSAAVLVRYPFGIPMELIKEL
AKNDKVITIVASESQKNTVITQYTQSGVNLSNCDFIIAKTDSYWTRDYTGWFAMYDTNKVGLVDFIYNRPRPNDDEFPKYEAQ
YLGIEMFGMKLKQTGGNYMTDGYGSAVQSHIAYTENSSLSQAQVNQKMKDYLGITHHDVVQDPNGEYINHVDCWGKYLAPNKI
LIRKVPDNHPQHQALEDMAAYFAAQTCAWGTKYEVYRALATNEQPYTNSLILNNRVFVPVNGPASVDNDALNVYKTAMPGYEI
IGVKGASGTPWLGTDALHCRTHEVADKGYLYIKHYPILGEQAGPDYKIEADVVSCANATISPVQCYYRINGSGSFKAADMTME
STGHYTYSFTGLNKNDKVEYYISAADNSGRKETYPFIGEPDPFKFTCMNETNTCTVTGAAKALRAWFNAGRSELAVSVSLNIA
GTYRIKLYNTAGEEVAAMTKELVAGTSVFSMDVYSQAPGTYVLVVEGNGIRETMKILK 
 
PCR for both full-length and “mature” form was performed in a total reaction volume of 50 
l containing 50 ng W83 genomic template DNA (1 g/ml final concentration), 500 nM of 
each primer, 200 M of each dNTP, 1 unit Phusion High-Fidelity Polymerase (20 U/ml final 
concentration), 1x HF Buffer, 3% DMSO and deionised, autoclaved and sterile-filtered water 
to a total volume of 50 l.  
The cycling parameters were: 
1 x 98˚C 30 sec 
25 x   98˚C 10 seconds 
  58˚C 30 seconds 
  72˚C 60 seconds 
1 x 72˚C 5 minutes 
1 x 4˚C ∞ 
                                                 
15
 http://www.ncbi.nlm.nih.gov/gene/2552184 
16
 http://www.ncbi.nlm.nih.gov/protein/NP_905579.1 
17
 http://www.uniprot.org/uniprot/Q9RQJ2 
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Restriction digestion of PCR product and expression vector 
1 μg of pET-48b(+) vector, 2.3 μg of full-length PAD PCR poduct and 1.6 μg of “mature” 
PAD PCR poduct were digested separately with the restriction enzymes KpnI and SacI 
according to the following protocol: In a total volume of 50 μl, the DNA was mixed with 
NEB1 Buffer (final concentration 1x), BSA (final concentration 1x), 1 μl SacI (20 U), 1.5 μl 
KpnI (15U), and ddH2O to 50 μl. The reactions were incubated for 3 hours at 37˚C.  
 
Ligation 
The digested and purified PCR products were ligated between KpnI and SacI restriction sites 
of the digested pET48b(+) vector with a molar insert:vector ratio of 4 (75 ng vector, 91 ng 
full-length PPAD, 80 ng “mature” PPAD). NEB T4 ligase was used. The ligation mix was 
incubated overnight at 16C. 
 
Ligation PCR with T7 promoter (5‟-TAATACGACTCACTATAGGG) and T7 terminator 
primer (5‟-CTAGTTATTGCTCAGCGGT) was used to control for successful ligation prior 
to proceeding with transformation. Phusion High-Fidelity Polymerase in a total volume of 50 
l was used according to the manufacturer‟s instructions.  
 
The cycling parameters were: 
1 x 98˚C 30 sec 
30 x   98˚C 10 seconds 
  55˚C 30 seconds 
  72˚C 60 seconds 
1 x 72˚C 5 minutes 
1 x 4˚C ∞ 
 
The expected product size for full-length PPAD was 2.5 kb and 2.3 kb for “mature” PPAD. A 
lack of insert in a circular vector was expected to yield a band of 0.8 kb. 
 
Transformation, colony PCR, and analytical digest 
Supercompetent NEB 5-alpha F’Iq E. coli cells were used for transformation according to the 
standard protocol described above.  
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Colony PCR with T7 promoter (5‟-TAATACGACTCACTATAGGG) and T7 terminator 
primer (5‟-CTAGTTATTGCTCAGCGGT) was used to select clones containing the 
expression construct. All steps were performed as described for the standard protocol above. 
Phusion High-Fidelity Polymerase in a total volume of 40 l was used according to the 
manufacturer‟s instructions.  
The cycling parameters were: 
1 x 98˚C 30 sec 
35 x   98˚C 10 seconds 
  55˚C 30 seconds 
  72˚C 60 seconds 
1 x 72˚C 5 minutes 
1 x 4˚C ∞ 
 
Constructs were sent for nucleotide sequencing using a forward primer annealing ~ 50 bp 
upstream of the PPAD insert (5‟-TAACAATCCTCCTACTCCTAC) and a reverse primer 
annealing ~ 50 bp downstream of the PPAD insert (5‟-GTCCATGTGCTGGCGTTC). 
 
P. gingivalis PAD in pET-47b(+) 
 
The insert from the P. gingivalis PAD/pET-48b(+) construct was excised using restriction 
enzyme digestion with KpnI and SacI according to the standard protocol. The pET-47b(+) 
vector was linearised using the same enzymes. The purified insert and vector DNA was 
ligated using NEB T4 ligase in a molar vector-to-insert ration of 1:4. Supercompetent NEB 5-
alpha F’Iq E. coli cells were used for transformation. Colony PCR was performed as 
described for the pET48b(+) construct above. 
 
P. gingivalis PAD in pET-49b(+) 
 
The insert from the P. gingivalis PAD/pET-48b(+) construct was excised using restriction 
enzyme digestion with KpnI and SacI according to the standard protocol. The pET-49b(+) 
vector was linearised using the same enzymes. The purified insert and vector DNA was 
ligated using NEB Quick Ligase in a molar vector-to-insert ration of 1:4. Supercompetent 
NEB 5-alpha F’Iq E. coli cells were used for transformation.  
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Site-directed mutagenesis of P. gingivalis PAD 
Expression constructs encoding PPAD with single amino acid substitutions were created to 
assess the contribution of these amino acids to enzymatic activity. A list of the generated 
constructs is presented in Table 2.1. 
 
Site-directed mutagenesis was performed in four steps: 
 
1. PCR amplification: Point mutations were created by designing a mismatch in the forward 
primer. The reverse primer was designed to anneal back-to-back with its 5‟-end to the 5‟-end 
of the forward primer. A deletion was created by designing primers that border the deleted 
area on both sides with their 5‟-ends (Fig. 2.1). The PCR resulted in an amplified linear target 
plasmid. 
 
 
 
 
 
 
  
 
 
 
Figure 2.1 Schematic representation of primer annealing sites for point mutation 
and deletion. “F” and “R” stands for forward and reverse primer, respectively. “X” 
represents the mismatched nucleotide(s). The primers are drawn in the 5‟-3‟ direction. 
 
2. Ligation: The plasmid was re-circularised by ligation. 
 
3. Transformation: E.coli cells were transformed with the re-circularised plasmid. 
Background from the parent plasmid was expected to be low due to the exponential PCR 
amplification of the mutation/truncated plasmid. 
 
4. Sequencing: Successful mutagenesis was confirmed by DNA sequencing. 
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PCR amplification 
Ultra-pure primers (commercially purified by polyacrylamid gel electrophoresis, HYPUR-
grade from MWG Eurofins) with 5‟-phosphorylation, which is crucial for re-circularisation of 
plasmids in step 2, were used (Table 2.2). 
 
Table 2.2 Primers used for site-directed mutagenesis of PPAD. 
Mismatched nucleotides are underlined. Primers are written in the 5’-3’ direction. 
 
Construct Forward primer Reverse primer 
D130A/pET48 actggacacgcgcctataccggtt aagagtcagttttcgcaatgatgaaatc 
H236A/pET48 gcgaatatatcaacgccgtggactgttgg cgttcggatcttgtaccacatcatg 
D238A/pET48 caaccatgtggcctgttgggg atatattcgccgttcggatcttgtacc 
N297A/pET48 aacaaccgtacacggcctctctgattctg cattggtggccaaagcgc 
C351A/pET48 atgccctgcatgcccgtactcacgag ctgttcctaaccaaggtgttcctgaag 
 
PCR was performed using Phusion Hot Start High-Fidelity DNA Polymerase in a total 
volume of 50 μl, with HF buffer, 200 μM dNTPs, 0.5 μM of each primer, 1 ng template DNA 
(PPAD/pET48) and 0.5 μl Polymerase. 
 
A two-step PCR protocol was employed for all constructs except D238A/pET48, as it proved 
unsuccessful for this construct. The cycling parameters were: 
 
All except D238A/pET48:  D238A/pET48: 
 
1 x 98˚C 30 sec   1 x 98˚C 30 sec 
25 x   98˚C 10 seconds  25 x   98˚C 10 seconds 
  72˚C 3.5 minutes   66˚C 10 seconds 
1 x 72˚C 10 minutes   72˚C 3 minutes 
1 x 4˚C ∞   1 x 72˚C 10 minutes 
     1 x 4˚C ∞ 
 
5 μl of the PCR product were loaded onto an agarose gel to verify successful amplification 
and estimate the DNA concentration for ligation. The expected product size was 7305 bp. 
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Ligation 
25 ng PCR product were mixed with nuclease-free water to a final volume of 5 μl. 5 μl 2x 
NEB Quick Ligase buffer were added and mixed. 0.5 μl of NEB Quick Ligase was added, 
mixed thoroughly and incubated on the bench for 1 hour. 
 
Transformation 
20 μl super-competent NovaBlue cells and 1 μl of the ligation reaction were used according 
to the standard protocol as described above. Four colonies for each construct were picked and 
grown as described previously. Plasmid DNA was isolated as described previously. 
 
Sequencing 
Constructs were sent for nucleotide sequencing using a forward primer annealing ~ 50 bp 
upstream of the PPAD insert (5‟-TAACAATCCTCCTACTCCTAC) and a reverse primer 
annealing ~ 50 bp downstream of the PPAD insert (5‟-GTCCATGTGCTGGCGTTC). 
 
Construction of single kgp and double rgp/rgpB P. gingivalis mutants 
These mutants were a gift from Jan Potempa (Jagiellonian University, Krakow, Poland).  
The general procedure is described elsewhere (Simpsonv et al. 2004; Nguyen et al. 2007). 
Briefly, the 1-kb flanking regions surrounding the rgpA gene were amplified by PCR and 
ligated into the multiple cloning site in the pUC19 vector along with an intervening 
chloramphenicol resistance gene. A similar approach was used for rgpB, except that the final 
construct contained an erythromycin resistance cassette and a truncated version of the rgpB 
gene (Δ410, C-terminal 97 amino acids deleted, resulting in a complete loss of arginine-
specific protease activity). For the kgp mutant (deletional inactivation) a chloramphenicol 
resistance cassette was used. The resulting plasmids were electroporated into competent W83 
cells and mutants were selected on antibiotic selective media. Genetic integration via a 
double crossover event was confirmed by PCR using primers annealing outside the zone of 
integration. The absence of arg-specific proteolytic activity in the double rgpA rgpB mutant 
and lysine-specific proteolytic activity in the kgp mutant was confirmed using enzymatic 
assays (Simpsonv et al. 2004; Nguyen et al. 2007). 
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Construction of ppad P. gingivalis mutants 
These mutants were constructed in collaboration with Ky-Anh Nguyen (Institute of Dental 
Research, Westmead Centre for Oral Health, Sydney, Australia and Faculty of Dentistry, 
University of Sydney, Sydney, Australia).  
A 1-kb region 3′ to the P. gingivalis ppad gene (Genbank accession number 2552184; locus 
tag PG1424) was amplified by PCR (primers: 5‟-
GCTCTAGATGGAATCCGTGAGACAATG and 5‟-
TAAGCATGCGATATTTGTCGGAAGGACTC) for insertion into XbaI and SphI sites of 
the pUC19 plasmid (New England Biolabs Inc., USA). An erythromycin resistance cassette 
ermF/ermAM from plasmid pVA2198 was amplified and inserted it into SmaI and XbaI sites 
of the modified pUC19 plasmid. The resultant plasmid was modified further by incorporating 
(i) an amplified 1-kb region 5′ to the ppad gene (primers: 5‟-
AAGAGCTCAAGCACGTAATAAGGACAATGA and 5‟-
TTATCCCGGGTGTTCCTGAACATATGATAAGATCT) into SacI and SmaI sites to create 
the deletional inactivation plasmid construct (pΔppad) or (ii) the entire ppad gene and a 1-kb 
region 5′ to the gene (primers: 5‟-AAGAGCTCAAGCACGTAATAAGGACAATGA and 5‟-
TTATCCCGGGTGTCTACCTGAGGAGTATTCT) into SacI and SmaI sites to create the 
control mutant construct (pppad+) to control for possible polar effects. The correct placement 
and orientation of the DNA segments were confirmed by sequencing. The modified plasmid 
constructs were integrated into the P. gingivalis W83 or ATCC 33277 genome by a double 
crossover recombination event by electroporation using standard protocols (Nguyen et al. 
2007). Erythromycin-resistant clones were subcultured on selective plates and genomic 
integration confirmed by PCR, using primers from outside of the cloned regions surrounding 
the ppad gene. The absence of the ppad gene in the resulting P. gingivalis cultures was 
confirmed using PCR with purified genomic DNA from these strains and primers annealing 
to the 5‟ and 3‟ ends of full-length PPAD (expected product size: 1.7 kb). As a positive 
control, primers for the P. gingivalis 16S gene were used (expected product size: 0.4 kb). 
 
PPAD forward primer: 5‟ CATATCGGTACCTGAAAAAGCTTTTACAGGCTAAAGCCTTGATTC 
PPAD reverse primer: 5‟ TCAAATAAGAGCTCTTATTTGAGAATTTTCATTGTCTCACGGATTC 
 
P.g. 16S forward primer: 5‟ AGGCAGCTTGCCATACTGCG 
P.g. 16S reverse primer: 5‟ AGCGAAAACTGTTAGCAACTACCGATGT 
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PCR was performed using 50 ng template DNA and KOD polymerase according to the 
manufacturer‟s recommendations. Annealing temperature for both primer pairs was 60˚C. 
 
Expression and purification of recombinant proteins 
Small-scale protein expression and solubility testing 
The expression of the recombinant proteins encoded on the generated constructs was tested in 
a small scale first to determine whether the protein is expressed and whether it is expressed in 
a soluble form. Expression parameters (E. coli host strain, temperature, IPTG concentration, 
optical density at induction) were optimised if necessary. 
 
Transformation of E. coli expression hosts 
 
Transformation was performed according to these standard protocols:  
Self-prepared BL21 and BL21 (DE3) cells: 1 μl of a 10 ng/μl plasmid solution was mixed 
with 100 μl cells and incubated on ice for 30 min. Heat-shock was carried out at 42˚C for 45 
seconds. Cells were recovered on ice for 2 min. 900 μl SOC was added and the mixture 
incubated at 37˚C and 220 rpm for 1 hour. 100 μl were spread onto LB-agar plates containing 
the appropriate antibiotics for selection of cells containing the construct. 
 
Commercial BL21, BL21 (DE3) and BL21 (DE3) pLysS cells: 1 μl of a 10 ng/μl plasmid 
solution was mixed with 20 μl cells and incubated on ice for 15 min. Heat-shock was carried 
out at 42˚C for 30 seconds. Cells were recovered on ice for 2 min. 80 μl SOC was added and 
the mixture incubated at 37˚C and 220 rpm for 1 hour. 10 μl were spread in a pool of 90 μl 
LB medium onto LB-agar plates containing the appropriate antibiotics for selection of cells 
containing the construct. 
 
Commercial C41 (DE3), C41 (DE3) pLysS, C43 (DE3) and C43 (DE3) pLysS cells: 1 μl of a 
10 ng/μl plasmid solution was mixed with 20 μl cells and incubated on ice for 15 min. Heat-
shock was carried out at 42˚C for 45 seconds. Cells were recovered on ice for 2 min. 950 μl 
“Expression Recovery Medium” (provided with cells) was added and the mixture incubated 
at 37˚C and 220 rpm for 1 hour. 50 μl were spread onto YT-agar plates containing the 
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appropriate antibiotics for selection of cells containing the construct. 
 
A single colony was picked from the plate and used to inoculate 3-6 ml LB medium 
containing the appropriate antibiotic for overnight growth as described previously. 
 
Small-scale expression 
 
250-ml concial flasks containing 50 ml LB medium+antibiotic were used, with the lid 
loosened, to allow sufficient aeration. 250 μl of the overnight culture (dilution 1:200) were 
transferred to into the flask and the culture grown at 37˚C and 220 rpm. The OD600 was 
monitored regularly with a spectrophotometer, using plain LB medium as blank. Once an 
OD600 value of 0.6-0.8 was reached (~3.5 hours), protein expression was induced by the 
addition of IPTG and the incubation temperature was set to the required value. As controls, 
uninduced cells (no IPTG added) and cells transformed with an empty vector (+/- IPTG) were 
used. The cultures were incubated for 3-5 hours to allow for sufficient protein expression. 
250 μl of culture was centrifuged to harvest cells (8.000 rpm, tabletop centrifuge, 5 min, 4ºC) 
and the pellet resuspended in 25 μl lysis buffer (depending on protein to be expressed, see 
“Solutions and Buffers” and sonicated (Vibra-cell Sonicator, Sonics & Materials Inc) if 
required. The mix was rotated at RT for 10 min. 25 μl 4x LDS sample buffer was added, the 
sample heated to 70˚C for 10 min, centrifuged briefly and 10 μl per lane analysed on a SDS-
PAGE gel. Expression of recombinant protein was detected by the presence of a prominent 
band in the IPTG-induced extract but not in the uninduced control.   
 
Solubility testing 
 
To determine whether the recombinant protein detected in the whole cell extract, as described 
above, can be conveniently purified from the soluble cell extract fraction, the solubility of the 
recombinant protein had to be evaluated. To this end, 1 g (ca. 25 ml culture) of cell pellet 
from the induced culture was resuspended in 5 ml lysis buffer and incubated on a rotary 
mixer for 20 min at RT or 4˚C, depending on protein. The mix was then sonicated, if required. 
The insoluble fraction was separated from the soluble fraction by centrifugation (16.000g, 20 
min, 4˚C or RT). The supernatant was defined as the soluble fraction. The pellet was 
resuspended in 5 ml ice-cold denaturing lysis buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 
M urea, pH 8.0) and rotated at RT for 20 min. The sample was then centrifuged (16.000g, 20 
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min, RT) and the resulting supernatant defined as the insoluble fraction, whereby “insoluble” 
refers to solubility in native buffers. 7.5 μl of each fraction were analysed on a SDS-PAGE 
gel. As the recombinant protein present in the soluble fraction typically is not as concentrated 
as in the total cell extract or insoluble fraction, immunoblotting was used to confirm presence 
of the recombinant protein. 
 
Variation of parameters affecting expression and solubility of recombinant proteins 
 
In cases were proteins were expressed for the first time and without previous references, such 
as all PPAD proteins, several E. coli strains were tested as host strains. These included BL21, 
BL21 (DE3), BL21 (DE3) pLysS, C41 (DE3), C41 (DE3) pLysS, C43 (DE3), C43 (DE3) 
pLysS. Once a suitable strain was found, factors resulting in maximum soluble protein yield 
were investigated, including expression temperature (25-30˚C), expression time (1-24 hours), 
IPTG concentration (0.1 - 1 mM) and optical density at induction (OD600 =  0.6 - 1.0). as a 
starting point, for pGEX vectors BL21 cells were used as hosts, with induction at OD 0.6-0.8 
with 0.1 mM IPTG, expression at 28˚C for 5 hours. For pET vectors, BL21 (DE3) cells were 
used, with induction at OD 0.6-0.8 with 1 mM IPTG and expression at 30˚C for 5 hours. 
When the optimal or sufficient levels of soluble protein yield were achieved, the recombinant 
protein was expressed in large-scale cultures and purified for further studies. 
 
Large-scale protein expression 
A single colony harbouring the construct of interest or a scraping from a glycerol stock of the 
expression transformed with the construct of interest was used to inoculate 6 ml of LB 
medium containing the appropriate antibiotic. Overnight cultures were grown at 37˚C, 220 
rpm. The following morning, 500 ml LB medium + antibiotic, in a 2-L conical flask, were 
inoculated with 1 ml overnight culture. Typically, a total of 3 L (6x500 ml) was cultured. The 
optical density (OD600) of the cultures was monitored regularly. Once an OD600 value of 0.6-
0.8 was reached, protein expression was induced by the addition of IPTG and the incubation 
temperature was set to the required value for a further 5 hours (see Table 2.3). 
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Table 2.3 Expression parameters for large-scale protein expression 
E. coli host strains, induction temperature and IPTG concentration used for successful 
expression of recombinant proteins are listed for each construct. All cultures were induced at 
OD600 0.6-0.8 and expressed for 5 hours.”Heno/pGEX” stands for human α-enolase in pGEX 
6P-3. 
 
Construct E. coli host Induction 
Temperature (˚C) 
IPTG concentration 
for induction (mM) 
Peno/pGex BL21 28 0.1 
Heno/pGex Rosetta 28 0.1 
PPAD/pET48 BL21 (DE3) 30 1 
mPPAD/pET48 BL21 (DE3) 30 1 
PPAD/pET47 BL21 (DE3) 30 1 
PPAD/pET49 BL21 (DE3) 30 1 
D130A/pET48 BL21 (DE3) 30 1 
H236A/pET48 BL21 (DE3) 30 1 
D238A/pET48 BL21 (DE3) 30 1 
N297A/pET48 BL21 (DE3) 30 1 
C351A/pET48 BL21 (DE3) 30 1 
 
The cultures were then transferred to 500-ml centrifuge tubes (Corning Inc.) and centrifuged 
at 2500 g for 10 min at RT. The supernatants were discarded and the pellets weighted. The 
pellets were resuspended in 5 ml lysis buffer per g pellet. For recombinant enolase, this was 
followed by sonication according to the manufacturer‟s recommendations. For all PPAD 
proteins, the lysates was simply rotated at RT for 30 min. A 20-μl sample was taken as the 
“total cell extract (TCE)”. The remaining sample was then centrifuged (Sorvall Evolution RC, 
SA600 rotor) at 16000g, 20 min, 4˚C (enolase) or RT (PPAD). The supernatant was filtered 
using a 50-ml syringe and 0.45 μm filter. A 20-μl sample was taken as the “soluble cell 
extract (SCE)”. The recombinant protein was then purified from the filtered supernatant using 
a resin pull-down approach, in which the resin specifically captures the tag present in the 
recombinant protein.  
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Pull-down 
For His- and Thioredoxin-His-tagged proteins Talon metal affinity resin was used, and for 
GST- and GST-His-tagged proteins Glutathione Sepharose 4B resin was used. Preparation of 
the resins prior to use and the required buffers are described in the section “Solutions and 
Buffers”. 
 
The required amount of resin was added to the filtered extract and rotated for 30 min at RT to 
allow the recombinant protein to bind to the resin. The mix was then transferred to 10-ml 
Pierce centrifuge disposable columns with the end cap on and the resin allowed to settle. The 
end cap was removed and the flow-through collected. The resin was then washed 6 x 10 min 
with 10 ml binding/wash buffer. To elute, 1 bed volume (the volume equivalent to 100% 
resin) of elution buffer was added, incubated for 5 min at RT, and the flow though collected 
as eluate fraction 1. This was repeated to a total of 6 times, resltung in eluate fractions 2-6. 
 
In cases were this procedure was carried out for the first time, all collected fractions (total 
cell extract, soluble cell extract, flow-though, washes (all 5 μl), eluates (2.5 μl) were analysed 
on a SDS-PAGE gel. For established protocols, flow-though and washes were not analysed. 
 
Tag cleavage 
All expression vectors harboured a cleavage site recognised by the HRV 3C protease, 
resulting in enzymatic cleavage of amino-terminal tag(s). For His- and Thioredoxin-His-
tagged proteins His-tagged “HRV 3C protease” from Novagen was used. For GST- and GST-
His-tagged proteins GST-tagged “PreScission protease” was used. Both recombinant 
enzymes recognise the same cleavage site but differ in the tag they are coupled to, allowing 
their pull-down along with uncleaved protein and fragment. All required buffers are 
described in the section “Solutions and Buffers”. 
 
On-column cleavage with PreScission protease was used for all enolase constructs. Here, the 
protein was not eluted from the resin. Instead, after the last wash step, the resin was 
equilibrated in 10 ml PreScission protease buffer. Then, the PreScission protease mix was 
prepared by mixing 80 μl (160 U) of PreScission protease and 920 μl of PreScission protease 
buffer for each ml of resin bed volume. PreScission Protease buffer was drained from the 
column and the mix added to the resin. The column was sealed and incubated overnight at 
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4˚C on a rotary device. Following incubation, the cleaved protein was eluted in the flow 
through. To maximise yield, the column was eluted a total of 6 times with 1 bed volume 
PreScission protease buffer and the cleaved protein collected in the eluate. 
 
Cleavage in solution was used for all PPAD constructs, as tag cleavage proved inefficient and 
on-column cleavage further educes efficiency. The eluted protein was dialysed into HRV 3C 
protease buffer. The dialyed protein was mixed with 200 U (100 μl) HRV 3C protease per mg 
protein in 1 mM DTT, 1 mM EDTA, 0.1% Triton X-100 and HRV-3C buffer to 2.5 ml. The 
mix was incubated at 4˚C overnight on a rotary device. To remove the His-tagged protease, 
his-tagged cleavage products and uncleaved protein, 500 μl of 50% Talon resin in HRV 3C 
buffer was added to the mix and incubated for 20 min at RT. The mix was then transferred to 
a 2-ml Pierce centrifuge disposable column. The column was placed into a 14-ml Falcon tube 
and the cleaved protein was collected by centrifugation at 1000g for 1 min at RT. To increase 
yield, the original volume of HRC 3C buffer (2.5 ml per mg protein) was added to the resin, 
mixed, and the flow-though collected as described. To recover all bound proteins and 
fragments, the same volume of imidazole-containing elution buffer (see “Solutions and 
Buffers”) was added to the resin, mixed, and recovered by centrifugation as described.  
 
Size exclusion chromatography  
Size exclusion chromatography was used as a final purification step for Thioredoxin-His-
PPAD for subsequent enzymatic analysis and inhibitor studies. A Sephacryl 200 (XK 16/100 
200 cm
3
) column (Pharmacia/GE Healthcare) was used coupled to an ÄKTA FPLC P-920 
system with an UPC-900 UV monitor and an Frac-950 fraction collector. Unicorn 3.20 
software was used. The storage buffer was washed out with deionised water and the column 
then equilibrated in PBS. The concentrated protein sample (500 μl at 2 mg/ml) was loaded 
directly onto the column using a syringe. The proteins were then eluted with 200 ml of PBS 
at 0.5 ml/min (linear flow rate: 15 cm/hour) and a maximum pressure of 0.5 mPa. 1-ml 
fractions were collected. All steps were performed at RT. UV (280 nm) was plotted against 
elution volume. The fractions corresponding to peaks were analysed by SDS-PAGE (10-20 μl 
per 1-ml fraction) and the presence of PPAD activity was assessed by an enzymatic activity 
assay (30 μl per 1-ml fraction) using BAEE as substrate. The fractions of interest were then 
concentrated and the protein concentration was determined using the BCA assay. 
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Protein analysis 
Calculation of theoretical protein parameters 
Protein parameters such as theoretical molecular weight, amino acid composition and 
extinction coefficient at 280 nm were determined using the Protparam tool at the Expasy 
Server (http://www.expasy.ch/tools/protparam.html). 
 
Determination of protein concentration 
Samples free of interfering substances (reducing agents, detergents) either Bradford 
Coomassie Plus Reagent was used, according to the standard microplate protocol, or the BCA 
Protein Assay Kit, according to the microplate procedure. For samples containing detergents, 
the BCA Protein Assay Kit was used. For samples containing reducing agents, the Bradford 
Coomassie Plus Reagent was used. For samples containing both detergents and reducing 
agents the RC DC Protein Assay was used. Standard curves were prepared with BSA 
following each of the manufacturer‟s instructions. 
 
Concentration of protein samples 
Proteins were concentrated using Vivaspin columns (GE Healthcare). The cut-off and column 
size was chosen according to the protein of interest and the sample volume. A 3 K cut-off 
was used to concentrate the Thioredoxin-His tag and whole bacterial lysates. A 10 K cut-off 
was used for all enolase proteins. A 30 K cut-off was used for all full-length PPAD proteins. 
All steps were performed according to the manufacturer‟s instructions. 
 
Dialysis 
Proteins were dialysed using either 3-ml Slide-A-Lyzer Dialysis cassettes, 10 K MWCO or, 
for larger volumes, SnakeSkin Pleated Dialysis Tubing, 10 K MWCO (both from Pierce). 
Typically, dialysis was performed in 3 changes of buffer with least 100x sample volume for 2 
hours at RT and 1 change of buffer with at least 500x sample volume overnight at 4˚C. 
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In vitro citrullination of recombinant proteins 
Citrullinated proteins were often required as a positive control in analysis of protein 
citrullination of unknown samples (for example in P. gingivalis cell lysates). To generate 
citrullinated proteins in vitro, equal volumes of recombinant protein and 2x PAD buffer (200 
mM Tris-HCl, pH 7.6, 20 mM CaCl2, 10 mM DTT) were mixed and incubated with rabbit 
skeletal PAD at a concentration of 8.75 U per mg substrate protein, for 3 hours, at 37C. 
Citrullination was terminated by the addition of EDTA (final concentration 10 mM). As a 
control reaction, deionised water instead of PAD was added. All samples were stored at -
20°C until further use.  
 
SDS-Polyacrylamide gelectrophoresis (SDS-PAGE) 
Pre-casted minigels (Invitrogen) were used for all PAGE applications. 4-12% or 12% 
NuPAGE Bis-Tris gels, with 10, 12, or 15 wells per gel, were used for resolution of standard 
protein samples (20-200 kDa), together with 4x LDS sample buffer, 20x MOPS running 
buffer (all from Invitrogen). 10-20% Novex Tricine gels, with 10 wells per gel, were used for 
resolution of peptide samples (2.5-50 kDa), together with 2x Tricine sample buffer and 10x 
Tricine running buffer. The sample buffers do not contain reducing agents; therefore, DTT 
was added to a final concentration of 50 mM to all samples just before use. Samples for Bis-
Tris gels were heated at 70°C for 10 min, samples for Tricine gels were heated at 85°C for 3 
min. When handling cell lysates of P. gingivalis and other oral bacteria, the samples were 
heated in non-reducing sample buffer, allowed to cool down on ice for 2 min, before adding 
DTT to a final concentration of 50 mM. This procedure was found to minimise protease 
activation and protein degradation. Bis-Tris gels were resolved at 180 V, Tricine gels were 
resolved at 80V. Protein molecular mass markers were Full-range rainbow molecular weight 
markers or low-range rainbow molecular weight markers. 
 
Immunoblotting analysis 
After electrophoresis, membranes were assembled in a sandwich using the XCell Sure Lock 
(Invitrogen) module, according to the manufacturer‟s instructions. Nitrocellulose membranes, 
pre-soaked in transfer buffer, were routinely used. The transfer buffer (1 L) was composed of 
50 ml NuPAGE 20x transfer buffer (Invitrogen), 750 ml deionised water and 200 ml 
methanol. The transfers were performed either for 2 hours at 30 V, RT or overnight at 12 V, 
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4˚C. After transfer, membranes were transferred to platic containers and blocked in 5% (w/v) 
non-fat dried milk in TBS-T or PBS-T for 2 hours at RT or overnight at 4˚C, under constant 
agitation. The primary antibody was diluted in TBS-T or PBS-T (details for the individual 
antibodies can be found in the “List of Materials and Reagents”). The blocking milk was 
discarded and the diluted primary antibody added to the membrane and incubated for 1 hour 
at RT or overnight at 4˚C. The membrane was then thoroughly washed (1x 15 min then 3x 5 
min, RT, agitation) with TBS-T or PBS-T. The secondary HRP-conjugated antibody was 
diluted in in TBS-T or PBS-T, added to the membrane and incubated for 1 hour at RT. The 
membrane was again thoroughly washed (1 x 15 min then 3 x 5 min, RT, agitation) with 
TBS-T or PBS-T. The bound secondary antibody was detected using ECL or ECL Plus (3 ml 
per minigel membrane) according to the manufacturer‟s instructions.  
 
Experimental details for detection of individual proteins: 
 
His-tagged proteins 
Non-fat dried milk was used at 10%. Mouse anti-his antibody was diluted at 1:1000. Proteins 
were detected using HRP-conjugated goat anti-mouse IgG, diluted 1:5000. Membranes were 
developed using the ECL. 
 
Citrullinated proteins 
Citrullinated proteins were detected using the anti-citrulline (modified) detection kit in 
accordance with the manufacturer's instructions. Briefly, after electrophoresis and transfer of 
proteins onto nitrocellulose membranes, membranes were incubated in 3 ml solution A (25% 
v/v H2SO4, 20% v/v H3PO4, 0.025% w/v FeCl3) mixed with 3 ml solution B (0.5% w/v 2,3-
butanedione monoxime, 0.25% w/v antipyrine, 0.5 M acetic acid) at 37°C for 7 hours. This 
step modifies the guanidino group of the citrulline side-chain into a pyrimidine ring 
derivative. The membranes were then processed in a standard immunoblotting procedure. 
Non-fat dried milk was used at 5%. Rabbit anti-citrulline (modified) antibody was diluted at 
1:1000 and incubated overnight at 4˚C. Proteins were detected using HRP-conjugated goat 
anti-rabbit IgG, diluted 1:5000. Membranes were developed using the ECL Plus. Controls 
were performed in which the modification step or the primary antibody were omitted, to 
control for non-specific binding by the primary antibody to structures other than modified 
citrulline side chains, or binding of the secondary antibody to proteins other than the primary 
antibody, respectively. For the modification control, membranes were incubated in 3 ml 
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solution A and 3 ml 0.5 M acetic acid, resulting in a mix lacking the guanidino-group 
modifying chemicals. 
 
Fibrinogen 
Non-fat dried milk was used at 5%. Membranes were incubated with a mixture of three anti-
fibrinogen antibodies (goat anti-fibrinogen α, anti-fibrinogen β, anti-fibrinogen γ; each 
diluted 1:500). Proteins were detected using HRP-conjugated donkey anti-goat antibody, 
diluted 1:3000. Membranes were developed using ECL Plus. 
 
PPAD 
Non-fat dried milk was used at 5%. Rabbit anti-PPAD antibody (TEA eluate) was diluted at 
1:500 (cell lysates) or 1:1000 (recombinant protein). Proteins were detected using HRP-
conjugated swine anti-rabbit Ig, diluted 1:5000. Membranes were developed using the ECL 
Plus. 
 
CEP-1 
Non-fat dried milk was used at 5%. Rabbit anti-CEP-1 antibody was diluted at 1:200. 
Proteins were detected using HRP-conjugated goat anti-rabbit IgG, diluted 1:2000. 
Membranes were developed using the ECL Plus. 
 
Dotblot analysis  
For dot blotting, 10 μL of protein sample was spotted directly onto an nitrocellulose 
membrane equilibrated in transfer buffer. The sample was allowed to dry before proceeding 
with the standard immunoblotting protocol as outlines above (starting with the blocking step).  
 
Protein visualisation 
 
Coomassie 
InstantBlue reagent, a ready-made, non-toxic Coomassie-based stain, was used for staining of 
protein bands on polyacrylamide gels. The bottle was inverted a few times, and 10 ml 
solution per gel were added to a plastic dish containing the gel and stained with gentle 
agitation at RT until the protein bands reached the desired intensity (15-60 min). To reduce 
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background staining, the gel was then washed in ddH2O two to three times for 15 min each. 
 
Silver staining 
Silver staining was used for polyacrylamide gels when a lower detection limit was required 
(5-10 ng/band). The following solutions were made up as stock solutions: A) 50% (v/v) 
methanol, 5% (v/v) acetic acid; B) 50% (v/v) methanol; C) 0.02% (w/v) sodium thiosulfate 
pentahydrate (Na2S2O3 · 5H20); F) 5% (v/v) acetic acid. The following solutions were made 
up fresh (50 ml/gel): D) 0.2% (w/v) silver nitrate (AgNO3), 50 ml/gel, avoid exposure to light; 
E) 2% (w/v) sodium carbonate (Na2CO3), add 0.05 % (v/v) formaldehyde (37%) just before 
use, 150 ml/gel. The plastic dish to be used for staining was cleaned thoroughly with washing 
up liquid and then rinsed with methanol. It was important to avoid touching the gel or any 
materials without gloves as this leaves marks on the gel. Instead, forceps with flat ends were 
used for handling the gel. All steps were carried out with gentle agitation at RT, unless stated 
otherwise. The protein bands were fixed in A for at least 30 min. The gel was washed in B for 
30 min, and then three times in ddH2O for 10 min each. The gel was sensitised in C for 1 min, 
washed in ddH2O twice for 1 min each, and then stained in D for 20 min, at 4°C in the dark. 
The gel was washed in ddH2O twice for 1 min each. Protein bands were developed in E. It 
was important to discard solution E after it turned yellow (1-5 min) and add fresh solution E. 
When the bands had reached the desired intensity, the reaction was stopped with addition of F 
for 10 min. Finally, the gel was washed in ddH2O for 15 min. 
 
Ponceau S staining 
Ponceau S staining was used to reversibly stain protein bands on nitrocellulose membranes 
after transfer. 0.1% (w/v) Ponceau S in 5% acetic acid was used. The membrane was 
incubated for 1-5 minutes in the solution until the bands became visible. The stain was 
removed by washing the membrane in deionised water with frequent changes.  
 
Growth and preparation of oral bacterial strains 
P. gingivalis and other oral bacteria cultures 
Porphyromonas gingivalis wild-type strains (W83, W50, ATCC 33277), P. gingivalis clinical 
isolates (MaRL, D243, JH16, J430), obtained from patients with severe periodontitis, and P. 
gingivalis mutants (Δppad, ppad+, Δrgp, Δkgp, Δrgp+kgp) were grown in Schaedler 
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anaerobe broth (Oxoid, UK), supplemented with 5% sheep blood, at 37C in an anaerobic 
chamber (90% N2, 5% CO2, 5% H2). Erythromycin or tetracycline was used at 5 g/mL or 1 
μg/mL, respectively, on solid media. The concentrations were doubled for selective growth in 
liquid culture. Other anaerobic oral bacteria (Prevotella intermedia H13 (clinical isolate), 
Prevotella oralis ATCC 33269, Capnocytophaga gingivalis ATCC 33624, Capnocytophaga 
ochracea ATCC 27872) were grown in Schaedler anaerobe broth, supplemented with 2.5 
g/L vitamin K, at 37C in an anaerobic chamber (90% N2, 5% CO2, 5% H2). Fusobacterium 
nucleatum ATCC 10953 was grown in Schaedler anaerobe broth in an anaerobic chamber 
with 80% N2, 10% CO2 and 10% H2 at 37
o
C. Aggregatibacter actinomycetemcomitans ATCC 
43718 was grown in Tryptic soy broth (Sigma, UK), supplemented with 6% yeast extract and 
8% glucose, in 5% CO2 at 37
o
C. Aerobic bacteria (Streptococcus constellatus ATCC 27823, 
Streptococcus gordonii ATCC 10558, Streptococcus sanguinis ATCC 10556, Streptococcus 
salivarius ATCC 7073) were grown on Columbia agar plates, supplemented with 8% 
defibrinated sheep blood or brain heart infusion broth.  
 
Preparation of bacterial whole protein extracts 
All oral bacterial extracts were kindly provided by Aneta Sroka from Jagiellonian University 
Krakow, Poland, Dr. Sigrun Eick from Bern University, Switzerland, and Shauna Culshaw 
from Glasgow University, UK.  
Bacterial cultures were grown in liquid media until early stationary phase (24 hours). Twenty 
mL of culture was centrifuged at 10,000 × g for 15 min at 4°C. The resulting bacterial pellet 
was resuspended in phosphate buffered saline (PBS) and the optical density (at 600 nm) was 
measured and adjusted to 1.0 with PBS. Samples were sonicated on ice for 5 min (5 sec on – 
10 sec off). Sodium azide (final concentration 0.02% v/v) was added to all samples as 
preservative. 
 
Cellular compartment fractionation of P. gingivalis 
The procedure was adapted from published protocols (Filip et al. 1973; Parker et al. 1993). 
15 ml of P. gingivalis W83 culture was grown as described and the OD600 adjusted to 1.5. 15 
ml of the adjusted culture were centrifuged at 4,500 x g for 30 min at 4˚C. 1 ml of 
supernatant was collected as the “vesicle” fraction. A further 5 ml of the supernatant were 
ultracentrifuged at 150,000 x g for 1 hour at 4˚C and 1 ml of the supernatant was collected as 
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the “medium” sample. The cell pellet was washed once with 15 ml PBS at 4˚C by 
resuspension and centrifugation (4,500 x g, 15 min, 4˚C). 
 
From here on, two similar but not identical protocols were used by different people (myself 
and Yonghua Gho) in different laboratories (Krakow University and Louisville University). 
 
Protocol used for analysis of the subcellular localization of citrullinated proteins (samples 
prepared by myself) 
 
The resulting pellet was resuspended in 5 ml 0.25 M sucrose, 30 mM Tris, pH 7.6. Cells were 
left mixing gently for 15 min at 4˚C, and then pelleted at 12,500 x g for 15 min at 4˚C. The 
pellet was rapidly resuspended in 5 ml ice-cold deionised water. Cells were left mixing gently 
for 15 min at 4˚C. The suspension was then centrifuged at 12,500 x g for 15 min at 4˚C and 
the supernatant was designated the “periplasmic” sample. The remaining spheroblasts were 
washed once with 5 ml PBS, centrifuged at 10,000 x g for 15 min at 4˚C and the pellet was 
resuspended in 5 ml PBS and sonicated (10 times 5 sec pulses with 2 sec rest between each 
pulse) in an ice-water bath. Cellular debris and membranes were pelleted by 
ultracentrifugation at 150,000 x g for 1 hour at 4˚C. The supernatant was designated the 
“cytoplasm” sample. The pellet was washed once with 20 ml PBS and then dispersed by first 
scraping with the sonication tip in 5 ml ice-cold PBS and then by sonication (3 times 5 sec 
pulses). Ice-cold sodium-lauryl sarcosine (final concentration 1% v/v) was added and the 
mixture was left to mix gently for 20 min at 4˚C, and then ultracentrifuged at 150,000 x g for 
1 hour at 4˚C. The supernatant was designated as the “inner membrane” sample. The 
remaining pellet was washed once with 20 ml ice-cold PBS prior to dispersion in 5 ml PBS 
by sonication as described above and was designated as the “outer membrane” sample. 
Sodium azide (final concentration 0.02% v/v) was added to all samples. Proteins in the 
“vesicle”, “medium”, “periplasm” and “cytoplasm” samples were precipitated using a 
standard trichloroacetic acid (TCA)/acetone protocol. Briefly, equal volumes of protein 
sample and ice-cold 20% TCA in acetone (v/v) were mixed (10% v/v final TCA 
concentration) and left at -20˚C overnight. Precipitated proteins were pelleted by 
centrifugation at 14,000 rpm (Eppendorf Microfuge) for 30 min at 4˚C and washed three 
times in 200 μl ice-cold acetone. After the final wash, the supernatant was discarded and the 
protein pellet was air-dried and resuspended in 4x LDS SDS-PAGE sample buffer 
(Invitrogen).  
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Protocol used for analysis of the subcellular localization of P. gingivalis PAD (samples 
prepared by Yonghua Gho) 
 
The resulting pellet was resuspended in 5 ml PBS and ultrasonicated in an ice-water bath for 
10 x 5 sec (17 W per pulse), 3 cycles, with 2 sec rest between each pulse. Cellular debris and 
membranes were pelleted by ultracentrifugation at 150.000g for 1 hour at 4˚C. The 
supernatant was designated as the “Periplasmic+Cytoplasmic” (PP/CP) fraction. 
The pellet was washed once with 20 ml PBS and then dispersed by first scraping with the 
sonication tip in 5 ml ice-cold PBS and then by sonication (3 times 5 sec pulses). 0.5 ml were 
collected as the “Cell Envelope” fraction. 
Cold 1% Triton X-100 in 200 mM MgCl2 was added and the mixture was left to mix gently 
for 30 min at 4˚C to dossilve the inner membrane. Triton X-100 -resistant outer membrane 
was pelleted by ultracentrifugation at 150000g for 1 hour at 4˚C. The supernatant was 
designated as the “Inner Membrane” fraction. The remaining pellet was washed once with 20 
ml PBS prior to resuspension in 2.5 ml PBS by sonication as described before and was 
designated as the “Outer Membrane” fraction. Protein content in all fractions, except in the 
“vesicles” and “medium” fractions due to interfering agents, was determined by BCA assay. 
All fractions were freeze-dried and subsequently resuspended using 4x LDS sample buffer + 
1mM TLCK to a final protein concentration of 2 mg/ml. The “vesicles” and “medium” 
fractions, originally 1 ml, were resuspended with 300 μl 4x LDS buffer + 1 mM TLCK. 
Samples were heated for 5 min at 95˚C, aliquoted at stored at -20˚C. Prior to SDS-PAGE, 7 
μl of sample was mixed with 7 μl of reducing sample buffer and 14 μl of water (0.5 mg/ml 
protein concentration), heated for 3 min at 95˚C. 10 μl (5 μg) were loaded per lane. 
 
Analysis of P. gingivalis-mediated proteolysis and citrullination 
Incubation of P. gingivalis with fibrinogen and α-enolase 
The OD600 of 24 hour-old P. gingivalis W83 cultures was measured and noted. Bacteria were 
pelleted at 4,500 x g for 15 min at 4˚C, washed once in ice-cold PBS, and resuspend in assay 
buffer (10 mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.5, 10 mM L-Cysteine) to yield a 
final OD600 of 1.0. Human fibrinogen (Sigma, F3879) and recombinant human α-enolase 
were diluted in assay buffer at a concentration of 0.5 mg/ml. Equal volumes of protein 
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solution and bacterial cell suspension were mixed and an aliquot immediately withdrawn 
(corresponds to time point t = 1 min). The cultures were then incubated at 37˚C on a shaking 
platform, and further aliquots withdrawn after 1.5 h, 3 h and 6 h. Bacterial cells were 
immediately removed from all aliquots by centrifugation (10,000 x g, 5 min, 4˚C). The 
resulting supernatant was used for analysis by SDS-PAGE gels and immuno-/dot-blotting as 
described and for protein precipitation with 15% meta-phosphoric acid, leaving small 
peptides in solution, and subsequent analysis by mass spectrometry. 
 
Protein precipitation 
Five-hundred μl of each supernatant was mixed with 80 μl 15% meta-phosphoric acid by 
vortexing and incubated on ice for 10 min. Proteins were removed by centrifugation (14000 
rpm, tabletop centrifuge, 10 min, 4˚C). The resulting supernatant was freeze-dried and used 
for peptide analysis by mass spectrometry.  
 
Mass spectrometry  
Performed by Dr. Robin Wait, The Kennedy Institute 
In-gel digestion of proteins 
Protein bands were excised with a scalpel and in-gel digestion was performed using a robotic 
system (Investigator ProGest, Genomic Solutions, Huntingdon, UK). The bands were washed 
in 100 mM ammonium bicarbonate buffer and dehydrated in 100% acetonitrile. Cysteine 
residues were reduced with 10 mM DTT, then carboamidomethylated with 55 mM 
iodoacetamide. Digestion was performed for six hours at 37 ºC by addition of modified 
porcine trypsin (10 µL at 6.5 ng/µL in 25 mM ammonium bicarbonate) and peptides were 
recovered by sequential extraction with 25 mM ammonium bicarbonate buffer, 5% formic 
acid, and acetonitrile. Extracts were pooled, lyophilised and re-dissolved in 0.1% formic acid 
prior to mass spectrometry. 
 
Mass spectrometry analysis 
Tandem electrospray mass spectra were recorded with a Q-Tof hybrid quadrupole/orthogonal 
acceleration time-of-flight spectrometer (Waters, Manchester, UK) interfaced to a CapLC 
chromatograph. Freeze-dried peptide samples were redissolved in 0.1% formic acid, and 6 μL 
injected  onto a Pepmap C18 column (300 μm × 0.5 cm; LC Packings, Amsterdam, The 
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Netherlands), and eluted with an acetonitrile/0.1% formic acid gradient at 1 µl per minute. 
The capillary voltage was set to 3,500 V, and data-dependent product ion scans were 
performed on precursor ions with charge states of 2, 3 or 4 over a survey mass range of 400 
to 1,400. The raw spectra were smoothed, deisotoped, transformed onto a singly charged m/z 
axis using a maximum entropy method as implemented in the peptide auto module of 
MassLynx (Waters UK) and saved in the peaklist (pkl) format prior to database searching. 
Proteins were identified by correlation of uninterpreted spectra to entries in SwissProt / 
TrEMBL using ProteinLynx Global Server (version 1.1, Waters, Manchester, UK) and a local 
installation of Mascot (version 2.2: www.matrixscience.com). The database used was a 
FASTA format composite constructed in house by merging SwissProt, TrEMBL and 
associated splice variants (releases of 26/05/09; 8,413,758 sequences). Searches were run in 
error tolerant mode and no mass or taxomic constraints were applied. The initial enzyme 
specificity was set to trypsin, but subsequent searches of the P. gingivalis digestions of 
fibrinogen and enolase were repeated with no enzyme specificity in order to match peptides 
resulting from the combination of gingipain activity with other enzymes such as amino- and 
carboxy-peptidases. All spectra matching citrullinated peptides were reviewed manually by 
interpretation of sequence-specific fragment ions to confirm presence and location of the 
citrulline residue and to exclude other modifications such as deamidation of aspartic acid 
which also result in a mass increase of 1 Da. 
 
Production and evaluation of a polyclonal antibody against P. gingivalis 
PAD (anti-PPAD) 
 
A polyclonal antibody recognising P. gingivalis PAD was produced in rabbits in cooperation 
with Cambridge Research Biochemicals (CRB), Billingham, UK. The immunisation and 
evaluation procedure is outlined in Table 2.4. 
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Table 2.4 Overview of steps for production of a polyclonal antibody to P. gingivalis 
PAD. 
“N/A” stands not “not applicable”, as the date was not important for the respective steps. 
 
Schedule Step Details Carried 
out by 
N/A Preparation of the 
immunising protein antigen 
Thioredoxin-His-PPAD (1.5 mg), 
expressed in E. coli BL21 (DE3) 
cells, purified using Talon resin, 
dialysed into PBS (1 mg/ml)  
Natalia 
Wegner 
N/A Preparation of antigen for 
ELISA analysis 
Thioredoxin-His-PPAD (1 mg) and 
Thioredoxin-His-tag (1.2 mg), 
expressed in E. coli BL21 (DE3) 
cells, purified using Talon resin, 
dialysed into PBS (1 mg/ml) 
Natalia 
Wegner 
Day 1 Pre-immune bleed (PI) 
 
 CRB 
Day 1 Immunisation #1  2 rabbits 
Freund‟s complete adjuvant 
CRB 
Day 14 Immunisation #2 Freunds incomplete adjuvant CRB 
Day 21 Test Bleed #1 (TB1)  CRB 
N/A ELISA analysis on PI, TB1 Antigens: Thioredoxin-His-PPAD 
and Thioredoxin-His-tag 
CRB 
Day 28 Immunisation #3 Freunds incomplete adjuvant CRB 
Day 35 Test Bleed #2 (TB2)  CRB 
N/A ELISA analysis on TB2 Antigens: Thioredoxin-His-PPAD 
and Thioredoxin-His-tag 
CRB 
N/A Immunblot analysis of TB2 Antigens: Thioredoxin-His-PPAD, 
cleaved PPAD (no tag), Thioredoxin-
His-tag 
Natalia 
Wegner 
Day 42 Immunisation #4 Freunds incomplete adjuvant CRB 
Day 49 Test Bleed #3 (TB3)  CRB 
Day 56 Immunisation #5 Freunds incomplete adjuvant CRB 
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Day 63 Test Bleed #4 (TB4)  CRB 
N/A ELISA analysis on TB3, TB4 Antigens: Thioredoxin-His-PPAD 
and Thioredoxin-His-tag 
CRB 
Day 70 Immunisation #6 Freunds incomplete adjuvant CRB 
Day 77 Final Bleed (FB) 77 ml (pooled) CRB 
N/A ELISA analysis on FB Antigens: Thioredoxin-His-PPAD 
and Thioredoxin-His-tag 
CRB 
N/A Immunblot analysis of FB Antigens: cleaved PPAD (no tag), 
Thioredoxin-His-tag, P. gingivalis 
WT and Δppad lysates. 
Small-scale negative depletion 
studies with Thioredoxin-His-tag. 
Natalia 
Wegner 
N/A Preparation of antigen for 
affinity-purification  
GST-His-PPAD, expressed in E. coli 
BL21 (DE3) cells, purified using 
Glutathione resin, and dialysed into 
PBS. 
Natalia 
Wegner 
N/A Affinity purification of FB Serum pooled from both rabbits. 
Purification column: GST-PPAD 
coupled to thiopropyl sepharose. One 
purification pass. Two elutions 
(glycine and TEA). 
CRB 
N/A Immunblot analysis of 
affinity-purified antibody 
(glycine and TEA eluates) 
Antigens: cleaved PPAD (no tag), 
Thioredoxin-His-tag, P. gingivalis 
WT and Δppad lysates. 
Natalia 
Wegner 
 
 
The immunising antigen, Thioredoxin-His-PPAD, and all other antigens were prepared as 
outlined in the respective sections (“Expression and purification of recombinant proteins”).  
 
Immunoblot analysis was performed according to the standard protocol described in “Protein 
analysis”. Specifically for this application, the following details are important: The serum 
from the two rabbits was evaluated separately. Serum dilutions of 1:1000, 1:10.000 and 
1:100.000 were used. 5% milk in TBS-T was used as blocking and antibody buffer. 
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Secondary antibody was swine anti-rabbit iG, HRP-conjugated, used at a dilution of 1:5000. 
Blocking was performed for 1.5 hours at RT, primary antibody (=serum) incubation for 1 
hour at RT and secondary antibody incubation for 1 hour at RT. ECL was used to detect 
binding.  
 
For the small-scale negative depletion study, a 1:1000 serum dilution (in 5% milk and TBS-T) 
was pre-incubated with thioredoxin-his-tag at 1 μg/ml, 10 μg/ml and 100 μg/ml, for 1 hour at 
RT. All remaining steps were performed as described. 
 
Affinity purification of the final bleeds pooled from the two rabbits resulted in 11 ml of 
“glycine eluate” at 1.31 mg/ml in PBS and 40 ml of “TEA eluate” at 0.19 mg/ml in PBS. 
These two eluates were evaluated for their sensitivity and specificity to cleaved PPAD (no tag) 
and native PPAD (in P. gingivalis cell lysates) by immunoblotting as described above. 
 
Enzymatic studies with P. gingivalis PAD 
Colorimetric quantification of citrulline 
The citrulline side chain was detected using a colorimetric method (Knipp et al. 2000). A 
standard curve was created using free L-citrulline (0, 10, 50, 100, 200, 400 μM) in PPAD 
activity buffer (see “Solutions and Buffers”). The performance of this method was evaluated 
using various concentrations of free L-citrulline against free L-arginine. 
 
60 μl of citrulline-containing sample or standard was mixed with 200 μl of freshly prepared 
“citrulline detection reagent” (see “Solutions and Buffers”) in a 96-well ELISA plate. The 
plate was sealed with adhesive film and incubated at 95˚C for 15 min. The plate was then 
allowed to cool down on ice (5-10 min) and the absorbance read at 540 nm in an ELISA plate 
reader. 
 
The standard curve was created after substracting the blank absorbance value (0 μM) from all 
standards and plotting a linear function with x = μM citrulline and y = A (540 nm). The slope 
was used to determine the concentration of citrulline in μM in the unknown sample wells, 
after adjusting for background from substrate alone (control). A sample containing enzyme 
but no substrate was run to control for possible background from the enzyme itself. 
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“Gold standard” PPAD activity assay using BAEE as synthetic substrate 
In a 96-well microtitre plate the following components were combined: 30 μl 20 mM BAEE 
in PPAD activity buffer (see “Solutions and Buffers”), the desired amount of PPAD (0.5 - 2 
μM), and PPAD activity buffer to a final volume of 60 μl. Control wells and standard curve 
were prepared as described in the section above. The plate was sealed with adhesive film and 
incubated at 37˚C for 15 min. Citrulline was detected and quantified as described above. Free 
L-arginine and L-benzoyl-arginine as substrates were assessed in an analogous manner. 
 
Determination of enzymatic activity of PPAD 
 
The enzymatic activity (v) of PPAD was calculated using equation (1): 
 
(1)                                                       
        
   
 
 
where, 
 
v is the enzymatic activity, in μmol/min = U (unit), 
A is the absorption of enzymatic reaction (PPAD+substrate+buffer), in absorption units, 
A0 is the absorption of blank (substrate+buffer), in absorption units, 
V is the incubation volume, in L, 
B is the slope of the calibration curve, in 1/μM, and 
T is the time of enzymatic reaction, in min, 
 
at 37°C and pH 9.5. 
 
One unit of PPAD = Amount of enzyme that catalyses the production of 1 μmol of BCEE 
from BAEE per min at 37 °C at pH 9.5 
 
The enzyme activity unit U can also be expressed in the SI unit katal (mol/s), which is a very 
large unit and therefore less practical (1 U = 16.67 nanokatals). Therefore, the U was used in 
this study.  
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Calibration curves were generated using L-citrulline as standard as described above. The 
measured absorption values at 540 nm, corrected for blank (buffer), were plotted on the y-
axis against the L-citrulline concentration on the x-axis. A linear trendline was generated, 
intercepting at “0”, and the resulting slope B was used in equation (1). BAEE was used at a 
final concentration of 10 mM as the substrate and PPAD (>95% pure as determined by SDS-
PAGE) was used at a final concentration of 0.1, 0.5 and 1 μM. The incubation time was 10 
min at 37˚C as this was time was within the linear period of enzyme activity versus substrate 
concentration, as determined in previous experiments.   
 
Specific activity 
The specific activity of PPAD was calculated based on the results gained from the experiment 
outlined above for a final concentration of 0.1, 0.5 and 1 μM PPAD.  
 
The specific activity is the enzyme activity per milligram of total protein. The unit is 
μmol/min/mg = U/mg. The SI unit is katal/kg but will not be used for reasons mentioned 
above. In the case of a pure enzyme preparation, it measures enzyme processivity. In the case 
of an impure prepration, it indicates the purity of the sample (if the specific activity of a ~100% 
pure enzyme is known):  
 
% purity = 100% × (specific activity of enzyme sample / specific activity of pure enzyme).  
 
The impure sample has lower specific activity because some of the mass is not actually 
enzyme. If the specific activity of 100% pure enzyme is known, then an impure sample will 
have a lower specific activity, allowing purity to be calculated. This was done with PPAD 
preparations which were not further purified by size exclusion chromatography and therefore 
contained ~30% of a low-molecular-weight truncated protein, mostly made up of 
Thioredoxin-His-tag. This did not contribute to or interfere with PPAD enzyme catalysis, as 
determined in activity assays. The calculated purity of the respective PPAD preparations 
made it possible to use PPAD at a fixed concentration in all assays (e.g. 0.5 μM) and thereby 
eliminate variations in enzyme concentration.    
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PPAD activity assay using peptides 
Synthetic peptides were were diluted in PPAD activity buffer to a concentration of 4 mM, 2 
mM and 0.2 mM and 30 μl of each was mixed with 1 μM PPAD (final peptide concentration: 
2 mM, 1 mM, 0.1 mM). Control wells and standard curve were prepared as described in the 
section above. The plate was sealed with adhesive film and incubated at 37˚C for 15 min. 
Citrulline was detected and quantified as described above. 
 
PPAD activity assay with haemoglobin 
Oxy-haemoglobin was used at a final concentration of 100, 40, and 4 μM (referring to the 
tetrameric state). PPAD was used at a final concentration of 1 μM. Control wells and 
standard curve were prepared as described in the section above. The plate was sealed with 
adhesive film and incubated at 37˚C for 60 min. Citrulline was detected and quantified as 
described above. Citrullination in the sample using 4 μM haemoglobin was also confirmed by 
immunoblotting. 16.25 μl of the reaction mix were run on a SDS-PAGE gel, transferred onto 
nitrocellulose membrane and citrullination detected using the anti-(modified)-citrulline kit, as 
described previously. 
 
Time course of PPAD activity (progress curve) 
BAEE was used as substrate at a final concentration of 10 mM. PPAD was used at 0.5 μM. 
All components were combined in an Eppendorf tube and 60 μl were removed immediately 
as the t = 0 min sample. The tube was placed in an 37˚C incubator and 60 μl samples were 
withdrawn after 1, 2, 5, 10, 20, 40, 50, and 60 min. 200 μl citrulline detection reagents was 
added to each aliquot immediately after withdrawing the sample in order to stop the 
enzymatic reaction. All samples were transferred to a 96-well plate. Control wells and 
standard curve were prepared as described in the section above. The plate was sealed with 
adhesive film and citrulline was detected and quantified as described above. 
 
PPAD activity with different substrate concentrations (kinetics) 
PPAD was used at 0.5 μM and BAEE was used as a substrate at 0, 1x10-4, 1x10-3, 5x10-3, 
1x10
-2
, 1x10
-1
, 5x10
-1
, 1, 2, 5, and 10 mM. Control wells and standard curve were prepared as 
described in the section above. The plate was sealed with adhesive film and incubated at 37˚C 
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for 15 min. Citrulline was detected and quantified as described before. The enzyme activity 
for each substrate concentration was calculated according to equation (1). The enzyme 
activity was expressed as (μmol/min)x10-3. The data were fit with GraphPad Prism 5 to 
determine the Michaelis-Menten-Konstant Km and the maximal reaction rat vmax by non-linear 
regression. 
Inhibition studies 
The following compounds were tested for inhibition of PPAD enzymatic activity: 2-
chloroacetamidine, tetracycline, doxycycline, minocycline, sulfasalazine, methotrexate. 
PPAD was used at 0.5 μM. The compounds were used at final concentrations 0.01, 0.1, 1, 10, 
100 and 1000 μM. 30 μl of enzyme solution (0.5 μM PPAd in activity buffer) was mixed with 
30 μl of inhibitor in assay buffer and pre-incubated for 10 min at 37˚C. 3 μl of substrate (20 
mM BAEE, leading to a final concentration of 1 mM) was added and the mix incubated for 
15 min at 37˚C. Control wells lacking inhibitor, substrate, or enzyme were included. 
Citrulline was detected and quantified as described previously. Absorbance values of the 
respective control wells lacking enzyme were substracted from the values gained with 
enzyme. The activity value gained from the contol lacking inhibitor was defined as “100 % 
activity”. All other activity values were calculated as a fraction thereof.   
Activity studies with PPAD mutants 
The PPAD mutants D130A, H236A, D238A, N297A and C351A were used alongside the 
PPAD wild-type to assess whether the introduced amino acid substitutions affected PPAD 
activity. BAEE and fibrinogen-derived peptides were used as substrates, both at a final 
concentration of 1 mM. Each of the PPAD enzymes was used at a final concentration of 1 
μM. Control wells and standard curve were prepared as described in the section above. The 
plate was sealed with adhesive film and incubated at 37˚C for 15 min. Citrulline was detected 
and quantified as described above. 
 
Analysis of antibody responses by ELISA 
Patients  
Reactivity of RA and healthy control serum to fibrinogen peptides 
Samples were kindly provided by Dr. Peter Charles, Kennedy Institute of Rheumatology 
Serum samples from 48 RA patients were collected from patients attending rheumatology 
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clinics at Charing Cross Hospital following consent under approval from the local ethics 
committee and anonymised before storage at -80˚C. All patients met the American College of 
Rheumatology (ACR) 1987 classification criteria for definite or probable RA (Arnett et al. 
1988). Serum samples from 33 healthy controls were obtained by National Blood Transfusion 
Service after consent and were anonymised before storage at -80˚C. 
Peptide synthesis and sequences 
All peptides were synthesised by Cambridge Research Biochemicals (Billingham, UK) and 
purified by HPLC to a purity of >70%. The C-terminal amino acid was routinely in the amide 
form, except for all peptides where the C-terminal amino acid was citrulline or arginine, in 
which case it was synthesised in the acid form so as to resemble the physiological state after 
proteolytic cleavage by gingipains (Table 2.5). All fibrinogen peptides were resuspended at 
10 mg/ml in sterile, deionised water, aliquoted and stored at -20˚C. CEP-1/REP-1 peptides 
were resuspended in 10% DMSO in sterile, deionised water and stored as described above. 
 
Table 2.5 Amino acid sequences of synthetic peptides used for ELISA analysis. 
“Cit” stands for “citrulline”. “P.g.” stands for “P. gingivalis”. 
 
Name Sequence 
FibA-Cit CESSSHHPGIAEFPS-Cit-acid 
FibA-Arg CESSSHHPGIAEFPS-R-acid 
FibA-Cit-XX CESSSHHPGIAEFPS-Cit-GK-amide 
FibA-Arg-XX CESSSHHPGIAEFPS-R-GK-amide 
FibB-Cit CPAPPPISGGGY-Cit-acid 
FibB-Arg CPAPPPISGGGY-R-acid 
FibB-Cit-XX CPAPPPISGGGY-Cit-AR-amide 
FibB-Arg-XX CPAPPPISGGGY-R-AR-amide 
CEP-1 (human) CKIHA-Cit-EIFDS-Cit-GNPTVEC-amide 
REP-1 (human) CKIHA-R-EIFDS-R-GNPTVEC-amide 
CEP-1 (P.g.) CKIIG-Cit-EILDS-Cit-GNPTVEC-amide 
REP-1 (P.g.) CKIIG-R-EILDS-R-GNPTVEC-amide 
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ELISA protocol 
Peptides were diluted at 10 µg/ml in coating buffer (see “Solutions and Buffers”). 96-well 
EIA/RIA plates (Costar) were coated with 100 μl/well peptide solution or with coating buffer 
alone, and incubated overnight at 4˚C. Wells were washed 4x with PBS-Tween (0.05%) and 
blocked with 200 μl/well 2% BSA (diluted in PBS) for 3 hours at RT. Serum was diluted 
1:100 in RIA buffer (see “Solutions and Buffers”), and 100 μl/well was added in duplicates 
and incubated for 1.5 hours at RT. Plates were washed as described above. Peroxidase-
conjugated mouse anti-human IgG or IgA was diluted 1:1000 in RIA-buffer and added to the 
wells (100 μl/well). Plates were incubated for 1 hour at RT. After a final wash, bound 
antibodies were detected with TMB substrate. 100 μl/well were added and incubated for 2 
minutes. The reaction was stopped by the addition of 1M H2SO4 and absorbance measured at 
450 nm in a Multiscan Ascent microplate reader (Thermo Labsystems). A control serum was 
included on all plates to correct for plate-to-plate variation. The OD450 value of the arginine-
containing control peptides was subtracted from the OD450 of the corresponding citrulline-
containing peptides to calculate the citrulline-specific response. The positive cut-off value 
was defined as the 98
th
 percentile of the healthy control population.   
 
Statistical analyses 
The Mann-Whitney test (non-parametric, unmatched groups) was used to compare 
differences between antibody responses to specific peptides in serum samples from RA 
patients and healthy controls and to compare the response to different peptides within the RA 
group. The Fisher‟s exact test was used to compare the percentage of positive serum samples 
(above cut-off) to specific peptides from RA patients and healthy controls. Calculations were 
performed using GraphPad Prism. P-values below the value of 0.05 were considered 
significant.  
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Chapter 3          
Investigation of protein citrullination by P. gingivalis and the 
associated host antibody response 
Background 
The results and some text presented in this chapter (p.124-142) were partly published in a 
paper authored by myself in the journal Arthritis & Rheumatism; please see attached paper 
(Wegner et al. 2010b). 
A functional PPAD enzyme had previously been isolated and purified from the culture 
supernatant of a P. gingivalis mutant strain (McGraw et al. 1999), however this enzyme was 
poorly characterised and its role was unknown. For example, it was unclear whether P. 
gingivalis citrullinates its own and/or foreign (host) proteins using PPAD, which arginine 
residues can be citrullinated and whether this is the only citrullinating enzyme in the 
bacterium. Further, it had been speculated that gingipains, the major proteolytic virulence 
factors of P. gingivalis, were involved in processing of PPAD into an active form and/or in 
processing of PPAD substrates (McGraw et al. 1999). It has even been claimed that  P. 
gingivalis citrullinates human fibrinogen in the periodontal pocket (Rosenstein et al. 2004), 
despite the lack of any experimental data, including the referenced article (Travis et al. 1997). 
Unfortunately, this claim has since been repeatedly cited (de Pablo et al. 2008; de Pablo et al. 
2009; Liao et al. 2009; Mikuls et al. 2009; Berthelot et al. 2010; Routsias et al. 2011), adding 
to confusion and misperceptions in this field. 
The preliminary data leading up to this project (p. 44-46) identified citrullinated P. gingivalis 
enolase as a cross-reactive antigen with RA serum. However, it was impossible to conclude 
whether this had biological significance, since it was unknown whether P. gingivalis 
expresses citrullinated enolase and whether in particular the equivalent of the CEP-1 epitope 
can be generated by PPAD. The aim of the work presented in the first part of this chapter was 
to investigate the first step of the hypothesis as highlighted in Figure 3.1: Does P. gingivalis 
generate citrullinated human and bacterial proteins and how does it do it? 
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Figure 3.1     Schematic illustration of the first step of the aetiological hypothesis for P. gingivalis 
involvement in RA. For the full picture and a detailed explanation please refer to Figure legend 1.10. 
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Results 
Expression of endogenous citrullinated proteins in P. gingivalis reference strain W83 
In order to test whether P. gingivalis citrullinates its own proteins, a culture of the P. 
gingivalis wild-type reference strain W83 was grown under standard conditions for 24 hours 
(representing early logarithmic phase) or 72 hours (representing late logarithmic phase), and 
whole cell lysates or concentrated culture supernatant were analysed by immunoblotting 
(Figure 3.2). 
 
 
 
Figure 3.2 Endogenous citrullinated proteins in P. gingivalis W83. The soluble fractions of total cell 
lysates of P. gingivalis cultures (“lys”) and 20-fold concentrated culture medium (“med”), after 24 hours and 72 
hours of growth, were resolved on a 10% tris-glycine gel and either stained with Coomassie (A) or transferred 
onto nitrocellulose membranes and analysed for citrullinated proteins using the anti-modified citrulline antibody 
(AMC) (B). As a negative control, unmodified recombinant P. gingivalis enolase was used (eno). In vitro 
citrullinated recombinant P. gingivalis enolase was used as a positive control (c-eno). The positions of the 
protein molecular mass markers in kilodalton (kDa) are indicated on the left. 
 
Strong, distinct bands were observed in the lysates and only weak bands in the concentrated 
culture supernatant. The citrullination patterns changed with growth stage, as there were 
observable differences in the number and intensity of citrullinated protein bands between cell 
lysates of a 24 hour and a 72 hour culture. Twenty-four hour cultures were chosen for all 
subsequent experiments. 
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To test reproducibility, P. gingivalis W83 cell lysates from three different sources (two 
different starter cultures from Jan Potempa, Jagiellonian University, Krakow, Poland and one 
from Sigrun Eick, University of Jena, Germany) were used. Similar patterns of citrullinated 
proteins were observed (Figure 3.3). Minor variability between the samples was observed and 
might result from different storage times and conditions.  
 
 
Figure 3.3 Comparison of citrullinated proteins from three separate preparations (1-3) of P. 
gingivalis W83 whole cell lysate. The soluble fractions of total cell lysates of P. gingivalis cultures were 
resolved on a 12% Bis-Tris gel and either stained with Coomassie (A) or transferred onto nitrocellulose 
membranes and analysed for citrullinated proteins using the anti-modified citrulline antibody (AMC) (B). The 
positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the left. 
 
Citrullinated proteins in other P. gingivalis reference strains and clinical isolates 
Citrullinated proteins were found in various different P. gingivalis strains, including clinical 
isolates (Figure 3.4). The clinical isolates were obtained by Sigrun Eick (University of Jena, 
Germany) from diseased sites from periodontitis patients and, after initial cultivation and 
verification, grown in the same way as the wild-type reference strains. 
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Figure 3.4  Expression of endogenous citrullinated proteins is ubiquitous in P. gingivalis. Protein 
citrullination in total cell extracts of the P. gingivalis wild-type reference strain W83 (1-3) and four clinical 
isolates (4-7; corresponding to strains MaRL, D243, JH16, J430) was analysed by immunoblotting with the anti-
modified citrulline antibody. Lanes 1 and 2 are controls in which the modification step (1) or secondary 
antibody (2) was omitted. The positions of the protein molecular mass markers in kilodalton (kDa) are indicated 
on the left. 
 
The gene encoding PPAD was detected in all tested P. gingivalis strains, including the 
clinical isolates, by PCR (Figure 3.5).  
 
Figure 3.5  The PPAD gene is present in all tested P. gingivalis strains. Genomic DNA was isolated 
from P. gingivalis reference strain W83 (Ref) and four clinical isolates (1-4, corresponding to strains MaRL, 
D243, JH16, J430) and subjected to PCR analysis using ppad-specific primers amplifying the full-length gene 
(1.7 kb). The ethidium-bromide stained agarose gel of the PCR product is shown. The position of the nucleotide 
ladder in kilobases (kb) is indicated on the left.  
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Subcellular localisation of citrullinated proteins 
The subcellular distribution of citrullinated proteins was studied using a cell fractionation 
procedure with P. gingivalis strain W83, resulting in six fractions: medium+vesicles (little 
outer membrane bubbles released from the cell surface, containing virulence factors (Haurat 
et al. 2010)), medium (culture supernatant without vesicles), periplasm (containing soluble 
periplasmic proteins), cytoplasm (containing soluble cytoplasmic proteins), inner membrane 
(containing proteins which can be solubilised by the detergent sodium lauryl sarcosine which 
applies to the majority of proteins attached to or integrated into the inner membrane), and 
outer membrane (all other proteins which cannot be solubilised by sodium lauryl sarcosine, 
which is mostly true for proteins from the outer membrane). Immunoblotting with the anti-
modified citrulline antibody showed that the majority of citrullinated proteins are associated 
with the periplasm and the membrane fractions. Only faint bands were detected in the 
cytoplasm fraction, and one prominent band was detected in the vesicles+medium and 
medium fractions (Figure 3.6). These results imply that PPAD either citrullinates proteins 
directly on the cell surface or in the periplasm or that the proteins are translocated to these 
compartments or secreted/shedded after citrullination. 
 
Figure 3.6 The majority of endogenous citrullinated proteins in P. gingivalis W83 is associated with 
the periplasm and membrane fractions. P. gingivalis strain W83 was fractionated into vesicles+medium 
(„vesicles‟), medium, periplasm, cytoplasm, outer membrane (OM) and inner membrane (IM) and the fractions 
analysed for citrullinated proteins using the anti-modified citrullinated (AMC) antibody. The corresponding 
Coomassie-stained gel showing total protein in each of the fractions is shown on the right. The positions of the 
molecular mass markers in kilodalton (kDa) are indicated on the left.  
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Protein citrullination in other oral bacteria 
 
To examine whether endogenous citrullination is a unique ability of P. gingivalis within the 
community of oral pathogens, whole cell lysates of ten other oral organisms were tested for 
the presence of citrullinated proteins. None were detected except in P. gingivalis (Figure 3.7), 
suggesting that functional PAD enzymes are absent from the other strains tested.  Weak 
bands were noticeable in a number of strains, but were the result of non-specific antibody 
binding (see „control‟).  
 
 
Figure 3.7 Lack of protein citrullination in ten other oral bacteria. Total cell extracts of P. gingivalis 
W83 and ten other prominent oral bacteria were tested for endogenous protein citrullination using the AMC 
antibody. Background signals were confirmed to stem from non-specific binding of the primary antibody 
(„control‟). Pg: Porphyromonas gingivalis; Fn: Fusobacterium nucleatum; Aa: Aggregatibacter 
actinomycetemcomitans; Pi: Prevotella intermedia; Po: Prevotella oralis; Cg: Capnocytophaga gingivalis; Co:  
Capnocytophaga ochracea; Sc: Streptococcus constellatus; Sg: Streptococcus gordonii; Sn: Streptococcus 
sanguinis; Sl: Streptococcus salivarius. The positions of the protein molecular mass markers in kilodalton (kDa) 
are indicated on the left. 
 
These findings are in accordance with PPAD homology searches in oral bacteria genome 
sequences. Amongst the bacteria tested here, the genome sequences are available for 
Porphyromonas gingivalis W83 (Nelson et al. 2003), Porphyromonas gingivalis ATCC 
33277 (Naito et al. 2008), Fusobacterium nucleatum (Kapatral et al. 2002) and Prevotella 
intermedia (provided prior to publication by John Heidelberg at TIGR and by Margaret 
 133 
Duncan at the Forsyth Institute, available on the Oral Pathogen Sequence Database
18): 
Nucleotide sequence homology searches with the BLASTN programme (Altschul et al. 1990) 
using PPAD (GenBank ID 34541100) as input sequence show hits for both P. gingivalis 
strains but no significant matches (E-value < 0.0001) in F. nucleatum or P. intermedia. 
Similarity searches using BLAST against all published sequences available revealed a 
number of candidate orthologues, all originating from non-oral bacterial species (Table 3.1).   
Most share the predicted conserved catalytic residues of PPAD and other members of the 
guanidino-group modifying enzymes superfamily (for a representative alignment please see 
Appendix, p. 243). As these are similar between peptidylarginine deiminases and agmatine 
deiminases, the actual enzymatic activity might be that of agmatine deiminases, but should be 
investigated. If confirmed, the presence of a PAD in these bacteria could provide further 
clues to the physiological role of PADs in bacteria. 
 
Table 3.1 Potential peptidylarginine deiminase enzymes in other bacterial species. 
Hits were identified by BLAST using Porphyromonas gingivalis W83 peptidylarginine 
deiminase (Q9RQJ2) as query sequence. Entry names refer to the Uniprot database. Identity 
in % was calculated as the number of identical amino acids divided by the number of total 
aligned amino acids. 
 
Organism Database protein 
name  
Entry name % Identitiy 
to PPAD 
Cloacamonas 
acidaminovorans 
Peptidylarginine 
deiminase 
B0VH37_CLOAI 44% 
unidentified 
eubacterium SCB49 
Peptidylarginine 
deiminase 
A6ES44_9BACT 29% 
Flavobacteriales 
bacterium HTCC2170 
Peptidylarginine 
deiminase 
A4AR43_9FLAO 26% 
Clostridium difficile 
(strain 630) 
Putative 
peptidylarginine 
deiminase 
Q188A5_CLOD6  24% 
 
 
                                                 
18
 http://www.oralgen.lanl.gov 
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The role of PPAD and arginine-gingipains in endogenous protein citrullination by P. 
gingivalis 
 
To confirm that the observed endogenous protein citrullination in P. gingivalis is due to the 
enzymatic activity of PPAD, and to rule out the possibility of a second, uncharacterized, 
bacterial PAD enzyme, a P. gingivalis W83 knockout strain (Δppad) was created by 
replacement of the entire ppad-encoding DNA sequence with an antibiotic cassette. A strain 
in which the antibiotic cassette was inserted downstream of the ppad gene was used as a 
control against polar effects from genetic manipulations (ppad+). Figure 3.8 demonstrates 
successful genetic manipulation. 
 
 
 
Figure 3.8 The ppad gene is absent in a deletional inactivation mutant of P. gingivalis Δppad. 
Genomic DNA was isolated from the P. gingivalis wildtype strain W83 (WT) and from a mutant strain lacking 
the peptidylarginine deiminase gene (Δppad). PCR analysis was performed using primers amplifying the full-
length ppad gene (upper panel) or, as a positive control, a fragment from the P. gingivalis 16S rRNA gene 
(lower panel). As a negative control, template DNA was left out of the reaction mixture („blank‟).  
 
Immunoblotting of the total cell lysates for citrullinated proteins showed that the Δppad strain 
entirely lacks endogenous citrullinated proteins, while the wild-type strain (WT) and the 
control strain (ppad+) showed a similar pattern and intensity of citrullinated proteins (Figure 
3.9). These data demonstrate that PPAD is essential for citrullination of endogenous proteins 
in P. gingivalis and that it possesses only one peptidylarginine deiminase.  
 
It was then examined how citrullination depends on the activity of gingipains, the major 
virulence factors in P. gingivalis. As arginine-gingipains cleave various proteins/peptides 
after arginine residues and thereby generate peptides with carboxy-terminal arginines, their 
activity could explain the previously suggested preference of native PPAD for carboxy-
terminal arginine residues in vitro (McGraw et al. 1999). 
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Figure 3.9 Citrullination in P. gingivalis depends on the bacterial peptidylarginine deiminase 
enzyme. A P. gingivalis mutant strain lacking the bacterial peptidylarginine deiminase gene (Δppad) was 
constructed and total cell extracts were analysed for the presence of citrullinated proteins (AMC). A control 
mutant containing the entire ppad gene and the antibiotic cassette (ppad+) was created to control for possible 
polar effects. The wild-type strain W83 was used as positive control (WT). 
 
Hence, P. gingivalis mutants lacking functional arginine-gingipains (Δrgp), lysine-gingipains 
(Δkgp), or both types of gingipains (Δrgp+kgp) were analysed for endogenous citrullination. 
Immunoblotting of whole cell lysates showed that there is a significantly decreased level, but 
not complete abrogation, of citrullinated proteins in the Δrgp and Δrgp+kgp strains, but not 
in the Δkgp strain (Figure 3.10), confirming that arginine-gingipains play a role in protein 
citrullination, probably by generating proteins with carboxy-terminal arginine residues that 
are subsequently citrullinated by PPAD. However, an indirect adverse effect on PPAD 
activity via altered processing of PPAD due to the lack of arginine-gingipains cannot be 
excluded. The residual citrullinated proteins seen in the Δrgp and Δrgp+kgp strains might be 
due to proteins naturally containing a carboxy-terminal arginine residue, which have not been 
proteolytically processed, and therefore appear at different molecular weights compared to 
the wildtype. 
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Figure 3.10 Citrullination in P. gingivalis is influenced by arginine-gingipain mediated proteolytic 
cleavage of substrate proteins. Total cell extracts of P. gingivalis wild-type W83 („WT‟) and mutant strains 
lacking all proteolytic gingipain activity (Δrgp+kgp) or either arginine-gingipain (Δrgp) or lysine-gingipain 
(Δkgp) were analysed for the presence of citrullinated proteins by immunoblotting with the AMC antibody. 
 
Citrullination of human fibrinogen and α-enolase by P. gingivalis 
Having shown that citrullination of endogenous P. gingivalis proteins depends on the 
presence of PPAD and is influenced by arginine-gingipains, the question arose whether the 
same principles apply to human proteins.  
Human fibrinogen was initially chosen for this study as it is a major RA autoantigen in its 
citrullinated form (Masson-Bessiere et al. 2001; Sebbag et al. 2006) and an important part of 
the inflammatory response in general, due to its function in the coagulation and platelet 
aggregation cascade. Fibrinogen is also involved in the pathogenesis of periodontitis, where it 
is found abundantly in the periodontal lesion, being an established target protein of gingipains 
(Imamura et al. 1995).  
 
The potential of P. gingivalis to citrullinate human fibrinogen was initially investigated using 
intact, live wild-type W83 strain. The culture medium was removed by centrifugation and the 
bacteria were washed, fibrinogen was added, and the suspension incubated at 37˚C. Aliquots 
were removed immediately after mixing bacteria and fibrinogen („0 hours‟), and after an 
incubation time of 1.5 hours and 3 hours. Immediately after withdrawing each aliquot, 
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bacterial cells were removed from the samples by centrifugation and discarded. The 
supernatant was then analysed on SDS-PAGE. Figure 3.11 A shows that fibrinogen was 
rapidly cleaved by P. gingivalis, which is consistent with previous publications (Ally et al. 
2003). To confirm that these bands were indeed fibrinogen products and not contaminants, all 
protein bands were excised and analysed by MS/MS (done in collaboration with Robin Wait, 
The Kennedy Institute of Rheumatology). All bands that could be identified are marked in 
Figure 3.11 A (numbers 1-18) and are listed in Figure 3.11 B. In summary, no proteins from 
P. gingivalis were detected and only one contaminating protein from the fibrinogen 
preparation (human Igκ chain C region) was detected; all other protein bands are derived 
from one or more of the three (α, β, γ) fibrinogen chains. The expected molecular masses of 
the fibrinogen chains were quoted by the manufacturer (Sigma) as 63.5 kD (α chain), 56 kD 
(β chain) and 47 kD (γ chain). Comparing this information to the experimental results, it 
seems that the γ chain forms a dimer (bands 1-3 in Figure 3.11 A), and that the α chain is 
rapidly degraded, as the estimated molecular mass of the largest band assigned to fibrinogen 
α chain at „0 h‟ is less than 31 kD (band 9 in Figure 3.11 A). The presence of fibrinogen was 
also confirmed by immunoblot using a mixture of three antibodies, each raised against a 
fibrinogen-derived peptide within fibrinogen α, β, or γ chain, therefore recognising only 
fibrinogen fragments that contain the respective peptide sequence (Figure 3.11 C).  
 
To test for citrullination of the fibrinogen peptides, samples were applied as a spot directly 
onto a nitrocellulose membrane and the membrane was then processed in a standard 
immunoblot procedure using the anti-modified citrulline antibody. Figure 3.11 D shows that 
the samples after 1.5 hours and after 3 hours incubation contained citrullinated fragments. To 
identify these citrullinated peptides by MS/MS, the larger protein fragments were removed 
from the samples by precipitation using using meta-phosphoric acid, leaving small peptides 
in solution. Meta-phosphoric acid was used because it is compatible with the subsequent 
high-perfomance liquid chromatography (HPLC) analysis. The resulting soluble fractions 
from samples „1.5 hours‟ and „3 hours‟ were then analysed by HPLC on a reverse-phase 
column (performed by myself with technical help from Marysia and Andrzej Kozik, 
Jagiellonian University Krakow, Poland). After an initial run to determine the amount and 
number of peaks, the eluted fractions from the „3 hour‟ sample were collected, as there were 
more peaks of higher intensity, and hence probably more peptides in higher amounts. 
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No. Identity No. Identity 
1 Fibrinogen γ chain 10 Fibrinogen α chain 
2 Fibrinogen γ chain 11 Fibrinogen α chain 
3 Fibrinogen γ chain 12 Fibrinogen α chain 
4 Fibrinogen β chain 13 Fibrinogen α chain 
5 Fibrinogen β chain 
Fibrinogen γ chain 
14 Fibrinogen β chain 
6 Fibrinogen γ chain 15 Fibrinogen γ chain 
7 Fibrinogen β chain 16 Fibrinogen γ chain 
Human Igκ chain C region 
8 Fibrinogen γ chain 17 Fibrinogen α chain 
9 Fibrinogen α chain 18 Fibrinogen γ chain 
Human Igκ chain C region 
 
Figure 3.11 P. gingivalis cleaves and citrullinates small peptides from human fibrinogen. Whole, live 
P. gingivalis W83 cells were washed and mixed with human fibrinogen, and incubated at 37˚C. Samples were 
removed immediately after mixing (0 h), after 1.5 hours incubation (1.5 h) and after 3 hours incubation (3 h). 
Bacterial cells were removed by centrifugation and the resulting supernatant was resolved on a 12% Bis-Tris 
SDS-PAGE for detection of total protein by Coomassie (A) and for immunoblotting using anti-fibrinogen (α, β 
and γ chain) antibody (C), or applied directly onto a nitrocellulose antibody for detection of citrullinated 
peptides using the anti-(modified) citrulline (AMC) antibody (D). Protein bands in gel A were excised and 
analysed using MS/MS (B). The positions of the protein molecular mass markers in kilodalton (kDa) are 
indicated on the left. 
B 
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Equal volumes of all collected peak fractions were then analysed by MS/MS (without trypsin 
digestion) to confirm the identity of the fragments and the presence and position of 
citrullination (performed in collaboration with Robin Wait, The Kennedy Institute, London). 
16 fibrinogen-derived peptides could be unambiguously identified, 14 of which harboured a 
C-terminal lysine residue, and two contained a C-terminal citrulline in place of an arginine: 
237
GGSTSYGTGSETESPCit
252
 and 
524
ESSSHHPGIAEFPSCit
538
 (please see Appendix for 
mass spectrum and detailed analysis, p. 244). Peptides with internal citrulline or internal or 
C-terminal arginines were not detected. 
 
Based on this encouraging pilot experiment, the setup was repeated including fibrinogen and 
α-enolase as protein substrates, control strains (Δppad and Δrgp knockout strains), control 
reactions (incubate protein alone, bacteria alone), and more time points (pre-incubation, 1 
min, 1.5 hours, 3 hours, 6 hours). 
Analogous to the previous experiment, fibrinogen was rapidly cleaved by wild-type P. 
gingivalis (Figure 3.12 A). A similar degradation pattern was observed with the Δppad strain, 
indicating that citrullination of substrate proteins, including gingipains themselves, is not 
essential for the proteolytic potency of gingipains. As expected, fibrinogen samples incubated 
with the Δrgp strain showed a considerably decreased proteolytic cleavage and a different 
pattern of cleaved peptides, with the residual proteolytic activity mainly due to cleavage by 
lysine-gingipains and other proteinases and peptidases from P. gingivalis (Jagels et al. 1996; 
Nelson et al. 1999; Banbula et al. 2000; Masuda et al. 2002). Analysis of the identity of the 
protein bands by mass spectrometry confirmed that the majority were derived from any of the 
three fibrinogen chains (Figure 3.12 A). To exclude cleavage of protein by plasma-derived 
proteases which may have been present as contaminants in the fibrinogen preparation, control 
reactions in which protein alone was incubated in assay buffer were performed, and no 
cleavage was detected (Figure 3.12 B). Similarly, P. gingivalis incubated without protein did 
not secrete signigficant amounts of protein which could interfere with analysis (Figure 3.12 
C).  
Next, it was examined whether the cleaved fibrinogen fragments visible in Figure 3.12 A had 
been citrullinated by P. gingivalis. Immunoblotting of all samples that contained protein 
bands detected two citrullinated peptide bands around 8.5 kDa, mapping to the amino-
terminal region of the fibrinogen α-chain, in samples incubated with P. gingivalis wild-type 
but not Δppad or Δrgp (Fig. 3.12 D), confirming that Arg-X proteolytic cleavage of 
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fibrinogen is a prerequisite for subsequent citrullination by PPAD. Further, a weak positive 
signal in fibrinogen samples taken before incubation with P. gingivalis („pre‟) and in the 
Δrgp „1 min‟ sample was observed, while the corresponding controls („pre ctrl1‟: 
modification control; „pre ctrl2‟: conjugate control) were negative (Fig. 3.12 D), suggesting 
that purified human fibrinogen, as used in these experiments, is already endogenously 
citrullinated by human PADs to some degree.   
 
 
 
 
Figure 3.12 P. gingivalis rapidly cleaves human fibrinogen through arginine-gingipain activity and 
the resulting peptides are citrullinated at the carboxy-terminus by bacterial peptidylarginine deiminase. 
(A) Fibrinogen fragments after incubation with P. gingivalis wild-type (WT), mutants lacking peptidylarginine 
deiminase (Δppad), or arginine-gingipains (Δrgp), for 1 min, 1.5, 3 and 6 hours, were resolved by SDS-PAGE 
and visualised using silver staining. A fibrinogen sample prior to incubation with P. gingivalis served as control 
(pre). Protein bands were analysed by mass spectrometry (α, β, γ for fibrinogen α-, β-, and γ- chains). (B) 
Fibrinogen was incubated without bacteria and visualised by silver staining. (C) P. gingivalis wild-type, Δrgp  
and Δppad strains were incubated without fibrinogen and the supernatant visualised by silver staining. (D) All 
samples with visible protein bands from A were tested for citrullination (AMC) by immunoblotting. Controls for 
the „pre‟ sample were performed in which the modification step (pre ctrl1) or secondary antibody (pre ctrl2) 
were omitted. (E) All samples from A were analysed for the presence of citrullinated peptides by dot blot. 
Crosses indicate areas on the membrane where samples were not applied. 
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The fact that the majority of fibrinogen had been degraded within minutes, and that only two 
citrullinated proteins/peptides could be detected by immunoblotting, suggested that the 
majority of generated peptides was smaller than the size limit of the peptide gels used for this 
analysis (around 3 kDa). Thus, a dot blot technique was applied that confirmed that wild-type 
P. gingivalis cells rapidly degrade and citrullinate fibrinogen into small citrullinated peptides 
(Fig. 3.12 E), and that both arginine-gingipains and PPAD are required, as no positive signals 
were observed with the Δppad and Δrgp strains. 
 
In order to identify the amino acid sequence of the citrullinated fibrinogen peptides and 
determine the position of the citrulline residue, peptides derived from the wild-type and 
Δppad strains were analysed by LC-MS/MS. A total of 30 peptides were identified, all 
derived from fibrinogen (see Appendix, p. 248). The majority of identified peptides were the 
product of proteolytic cleavage after either an arginine or lysine residue, which is consistent 
with the results described above, but further proteolytic processing by other peptidases, in 
particular at the amino-terminus after glycine-, alanine- and serine-residues, was also evident. 
In samples incubated with P. gingivalis wild-type but not in Δppad, four peptides were found 
that contained a carboxy-terminal citrulline residue (Figure 3.13):  
 
(1) 
1
ADSGEGDFLAEGGGVCit
16
,  
(2) 
31
PAPPPISGGGYCit
42
,  
(3) 
253
GGSTSYGTGSETESPCit
268
,  
(4)  
540
ESSSHHPGIAEFPSCit
554
.  
 
The corresponding carboxy-terminal arginine-containing peptides were detected only in the 
Δppad, but not in the wild-type (Table 3.2), suggesting that citrullination of fibrinogen is 
tightly linked to cleavage by arginine-gingipains. The combined data support the concept that 
target proteins such as human fibrinogen are cleaved by arginine-gingipains, generating 
suitable peptide substrates for subsequent citrullination at the exposed carboxy-terminal 
arginine residue by P. gingivalis PAD. 
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Figure 3.13  Sequences of citrullinated peptides from human fibrinogen generated after incubation 
with P. gingivalis. Amino acid sequences of human fibrinogen α-chain (Fib A, SwissProt entry P02671) and β-
chain (Fib B, SwissProt entry P02675) are shown. Peptides were detected using tandem mass spectrometry. 
Citrullinated peptides detected after incubation of fibrinogen with P. gingivalis wild-type are underlined. 
Fibrinopeptide A and B and the thrombin cleavage sites are indicated. Cit = citrulline. 
 
To further test this concept, analogous experiments were performed using recombinant 
human α-enolase. Similar to fibrinogen, enolase was rapidly degraded by the WT, Δppad and 
less so by the Δrgp strain (Figure 3.14). Using immunoblotting on peptide SDS-PAGE gels 
(Figure 3.14 B) and dot blot (Figure 3.14 C), no citrullination could be detected. Analysis of 
the WT and Δppad derived samples by mass spectrometry revealed only one citrullinated 
peptide in the WT (
41
TGIYEALELCit
50
, Fig. 3.14 D and Table 3.2), amongst a total of 17 
detected peptides (for a full list please see Appendix, p. 250). The arginine-containing 
counterpart of this citrullinated peptide (
41
TGIYEALELR
50
)
 
was detected in the samples 
incubated with Δppad.  Analogous to fibrinogen, no peptides with carboxy-terminal arginine 
were detected in the WT samples. The proportion of peptides cleaved at residues other than 
arginine and lysine was higher than that found in fibrinogen, suggesting extensive cleavage 
by non-argine/lysine specific peptidases. Combined with the higher relative number of lysine 
residues in α-enolase (8.8 % versus 6.9 % in fibrinogen), this might result in the generation of 
short peptides, some of which might be citrullinated but too short to be detectable using the 
methods employed. Therefore, P. gingivalis Δkgp was incubated with α-enolase (Figure 3.14 
A-C), and five citrullinated peptides were detected by mass spectrometry (Figure 3.14 D and 
Appendix. p. 251), confirming that PPAD is able to citrullinate α-enolase peptides. Using the 
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AMC dot blot, which relies on long peptides that are hydrophobic enough to bind to the 
membrane, weak positive signals were observed with the Δkgp strain, which decreased with 
time (Figure 3.14 C), again suggesting extensive proteolytic degradation by other proteinases. 
 
Table 3.2: Mass spectrometry analysis of citrullinated peptides generated after 
incubation of human fibrinogen or α-enolase with P. gingivalis wild-type (WT) and their 
respective arginated peptides generated with the Δppad strain.  
 
Sequence
1 
Protein Location  
(amino 
acids) 
Strain m/z ratio
2
 Mascot Score 
-.ADSGEGDFLAEGGGVCit.G Fibrinogen 
α-chain 
1-16  WT  769.29 (+2) 56 
-.ADSGEGDFLAEGGGVR.G     Δppad 768.77 (+2) 99 
R.GGSTSYGTGSETESPCit.N  Fibrinogen 
α-chain 
253-268 WT 546.91 (+3) 51 
R.GGSTSYGTGSETESPR.N   Δppad 786.82 (+2) 78 
K.ESSSHHPGIAEFPSCit.G Fibrinogen 
α-chain 
540-554 WT 819.83 (+2) 98 
S.SHHPGIAEFPSR.G  543-554 Δppad 445.54 (+3) 39 
R.PAPPPISGGGYCit.A Fibrinogen 
β-chain 
31-42 WT 585.30 (+2) 26 
R.PAPPPISGGGYR.A   Δppad 584.77 (+2) 65 
S.TGIYEALELCit.D α-enolase  41-50 WT 583.30 (+2) 24 
S.TGIYEALELR.D   Δppad 582.79 (+2) 56 
 
1 
Amino acids in the uncleaved proteins located carboxy- and amino-terminal to the identified peptides are 
indicated to demonstrate sites of proteolytic cleavage. Identified citrulline residues (Cit) are underlined. 
2
 m/z: mass-to-charge; numbers in brackets: peptide ion charge state 
For detailed analysis and explanations please see Appendix (p. 244).  
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Figure 3.14 Human α-enolase is rapidly cleaved by P. gingivalis gingipains and citrullinated peptides 
are detectable by mass spectrometry. (A) Experiments were performed analogous to fibrinogen (Figure 3.11). 
Fragments of human α-enolase after incubation with P. gingivalis wild-type (WT), mutants lacking 
peptidylarginine deiminase (Δppad), arginine-gingipains (Δrgp), or lysine-gingipains (Δkgp), for 1 min, 1.5, 3 
and 6 hours, were resolved by SDS-PAGE and visualised using silver staining. An enolase sample prior to 
incubation with P. gingivalis served as control (pre). (B) All samples with visible protein bands from A were 
tested for citrullination (AMC) by immunoblotting. (C) All samples from A were analysed for citrullinated 
peptides by dot blot. Crosses indicate areas on the membrane where samples were not applied. (D) Citrullinated 
peptides detected by mass spectrometry after incubation of enolase with P. gingivalis wild-type and Δkgp are 
underlined with a continuous and dashed line, respectively. Amino acid sequence of human α-enolase: 
SwissProt entry P06733. Cit = citrulline. 
 
These results were further confirmed using the colorimetric method to detect citrulline. 
Figures 3.15 A and B show that the citrulline levels are elevated in both fibrinogen and α-
enolase samples incubated with WT and Δkgp and increase with incubation time, but are 
comparably low in Δppad and Δrgp. To exclude false-positive signals stemming from free L-
citrulline as a result of normal P. gingivalis metabolism, controls were performed in which 
bacteria were incubated alone without protein; these showed no positive signals in either 
strain in the citrullination assay (Figure 3.15 C). 
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Figure 3.15 Short citrullinated fibrinogen and α-enolase peptides are generated by P. gingivalis in 
the presence of arginine-gingipains and peptidylarginine deiminase. Human fibrinogen (A), α-enolase (B), 
or bacteria alone without protein (C) were incubated with P. gingivalis wild-type (WT), mutants lacking 
peptidylarginine deiminase (Δppad), arginine-gingipains (Δrgp), or lysine-gingipains (Δkgp) for 1 min, 1.5 and 
3 hours. Bacteria were removed and 60 μl of the supernatant were analysed for citrulline content in nmol by the 
colorimetric method as described in „Materials and Methods‟. A brief spin prior to photometric read-out ensured 
precipitated protein did not interfere with analysis. Due to sample volume restrictions Δkgp samples are not 
present in the controls.  
 
 
Analysis of antibody titres to P. gingivalis-generated citrullinated fibrinogen peptides  
Having identified the sequence of citrullinated peptides that are generated by P. gingivalis 
from fibrinogen and α-enolase, it was of interest to investigate whether an antibody response 
to these peptides exists in RA patients (Figure 3.16), as all identified human citrullinated 
epitopes that are targeted by anti-citrullinated protein antibodies in RA harbour internal and 
not C-terminal citrulline residues. 
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Figure 3.16     Schematic illustration of the aetiological hypothesis for P. gingivalis involvement in RA, 
with the focus on antibody reactivity (purple circle). For the full picture and a detailed explanation please 
refer to Figure legend 1.10. 
 
A pilot study using 48 RA and 33 healthy control serum samples was conducted using 
peptide 
540
ESSSHHPGIAEFPSCit
554
 derived from the fibrinogen α-chain, which is generated 
after incubation of fibrinogen with P. gingivalis, as identified by mass spectrometry (see 
Table 3.2). To determine the influence of the position of the citrulline residue within the 
peptide, the same cohort was evaluated using a peptide with two additional amino acid 
residues at the C-terminus (
540
ESSSHHPGIAEFPSCitGK
556
), representing an epitope that 
would be generated by human PADs. An N-terminally truncated version of this peptide 
(
542
SSHHPGIAEFPSCitGK
556
) had been described in a previous publication as one of the 11 
most frequent fibrinogen target epitopes for anti-citrullinated protein antibodies in RA, 
reactive with 25% (5 out of 20) of RA serum samples (Sebbag et al. 2006). The same epitope 
was also identified by another study as part of one of the three major epitopes reactive with 
RA serum and it was further confirmed that it is generated by the activity of human PADs 
(Van Beers et al. 2010). In a mass spectrometry-based study of fibrinogen isolated from 
rheumatoid arthritis synovial tissue, two citrullinated peptides were identified, both 
harbouring regions that were shown to be citrullinated C-terminally by P. gingivalis in this 
thesis (
540
ESSSHHPGIAEFPScitGK
556
 and 
22
KcitEEAPSLcitPAPPPISGGGYcitAcitPAK
47
 
(Hermansson et al. 2010); underlined regions are peptides generated by P. gingivalis with 
only the C-terminal citrulline present, as identified in this study). 
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Both peptides („XXX-Cit‟ = 540ESSSHHPGIAEFPSCit554; „XXX-Cit-XX‟ =  
540
ESSSHHPGIAEFPSCitGK
556
), along with their arginine-containing counterparts as 
controls („XXX-Arg‟ = 540ESSSHHPGIAEFPSR554; „XXX-Arg-XX‟ =  
540
ESSSHHPGIAEFPSRGK
556
) were tested for binding to IgG and IgA antibodies in RA and 
healthy control serum by indirect ELISA. Bound serum IgA was evaluated to account for the 
possibility of a mucosa-driven immune response. As only citrulline-specific responses were 
of interest, the OD values of the analogous arginine control peptides were substracted from 
the citrulline-peptide OD values (Figures 3.17-19).  
Using the Fisher‟s Exact test, the results show that a statistically significant difference in the 
number of positive (above cut-off) samples between RA and healthy controls was found only 
with the IgG response to the  XXX-Cit-XX peptide (46% vs. 0%; p<0.0001), but not with the 
C-terminal citrulline peptide XXX-Cit, or the IgA response to either peptide (Figure 3.17). 
 
Comparing all data points (as opposed to the numbers of positives) in the RA versus healthy 
control groups, using the Mann-Whitney U test, statistically significant differences were 
found only with the XXX-Cit-XX IgG response (***: p<0.0001) and marginally the IgA 
response (*: p=0.0487). Analysing the graphs visually, however, it seems surprising that the 
difference between RA versus healthy controls is significant for XXX-Cit-XX (IgA) but not 
XXX-Cit (IgG). This can be explained by the employed statistical test, highlighting the 
limitations of statistical tests. The test applied here, the Mann-Whitney U test, is used for 
non-Gaussian (and non-parametric in general) population and assesses the null hypothesis 
that two independent samples of observation have equally large values. To calculate 
statistical values, it uses the ranks of the data from both groups rather than their absolute 
values. As many values in the healthy control population with XXX-Cit (IgG) are marginally 
higher than the ones in RA, despite all of them being below threshold, and are therefore 
assigned higher ranks even if the differences in absolute values are small, the difference is 
calculated as not significant. In contrast, most values between RA and healthy controls in 
XXX-Cit-XX (IgA) are clustered equally around zero, with the exeption of the three values 
above threshold, resulting in a marginally statistically significant result (p=0.0487). The test 
does not take into account that the absolute positive values in XXX-Cit (IgG) are higher than 
the absolute positive values in XXX-Cit-XX (IgA) as it compares relative ranks alone. 
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Figure 3.17 Analysis of citrulline-specific antibody titres to two citrullinated fibrinogen-α peptides 
(FibA). Peptides were synthesised and purified by a commercial supplier. IgG (A) and IgA responses (B) to 
citrullinated peptides and the analogous arginine-containing control peptides were analysed in serum samples 
from rheumatoid arthritis patients (n=48) and healthy controls (n=33). Bound serum IgG/IgA was measured by 
indirect ELISA and data presented as citrullinated peptide OD450 nm - arginine peptide OD450 nm. One dot 
represents one sample. The red line indicates mean OD values. Cut-offs were calculated based on the 98
th
 
percentile of the healthy control sample values for the respective peptides and are indicated with a blue dashed 
line. The Mann-Whitney U test was used to calculate p values for all RA versus Healthy values. The Fisher‟s 
Exact test was used to compare % positives in RA versus Healthy samples, where indicated. ns = not significant; 
sig = significant; * = p<0.05; *** = p<0.0001; n.d. = not done. 
A 
B 
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The selection of cut-off points is another controversial issue. Here, the 98
th
 percentile of each 
healthy control population for each peptide was selected as a cut-off point. As the sample size 
was relatively small, this equalled the highest value in the healthy control group. This 
approach was chosen as the purpose was to establish whether there is a specific response in 
RA patients compared to healthy controls. Therefore, by definition the proportion of positives 
in each healthy control group is 0%. 
A second peptide was evaluated for IgG reactivity in an analogous manner. Again, the 
peptide sequence was chosen from the list of identified P. gingivalis-mediated citrullinated 
fibrinogen peptides (
31
PAPPPISGGGYCit
42
; Table 3.2). The C-terminally extended analogue 
was 
31
PAPPPISGGGYCitAR
44
. A similar peptide containing two additional citrulline 
residues (
30
CitPAPPPISGGGYCitACit
44
) was described as the most frequent fibrinogen 
target epitope for anti-citrullinated protein antibodies in RA, reactive with 70% (14 out of 20) 
of RA serum samples (Sebbag et al. 2006). Two other publications confirmed this finding. 
Van Beers et al. showed that this epitope, containing at least two (Cit-42 and Cit-44) but 
ideally all three (Cit-42, -44, -30) citrulline residues constitutes one of the three major 
citrullinated epitope regions in human fibrinogen (Van Beers et al. 2010). Zhao et al. 
identified the peptide sequence 
24
EEAPSLcitPAPPPISGGGYRA
43 
by mass spectrometry 
from fibrinogen-containing immune complexes isolated from the serum of a patient with RA 
(Zhao et al. 2008). 
The data, presented in Figure 3.18, give a similar picture to the previous results: a statistically 
significant difference in the number of positive samples between RA and healthy controls 
was found with the XXX-Cit-XX peptide (23% vs. 0%; p=0.0040), but not with XXX-Cit 
peptide. Comparing all data points in the RA versus healthy control groups using the Mann-
Whitney U test, a statistically significant difference was found only with the XXX-Cit-XX 
peptide (*: p=0.0345). 
In summary, these data show that the position of the citrulline residue in these two peptides is 
crucial. Moving the citrulline residue towards the N-terminus by just two positions 
significantly increases IgG antibody reactivity (Figure 3.19). Further, there is some overlap in 
the reactivity of a particular serum samples to the XXX-Cit and XXX-Cit-XX peptides within 
this peptide pair (colour-matched dots in Figure 3.19). To determine the extent of cross-
reactivity between the peptide pairs, cross-absoprtion studies should be performed. 
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Figure 3.18 Analysis of citrulline-specific antibody titres to two citrullinated fibrinogen-β peptides 
(FibB). IgG responses to citrullinated peptides and the analogous arginine-containing control peptides were 
analysed in serum samples from rheumatoid arthritis patients (n=44) and healthy controls (n=32). Bound serum 
IgG was measured by indirect ELISA and data presented as citrullinated peptide OD450 nm - arginine peptide 
OD450 nm. One dot represents one sample. The red line indicates mean OD values. Cut-offs were calculated based 
on the 98
th
 percentile of the healthy control sample values for the respective peptides and are indicated with a 
blue dashed line. The Mann-Whitney U test was used to calculate p values for all RA versus Healthy values. 
The Fisher‟s Exact test was used to compare % positives in RA versus Healthy samples, where indicated. ns = 
not significant; sig = significant; * = p<0.05. 
 
A much lower reactivity of RA serum with peptide
 31
PAPPPISGGGYCitAR
44 
was observed 
(23%), compared to the previously published reactivity of 70% with peptide 
30
CitPAPPPISGGGYCitACit
44
. This is most likely due to the two additional citrulline 
residues present in this peptide. As the numbers in this pilot study were small, it cannot be 
concluded whether the findings have a biological meaning or not, but it would be worth 
testing a higher sample size, including cross-absorption studies, and a higher number of 
peptides to evaluate the possibility that a small proportion of RA patients indeed has specific 
antibodies to peptides with C-terminal citrullines, as such peptides are to date not known to 
result from human physiological activities (PADs citrullinate internal arginines and there are 
no proteases known to cleave after citrulline residues). Further, possible technical limitations 
should be investigated, such as suboptimal conformation or binding of the C-terminal 
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citrulline peptides to the plate. This could be evaluated by linking the peptides to biotin at the 
amino-terminus and binding to streptavidin-coated ELISA wells. 
 
     
 
Figure 3.19 Comparison of IgG antibody reactivity of RA serum to two sets (FibA, FibB) of C-
terminal (XXX-Cit) and internal (XXX-Cit-XX) citrullinated peptides. Analysis was performed as 
described in Figures 3.17 and 3.18. One dot represents one serum sample. Dots of the same colour within each 
panel represent the same serum sample. The red line indicates mean OD values. The Mann-Whitney U test was 
used to calculate p values for XXX-Cit versus XXX-Cit-XX reactivities. *** = p<0.0001 for FibA and 
p=0.0009 for FibB. 
 
 
Summary 
 
Endogenous protein citrullination in P. gingivalis and other oral bacteria 
 PPAD is functional in P. gingivalis and unique amongst the bacterial strains tested: 
Endogenous protein citrullination was abundant in P. gingivalis wild-type and clinical 
isolates but lacking in ten other oral bacterias strains tested; PPAD gene was detected 
by PCR in all tested P. gingivalis strains; pattern of expressed citrullinated proteins 
varied slightly with growth stage and between strains 
 Majority of citrullinated proteins in P. gingivalis is associated with the periplasm and 
membrane fractions 
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 Deletion of the PPAD gene resulted in complete abrogation of protein citrullination, 
providing proof that only one functional peptidylarginine deiminase enzyme is present 
in P. gingivalis 
 Inactivation of arginine-gingipains, but not lysine-gingipains, led to significantly 
decreased levels of endogenous citrullination, indicating that arginine-gingipains are 
involved in the process 
P. gingivalis-mediated citrullination of human proteins 
 Incubation of P. gingivalis with human fibrinogen or α-enolase resulted in 
degradation of these proteins and, in wild-type but not PPAD or arginine-gingipain 
knockout strains, citrullination of the resulting peptides at carboxy-terminal arginine 
residues only 
 Arginine-gingipains are required for citrullination by P. gingivalis, presumably by 
proteolytic cleavage of proteins at arginine-X peptide bonds, followed by 
citrullination of the carboxy-terminal arginines by PPAD 
Antibody reactivity of RA serum with C-terminal citrulline peptides 
 5-6% of RA serum samples contain IgG antibodies that recognise the tested C-
terminal citrulline peptides, compared to 23-46% recognising the corresponding 
internal citrulline peptide 
 Statistically significant differences between RA and healthy controls could only be 
demonstrated with peptides containing internal citrulline 
 Results need to be confirmed with a larger number of samples and peptides but might 
indicate that antibodies towards C-terminal citrulline peptides exist in a subset of 
patients with RA where P. gingivalis plays a role in disease development 
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Chapter 4  
Expression and characterisation of recombinant P. gingivalis PAD 
 
Background 
The results presented in the previous chapter indicated that PPAD is crucial for citrullination 
of endogenous bacterial and exogenous human proteins and that citrullination occurs 
primarily at C-terminal arginines. To unambiguously answer the question as to which 
epitopes can be created by PPAD, the active recombinant enzyme was cloned and expressed 
in E. coli. Mutants were created by site-directed mutagenesis to pin down the catalytic 
residues. Further, a number of candidate compounds were tested as potential inhibitors of 
PPAD.  
 
When this work was started, no publications or protocols had been available for the cloning 
and expression of enzymatically active PPAD. Further, it was not known what the 
requirements for catalytic activity of PPAD are. In the first paper on PPAD, the authors 
isolated a truncated form from the supernatant of a mutant P. gingivalis strain that secretes all 
membrane-bound proteins into the medium. Therefore, it was unclear whether this represents 
the wild-type native enzyme or whether it is an artefact resulting from the mutated secretion 
apparatus or the co-purification with gingipains (McGraw et al. 1999). 
 
Results 
Cloning and expression of PPAD 
A strategy to clone both the full-length PPAD gene and the truncated form was developed 
(Figure 4.1). The pET48b(+) expression vector was chosen as host vector as it contains an N-
terminal cleavable His-tag for easy detection and purification and a thioredoxin (Trx)-tag (see 
Appendix). Thioredoxin-tagged proteins were shown to possess greater solubility (LaVallie 
et al. 1993). Thioredoxin also facilitates the reduction of proteins through the reversible 
oxidation of its own active center dithiol to a disulfide, thereby catalysing dithiol-disulfide 
exchange reactions. Hence, this vector was chosen as it was speculated that active PPAD had 
a reduced catalytic cysteine, and a greater amount of stable protein could potentially be 
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achieved using this strategy. 
 
-M--K--K--L--L--Q--A--K--A--L--I--L--A--L--G--L--F--Q--L--P--A--I--A--Q--T- 
ATGAAAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATCGCCCAAACG 
 
 
-Q--M--Q--A--D--R--T--N--G--Q--F--A--T--E--E--M--Q--R--A--F--Q--E--T--N--P- 
CAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAACGAGCATTCCAGGAAACGAATCCC 
 
 
-(...)-A--P--G--T--Y--V--L--V--V--E--G--N--G--I--R--E--T--M--K--I--L--K--*- 
-(...)GCTCCGGGCACATATGTTCTGGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA 
 
Figure 4.1 Cloning strategy for PPAD. Amino acids 1-50 and 534-556 together with the corresponding 
nucleotides are shown. Section highlighted in grey indicates the full-length PPAD construct (amino acids 2-556), 
arrow labelled „mature PPAD‟ indicates the truncated construct (amino acids 44-556).  
Initial attemps to clone PPAD suffered from a high frequency of multiple non-synonymous 
mutations, especially within repeat regions (for example 
289
CAAAAAAAC
297
, or
  
604
TCCTCTCTGTCTCAA
618
). Site-directed mutagenesis to correct these mutations was of 
limited success, as the procedure introduced new mutations. Hence, several high-fidelity 
proof-reading polymerases, primer combinations, and PCR conditions were tested, eventually 
leading to a successful method using Finnzymes Phusion High-Fidelity DNA polymerase 
(Figure 4.2). 
 
 
Figure 4.2 Amplification PPAD inserts and vector. Agarose gel after PCR amplification of the P. 
gingivalis W83 PAD gene (locus PG_1424), either the full-length („full PPAD‟, 1.67 kb) or the truncated form 
(„mat PPAD‟, 1.54 kb), from genomic DNA. 3 l and 6 l from a total reaction volume of 100 l were loaded. 
30 ng of purified circular pET48b vector (5.6 kb) were loaded. The positions of the relevant DNA size markers 
(in kilobases, kb) are shown on the left. 
 
Following restriction digest and ligation, progress was controlled by ligation PCR using 
primers annealing up- and downstream of the vector-insert junction. As demonstrated in 
Figure 4.3, ligation was successful for both PPAD inserts.  
Stop 
‘Mature’ PPAD 
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As it was unclear whether the PPAD gene product might cause toxicity in E. coli, a standard 
cloning strain (Novagen NovaBlue) and a strain with a tighter control of low-level gene 
expression by the lacI
q
 promoter (NEB 5-alpha F’Iq) were used for transformation. The 
number of colonies obtained was slightly higher (~30%) with NEB 5-alpha F’Iq. However, 
fewer colonies were obtained with the construct containing the „mature PPAD‟ insert 
compared to the construct with full-length PPAD (factor 10), despite equal DNA amounts 
and all steps performed in parallel. 
 
 
Figure 4.3 Ligation PCR of PPAD-pET48 constructs and controls. Agarose gel after ligation PCR 
using primers annealing up- and downstream of the insert-vector junction sites. Successful insertion of the 
PPAD inserts results in product of 2.3 (mature PPAD+pET48) and 2.5 kb (full-length PPAD+pET48). Vector 
lacking insert results in a 0.8 kb product. „pET‟ stands for ligation control where linearised vector alone was 
used. „pET ‟ stands for a PCR control where circular vector was used as a positive control for the 0.8 kb 
product. The positions of the relevant DNA size markers (in kilobases, kb) are shown on the left. 
 
  
 
Figure 4.4 Successful cloning of PPAD-pET48 constructs. Agarose gel after diagnostic digest of 
PPAD-pET48 constructs containing either the „mature PPAD‟ insert (1.54 kb) or the full-length PPAD insert 
(1.67 kb). On the far right, linearised pET48 vector (5.6 kb) was loaded as a control. The positions of the 
relevant DNA size markers (in kilobases, kb) are shown on the left. 
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Colony PCR was used to select E. coli clones that contained the correct constructs. For both 
constructs the success rate was 50%. A diagnostic restriction enzyme digest of the isolated 
plasmid DNA confirmed successful insertion of the insert DNA (Figure 4.4). 
 
DNA sequencing confirmed the correct reading frame and the absence of mutations in one 
out of four constructs containing the „mature PPAD‟ insert and in five out of five constructs 
containing the full-length PPAD insert (see Appendix). These were used for all subsequent 
experiments. 
 
To increase chances of success, several transformation hosts were initially used to test for 
recombinant protein expression: Novagen BL21 (DE3), Lucigen C41 (DE3), and Lucigen 
C43 (DE3). Although transformation was successful with all three strains and both constructs, 
undegraded recombinant protein could only be obtained with the Novagen BL21 (DE3) host 
transformed with the full-length PPAD vector (Figure 4.5).  
 
 
Figure 4.5 Screening for expression of recombinant PPAD. E.coli BL21 (DE3), C41 (DE3), or C43 
(DE3) cells were transformed with constructs encoding Trx-His-mature PPAD („m‟; expected size 72 kDa) or 
Trx-His-full length PPAD („f‟; expected size 77 kDa) and recombinant protein expression was induced with 
IPTG. Cell lysates were then resolved on SDS-PAGE gels and total protein stained with Coomassie (A) or 
transferred onto membranes and immunblotted with anti-His tag antibody (B). The positions of the protein 
molecular mass markers in kilodalton (kDa) are indicated on the left. 
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„Mature‟ PPAD with a predicted size of 72 kDa (including tags) could not be detected in any 
of the strains. It is possible that it was degraded, as a major His-tagged product at ~25 kDa 
and several minor products are visible on the anti-His tag immunoblot in the BL21 (DE3) 
strain (Figure 4.5 B). A protein of ~15 kDa is visible in all samples, which could be explained 
by aborted expression, resulting in expression of the tag alone (15 kDa). As a result, it was 
speculated that „mature‟ PPAD is the enzymatically active form, causing toxicity to the E. 
coli cell and is therefore degraded. Hence, the BL21 (DE3) pLysS strain was transformed 
with both the „mature‟ and full-length PPAD constructs and tested for expression. pLysS 
strains are recommended for the expression of potentially toxic proteins as the pLysS plasmid 
produces a T7 lysozyme that inhibits transcription by the T7 RNA polymerase, thereby 
reducing basal level expression of the gene of interest. However, no overexpression of either 
full-length or „mature‟ recombinant PPAD could be detected with this strain (Figure 4.6). 
 
 
 
Figure 4.6 Comparison of the strains BL21 (DE3) and BL21 (DE3) pLysS for the expression of 
recombinant PPAD. E.coli BL21 (DE3) or BL21 (DE3) pLysS cells were transformed with constructs 
encoding Trx-His-mature PPAD („mature‟; expected size 72 kDa) or Trx-His-full length PPAD („full-length‟; 
expected size 77 kDa) and recombinant protein expression was induced with IPTG („+). No IPTG was added as 
a control („-„). Cell lysates were resolved on an SDS-PAGE gel and total protein stained with Coomassie. The 
positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the left. 
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BL21 (DE3) cells transformed with the full-length PPAD constructs were therefore chosen 
for subsequent experiments to assess the solubility of the recombinant protein, tag cleavage, 
and enzymatic activity. 
 
For determination of protein solubility, two cell lysis methods were initially evaluated: 
standard sonication and a milder, detergent-assisted cell lysis („BugBuster‟ reagent). The total 
cell lysates was further fractionated into native and denaturing fraction by centrifugation and 
all three samples were analysed by SDS-PAGE and Coomassie staining. The majority of the 
recombinant protein was present in the insoluble (denaturing) fraction. However, a thin 
overexpressed band corresponding in size to recombinant full-length PPAD was observed in 
the soluble (native) fraction lysed with detergent (Figure 4.7, arrow), but not in the soluble 
fraction lysed by sonication.  
 
 
 
Figure 4.7 Solubility testing of recombinant PPAD. E.coli BL21 (DE3) cells were transformed with a 
construct encoding Trx-His-full length PPAD (expected size 77 kDa). Cells were lysed using a detergent-
containing buffer or sonication. The resulting total cell extracts („TCE‟) were further fractionated into 
native/soluble („N‟) and denaturing/insoluble („D‟) fraction by centrifugation. Samples were resolved on an 
SDS-PAGE gel and total protein stained with Coomassie. The arrow indicates the overexpressed protein in the 
native fraction lysed using detergents. The positions of the protein molecular mass markers in kilodalton (kDa) 
are indicated on the left. 
 
To confirm this result, a protein pull-down of each native fraction using His-tag affinity resin 
(Talon) was performed. Figure 4.8 clearly demonstrates that more recombinant PPAD could 
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be extracted with the detergent method compared to sonication. The detergent  method was 
therefore chosen for cell lysis in subsequent experiments. 
 
 
 
Figure 4.8 Pull-down of soluble PPAD. E.coli BL21 (DE3) overexpressing Trx-His-full length PPAD 
(expected size 77 kDa) were lysed using a detergent-containing buffer or sonication. The native/soluble fraction 
of each lysis method was subjected to protein pull-down using His-tag affinity resin. Flow-through („FT‟), wash 
(„W‟) and eluate fractions („EL‟, containing recombinant PPAD) were collected and  and visualised on an SDS-
PAGE gel by Coomassie staining. The arrow indicates the size of recombinant PPAD. The positions of the 
protein molecular mass markers in kilodalton (kDa) are indicated on the left. 
 
In an attempt to further increase the amount of soluble protein, the detergent-based extraction 
buffer (from hereon called BugBuster) was supplemented with either 10% glycerol, 5 mM β-
mercaptoethanol, or both. Based on the results in Figure 4.9 it was concluded that 10% 
glycerol might increase the yield slightly. 
 
The recombinant PPAD contained N-terminal tags (Trx and His) and had been generated 
with the aim of performing activity assays and producing a polyclonal anti-PPAD antibody. 
As it is known that tags can interfere with activity, and that immunisation with a tagged 
antigen may lead to antibodies reactive with the tag rather than the antigen, a protocol for 
efficient tag cleavage was attempted. The pET48b vector contains a human rhinovirus (HRV) 
3C protease cleavage site, resulting in tag-free PPAD (predicted size 62 kDa) and only four 
additional vector-derived N-terminal amino acids (Gly-Pro-Gly-Tyr). 
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Figure 4.9 Optimisation of detergent-based buffer conditions for extraction of soluble PPAD. E.coli 
BL21 (DE3) overexpressing Trx-His-full length PPAD were lysed using a detergent-containing buffer without 
any supplements (lane 1), or with 10% glycerol (lane), 5 mM β-mercaptoethanol (lane 3), or both 10% glycerol 
and 5 mM β-mercaptoethanol (lane 4). Trx-His-PPAD was then pulled down using His-tag affinity resin and 
analysed on an SDS-PAGE gel and visualised by Coomassie staining. The positions of the protein molecular 
mass markers in kilodalton (kDa) are indicated on the left. 
 
In a small-scale experiment, purified Trx-His-PPAD was incubated with His-HRV 3C 
protease with various protease-to-protein ratios and incubation times (24 hours). However, 
only a small fraction of the tagged protein was cleaved (Figure 4.10 A), even with a high 
protease-to-protein ratio (1:5) and prolonged incubation time. Therefore, various buffer 
conditions were tested, as recommended by the manufacturer (Figure 4.10 B). 100% cleavage 
could not be achieved under any conditions. The highest cleavage efficiency was attained 
with the standard buffer (50 mM Tris, 150 mM NaCl) supplemented with DTT (1 mM), 
EDTA (1 mM) and Triton X-100 (0.1%) (Figure 4.10 B lane 14).  
 
These optimised buffer conditions were used to re-evaluate the protease-to-protein ratio, 
since a ratio of 1:5, as used for the experiment in Figure 4.10 B is too costly for large-scale 
production. However, as shown in Figure 4.11 A, satisfactory results (>50% cleavage) were 
achieved only with the 1:5 ratio; hence, this condition was used to generate cleaved PPAD for 
activity measurements (Figure 4.11 B, „FT1‟).  
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Figure 4.10 Optimisation of tag cleavage of Trx-His-PPAD. (A) Purified Trx-His-PPAD was incubated 
for 3, 19, or 24 hours without protease (8 μg PPAD, no protease), with a 1:25 ratio of protease-to-protein (2 U 
protease, 50 μg PPAD), or with a 1:5 ratio of protease-to-protein (2 U protease, 8 μg protein) in standard 
cleavage buffer (50 mM Tris-HCl, 150 mM NaCl) and visualised on an SDS-PAGE gel by Coomassie staining. 
The arrows indicate the expected size of the reaction components. (B) Purified Trx-His-PPAD (10 μg) was 
incubated for 24 hours without protease („pre‟), or with a 1:5 ratio of protease-to-protein (2 U protease) in 
various buffer conditions, as indicated on the right, and visualised on an SDS-PAGE gel by Coomassie staining. 
The positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the left. 
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Figure 4.11 Generation of cleaved PPAD for activity assays. (A) Purified Trx-His-PPAD (10 μg) was 
incubated for 24 hours with various protease-to-protein (U:μg) and visualised on an SDS-PAGE gel by 
Coomassie staining. (B) Purified Trx-His-PPAD (10 μg) was incubated for 48 hours and a 1:5 ratio of protease-
to-protein in a buffer containing 50 mM Tris, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.1% Triton X-100 
(„pre‟). His-tagged protease and protein truncations were then removed using His-tag affinity resin, and cleaved 
PPAD collected in the flow-through („FT1‟). A second wash ensured complete collection of cleaved PPAD 
(„FT2‟). Bound entities were subsequently eluted from the resin („EL‟). The positions of the protein molecular 
mass markers in kilodalton (kDa) are indicated on the left. 
 
Activity studies with recombinant PPAD 
 
In vitro enzymatic activity of native PPAD isolated from the culture supernatant of P. 
gingivalis has been previously evaluated (McGraw et al. 1999) using free L-arginine, 
synthetic arginine derivates (benzoyl-L-arginine [BA], benzoyl-L-arginine-ethylester [BAEE], 
benzoyl-L-arginine amide [BAA]), a short peptidylarginine derivates (benzoyl-glycyl-L-
arginine) and the short peptide bradykinin (Figure 4.12). Enzyme activity was expressed as 
the Vmax/Km quotient, which serves as an index for the potential enzyme activity. The 
highest activity was reported for benzoyl-L-arginine (35.9 x 10
-3
), followed by benzoyl-
glycyl-L-arginine (6.6 x 10
-3
) and bradykinin (2.5 x 10
-3
), and lower activities with BAA, L-
arginine, and BAEE (0.1 - 0.5 x 10
-3
), demonstrating a preference of this enzyme for 
peptidylarginine substrates with an unsubstituted carboxy-terminal arginine. Nonetheless, 
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BAEE had been used as the standard substrate in all subsequent assays as it is easy to work 
with (solubility, pH) and inexpensive. Activity had been demonstrated within a wide pH 
range (3-11), with optimum activity at ~ pH 9.3. McGraw et al. also reported that addition of 
flavin nucleotides was essential for enzyme stability and increased enzymatic activity. 
 
 
 
Figure 4.12 Structural formulae for a selection of synthetic PPAD substrates. 
 
Based on this information, BAEE was chosen as a substrate for initial activity assays in this 
thesis, in a CHES buffer system (pH 9.5). No additional components except purified, cleaved 
PPAD were added to the assay mix. Citrulline was quantified using a colorimetric method 
(Knipp et al. 2000), which was first evaluated using L-arginine and L-citrulline as it had not 
been used in this laboratory before. It was found that absorbance at 540 nm is linear with L-
citrulline concentration (0-400 μM) and that L-citrulline can be differentiated from L-arginine 
at a concentration >10 μM (0.6 nmol in a total reaction volume of 60 μl), which was 
satisfactory for the purposes of this study (Figure 4.13). 
 
In a second evaluation experiment, commercially available rabbit skeletal PAD was used 
with BAEE as substrate. A standard curve was created using L-citrulline to quantify the 
obtained citrulline levels. The results (Figure 4.14) show a near-linear correlation between 
substrate concentration and PAD-catalysed citrulline formation within the range examined (0-
500 μM BAEE), and the absence of significant positive signals in samples where PAD had 
not been added. Next, three different substrates were compared (Figure 4.15), demonstrating 
highest activity towards the double substituted arginine derivative BAEE and lowest towards 
free L-arginine, as is to be expected for mammalian PADs (Sugawara et al. 1982). 
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Figure 4.13 Evaluation of the colorimetric method for detection of citrulline. Various concentrations 
of either L-citrulline or L-arginine (0-400 μM) were mixed with PPAD activity buffer (50 mM CHES, 10 mM 
DTT, pH 9.5). Citrulline detection reagent (see Materials and Methods) was added and the mixture heated for 15 
min at 95˚C. Absorbance was read at 540 nm and blank values (buffer alone) substracted from each value for 
analysis. All samples were measured in triplicates. Error bars indicate standard deviation of triplicate 
measurements.   
 
Figure 4.14 Quantification of citrullination of benzoyl-arginine ethylester (BAEE) by rabbit skeletal 
PAD. Various concentrations of BAEE were incubated in the presence („+PAD‟) or absence („-PAD‟) of 0.07 U 
rabbit skeletal PAD (Sigma) for 1 hour at 52˚C in rabbit PAD activity buffer (100 mM Tris-HCl, 10 mM CaCl2, 
5 mM DTT, pH 7.4). After photometric readout, blank values (buffer alone) were substracted from each value 
for analysis. All measurements were performed in triplicates. Error bars indicate standard deviation of triplicate 
measurements. 
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Figure 4.15 Comparison of substrates for rabbit skeletal PAD. Three substrates (5 mM each) were 
incubated in the presence („+PAD‟) or absence („-PAD‟) of 0.07 U rabbit skeletal PAD in PAD activity buffer 
(100 mM Tris-HCl, 10 mM CaCl2, 5 mM DTT, pH 7.4) for 30 min at 52˚C. After photometric readout, blank 
values (buffer alone) were substracted from each value for analysis. All measurements were performed in 
triplicates. Error bars indicate standard deviation of triplicate measurements. L-Arg: L-arginine; Bz-Arg: 
Benzoyl-L-arginine; BAEE: Benzoyl-l-arginine ethylester. 
 
 
The combined results were regarded as promising and prompted the investigation of PPAD 
activity using an analogous protocol. In an initial experiment to assess whether the full-length 
enzyme (preparation from Figure 4.11 B „FT1‟) was enzymatically active or not, a large 
amount of the PPAD preparation (10 μg) was incubated in the presence or absence of 
substrate (10 mM BAEE) in CHES activity buffer (pH 9.5) supplemented with DTT (10 mM), 
for 1 hour at 37˚C. As a control, substrate alone was incubated. Figure 4.16 shows that full-
length PPAD was active, and that either PPAD or substrate incubated on their own gave only 
low background readings.  
 
To verify these results, a time course (progress curve) was performed and boiled PPAD was 
additionally included in the setup. Figure 4.17 shows a typical enzymatic progress curve for 
PPAD+substrate, and a flat line for boiled PPAD+substrate and substrate or PPAD alone, 
confirming that the observed citrulline readout stems from enzymatic activity of PPAD. It 
further confirms that BAEE contributes to a background reading, and a „substrate alone/-
PPAD‟ control was therefore included in all subsequent experiments and corrected for by 
substracting the value from all readings containing substrate. 
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Figure 4.16 Recombinant PPAD is enzymatically active. 10 μg PPAD preparation was incubated in the 
presence („PPAD+BAEE‟) or absence („PPAD‟) of substrate (10 mM BAEE) in PPAD activity buffer (50 mM 
CHES, 10 mM DTT, pH 9.5) for 1 hour at 37˚C. Substrate alone was used as control. After photometric readout, 
blank values (buffer alone) were substracted from each value for analysis. All measurements were performed in 
triplicates. Error bars indicate standard deviation of triplicate measurements. BAEE: Benzoyl-l-arginine 
ethylester. 
 
 
 
Figure 4.17 Time course experiment for recombinant PPAD activity. 10 μg PPAD preparation was 
incubated at 37˚C in the presence („PPAD+sub‟) or absence („PPAD‟) of substrate (10 mM BAEE) in PPAD 
activity buffer (50 mM CHES, 10 mM DTT, pH 9.5). Substrate alone („sub) and boiled PPAD in the presence of 
substrate („PPAD ko + sub‟) were used as control. Samples were removed before addition of substrate (0 min) 
and after 1, 3, 15, 30, 45, and 60 min. After photometric readout, blank values (buffer alone) were substracted 
from each value for analysis. All measurements were performed in dublicates. The average of two independent 
experiments is shown. Error bars represent the standard error of the mean (SEM). Citrulline is expressed as 
nmol in a total reaction volume of 60 μl. BAEE: Benzoyl-l-arginine ethylester. 
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Next, analogous to Figure 4.15, L-arginine, benzoyl-arginine and BAEE were compared as 
substrates for PPAD. The results qualitatively reflected the data from native PPAD published  
previously (McGraw et al. 1999), in that L-arginine is citrullinated by PPAD, but to a lesser 
extent compared to benzoyl-arginine or BAEE (Vmax values from McGraw et al.: L-arginine 
26 nmol/min/mg, Bz-arginine 104 nmol/min/mg, BAEE 90 nmol/min/mg). The combined 
results establish that full-length PPAD is enzymatically active; hence cleavage of the 43 N-
terminal amino acids, as suggested in the publication by McGraw et al., is not essential for 
“activation” of PPAD. 
 
 
Figure 4.18 Comparison of substrates for PPAD. L-arginine, benzoyl-L-arginine, and BAEE (benzoyl-l-
arginine ethylester) (10 mM each) were incubated with PPAD for 1 hour at 37˚C in PPAD activity buffer (50 
mM CHES, 10 mM DTT, pH 9.5). After photometric readout, blank values (substrate alone) were substracted 
from each value for analysis. The average of three independent experiments is shown. Error bars represent the 
standard error of the mean (SEM). 
 
As described above, cleavage of the Trx-His tag in recombinant PPAD was only satisfactorily 
efficient in the presence of reducing agents and detergent. This was not only costly and time-
consuimg, but further posed an obstacle for some applications of recombinant PPAD, for 
example when used as an immunising antigen in animals and also in downstream application 
such as protein determination. Therefore, it was evaluated whether the tagged form would 
give similar results in terms of activity and could therefore be used in all subsequent 
experiments instead. Equimolar amounts of both enzymes were compared for activity with 
BAEE as substrate and their activity was almost identical (Figure 4.19), indicating that the 
presence of the tag does not interfere with activity and therefore most likely the three-
dimensional structure, which is important for antibody development. 
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Figure 4.19 Comparison of the activity of cleaved and tagged PPAD. 1 μM of tag-free („PPAD‟) and 
tagged PPAD („Trx-His-PPAD‟) were incubated with substrate (BAEE, 10 mM) in PPAD activity buffer (50 
mM CHES, 10 mM DTT, pH 9.5) for 45 min at 37˚C and formed citrullinated product was quantified. The 
average of two independent experiments is shown. Error bars represent the standard error of the mean (SEM). 
 
However, ~30% of the Trx-His-PPAD preparation contained a ~15 kDa Trx-His truncation 
product (by weight; estimated from SDS-PAGE). In order to obtain a reference value for 
enzymatic activity of 100% Trx-His-PPAD, the enzyme preparation was further purified by 
size exclusion chromatography (gel filtration), by which molecules are sorted based on their 
hydrodynamic radius (simplified: shape and molecular mass). Molecules with the biggest 
hydrodynamic radius exit the column first. Figure 4.20 A+C shows that pure Trx-His-PPAD 
could be successfully separated from the truncation. The enzyme activity of the Trx-His-
PPAD fractions mirrored their respective protein concentration (mAU reading) (Figure 4.20 
B). Fractions containing pure Trx-His-PPAD were pooled, concentrated and used for 
subsequent experiments. 
 
The influence of reducing agents on enzyme activity was first assessed. 0-10 mM of DTT or 
L-cysteine were added to the assay mix and PPAD activity was quantified. The data in Figure 
4.21 demonstrate that some activity can be observed in the absence of reducing agent. 
However, activity increases significantly with the concentration of reducing agent, and this is 
comparable between DTT and L-cysteine, supporting the view that a reduced cysteine side 
chain is present in the active catalytic centre. 
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Figure 4.20 Purification of Trx-His-PPAD by size exclusion chromatography. (A) Representative 
SDS-PAGE gel showing purification of Trx-His-PPAD by His-tag affinity chromatography. TCE: Total cell 
extract of E. coli BL21 (DE3) overexpressing Trx-His-PPAD. 1-6: Eluate fractions of affinity-purified Trx-His-
PPAD. The average yield of recombinant Trx-His-PPAD was 2 mg per Liter of culture. (B) Size exclusion 
chromatogram after fractionation of the pooled Trx-His-PPAD eluates. Peaks are labelled 1-3. Collected 
fractions (1 ml each) are indicated at the bottom. (C) SDS-PAGE gel of a selection of the eluted fractions from 
(B). mAU: milli absorbance units. 
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Figure 4.21 Enzymatic activities of Trx-His-PPAD fractions after size exclusion chromatography. 30 
μl of several 1-ml fraction corresponding to peak 1 in Figure 3.34 B were tested for citrullinating activity with 
10 mM BAEE as substrate. Samples were incubated for 30 min at 37˚C in PPAD activity buffer (50 mM CHES, 
10 mM DTT, pH 9.5) and citrullinated product was quantified. Single measurements were performed due to 
available sample volume restrictions.  
 
 
Figure 4.22 Influence of reducing agents on the enzymatic activity of PPAD. 1 µM Trx-His-PPAD was 
incubated in the presence of varying amounts of reducing agent (DTT or L-Cysteine) with 10 mM BAEE in 
PPAD activity buffer (50 mM CHES, pH 9.5)  as substrate for 15 min at 37˚C and citrullinated product was 
quantified. Measurements were performed in triplicates. Error bars indicate standard deviation of triplicate 
measurements. DTT: Dithiotheitol. 
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In order to determine a reference value for PPAD activity in a pure preparation, different 
molar amounts of the gel-purified Trx-His-PPAD were incubated with substrate and the 
specific activity was calculated as a mean of the values obtained for each setup. Based on the 
data presented in Figure 4.23, the specific activity of pure Trx-His-PPAD was calculated as 
23.8 U/mg, under the specified conditions (pH 9.5, 37˚C, 10 mM BAEE).  
  
 
 
 
Figure 4.23 Determination of the specific activity of pure PPAD. Various concentrations of gel-purified 
Trx-His-PPAD (0, 0.1, 0.5, 1 μM) were incubated with substrate (10 mM BAEE) in PPAD activity buffer (50 
mM CHES, 10 mM DTT, pH 9.5) for 10 min at 37˚C and the formed citrullinated product quantified. 
Measurements were performed in dublicate. Error bars indicate standard deviation of dublicate measurements. 
 
The background to the calculations is explained in detail in „Materials and Methods‟ 
(p.118/119). For the purpose of clarity, the calculation for 1 μM PPAD is reproduced here: 
 
First, the enzymatic activity v in Units (U = μmol/min) is calculated: 
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A is the absorption of enzymatic reaction (PPAD+substrate+buffer), in absorption units:  
 0.695 
A0 is the absorption of blank (substrate+buffer), in absorption units: 
 0 
V is the incubation volume, in L: 
 0.006 
B is the slope of the calibration curve, in 1/μM: 
 0.0035 
T is the time of enzymatic reaction, in min: 
 10 
 
  
               
         
                
 
The specific activity is the enzyme activity in U per milligram of total protein. 
 
     
           
           
 
This procedure was repeated for the other enzyme concentrations and the average was 
calculated as 23.8 U/mg. This allowed the calculation of % enzyme purity in subsequent 
preparations that had not been gel-purified and thereby proper adjustment for active enzyme 
concentration. 
 
The pure enzyme preparation was then used for the study of Michaelis-Menten kinetics with 
the substrate BAEE. Briefly, Michaelis-Menten kinetics describes how the initial reaction 
rate of an enzymatic reaction (time period in which product formation is linear with time) 
depends on substrate concentration, applying a number of assumptions (eg. the reverse 
reaction is negligible during the measurement period). Using non-linear regression algorithms 
to fit the Michaelis-Menten equation, the constants KM and Vmax can be accurately calculated.  
 
Michaelis-Menten equation:       
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[S] stands for substrate concentration, v0 for the initial reaction rate, and KM is the substrate 
concentration concentration at which the rate of the enzyme reaction is half the maximal 
reaction rate Vmax. 
Previous time course experiments showed that even with relatively high enzyme 
concentration (2.7 μM) the reaction rate is linear at least for 15 min (for a representative 
graph see Figure 4.17). With an enzyme concentration of 0.5 μM, the linear period lasted for 
40 min (not shown). Therefore, an incubation time of 15 min (and 0.5 μM enzyme) was 
chosen as this should guarantee to be in the linear region. Various concentrations of substrate 
(BAEE) were incubated with 0.5 μM Trx-His-PPAD and the enzyme activity quantified and 
plotted against substrate concentration. Using non-linear regression (Graphpad Prism), a 
graph was fitted to the data points (r
2
 goodness of fit: 0.9817), showing decreasing activity 
after a maximum at 1 mM substrate, as shown in Figure 4.24. This is called „substrate 
inhibition‟. Based on this data and the Michaelis-Menten equation, the Michaelis-Menten 
constants were calculated as Vmax 0.78 ± 0.04 (μmol/min)x10
-3
 and KM 0.10 ± 0.02 mM under 
the applied experimental conditions. These values are useful when comparing different 
substrates, as they are a measure for the affinity of the enzyme to a substrate (the lower KM 
the higher the affinity) and the maximum activity that can be achieved under conditions of 
substrate saturation (the higher Vmax the higher the activity at substrate saturation). 
 
 
Figure 4.24 Determination of Michaelis-Menten kinetic constants for PPAD and the substrate BAEE. 
0.5 µM Trx-His-PPAD was incubated with 0-10 mM BAEE for 15 min at 37˚C in PPAD activity buffer (50 mM 
CHES, 10 mM DTT, pH 9.5) and enzymatic activity quantified. The average of two independent experiments is 
shown. Error bars represent the standard error of the mean (SEM). The calculated vaues for Vmax and Km are 
displayed. 
Vmax: 0.78 ± 0.04 (μmol/min)x10
-3 
 
KM: 0.10 ± 0.02 mM  
 
 174 
The analogous kinetic data from native PPAD from P. gingivalis culture supernatants and 
BAEE as substrate (McGraw et al. 1999) were KM=874 µM (versus 100 μM here) and 
Vmax=90 nmol/min/mg (versus 339 nmol/min/mg here). The results are different but lie in the 
same range. Deviations are probably attributable to the different experimental conditions: 
McGraw et al. used native, truncated PPAD (versus recombinant full-length PPAD), pH 8.0 
(versus pH 9.5), and a completely different assay buffer composition (200 mM Tris, 1 mM 
EDTA, 25 μM FMN, 25 μM FAD, 100 μM NADPH, 10 mM cysteine, versus 50 mM CHES, 
10 mM DTT). 
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Citrullination of fibrinogen and enolase peptides by recombinant PPAD 
A preference of PPAD towards C-terminal arginine residues was previously indirectly 
indicated based on the lack of detected peptides containing internal citrulline residues after 
incubation with P. gingivalis. An in vitro assay using recombinant Trx-His-PPAD and 
synthetic peptides containing arginine residues in three different positions (C-terminus, near 
C-terminus, internal) was performed to directly investigate the issue. The peptide substrate 
containing a C-terminal arginine („Fib-R‟) corresponded in sequence to a peptide detected by 
MS/MS after incubation of fibrinogen with P. gingivalis (Table 3.2). Peptide „Fib-R-XX‟ 
corresponds to the same sequence but with two amino acids added after the arginine. Peptide 
„Eno-REP1‟ corresponds to the CEP-1 peptide with arginine instead of citrulline.  
 
Figure 4.25 Citrullination of fibrinogen and enolase peptides by PPAD. 1 µM Trx-His-PPAD was 
incubated with 2, 1, or 0.1 mM peptide substrate („+PPAD‟) in PPAD activity buffer (50 mM CHES, 10 mM 
DTT, pH 9.5). Samples without enzyme were used as controls („-PPAD‟). The sequences of the peptides are 
shown. 10 mM BAEE was used as positive control substrate. The reactions were incubated for 15 min at 37˚C 
and enzymatic activity quantified. The average of two independent experiments is shown. Error bars represent 
the standard error of the mean (SEM). The activity for 10 mM BAEE was 125 µM (+PPAD) and 22 µM (-
PPAD). 
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Figure 4.25 shows that indeed only the peptide containing a C-terminal arginine residue is 
citrullinated. The addition of just two amino acids to the C-terminus of this peptide reduced 
the citrulline signal to nonsignificant background levels, as was the case with the REP-1 
peptide. A further experiment supported this finding: equimolar amounts, referring to the 
number of arginine residues, of human α-enolase and fibrinogen were either directly 
incubated with PPAD or first digested with trypsin and then incubated with PPAD. Trypsin, 
like gingipain, cleaves after arginine and lysine residues. Figure 4.26 shows that whole 
enolase or fibrinogen was not citrullinated by PPAD; in contrast pre-incubation of the same 
amount of protein with trypsin resulted in substantial levels of citrullination for both 
substrates. This data unequivocally supports previous indications for strong substrate 
specificity of PPAD towards C-terminal arginine over internal arginine.  
 
 
Figure 4.26 Citrullination of whole and trypsin-digested enolase and fibrinogen by PPAD. Equimolar 
amounts (26.4 nmol, referring to the number of arginine residues) of human α-enolase or fibrinogen were 
incubated in the presence („+tryp‟) or absence of trypsin. Samples were freeze-dried, resuspended in PPAD 
activity buffer (50 mM CHES, 10 mM DTT, pH 9.5) with 2.7 µM Trx-His-PPAD, and incubated for 30 min at 
37˚C and enzymatic activity quantified. Single measurements were performed due to sample volume restriction. 
 
Citrullination of hemoglobin by PPAD 
 
As presented in the previous section, the P. gingivalis mutant strains Δrgp and Δrgp+kgp 
contained residual citrullinated proteins, despite the absence of arginine-gingipains that could 
generate C-terminal arginines as a substrate for PPAD. It was discussed that this might be due 
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to proteins naturally containing a carboxy-terminal arginine residue. To test this hypothesis, a 
protein with a naturally occurring C-terminal arginine, hemoglobin, was chosen to be studied 
as a substrate for PPAD. Hemoglobin plays an important physiological role for P. gingivalis 
as a source of iron for nutrition and of iron protoporphyrin IX (FePPIX) dimer as oxidative 
protective shield, giving the bacterium its distinctive black pigmentation (see Figure 1.11) as 
it accumulates on the cell surface. Gingipains and the outer membrane proteins HmuR and 
HmuY are critical for binding and degradation of hemoglobin and acquisition of the heme 
group (Smalley et al. 1998; Olczak et al. 2006). 
 
Hemoglobin A is the most common type in adult humans and comprises two α chains (14 
kDa) and two β chains (17 kDa), each binding a heme group. Hemoglobin can be saturated 
with oxygen or desaturated with oxygen, and is accordingly called oxy-hemoglobin and 
deoxy-hemoglobin, respectively. Met-hemoglobin is another form, in which the iron of the 
heme group is in the Fe
3+
 state and cannot bind oxygen. It is known that P. gingivalis uses 
oxy-hemoglobin, which is converted into met-hemoglobin by arginine gingipains (possibly 
indirectly/non-proteolytically) and then degraded by lysine-gingipains to form the FePPIX 
pigment (Smalley et al. 2004). The hemoglobin α chain contains a C-terminal arginine 
residue, the citrullination of which by PPAD might affect the susceptibility of oxy-
hemoglobin to be converted into met-hemoglobin and therefore its degradation by lysine-
gingipains.  
 
For this experiment, horse oxy-hemoglobin was kindly provided by John Smalley, University 
of Liverpool. Horse and human hemoglobin α chains are 89% identical, including the C-
terminal arginine residue (Figure 4.27 A). An analysis of the three-dimensional structure of 
the human oxy-hemoglobin A tetramer shows that the two C-terminal arginine residues are 
facing inwards and a computational analysis of the accessible surface indicated that only 20% 
of the surface of these two residues is accessible (calculated with DeepView) (Figure 4.27 B).  
 
Citrullination of hemoglobin by PPAD was first assessed using a standard PPAD activity 
assay with varying concentration of hemoglobin. DTT was excluded from the assay mix in 
order to avoid any direct effects caused by its reducing activity on hemoglobin. Further, two 
different buffers with pH 7.5 or 9.5 were tested because the pH, along with the tetrameric 
hemoglobin concentration, affects the dimer/tetramer ratio present in solution. The data 
presented in Figure 4.28 A show that hemoglobin is citrullinated under these conditions, with 
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2-3 fold higher levels of citrullination observed at pH 7.5 compared to 9.5, despite an 
expected ~2 fold higher level of PPAD activity at pH 9.5 compared to 7.5 (McGraw et al. 
1999). 
 
 
 
 
Figure 4.27  Haemoglobin. (A) Amino acid alignment of the α-chains of human and horse haemoglobin. 
The C-terminal arginine residue is highlighted in red. (B) Three-dimensional X-ray model of human oxy-
hemoglobin (1GZX)
19
. The C-terminal arginine residue of the two α chains is highlighted in red and with red 
arrows. Dark-blue and purple: α chains; turquoise and green: β chains; grey: loops. This figure was generated by 
myself using the software DeepView v4.0 (http://spdbv.vital-it.ch/). 
 
 
                                                 
19
 www.rcsb.org/pdb/explore.do?structureId=1GZX 
 179 
This could be explained by the aforementioned effect of the pH on the tetramer dissociation 
constant. The tetramer-dimer dissociation constant of oxy-hemoglobin (Kdiss = 
[Dimer]
2/[Tetramer] ≈ 10-6 M) decreases as the pH goes up, therefore there is a higher 
proportion of dimer compared to tetramer at pH 7.5. Combined with a higher accessibility of 
the C-terminal arginine residue in the α-β dimeric form, this might explain the higher 
citrullination levels at pH 7.5 compared to 9.5 despite lower PPAD activity. 
Controls were performed in which substrate (hemoglobin) alone was incubated without 
PPAD and the absorption values substracted from the substrate+PPAD value. This was 
especially critical in this experiment as hemoglobin absorbs light in the 540 nm range, which 
is the wavelength used for the readout of the citrulline assay. To confirm the results, 
citrullination was also assessed by anti-citrulline immunoblot, which showed a band at the 
size expected for hemoglobin α chain (14 kDa) (Figure 4.28 B), confirming that PPAD 
citrullinates hemoglobin. 
 
 
 
Figure 4.28 Citrullination of haemoglobin by PPAD. (A) 1 µM Trx-His-PPAD was incubated with 4, 40, 
or 100 µM horse oxy-haemoglobin tetramer for 60 min at 37˚C at pH 9.5 (50 mM CHES) or pH 7.5 (50 mM 
Tris-HCl). Enzymatic activity was quantified. Single measurements were performed due to sample volume 
restrictions. (B) 1 µM Trx-His-PPAD was incubated with 4 µM horse oxy-haemoglobin tetramer for 60 min at 
37˚C at pH 7.5 (50 mM Tris-HCl). As controls, either haemoglobin or PPAD were left out. PPAD and 
haemoglobin without incubation served as pre-reaction controls. The samples were resolved by SDS-PAGE and 
citrullinated protein detected by anti-modified citrulline immunoblot. The constituents of each reaction mix are 
indicated by „+‟: Hb = horse oxy-haemoglobin; PPAD = Trx-His-PPAD; 37˚C = reaction was incubated at this 
temperature. The positions of the relevant molecular mass markers are indicated on the left. Hemoglobin protein 
was kindly provided by John Smalley, University of Liverpool.  
 
 180 
Inhibition of PPAD 
Three groups of compounds were tested for their potential to inhibit PPAD activity: (1) 
tetracyclines and derivatives; (2) sulfhydryl-reactive compounds; (3) disease-modifying anti-
rheumatic drugs (Figure 4.29).  
 
Group 1 comprised tetracycline, doxycycline, and minocycline and was included based on the 
reported efficacy of tetracycline in human PAD inhibition (see p. 43) and the reported 
inhibitory effects on gingipains, where doxycycline was found to most effective compared to 
tetracycline and minocycline with an IC50 of 3 and 20 μM for arginine-gingipains and lysine-
gingipain, respectively (Imamura et al. 2001). The authors suggested that inhibition is due to 
interference with the oxidative state of the proteinases by doxycycline as the inhibitory 
activity was reduced to IC50 ~100 μM for arginine-gingipain in the presence of reducing 
agent (10 mM L-Cysteine). 
 
 
 
 
 Figure 4.29 Chemical structures of compounds tested for inhibition of PPAD.  
 
Group 2 was represented by 2-chloroacetamidine, a modest inhibitor of human PAD4 and 
bacterial DDAH (see p. 40). As this compound was suggested to block the catalytic cysteine 
residue in both PAD4 and DDAH, and PPAD contains a predicted catalytic cysteine, it was 
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chosen as a potential inhibitor. Other PAD4 inhibitors acting via the same mechanism such as 
Cl-amidine and F-amidine were not tested as they are not commercially available. 
Group 3 contained sulfasalazine and methotrexate, two common DMARDs, whose detailed 
mode of action in RA is unclear. They were included to test whether they might inihibit 
PPAD and possibly thereby be effective in RA. Metabolites of these drugs might also be 
important, in particular in the case of sulfasalazine which is metabolised into 5-
aminosalicylic acid and the antibiotic sulfapyridine. However, these were not tested. 
 
Varying concentrations of the compounds were pre-incubated with PPAD and then substrate 
(BAEE) was added and the formation of citrulline quantified. The data in Figure 4.30 show 
that no inhibition occurred with tetracycline/tetracycline-derivatives DMARDs, but efficient 
inhibition occurred with 2-choloracetamidine.  
 
 
 Figure 4.30 Relative residual PPAD activity in the presence of various compounds. 0.5 μM Trx-His-
PPAD was preincubated with varios concentrations of inhibitor for 10 min at 37˚C in PPAD activity buffer (50 
mM CHES, 10 mM DTT, pH 9.5). Substrate (1mM BAEE) was added and the reaction incubated for a further 
15 min at 37˚C. Citrulline was quantified according to the standard protocol. A control reaction to which no 
inhibitor was added was used as a reference value to calculate 100% PPAD activity. The activity in the presence 
of the described compounds was then expressed as a fraction relative to 100% activity. Error bars indicate 
standard deviation of triplicate measurements. 
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Further analysis of the inhibition data of PPAD with 2-choloracetamidine using non-linear 
regression (dose response, four-parameter sigmoidal; GraphPad Prism) calculated an IC50 
value of 21.5 ± 1.3 μM. The inhibitor dissociation constant Ki, which is an absolute value and 
does not depend on the specific reaction conditions, can be calculated from IC50, KM and the 
substrate concentration based on the equation (Cheng et al. 1973): 
 
   
    
   
   
  
 
       
  
       
      
         
 
which gives a value well below that found with human PAD4 or bacterial DDAH (Ki = 20 
mM and 3.1 mM respectively). Ki equals the concentration of competing substrate in a 
competition assay which would occupy 50% of the enzyme if no substrate was present. Here 
it was assumed that competitive inhibiton (inhibitor and substrate compete for binding to the 
active site) is taking place as this was shown to be the case for human PAD4 and DDAH with 
2-chloroacetamidine. In the case of noncompetitive inhibition (inhibitor reacts with enzyme-
substrate complex) or uncompetitive inhibition (inhibitor binds to the enzyme and enhances 
substrate binding but reduces the rate of product formation) the Ki would calculate as and 
21.5 and 19.5 μM, respectively, which is still well below the values for PAD4 and DDAH. 
 
Site-directed mutagenesis of proposed PPAD catalytic residues 
The functional residues of PPAD are not known, however a bioinformatics analysis of all 
members of the guanidino-group modifying enzymes superfamily identified five residues 
predicted to be crucial for catalysis (H-236, N-297, C-351) or substrate binding/stabilisation 
of the catalytic centre (D-130 and D-238) (Figure 4.31). In order to experimentally map the 
crucial residues, site-directed mutagenesis was used to replace each of these five amino acids 
with alanine in the recombinant Trx-His-PPAD protein.  
 
After the successful amino acid code substitution in the generated constructs was confirmed 
by nucleotide sequencing (see Appendix for alignments), expression in the total cell lysates  
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MKKLLQAKALILALGLFQLPAIAQTQMQADRTNGQFATEEMQRAFQETNPPAGPVRAIAE 
YERSAAVLVRYPFGIPMELIKELAKNDKVITIVASESQKNTVITQYTQSGVNLSNCDFII 
AKTDSYWTRDYTGWFAMYDTNKVGLVDFIYNRPRPNDDEFPKYEAQYLGIEMFGMKLKQT 
GGNYMTDGYGSAVQSHIAYTENSSLSQAQVNQKMKDYLGITHHDVVQDPNGEYINHVDCW 
GKYLAPNKILIRKVPDNHPQHQALEDMAAYFAAQTCAWGTKYEVYRALATNEQPYTNSLI 
LNNRVFVPVNGPASVDNDALNVYKTAMPGYEIIGVKGASGTPWLGTDALHCRTHEVADKG 
YLYIKHYPILGEQAGPDYKIEADVVSCANATISPVQCYYRINGSGSFKAADMTMESTGHY 
TYSFTGLNKNDKVEYYISAADNSGRKETYPFIGEPDPFKFTCMNETNTCTVTGAAKALRA 
WFNAGRSELAVSVSLNIAGTYRIKLYNTAGEEVAAMTKELVAGTSVFSMDVYSQAPGTYV 
LVVEGNGIRETMKILK 
 
Figure 4.31 Site-directed mutagenesis of predicted functional residues in PPAD. (A) Predicted three-
dimensional structure of PPAD (residues 44-357) with proposed functional residues highlighted. The structure 
was computed based on the X-ray structure of agmatine deiminase from Streptococcus mutans (PDB ID 
Q8DW17) (sequence identity 19%, please see Appendix for an amino acid alignment) as a template.  Helices are 
represented in yellow, strands in blue and loops in grey. This figure was generated by myself using the software 
DeepView v4.0. (B) Amino acid sequence of full-length PPAD (residues 1-556) with the residues represented in 
(A) underlined. Proposed functional residues are highlighted and colour-coded according to (A). 
 
A 
B 
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was tested in a small-scale experiment. All five mutant proteins could be expressed in E. coli 
BL21 (DE3) (Figure 4.32 A). In a larger-scale setup (1L culture), the mutant proteins were 
expressed along with the unmutated wild-type PPAD, taking extreme care as not to cross-
contaminate the cultures, and the soluble proteins were purified with His-affinity resin. The 
yield was comparable between proteins (Figure 4.32 B). The proteins were then assessed for 
enzyme activity, using three different substrates: BAEE and two fibrinogen peptides 
containing a C-terminal arginine residue, both corresponding to originally identified peptides 
in P. gingivalis-fibrinogen digests (Fib-A: ESSSHHPGIAEFPSR; Fib-B: PAPPPISGGGYR). 
No detectable activity was observed with any of the five mutants. This was a surprising result, 
as it was expected that the bioinformatic prediction was not 100% correct and that at least 
some activity would be present with some of the mutants, as only one amino acid had been 
replaced in each mutant. Therefore, the experiment was repeated entirely beginning with 
recombinant protein expression, but the same result was found in repeated analysis 
(combined results in Figure 4.32 C). As all steps had been performed in parallel with the 
wild-type enzyme, and the wild-type enzyme showed activity in the expected range with all 
three substrates, but none of the mutants did with any of substrates, this was considered to be 
a true result, i.e. residues C-351, N-297, H-236, D-130 and D-238 are indeed crucial 
functional residues in the enzymatic mechanism of PPAD. Table 4.1 presents the data from 
Figure 4.32 C relative to the wild-type enzyme along with the proposed function of the 
respective mutated residue (Shirai et al. 2006) 
 
 
Table 4.1 Relative activity of PPAD mutants. Calculations are based on the data 
presented in Figure 4.32 C using Fib-A as substrate.   
 
Enzyme Relative activity (%) Proposed function of mutated residue 
wild-type 100.0 - 
C351A 1.0±0.8 Catalytic residue 
N297A 0.8±0.4 Catalytic residue 
H236A 0.9±0.5 Catalytic residue 
D130A 0.9±0.3 Substrate binding, catalytic center stabilisation 
D238A 1.3±0.2 Substrate binding, catalytic center stabilisation 
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Figure 4.32 Expression, purification, and activity of PPAD mutants. (A) E.coli BL21 (DE3) cells were 
transformed with a constructs encoding mutated versions of Trx-His-full length PPAD, as indicated (expected 
size 77 kDa). Protein expression was initiated with the addition of IPTG („+‟). No IPTG was added as control („-
„). Total cell extracts were resolved on an SDS-PAGE gel and total protein stained with Coomassie or 
transferred onto nitrocellulose membranes and immunoblotted for the his-tag. (B) Wild-type and mutant PPAD 
was expressed as described in (A) and then purified using his-tag affinity resin and analysed by SDS-PAGE and 
Coomassie staining. The positions of the protein molecular mass markers in kilodalton (kDa) are indicated on 
the left. (C) 1 μM wild-type PPAD and mutants were tested for enzyme activity using 1 mM BAEE, Fib-A 
(ESSSHHPGIAEFPSR) or Fib-B peptide (PAPPPISGGGYR) as substrate.  The reactions were incubated for 15 
min at 37˚C in PPAD activity buffer (50 mM CHES, 10 mM DTT, pH 9.5) and citrullinated product was 
quantified spectrophotometrically. Error bars indicate the SEM from two independent experiments. 
A 
B C 
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Auto-citrullination of PPAD 
 
During expression of recombinant wild-type PPAD and mutants, it was observed that it took 
consistently approximately twice as long for E. coli cultures expressing wild-type PPAD to 
reach a certain OD600 value compared to cultures expressing mutant proteins or the empty 
expression vector. It was concluded that the wild-type enzyme might exert a stress on E. coli 
through its enzymatic activity by depleting energy or nutrient resources. Further, previous 
experiments where reactions containing recombinant PPAD and protein substrate were tested 
for citrullination using anti-citrulline immunoblot, showed an anti-citrulline signal in the 
molecular mass region of the PPAD enzyme. Taken together, this prompted the investigation 
of citrullination taking place in E. coli lysates expressing recombinant PPAD. The availability 
of the inactive mutant enzymes represented a negative control.  
 
Figure 4.33 A demonstrates that E. coli total cell lysates expressing the wild-type PPAD 
enzyme show strong citrullinated protein bands, but not those expressing the mutant PPADs 
or the tag alone. Next, purified wild-type Trx-His-PPAD was immunoblotted with anti-
citrulline antibody with and without prior incubation at 37˚C (Figure 4.33 B). The resulting 
pattern of citrullinated bands was similar but not identical to the one found in the whole cell 
lysates in Figure 4.33 A, where a few additional bands in the 15-30 kDa region were visible. 
Taken together, these data show that under the artificial conditions of recombinant protein 
overexpression, where the recombinant protein represents the majority of the total cellular 
protein and lacks an excess of natural substrate, citrullination of the full-length Trx-His-
PPAD itself, and of one or two N-terminal ~45 kDa PPAD truncations, and possibly also E. 
coli-derived proteins, occurs. Post-expression incubation of the purified enzyme does not 
increase citrullination levels, indicating that citrullination takes place primarily during the 
described artificial environment of recombinant protein overexpression. 
 
Of note, not in any of the colorimetric citrulline detection experiments where a control 
reaction containing recombinant PPAD alone was tested, a positive signal above background 
level was detected. This can be explained however by the lower detection level of the 
colorimetric assay and the much lower amount of enzyme used compared to blotting. 
Assuming a sensitivity of 1 ng protein for immunoblot, and the calculated sensitivity of the 
colorimetric assay, the immunoblot would be more than 3,000-fold more sensitive per 
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citrulline residue. An open question is the citrullination of full-length PPAD despite the lack 
of a C-terminal arginine residues in its sequence. A possible explanation is that internal 
arginine residues may become a substrate for PPAD under such unphysiological conditions. 
However, this would have to be evaluated in further experiments.      
 
 
 
     
 
Figure 4.33 Auto-citrullination of PPAD during protein overexpression in E. coli. (A) Total cell 
lysates of E.coli BL21 (DE3) cells overexpressing the Trx-His-tag alone, PPAD mutants, or wild-type were 
resolved by SDS-PAGE, transferred onto a nitrocellulose membrane and total protein stained by Ponceau S or 
citrullinated proteins detected with an anti-modified citrulline antibody.  (B) 1.5 μg purified wild-type Trx-His-
PPAD was incubated in PPAD activity buffer (50 mM CHES, 10 mM DTT, pH 9.5) without additional substrate 
at 37˚C for 1 hour („+‟) or stored as as usual after purification and not incubated („-„). Coomassie stained total 
protein, anti-His immunoblot detected the His-tagged full-length and truncated PPAD and anti-modified 
citrulline immunoblot detected citrullinated PPAD. The positions of the protein molecular mass markers in 
kilodalton (kDa) are indicated on the left. 
A 
B 
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Summary  
 
Expression and purification of PPAD 
 Full-length PPAD can be expressed in E. coli BL21 (DE3) and purified most 
efficiently using a detergent-based cell lysis method 
 The hypothesised „mature‟ form of PPAD lacking the N-terminal 43 amino acids is 
degraded during expression/purification 
 Cleavage of the Thioredoxin-His tag is efficient only in the presence of the reducing 
agent dithiothreitol and the detergent Triton X-100, which may interfere with 
downstream applications 
 
Activity studies, site-directed mutagenesis and self-citrullination of PPAD 
 Recombinant full-length PPAD is enzymatically active 
 Cofactors, particular ions, reducing agents or other additives are not required for 
enzymatic activity, as opposed to human PADs which are Ca
2+
-dependant 
 Reducing agents (L-Cysteine, dithiothreitol) increase enzymatic activity 
 Enzymatic activity is not influenced by the presence of the Thioreoxin-His tag 
 Synthetic substrates: L-arginine, benzoyl-L-arginine (N-terminally substituted L-
arginine) and benzoyl-L-arginine ethylester (N- and C-terminally substituted L-
arginine) are substrates for PPAD; activity is lowest with L-arginine 
 Peptide substrates: Peptides with C-terminal arginines only are substrates for PPAD. 
Peptides with internal arginines are not citrullinated. 
 Protein substrates: Proteins with C-terminal arginines only (e.g. hemoglobin A) are 
substrates for PPAD. Proteins with internal arginines (e.g. enolase, fibrinogen) are not 
citrullinated unless cleaved into peptides harbouring C-terminal arginines. 
 Using benzoyl-arginine ethylester as substrate the following constants were 
determined: 
Specific activity: 23.8 U/mg
20
 enzyme 
Km = 0.10 mM 
Vmax = 0.78 nmol/min 
                                                 
20
 see p. 118/119 for definition of „U‟ and „specific activity‟ 
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 Site-directed mutagenesis: Cysteine-351, Asparagine-297, Histidine-236, Aspartic 
acid-130 and -238 are each essential for PPAD activity. Substitution of any of these 
amino acids with alanine results in enzymatic activity of ≤1.3% of that of the wild-
type enzyme 
 Full-length recombinant wild-type PPAD is auto-citrullinated in E. coli. PPAD 
mutants are not citrullinated. 
 
Inhibition of PPAD 
 Tetracycline and the derivatives doxycycline and minocycline, or the DMARDS 
sulfasalazine and methotrexate do not inhibit PPAD activity at 10 nmol-0.1 mM. This 
demonstates that these agents cannot derive their therapeutic efficiency in RA from 
the direct inhibition of PPAD, but does not exclude a role of PPAD further upstream 
in the disease process. 
 The sulfhydryl-reactive compound 2-chloroacetamidine inhibits PPAD with an IC50 = 
21.5 μM. Complete inhibition accurs at 1 mM 2-chloroacetamidine. This agent could 
be further explored as a basis for developing specific PPAD inhibitors. 
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Chapter 5   
Generation and evaluation of an anti-PPAD antibody and analysis 
of native PPAD and citrullination in vivo 
 
Background 
Having shown that P. gingivalis generates endogenous and host citrullinated proteins and 
peptides in vitro, and that recombinant PPAD is enzymatically active in its full-length form, it 
was of interest to test whether citrullinated proteins are also generated in vivo at site of 
periodontal inflammation and investigate the native form of PPAD. To this end, an anti-
PPAD antibody was required, the production, evaluation and application of which is 
described in this chapter. 
 
Results 
Antigen preparation 
The ideal immunising antigen does not contain protein tags that could result in the generation 
of tag-reactive antibodies. As the Trx-His-PPAD proved to be difficult to cleave with high 
efficiency, it was attempted to re-clone PPAD into a His-tag vector (pET-47b(+), see 
Appendix for detailed information) and use His-tag PPAD as immunising antigen. This 
would add only 19 additional amino acids to the N-terminus of PPAD, possibly increasing 
cleavage efficiency or if that proved to be unsuccessful, result in a shorter, less immunogenic 
tag compared to Trx-His-PPAD. 
 
The PPAD insert was cut from the Trx-His-PPAD construct using the same restriction 
enzyme sites as before, and inserted into the His-vector. Successful and correct insertion was 
confirmed by colony PCR, analytical digest, and nucleotide sequencing (please see Appendix 
for alignments). 
 
Expression of the recombinant protein was tested in BL21 (DE3) and BL21 (DE3) pLysS 
cells. The protein expressed successfully, but only in BL21 (DE3) cells (Figure 5.1), as was 
also the case for Trx-His-PPAD (see Figure 4.6). 
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Figure 5.1 Expression and purification of His-PPAD. (A) E.coli BL21 (DE3) or BL21 (DE3) pLysS 
cells were transformed with a construct encoding His-PPAD (expected size 64 kDa) and recombinant protein 
expression was induced with IPTG („+). No IPTG was added as a control („-„). Cell lysates were resolved on an 
SDS-PAGE gel and total protein stained with Coomassie or transferred onto nitrocellulose membrane and 
recombinant protein detected with anti-his-tag antibody. (B) His-PPAD was purified from BL21 (DE3) 
transformed with His-PPAD construct using his-tag affinity resin. Elution fractions (1-5) are shown. The 
positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the left. 
 
Large-scale expression (3-6 L) was performed twice, but the average recombinant protein 
yield was very low (66 μg/L culture; compared to Trx-His-PPAD: ~750 μg/L culture). As 
~40 L of culture would have been required to produce the required amount of antigen (~2.5 
mg), this approach was deemed ineffectual. 
 
The alternative approach was therefore chosen, in which Trx-His-PPAD was used as an 
antigen, and tag-reactive antibodies would then be removed from the serum by positive 
selection towards a differently tagged PPAD (e.g. GST-PPAD) and/or negative selection 
against the purified Trx-His-tag. For this purpose, Trx-His-PPAD and Trx-His-tag were 
expressed and purified as described previously. 
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An expression vector encoding GST-PPAD was constructed by transferring the PPAD insert 
from the Trx-His-PPAD construct into a GST-encoding construct (pET49b(+)), using the 
same restriction sites. A GST-tag was chosen as it is a large solubility-enhancing tag and easy 
to detect with antibodies. BL21(DE3) and BL21 (DE3) pLysS cells were transformed with 
the expression construct and two clones from each strain were picked to assess recombinant 
protein expression in total cell lysates. Figure 5.2 indicates that full-length GST-PPAD was 
expressed only in BL21 (DE3) cells, as was also the case for Trx-His-PPAD and His-PPAD. 
It should be mentioned at this point that the BL21 (DE3) pLysS cells from the same batch 
were used successfully for expression of other proteins, therefore it can be excluded that they 
were faulty. 
 
 
 
Figure 5.2 Expression of GST-PPAD. E.coli BL21 (DE3) or BL21 (DE3) pLysS cells were transformed 
with a construct encoding GST-PPAD (expected size 87 kDa) and two clones each were chosen to assess 
recombinant protein expression after induction with IPTG („+) or in the absence of IPTG as control („-„). Cell 
lysates were resolved on an SDS-PAGE gel and total protein stained with Coomassie. Probable recombinant 
full-length GST-PPAD is highlighted with a white box and arrow. The positions of the protein molecular mass 
markers in kilodalton (kDa) are indicated on the left. 
 
Next, it was determined whether soluble GST-PPAD can be purified. The total cell extract of 
BL21 (DE3) cells was split into soluble and insoluble fraction by centrifugation and the 
soluble fraction analysed by SDS-PAGE and anti-GST immunoblot. Figure 5.3 A shows that 
soluble full-length GST-PPAD could be purified, along with a truncation of ~31 kDa. In a 
next step, it was assessed whether cleaving the GST-tag is an option. However, as shown in 
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Figure 5.3 B, cleavage was inefficient compared to simple elution of the tagged protein from 
the resin, as had also been the case for Trx-His-PPAD as described previously. Full-length 
GST-PPAD was therefore expressed and purified in large scale (6 L) to be used as an antigen 
for positive affinity purification of anti-PPAD antibodies. The yield was relatively high with 
~2.4 mg/L culture (~3-fold higher compared to Trx-His-PPAD). 
 
 
 
Figure 5.3 Purification of GST-PPAD. (A) E.coli BL21 (DE3) cells were transformed with a construct 
encoding GST-PPAD (expected size 87 kDa) ) and two clones (A and B) were chosen to assess recombinant 
protein expression in the soluble cell fraction after induction with IPTG („+) or in the absence of IPTG as 
control („-„). Total protein was stained with Coomassie or transferred onto nitrocellulose membrane and 
recombinant protein detected with anti-GST-tag antibody. (B) Soluble GST-PPAD was purified from BL21 
(DE3) transformed with GST-PPAD construct using GST-tag affinity resin. GST-PPAD was either eluted from 
the resin using glutathione („Glut-Elution‟) or PPAD was cleaved from the GST tag by PreScission protease and 
the cleaved PPAD eluted from the resin (expected size: 62 kDa). Elution fractions (1-6) and non-eluted proteins 
from the resin beads („B‟) are shown. The positions of the protein molecular mass markers in kilodalton (kDa) 
are indicated on the left. 
 
Screening of rabbit antiserum for anti-PPAD reactivity 
Test bleed #2 (after the initial and two booster immunisations) and final bleed (after a further 
three booster immunisations) were screened for reactivity against Trx-His-PPAD and Trx-
His-tag by ELISA, performed by the manufacturer, and by immunoblot, carried out by myself 
(see Material & Methods for the immunisation timetable). The ELISA results of the serum 
response can be found in the Appendix. In summary, after two booster immunisations, the 
immune response against both Trx-His-PPAD and tag was so strong that the OD values 
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exceeded the maximum value on the standardised chart, therefore appearing as a straight line 
at the top. This showed that the immune response is very effective, but also that there is 
reactivity towards the tag alone.  
 
For the first screening with test bleed #2, serum from the two rabbits that were used for this 
experiment was assessed individually, even though the ELISA results indicated that the 
response is comparable between animals. The serum was assessed at dilutions 1:1,000 (=10
3
), 
1:10,000 (=10
4
) and 1:100,000 (=10
5
). The test antigen was a cleaved PPAD preparation 
which had not been further purified by size-exclusion chromatography and therefore 
contained some uncleaved Trx-His-PPAD and Trx-His-tag (please see Figure 4.11 B).  
 
 
 
Figure 5.4 Screening of rabbit antiserum for reactivity towards PPAD. Two rabbits (No. 4488 = „A‟; 
No. 4489 = „B‟) were immunised with Trx-His-PPAD in complete Freund‟s complete adjuvant. After two 
booster immunisations bleed #2 (A) was collected; the final bleed (B) was collected after another three booster 
immunisations. Serum was diluted as indicated and the reactivity towards 2.5 μg/lane of a PPAD preparation 
was evaluated using an immunoblot procedure. Bound antibodies were detected using HRP-conjugated swine 
anti-rabbit-Ig antibodies (1:5000). Exposure time was 20 seconds for both blots. The positions of the protein 
molecular mass markers in kilodalton (kDa) are indicated on the left. 
 
Figure 5.4 A reflects the ELISA results, showing that reactivity is strong, but is directed 
towards both PPAD and tag. This reactivity increased in the course of the immunisation 
experiment, as stronger signals were obtained at lower dilutions with the final bleed in Figure 
5.4 B.  
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From these results it was clear that the reactivity towards the tag must be eliminated to reduce 
potential cross-reactivity with thioredoxin, especially in bacterial samples, as thioredoxin is a 
conserved protein. A small-scale experiment aimed at negative depletion of tag-reactive 
antibodies by pre-incubating the immune serum with Trx-His-tag did not give the desired 
results, showing that the net effect is a much weaker reactivity towards PPAD compared to 
Trx-His-PPAD or Trx-His tag (Figure 5.5).  
 
 
 
Figure 5.5 Small-scale negative depletion of antiserum with Trx-His-tag. Final bleed serum from 
rabbit B was pre-incubated with purified Trx-His-tag at 1, 10, 100 μg/ml for 1 hour at room temperature. The 
mix was then diluted to 1:1,000 and reactivity assessed towards 2.5 μg/lane of a PPAD preparation by 
immunoblotting. Bound antibodies were detected using HRP-conjugated swine anti-rabbit-Ig antibody. The 
positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the left.  
 
This result was confirmed using P. gingivalis wild-type, Δppad, and E. coli total cell lysates. 
As seen in Figure 5.6, without pre-incubation with tag, the antiserum recognised a doublet 
band in both P. gingivalis wild-type strains around 76 kDa, but not in Δppad or E. coli. A 
second strong band is visible around 12 kDa, most likely representing cross-reactivity with 
bacterial thioredoxin (predicted molecular weight 11.4, 11.8, and 15.5 kDa for P. gingivalis 
thioredoxin and E. coli thioredoxin-1 and -2, respectively). Upon pre-incubation of the 
antiserum with 10 μg/ml Trx-His-tag, the intensity of the majority of cross-reactive bands is 
reduced or eliminated, but so is the PPAD signal. Therefore the alternative approach, positive 
affinity purification using a GST-PPAD affinity resin column, was chosen. 
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Figure 5.6 Negative depletion of antiserum on P. gingivalis cell lysates. Final bleed serum from rabbit 
B was pre-incubated with 10 μg/ml purified Trx-His-tag for 1 hour at room temperature, diluted 1:1000, and 
reactivity assessed towards total cell lysates of two P. gingivalis wild-types (clinical isolates D245 and MaRL), 
a P. gingivalis Δppad knockout strain, and an E. coli strain (DH5α). Bound antibodies were detected using HRP-
conjugated swine anti-rabbit-Ig antibody. The positions of the protein molecular mass markers in kilodalton 
(kDa) are indicated on the left.  
 
Affinity purification was performed by the antibody manufacturer; GST-PPAD for 
derivatisation of the column was prepared by myself (12 mg). 77 ml harvest bleed from the 
two rabbits (pooled) resulted in two eluate fractions: glycine eluate (11 ml at 1.31 mg/ml 
protein) and TEA eluate (40 ml at 0.19 mg/ml protein). These two eluate fractions were then 
evaluated for reactivity towards recombinant PPAD and native PPAD (in P.gingivalis cell 
lysates) by myself using immunoblotting. Figure 5.7 shows that affinity purification of the 
antiserum, most evident with the TEA eluate at a dilution of 1:1000, resulted in a stronger 
reactivity towards PPAD compared to Trx-His-PPAD, tag, or truncated versions. P. 
gingivalis wild-type and Δppad cell lysates were then tested using the TEA eluate at different 
dilutions to establish the optimal concentration for studies of native PPAD. The result was 
positive, as a clean blot without thioredoxin crossreactivity was obtained at all dilutions 
(Figure 5.8). 
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Figure 5.7  Testing of affinity-purified antiserum. 2.5 μg of a cleaved PPAD preparation (A) or a GST-
PPAD preparation (B) were resolved by SDS-PAGE, transferred onto nitrocellulose membrane and 
immunoblotted with different dilutions of either TEA or glycine eluate. Bound antibodies were detected using 
HRP-conjugated swine anti-rabbit-Ig antibody. The positions of the protein molecular mass markers in 
kilodalton (kDa) are indicated on the left.  
 
 
 
 
Figure 5.8  Testing of TEA antiserum eluate on lysates of P. gingivalis WT and Δppad strain. P. 
gingivalis total cell lysates of a wild-type (ATCC 33277) or the corresponding Δppad strain (indicated by „+/- 
PPAD‟) were resolved by SDS-PAGE, transferred onto nitrocellulose membrane and immunoblotted with 
different dilutions of TEA antiserum eluate. Bound antibodies were detected using HRP-conjugated swine anti-
rabbit-Ig antibody. The positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the 
left.  
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Next, native PPAD was detected in a number of P. gingivalis wildtype, clinical isolate and 
Δrgp strains, and compared to recombinant full-length PPAD. Figure 5.9 shows that native 
PPAD appears as a doublet band with approximately the same molecular mass as the full-
length recombinant PPAD (no tag), in all strains except Δppad. A band that would indicate 
the proposed „mature‟ form of PPAD (~46 kDa) was not detected. A weak band in this 
molecular weight range appeared in wildtype strain 33277 but was not reproducible and not 
found in other wild-type or clinical isolate strains. Another finding that supports a full-length 
versus „mature‟ native PPAD is that deletion of arginine-gingipains did not affect the 
molecular mass of the detected PPAD. Arginine-gingipains were suggested to process PPAD. 
The lack of any effect of deletion of arginine-gingipains at least on the molecular mass of 
PPAD indicates that PPAD is not proteolytically processed by arginine-gingipains. 
 
 
 
Figure 5.9  Detection of native PPAD in P. gingivalis strains. Total cell lysates of a wild-type strain 
(ATCC 33277), the corresponding Δppad strain, two clinical isolates (D243, MaRL), and the Δrgp strain were 
resolved by SDS-PAGE, transferred onto nitrocellulose membrane and total protein stained with Ponceau S and 
immunoblotted with the TEA anti-PPAD antiserum (1:1000). A recombinant cleaved PPAD preparation was 
used as positive control („PPAD‟). Bound antibodies were detected using HRP-conjugated swine anti-rabbit-Ig 
antibody. The positions of the protein molecular mass markers in kilodalton (kDa) are indicated on the left.  
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Subcellular localisation of PPAD 
The subcellular localisation of PPAD was examined using fractions prepared from P. 
gingivalis wild-type strain W83. From Figure 5.10 it becomes evident that PPAD is 
associated with fractions containing membrane, but not with the periplasm+cytoplasm 
fraction. The strongest band was observed in the outer membrane fraction. In conclusion, 
PPAD is most likely located on the bacterium‟s cell surface. No conclusions can be made 
about the vesicle+medium and medium fractions as the protein content was too low.  
 
 
 
Figure 5.10  Subcellular localisation of PPAD in P. gingivalis. P. gingivalis strain W83 total cell extract 
(TCE) was fractionated into cell envelope (CE), outer membrane (OM), inner membrane (IM), 
periplasm+cytoplasm (PP/CP), vesicles+medium (V/M) and medium (M) fractions, which were then analysed 
with the anti-PPAD antibody by immunoblotting. The corresponding Coomassie-stained gel showing total 
protein in each of the fractions is shown on the left. The positions of the molecular mass markers in kilodalton 
(kDa) are indicated on the left. Fractions were kindly provided by Yonghua Gho, Louisville University, 
Kentucky. 
 
These results support previous indirect data pointing to a cell surface location of PPAD: (1) 
In Chapter 3 it is described that incubation of whole P. gingivalis cells with 
fibrinogen/enolase results in the citrullination of the proteolytically processed peptides - 
assuming that the majority of bacterial cells are intact, citrullination would require cell-
surface exposed PPAD; (2) In a previous publication (McGraw et al. 1999) PPAD activity 
was determined using either whole cells, supernatant or vesicles, and highest activity was 
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found with whole cells and vesicles, indicating that PPAD is membrane-attached; (3) Figure 
3.6 in Chapter 3 shows that the majority of citrullinated proteins are found in the periplasm 
and membrane fraction, but not in the cytoplasm. Assuming that extensive translocation of 
citrullinated proteins between different subcellular compartments does not take place, this 
indicates a periplasm/membrane location of PPAD. 
 
Cross-reactivity with human PADs 
The availability of the anti-PPAD antibody made it possible to study the cross-reactivity with 
human PADs as a measure of homology. Figure 5.11 shows that the anti-PPAD antibody 
specifically recognises PPAD but not human PAD2 or PAD4, despite the previously 
suggested structural homology between PPAD and human PADs (Shirai et al. 2006). This is 
surprising as the antibody was raised against the whole protein, and not a specific peptide 
sequence, which would have explained the lack of reactivity due to the non-homologous 
nature of the amino acid sequences. 
 
 
Figure 5.11  Cross-reactivity between P. gingivalis PAD and human PADs. Equivalent amounts of 
cleaved recombinant PPAD, three recombinant PAD2 preparations (two cleaved and one uncleaved GST-PAD2) 
and PAD4 (cleaved) were resolved by SDS-PAGE, transferred onto nitrocellulose membranes and probed with 
either anti-PPAD, anti-PAD2, or anti-PAD4 antibody. The positions of the protein molecular mass markers in 
kilodalton (kDa) are indicated on the left. Figure was contributed by our post-doc Dr. Elena Lugli.   
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On the other hand, immunoblotting is a denaturing technique and the results might simply 
reflect the different primary structure of PPAD and human PADs. Therefore, it is possible 
that the structural homology between PPAD and human PADs is not as significant as 
predicted, or that a sufficient amount of antibodies in the polyclonal anti-PPAD preparation 
recognise linear epitopes that are not present in human PADs due to the divergent amino acid 
sequences. A non-denaturing technique such as immunoprecipitation would be better suited 
to investigate this point further. 
 
Detection of PPAD and citrullinated proteins in periodontal tissue and cell culture 
Having shown that P. gingivalis generates endogenous and host citrullinated proteins and 
peptides in vitro, it was of interest to test whether these are also generated in vivo. First, 
gingival crevicular fluid (GCF) from 12 subjects with periodontitis was analysed. GCF is an 
inflammatory exudate containing bacterial and host products and can be collected by washing 
the gingival crevice with a saline solution using a micropipette. As the fluid has a serum-like 
constitution, occasionally mixed with blood, and contains large amounts of immunoglobulins 
and albumin, secondary antibody cross-reactivity in immunoblotting procedure is a point of 
concern and was always controlled for.  
Figure 5.12 shows that discrete citrullinated protein bands were detected in samples 1, 3, 7, 
10, 11, 12 and possibly also in 8 and 9 (difficult to judge because of the background). The 
citrullinated proteins are either in the ~15 kDa or ~50 kDa molecular mass range. Their 
identity was not investigated, but the ~15 kDa protein could be hemoglobin α chain (14 kDa), 
which is present in GCF and was shown to be citrullinated by PPAD (Figure 4.28). Human 
PADs could also contribute to citrullination in GCF as a result of inflammation and tissue 
damage. Unfortunately, these GCF samples are not well-characterised, and a correlation of 
protein citrullination to P. gingivalis load or inflammatory state is not possible. The anti-
PPAD antibody was not available yet at this stage of the project. GCF from healthy subjects 
cannot be obtained using the same method, as they normally do not have enlarged periodontal 
pockets holding significant amounts of GCF. 
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Figure 5.12  Analysis of protein citrullination in gingival crevicular fluid from periodontitis patients. 
Gingival crevicular fluid was collected from 12 periodontitis patients and resolved by SDS-PAGE (peptide gels). 
Total protein was visualised with Coomassie (A) or transferred onto nitrocellulose membranes for detection of 
citrullinated proteins with the anti-modified citrulline antibody (B) and positive signals due to cross-reactive 
secondary antibodies were control by omitting the primary antibody (C). The positions of the protein molecular 
mass markers in kilodalton (kDa) are indicated on the left. Gingival crevicular fluid samples were kindly 
provided by Dr. Sigrun Eick, Bern University, Switzerland. 
 
Next, periodontal tissue was analysed from 8 periodontitis patients and 4 controls for the 
presence of citrullinated proteins and PPAD. The control subjects were adults with no signs 
of periodontitis who were undergoing gingivectomy, which is a surgical aesthetic procedure 
including the removal of undesired gingival tissue. Some inflammation can therefore be 
expected in these tissues, even though much less severe than in periodontitis tissue. Figure 
5.13 shows that PPAD could not be detected in any of the samples (B). In periodontitis 
patients, the tissue is taken from sites that show evidence of periodontal tissue inflammation 
(Figure 5.14) but may not directly harbour P. gingivalis, which is most exclusively found 
deep in the pocket near the root of the tooth (see O'Brien-Simpson et al. 2009).  
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This could explain the lack of detectable PPAD in the periodontitis samples. Further, P. 
gingivalis might be completely absent in a subset of periodontitis patients. Alternatively, P. 
gingivalis might be present in these tissues, but the protein amount analysed was not high 
enough resulting in insufficient bacterial cell mass for detection.  
 
 
 
Figure 5.13  Analysis of protein citrullination and PPAD expression in gingival tissue from 
periodontitis patients and healthy controls. Gingival tissue from subjects with periodontitis (P1-P8) and non-
periodontitis controls undergoing gingivectomy (H1-H4) was lysed and total protein resolved by SDS-PAGE. 
(A) Total protein was stained with Coomassie; (B) Total protein was transferred onto nitrocellulose membrane 
and the presence of PPAD analysed using anti-PPAD antibody. Recombinant PPAD was used a control; (C) 
Representative anti-citrulline immunoblot showing the presence of citrullinated proteins in a selection of 
periodontitis (P2, P3, P6) and healthy (H1, H2, H4) tissue samples; (D) Conjugate control to C. Tissue samples 
were kindly provided by Dr. Shauna Culshaw, Glasgow University, UK. Figure panel B was contributed by our 
research assistant Dr. Anne-Marie Quirke.   
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A representative anti-citrulline blot shows that citrullinated proteins in the 40-80 kDa range 
were detected in all samples, irrespective of periodontal health status (Figure 5.13 C). The 
presence of citrullinated proteins in tissue from both periodontitis patients and controls 
indicates that protein citrullination does occur regardless of disease, and it is not clear what 
the source of the PAD activity is (PPAD, human PADs) and which physiological process the 
citrullinated proteins indicate (normal physiology, general inflammation, periodontitis). In 
summary, the presence of citrullinated proteins does not seem to be a marker for periodontal 
disease or the presence of P. gingivalis. 
 
 
 
 
Figure 5.14 Representative hematoxylin & eosin - stained periodontal tissue from two periodontitis 
patients. Inflamed periodontal tissue was removed from two patients (A, B) with periodontitis during a surgical 
treatment procedure and stained with hematoxylin & eosin (H&E). Nuclei are stained blue and eosiniphilic 
structures (mostly cytoplasm/proteins) is stained red. Inflammatory cells (blue) infiltrating the gingival 
connective tissue (red) can be seen in both samples. Magnification: x200. Pictures were kindly provided by Dr. 
Shauna Culshaw, Glasgow University, UK. 
 
To verify these results further, the anti-PPAD antibody was used to test for the presence of P. 
gingivalis by immunohistochemistry of periodontal tissue from a periodontitis patient. An in 
vitro cell culture using P. gingivalis-infected oral epithelial cells demonstrated that the 
antibody binds to P. gingivalis and does not cross-react with epithelial cells (Figure 5.15). No 
convincing evidence for the presence of P. gingivalis was obtained with a periodontal tissue 
sample (Figure 5.16). A small clump of stained objects was noticeable and could represent a 
cluster of P. gingivalis cells, but this would have to be confirmed in a larger number of 
samples.   
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Figure 5.15  PPAD-staining of an oral epithelial cell line infected with P. gingivalis.  An immortalised 
oral keratinocyte cell line (OKF6) was cultured under anaerobic conditions and stained with anti-PPAD 
antibody (A). As a positive control, cells were infected with P. gingivalis stained with anti-PPAD antibody (B) 
or isotype control (C). Cell nuclei were counterstained blue. Magnification : x400. Pictures were kindly 
provided by Dr. Shauna Culshaw, Glasgow University, UK. 
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Figure 5.16 Periodontal tissue from a periodontitis patient stained with anti-PPAD antibody. (A, B) 
Inflamed periodontal tissue stained with anti-PPAD antibody conjugate (brown). (C, D) Isotype staining to 
control for unspecific signals. Nuclei were counterstained blue. Original magnification : x100 (A, C) and x400 
(B, D). Pictures were kindly provided by Dr. Shauna Culshaw, Glasgow University, UK. 
 
Summary 
 
Anti-PPAD antibody generation and evaluation 
 Trx-His-PPAD was used as immunising antigen as cleavage of Trx-His-tag would 
involve the use agents interfering with immunisation and His-PPAD expression levels 
were insufficient 
 Rabbits developed a very strong immune response towards Trx-His-PPAD, with a 
considerable reactivity directed towards the Trx-His tag 
 Trx-His tag reactivity was eliminated by positive affinity purification with GST-
PPAD 
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 There is no cross-reactivity between PPAD and human PAD2/4: anti-PPAD antibody 
does not bind human PAD2 or PAD4; anti-PAD2 and anti-PAD4 antibodies do not 
bind PPAD 
 
Native PPAD in P. gingivalis 
 Native PPAD in P. gingivalis wild-type, clinical isolates and Δrgp appears as a 
doublet band corresponding in size to the full-length form, ruling out the necessity for 
proteolytic cleavage into a „mature‟ form by Rgp 
 Native PPAD in P. gingivalis wild-type is associated with the membrane fraction, 
suggesting a cell-surface location 
 
Citrullinated protein and PPAD expression in vivo 
 Evidence for citrullinated proteins in gingival crevicular fluid from periodontitis 
patients 
 Citrullinated proteins were also detected in gingival tissue from periodontitis patients 
and controls 
 Whole P. gingivalis cells can be visualised in an oral epithelial cell culture using the 
generated anti-PPAD antibody 
 PPAD could not be detected by immunoblot or immunohistochemistry in gingival 
tissue from periodontitis patients or controls 
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Chapter 6          Discussion and future directions 
 
The aim of this study was to investigate the mechanism of protein citrullination by PPAD, a 
novel bacterial peptidylarginine deiminase enzyme from the periodontal pathogen P. 
gingivalis, and its potential to contribute to anti-citrulline autoimmunity in the development 
of rheumatoid arthritis. 
 
The combined results provide evidence that P. gingivalis is an alternative source in the 
human host for generating citrullinated proteins and peptides. The underlying mechanism - 
proteolytic cleavage and subsequent citrullination at carboxy-terminal arginine residues - 
differs from that of the human PAD enzymes, which preferentially citrullinate internal 
arginine residues in whole proteins. Hence, PPAD creates (i) different epitopes as compared 
to established citrullinated RA autoantigens, and (ii) epitopes to which immunological 
tolerance may not exist, not only due to the presence of foreign citrullinated proteins from the 
bacterium, but also through a foreign mode of proteolytic processing and post-translational 
modification of host antigens. 
 
Using fibrinogen and α-enolase as model antigens, it has been demonstrated that P. gingivalis 
rapidly generates small peptides with carboxy-terminal citrulline residues (Chapter 3). In RA, 
fibrinogen that is citrullinated at internal arginines has at least two possible pathogenic roles, 
serving as an autoantigen and disturbing the coagulation cascade and linked pathways 
(Nakayama-Hamada et al. 2008). In periodontitis, P. gingivalis gingipain-mediated 
degradation of human fibrinogen inhibits fibrinogen polymerization and results in the 
localised bleeding tendency which is typical for chronic periodontitis (Imamura et al. 1995), 
providing valuable nutrients to P. gingivalis and facilitating spreading. However, the role of 
fibrinogen peptides with carboxy-terminal citrulline residues, generated by the combined 
action of gingipain and PPAD, is yet unknown and opens up a novel area for future 
investigations. Arginine-gingipains cleave a number of other human proteins, releasing 
biologically active peptides with C-terminal arginines that have important roles in immunity 
and inflammation, such as C5a (Popadiak et al. 2007) and bradykinin (Imamura et al. 1994; 
Monteiro et al. 2009). Simultaneous citrullination of these peptides by PPAD might have a 
previously unappreciated role in human disease. Chapter 4 shows that proteins with naturally 
occuring C-terminal arginines such as hemoglobin α chain are citrullinated by PPAD in vitro 
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and this might play a role in hemoglobin degradation and heme acquisition by P. gingivalis. 
An important next step would be to identify citrullinated peptides/proteins from in vivo 
sources such as gingival crevicular fluid and investigate their function in the pathophysiology 
of P. gingivalis and to explore their potency for triggering a specific pathogenic immune 
response in animal models of RA. 
 
In fact, the identification of in vivo citrullinated proteins was one of the initial aims of this 
study, but unfortunately could not be carried out because the only reliable antibody available 
on the market to detect citrullinated proteins (the anti-modified citrulline antibody) became 
unavailable in 2009 due to a problem in its manufacturing process. Alternative antibodies 
were tested but did not fulfil the requirements for these experiments, as they did not detect 
citrulline irrespective of neighbouring amino acids. The colorimetric method was 
subsequently chosen as a method of choice for detection of citrullination, which is suitable 
for the analysis of enzyme activity, but not sensitive enough to detect small amounts of 
citrullinated proteins. If the antibody or an alternative becomes available in the future, it 
would be interesting to investigate, in addition to the aims mentioned above, whether for 
example in a mouse model of P. gingivalis infection, citrullination at the site of infection 
differs between mice infected with wildtype P. gingivalis and those with the Δppad strain. 
This would allow a conclusion as to what extent citrullination by host PADs takes place at the 
site of infection. 
 
The pathophysiologic role of bacterial citrullinated proteins from P. gingivalis is unclear. The 
results from Chapter 5 demonstrate a cell-surface localisation of PPAD. In gram-negative 
bacteria, the cell surface is a complex mixture of carbohydrates, lipopolysaccharides, lipids 
and proteins. It protects from and interacts with the environment. Both protein and peptide 
citrullination causes a change in the charge state and thereby is expected to directly affect 
interaction with binding partners, or indirectly through a change in structure in the case of 
proteins. Citrullinated proteins/peptides could therefore have a role in biofilm formation, 
adherence to host cells or to other bacteria, in spreading, recruitment of inflammatory cells 
and inactivation of immunological mediators. For example, arginine and short peptides 
harbouring exposed arginines inhibit the hemagglutinating activity of P. gingivalis (Hayashi 
et al. 1992; Murakami et al. 1992; Hayashi et al. 1993), and peptides harbouring C-terminal 
arginines in particular were shown to inhibit the binding of P. gingivalis fimbriae to 
fibronectin (Kontani et al. 1997). Hence, citrullination of cell-surface attached or released 
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bacterial peptides and proteins with C-terminal arginines by PPAD could play a role in the 
inactivation of potential endogenous inhibitors of hemagglutination and adhesion to the 
extracellular matrix and thereby facilitate colonisation and virulence. Of note, the reverse 
reaction of citrullination has not been described to date, although it is possible that P. 
gingivalis proteolytically degrades citrullinated peptides/proteins and thereby reverses the 
effect of citrullination of these targets. Another pathogenic role of protein/peptide 
citrullination might be the production of ammonia, which increases the local pH in the favour 
of P. gingivalis. However, citrullination is not the only source of ammonia, as it is also 
generated by agmatine and arginine deiminases during catalysis by P. gingivalis and other 
oral bacteria. 
 
Apart from the specificity towards C-terminal arginine residues, it is unclear whether PPAD 
has stringent substrate specificity. Assuming a random selection of short peptides with a C-
terminal arginine residue, it is unknown whether PPAD would citrullinate all peptides with 
equal efficiency, or whether certain anchor residues are favourable. In this study, two 
fibrinogen peptides with C-terminal arginine were probed as PPAD substrates, resulting in a 
comparable degree of citrullination (Figure 4.32 C). However, both peptides were originally 
identified in their citrullinated form from fibrinogen+P. gingivalis cultures, and are therefore 
suitable PPAD substrates by definition, limiting the power of conclusion. Comparing all 
identified citrullinated peptides (Table 3.2), it becomes apparent that serine, proline, and 
glycine are prominent, which might indicate that the presence of these amino acids at certain 
positions within the peptide is favourable for citrullination by PPAD. 
 
The results of this study show that native PPAD in P. gingivalis cells is present in the full-
length form, and not a truncated „mature‟ form as has been suggested (McGraw et al. 1999). 
Chapter 4 shows that full-length recombinant PPAD is stable and active, whereas the „mature‟ 
version is degraded during expression/purification. Five amino acids residues crucial for 
catalysis were identified: Cysteine-351, Asparagine-297, Histidine-236, Aspartic acid-130 
and -238. Towards the final stages of this project, another research group published a paper 
(Rodriguez et al. 2009) presenting data that partly overlap with the work in this thesis (please 
see Table 6.1 for a comparison).  
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Table 6.1 Comparative summary of the resuls on PPAD expression and 
characterisation presented in this thesis and in a recently published paper (Rodriguez et 
al. 2009) 
 
Feature This thesis Rodriguez et al. 2009 
Expression and purification 
of „mature‟ PPAD 
Cloned into pET48b(+) 
vector encoding N-terminal 
thioredoxin-his tag, 
expressed in BL21 (DE3) 
cells at 30˚C, no expression 
in BL21 (DE3) pLysS cells, 
degraded during 
expression/purification 
Cloned into pCRT7/NT-
TOPO vector encoding N-
terminal His-tag and Xpress 
epitope, expressed in BL21 
(DE3) pLysS cells at 37˚C, 
no degradation 
Expression and purification 
of full-length PPAD 
Cloned into pET48b(+) 
vector encoding N-terminal 
thioredoxin-his tag or GST-
tag, expressed in BL21 
(DE3) cells at 30˚C, 
successful purification, no 
expression in BL21 (DE3) 
pLysS cells  
Cloned into pCRT7/NT-
TOPO vector encoding N-
terminal His-tag and Xpress 
epitope, expressed in BL21 
(DE3) pLysS cells at 37˚C, 
no degradation 
Growth kinetics of E. coli 
host cells containing PPAD-
encoding expression plasmid 
Retarded growth observed, 
slow-growing 
Retarded growth observed, 
slow-growing 
Stability of purified PPAD Full-length form: 
temperature-insensitive 
„Mature‟ and full-length 
forms: 
cold-sensitive (aggregation at 
4˚C) 
Enzymatic activity of 
purified „mature‟ PPAD 
not tested because enzyme 
unavailable 
100% 
= 0.175 U/mg 
KM 18 mM 
Enzymatic activity of 
purified full-length PPAD
1
 
23.8 U/mg 
KM 0.10 mM 
40% of „mature‟ PPAD 
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Feature This thesis Rodriguez et al. 2009 
Co-factor requirements for 
PPAD activity 
none none 
Substrate specificity of 
purified PPAD 
Full-length form: 
specificity for C-terminal 
arginines 
„Mature‟ form:  
specificity for C-terminal 
arginines 
Auto-citrullination of PPAD Full-length form: 
Active wild-type PPAD 
overexpressed in E. coli cells 
is auto-citrullinated, no 
additional measurable 
citrullination upon incubation 
in activity assay buffer or 
during storage 
„Mature‟ form: 
PPAD overexpressed in E. 
coli cells is not citrullinated, 
but auto-citrullination occurs 
during prolonged storage, 
resulting in decreased 
activity (see comment in 
text) 
 
1
 Same substrate, buffer, reaction conditions and calculations were used 
 
The biological meaning behind the observed higher activity of the „mature‟ form compared to 
the full-length form in the paper by Rodriguez et al. is unclear, as to date there is no evidence 
of such a „mature‟ form of PPAD in vivo. The findings with regard to substrate specificity are 
comparable to the results in Chapter 4, in that peptide substrates with a C-terminal arginine 
are preferred and the activity with substrates containing internal arginines is insignificant. 
 
One drawback to the paper is that the unspecific colour formation stemming from the 
substrate is not controlled for when using the colorimetric assay (buffer alone instead of 
buffer+substrate alone is used as blank), resulting in the interpretation of consistently low 
absorbance values as low but significant levels of enzyme activity. Notably, this is observed 
when using substrates containing internal arginine residues or lacking important elements of 
the arginine amino acid (e.g. agmatine, dimethyl-L-arginine), which supports the view that 
the “low activity” in fact is background colour formation stemming from the substrate.  
 
Auto-citrullination of PPAD was also addressed by Rodriguez et al., however with a different 
outcome and less convincing results. It is stated that recombinant PPAD, as freshly purified 
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from E. coli, does not contain citrulline residues, but slowly auto-citrullinates itself upon 
prolonged storage. Using quantitative amino acid analysis and the colorimetric citrulline 
detection assay, it is reported that zero citrulline residues are found with freshly purified 
PPAD, but 2 are found with PPAD that had been stored for 21 days, and that the activity of 
the enzyme decreases as a result. Unfortunately, it is not said whether this was reproducible 
and error bars are absent from all graphs, limiting the power to draw conclusions from this 
data. The results on PPAD auto-citrullination as presented in Chapter 4 of this thesis are more 
robust and better controlled, showing that freshly purified wild-type PPAD is already 
citrullinated and enzymatically active, whereas the functional mutants are not citrullinated. 
Here, the colorimetric assay did not give a significant positive signal in any of the 
experiments when used on wild-type PPAD alone, indicating that the absolute level of 
citrullination is low. Prolonged storage of the enzyme and re-assaying with the colorimetric 
method did not result in a change of signal. It is possible that the overall low enzymatic 
activity of PPAD in the study by Rodriguez et al. could have impacted on the ability of 
PPAD to citrullinate itself during expression. On the other hand, it seems surprising that 21 
days of incubation time at room temperature are required to catalyse auto-citrullination. It is 
still unclear whether PPAD auto-citrullination has any physiological significance or whether 
it is an artefact. A next step would be to identify the citrullinated residues of recombinant 
PPAD by mass spectrometry and compare this to native PPAD immunoprecipitated from P. 
gingivalis using the anti-PPAD antibody obtained in this project. 
 
A second paper was published by the same group in September 2010, identifiying cysteine-
351 as a crucial amino acid for catalysis (Rodriguez et al. 2010). Site-directed mutagenesis 
was used to generate a PPAD C351S mutant by replacing cysteine-351 with serine in the 
„mature‟ PPAD. A similar approach was used in Chapter 4 of this thesis, except that cysteine 
was replaced with alanine in full-length PPAD. The results are comparable, as the PPAD 
C351S mutant showed less than 0.01% activity of the wildtype enzyme, confirming that 
cysteine-351 is a crucial residue for analysis as shown in the present project. In this thesis, 
four additional residues have been identified that are required for catalysis: asparagine-297, 
histidine-236, aspartic acid-130 and -238. It is unknown whether the loss of enzymatic 
activity in these mutants is due to a direct loss of function because of missing functional 
elements or due to an indirect loss of function because of an altered three-dimensional 
structure. Spectroscopic analysis should help clarify this question. It has been suggested that 
these amino acids are directly involved in catalysis; therefore, a direct loss of function seems 
 214 
probable. This is also supported by the fact that the mutant proteins did not show any obvious 
alterations in physical properties, such as solubility or temperature sensitivity. 
 
The study by Rodriguez et al. (2010) also investigated iodoacetamide and iodoacetic acid as 
inhibitors of PPAD. Both compounds, like 2-chloroacetamidine which was used in Chapter 4 
of this thesis, are sulfydryl-reactive alkylating agents (Figure 6.1), again suggesting a crucial 
cysteine residue in the catalytic centre of PPAD. This is further supported by the fact that the 
presence of substrate protected from inactivation, as reported by the authors. Mass 
spectrometry analysis of iodoacetamide-treated PPAD showed modification of cysteine-351, 
providing further evidence that cysteine-351 is essential for catalysis and modified by 
alkylating agents, resulting in loss of activity. 
 
 
 
Figure 6.1 Chemical structures of PPAD inhibitors. The structures were created by myself using 
ACD/Chemsketch.  
 
PPAD inhibition is a potential strategy for the development of an antibacterial agent and also 
an anti-rheumatic drug, providing the link between P. gingivalis infection and RA is 
substantiated. Its role as a definite virulence factor for P. gingivalis has not yet been 
published, but preliminary studies with our collaborator Jan Potempa, Jagiellonian University 
Krakaw, Poland, convincingly show that PPAD is indeed a virulence factor in the 
subcutaneous chamber model of P. gingivalis infection. In this model, live P. gingivalis cells 
are injected into a small coil-shaped chamber that has been subcutaneously implanted into 
mice. The Δppad knockout strain is rapidly cleared by the immune system, whereas the wild-
type strain results in high levels of local and systemic inflammation. This is reflected by 
lower numbers of local pro-inflammatory cells but a higher proportion of viable pro-
inflammatory cells, and less weight loss in mice infected with the Δppad knockout strain as 
compared to wild-type (Jan Potempa and Katarzyna Maresz, personal communication). 
Indirect evidence comes from a recent proteomics study reporting that PPAD is one of 14 
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proteins that are upregulated in vivo using the same model, when compared to P. gingivalis 
grown in culture (Yoshimura et al. 2008).   
 
Targeting PPAD could be achieved by (i) direct inhibition with small chemical compounds; 
(ii) direct inhibition using monoclonal antibodies (passive vaccination); (iii) indirect 
inhibition using a PPAD vaccine (active vaccination). Chapter 5 shows that PPAD is surface-
exposed, making it a good drug target. Its catalytic mechanism is, in principle, analogous to 
human PADs and other members of the guanidine-group modifying enzymes superfamily, 
raising the question of specificity and potential side effects when using small chemical 
compounds that target the catalytic centre. Simple alkylating agents such as 
chloroacetamidine or iodoacetamide are unspecific and would be expected to be toxic due to 
their general alkylating activity. More sophisticated and targeted inhibitors would be required, 
such as those currently in development for human PADs (Knuckley et al. 2010b; Willis et al. 
2011). A potential strategy could be to capitalise on the substrate specificity of PPAD 
towards C-terminal arginines, by combining an alkylating warhead with a suitable peptide 
substrate containing a C-terminal arginine. 
 
 
 
Figure 6.2 Chemical structure of a potential peptide-based PPAD inhibitor. Depicted is a peptide 
consisting of n amino acids and a carboxy-terminal arginine derivative in which the ω amino group is replaced 
by a chloromethyl group. Alternatively, a fluoromethyl group could be used. R = amino acid side chain. This 
structure was created by myself using ACD/Chemsketch. 
 
A drawback to using peptide-based inhibitors is their bioavailability with the risk of 
degradation by proteases/peptidases. An alternative approach would be direct inhibition by 
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monoclonal antibodies. Monoclonal antibodies have the advantage of being highly specific, 
but are associated with higher development and production costs. Although having a similar 
catalytic mechanism, the amino acid sequence of PPAD has no significant similarity to any 
known human proteins. The three-dimensional structure of the catalytical domains of PPAD 
and human PADs were suggested to be homologous based on bioinformatic prediction (Shirai 
et al. 2006), but the overall surface-accessible structure might be significantly different, 
enabling the development of an inhibitory specific monoclonal antibody to PPAD without 
crossreactivity to human PADs or other members of the GME superfamily. 
 
The question arises, however, whether such an antibody would bind PPAD in a way that 
prevents enzymatic activity and whether the antibody would resist the proteolytic attack by 
gingipains. This is also important for the third approach, vaccination against PPAD. PPAD is 
surface-exposed and probably highly immunogenic due to its pathogenic origin. The 
extraordinarily high antibody response to PPAD in rabbits after immunisation, as reported in 
Chapter 5, supports this view. However, for a vaccine or an antibody to be effective, the 
antibodies must reach the site of infection, bind to their target(s) with high affinity and 
avidity and activate downstream effector mechanisms. A degradation of antibodies by 
gingipains would preclude efficient binding of the antibody and recruitment of downstream 
effectors. Therefore, a solution for both the monoclonal antibody and vaccine approach could 
be the combination of gingipain and PPAD antibodies/vaccine, targeting the two potentially 
most potent virulence factors in P. gingivalis. In fact, topical application of a monoclonal 
antibody (Mab 61BG1.3) that recognises the hemagglutinin domain of gingipains onto the 
cleaned tooth surfaces has been shown to prevent recolonisation by P. gingivalis for up to 6 
months. The association with periodontal disease activity was less evident (Booth et al. 1997). 
Vaccination efforts so far used heat- or formalin-killed whole P. gingivalis cells, or specific 
antigens, namely gingipains, fimbriae, and capsular polysaccharide (reviewed by Choi et al. 
2010), showing that immunised animals (mice, rats, guiny pigs, macaque monkey) produce a 
significant antibody response to P. gingivalis, compared to controls (reviewed by Persson 
2005). Protection from colonisation with P. gingivalis and lower levels of alveolar bone loss 
following immunisation were reported only in a few studies, most of them using whole cells 
as immunogen (reviewed by Persson 2005), further supporting the view that a combination of 
antigens that target multiple virulence pathways, such as gingipains and PPAD, might be the 
way forward. A major obstacle in the development of a vaccine is the fact that experimental 
animal models of periodontal disease are not representative of the multifactorial and 
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polymicrobial nature of human periodontitis, and trials in humans have not yet been 
performed. As periodontitis is a polymicrobial disease, prevention of colonisation by or the 
virulent activity of P. gingivalis alone might not eradicate the disease in all cases, but 
nevertheless would be expected to significantly lower incidence when used as a preventive 
strategy, and decrease disease activity when used as a therapeutic strategy. A major effort to 
develop a vaccine is underway at the Cooperative Research Centre for Oral Health Science 
from the University of Melbourne, in cooperation with the biopharmaceutical companies CSL 
Ltd and Sanofi Pasteur, reporting that clinical trials in humans are scheduled to start in three 
to four years.
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Summary and Outlook 
The initial simple hypothesis on which this project and several other studies and reviews at 
that time were based, is that periodontal inflammation in the presence of P. gingivalis results 
in protein citrullination by PPAD, which - in the context of genetic and environmental 
susceptibility factors - triggers a defensive antibody response against bacterial citrullinated 
proteins. These antibodies then cross-react with conserved human antigens in the joint (e.g. 
enolase), which are citrullinated by human PADs as a result of subclinical tissue injury, 
causing more tissue injury and contributing to the development of chronic joint inflammation. 
 
The discovery in the course of this project that PPAD citrullinates C-terminal arginines only 
was an important step towards evaluating this hypothesis. This indicated that citrullination of 
bacterial proteins at internal arginines by PPAD, as a potential mechanism for triggering 
autoantibodies to conserved human homologues (i.e. enolase) via molecular mimicry, which 
initially was the hypothesis behind this work (Lundberg et al. 2008 and Figure 1.10), is 
unlikely. Citrullination of bacterial proteins at internal arginines could still be the result of the 
action of human PAD enzymes present at the site of oral inflammation. To investigate this 
alternative scenario, it would be necessary to test whether human PADs are expressed and 
active at the site of oral inflammation, whether oral inflammation triggers citrullination, 
whether citrullinated (at internal arginines) bacterial antigens can be detected at the site, and 
whether an antibody response is triggered in periodontitis patients to these antigens. A recent 
study presented as an abstract at the American College of Rheumatology Meeting in 2009 
(Nesse et al. 2009) reported the presence of citrullinated proteins in periodontal tissue from 
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periodontitis patients (6 out of 15) using immunohistochemistry. Citrullinated proteins and 
human PAD2 were also demonstrated in gingival crevicular fluid of controls taken from sites 
with low levels of gingival inflammation (4 and 6 out of 8, respectively), using 
immunoblotting. Although healthy controls were not investigated in this study, the results 
show that protein citrullination is widespread in inflamed tissue and that human PAD2 is 
expressed at sites of gingival inflammation. These results support the findings in Chapter 5: 
analysis of in vivo citrullination in periodontal tissue showed that citrullinated proteins can be 
found in tissue from both healthy subjects and patients with periodontitis. Taken together, 
these results show that human PADs are active in healthy periodontal tissue as well as 
bacterial periodontal inflammation, which means that citrullination in gingival tissue is not in 
itself an indicator of periodontitis or infection with P. gingivalis and that citrullination by of 
proteins from pathogenic bacteria by human PADs during periodontal inflammation could 
contribute to the generation of bacterial antigenic epitopes, such as citrullinated P. gingivalis 
enolase. It must be noted that the potential contribution of other pathogenic oral bacteria or 
commensals is not taken into account here. 
 
The finding that PPAD and human PADs produce different citrullinated epitopes prompted 
the view that antibodies that are generated against PPAD-generated epitopes might not 
recognise proteins/peptides generated by human PADs. Thus, the antibody response in serum 
from RA patients against citrullinated fibrinogen peptides that are generated by P. gingivalis 
PAD (C-terminal citrulline) versus analogous peptides that are generated by human PADs 
(internal citrulline) was investigated. The results showed that reactivity to these PPAD-
generated peptides is infrequent (5-6%) and not statistically significant compared to healthy 
controls, whereas the reactivity to PAD-generated epitopes is frequent (23-46%) and 
statistically significant. Although only two such peptide pairs were tested, the results suggest 
that in active RA, reactivity to these PPAD-generated peptides is indeed absent or low. 
 
The findings and discussion presented here led to an amendment and refinement of the initial 
hypothesis: there are two sources for citrullinated proteins/peptides in periodontal tissue: (i) 
human citrullinated proteins generated by human PADs are constitutively expressed in health 
and/or induced temporarily as a result of local tissue injury (for example during surgery or 
gingival inflammation), an immune response to these proteins is not mounted as they are the 
result of normal physiology; (ii) human and P. gingivalis citrullinated proteins are generated 
during periodontal infection with P. gingivalis by both human PADs and P. gingivalis PAD. 
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Proteins/peptides citrullinated by P. gingivalis PAD contain C-terminal citrulline residues. 
Proteins/peptides citrullinated by human PADs contain internal citrulline residues. Human 
and bacterial peptides citrullinated by P. gingivalis PAD contain epitopes that cannot be 
generated by the activity of human PADs and are therefore likely to have been previously 
hidden from immune surveillance. In the context of bacterial infection and periodontal 
inflammation in a genetically susceptible host, this may trigger an immune response. 
Bacterial proteins citrullinated by human PADs at internal arginines (e.g. P. gingivalis 
enolase) may also trigger an immune response due to their foreign origin and presentation in 
an infectious context. Antibodies bind to internally citrullinated epitopes on joint proteins (e.g. 
fibrinogen, enolase) as a result of cross-reactivity and epitope spreading, causing more tissue 
injury and contributing to the development of chronic joint inflammation. Figure 6.3 depicts 
the amended hypothesis based on the results and discussion in this thesis.  
 
There are still several uncertainties in this hypothesis, which requires further careful testing. 
One important step will be to investigate a large and well-characterised cohort of serum from 
periodontitis patients for antibodies to P. gingivalis-generated citrullinated epitopes, as it is 
unknown whether the citrullinated proteins/peptides generated by P. gingivalis are 
immunogenic. If indeed an effective antibody response is mounted to citrullinated epitopes in 
periodontitis, longitudinal studies would be required to investigate whether there is an 
association with the development of seropositive RA. 
 
The potential role of T cells is another important factor to consider. In periodontal disease, 
different T cell subsets seem to predominate at different stages of disease (progressive vs. 
stable) and with this different cytokine profiles contribute to the disease course, with a bias 
towards a Th1-response at diseased sites, although this is much debated, and evidence for an 
involvement of Th17 cells exists (reviewed by Gemmell et al. 2007). However, studies also 
show that gingipains degrade a range of Th1 and Th2 cytokines (IL-12, INF-γ, IL-4, IL-5) 
(reviewed by Pathirana et al. 2010). The result might therefore be general immune 
dysregulation rather than a specific bias towards a certain T cell response. It is unknown how 
citrullinated peptides and proteins generated by P. gingivalis are processed and presented by 
antigen-presenting cells. 
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Figure 6.3 Schematic illustration of the amended hypothesis for the role of P. gingivalis-mediated 
citrullination in the development of RA. a) Gingiva: human proteins/peptides are citrullinated at internal 
arginines in healthy gingiva or during mild unspecific inflammation through the activity of human PADs (blue 
peptide). Citrullinated proteins are recognised as „self‟ and an immune response is not mounted. During 
periodontal inflammation in the presence of P. gingivalis, human and bacterial proteins/peptides are citrullinated 
at internal arginines by human PADs (blue peptides) and at C-terminal arginines by PPAD (red peptides). In the 
context of danger signals, the immune system is activated and antibodies against these citrullinated antigens are 
produced. Host and P. gingivalis citrullinated proteins/peptides generated by PPAD may assist the bacterium in 
adhesion to host cells, immune evasion and nutrient acquisition (symbolised by the red loop). b) Joint: a second 
inflammatory event occurs in the joint, leading to citrullination of joint proteins at internal arginines by human 
PADs. Anti-citrullinated protein/peptide antibodies initially formed as a result of P. gingivalis-mediated 
periodontal inflammation recognise citrullinated joint antigens as a result of epitope spreading and cross-
reactivity. The formation of immune complexes in the joint perpetuates the inflammatory process and 
contributes to the development of RA. Abbreviations: ACPA, anti-citrullinated protein/peptide antibody; APC, 
antigen presenting cell; LPS, lipopolysaccharide; P. gingivalis, Porphyromonas gingivalis; PAD, 
peptidylarginine deiminases; PPAD, P. gingivalis PAD; RA, rheumatoid arthritis; SE, shared epitope. „Bacterial‟ 
refers to P. gingivalis. The role of other oral pathogenic bacteria or commensals is not taken into account here. 
Question marks indicate areas for future investigation. This figure is based on a published review article co-
authored by myself (Lundberg et al. 2010). 
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Further, the activation of citrulline-specific B cells would rely on the presentation of the 
peptide in the peptide-binding groove of MHC molecules in such a manner than the C-
terminal citrulline residue is specifically recognised by T cell receptors. Studies aimed at 
demonstrating the activation of citrulline-specific T cells in human RA or animal models 
have been of only limited success, with only two studies demonstrating specific activation of 
T cells: peripheral blood mononuclear cells from RA patients but not from healthy controls 
proliferated upon stimulation with a citrullinated aggrecan peptide, but not when stimulated 
with the arginine-containing controls peptide (von Delwig et al. 2010); however, citrullinated 
aggrecan is not a known target of autoantibodies in RA. Further, a citrullinated vimentin-
derived peptide was shown to activate T cells from a DR4-IE transgenic mouse (Hill et al. 
2003). Studies using the CEP-1 peptide from enolase have been unfruitful so far (Patrick 
Venables, personal communication). These results may indicate that T cells do not play a 
major role in the induction of citrulline-specific autoantibodies in RA. Before any prediction 
for periodontitis can be made, more studies on the T cell and antibody response to 
citrullinated peptides in periodontitis patients are indicated.  
 
Despite the fact that bacterial citrullination offers an attractive hypothesis for the explanation 
of the association between periodontitis and RA on a molecular basis, this association might 
also be indirect, in that periodontal inflammation generates a chronic systemic pro-
inflammatory state where bacterial products (e.g.LPS) dysregulate the immune system, 
exacerbating joint inflammation and the formation of an autoimmune response (discussed by 
Mercado et al. 2003; de Pablo et al. 2009). A recent study might support this view. Sponges 
impregnated with heat-killed P. gingivalis were implanted into the backs of rats, establishing 
a chronic inflammatory lesion, and adjuvant arthritis was induced 35 days later. The authors 
reported that severe arthritis developed more rapidly in animals with pre-implanted P. 
gingivalis (Bartold et al. 2010). While the mechanism of arthritis enhancement cannot be 
deducted from the data, it shows that the presence of inactivated P. gingivalis has the 
potential to exacerbate the development of arthritis. It is unclear whether enzymatic 
mechanisms such as citrullination by PPAD could have partly mediated the effect, as the 
bacteria were heat-killed at 60˚C for 5 min, and it is not known to what extent PPAD resists 
such conditions. However, the contribution of human PADs at the site of inflammation 
cannot be excluded. Studies at a collaborator‟s laboratory have shown that CIA-induced 
arthritis in mice is more severe in the presence of (live) P. gingivalis wild-type bacteria as 
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compared to the Δppad strain, indicating an active role of PPAD in the exacerbation of 
arthritis (Jan Potempa and Katarzyna Maresz, personal communication). 
  
Whether direct or indirect, should a link between P. gingivalis and RA be confirmed, the 
prevention and treatment of periodontal disease would become an even more important health 
focus and drugs targeting important virulence factors such as PPAD and gingipains would be 
expected to be a promising strategy. 
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Appendix 
Alignment of P. gingivalis PAD with Cloacamonas acidaminovorans 
B0VH37 
 
PG = Porphyromonas gingivalis W83 peptidylarginine deiminase 
CA = Cloacamonas acidaminovorans B0VH37 
 
Predited catalytic residues in PPAD are highlighted in grey. 
 
PG 2   KKLLQAKALILALGLFQLPAIAQTQMQADRTNGQFATEEMQRAFQETNPPAGPVRAIAEY  61 
CA 4   QRILRILLLCSVLCILSSTAFAHHNLPADKANAEIR-------FTETNPPVAPVRPIAEF  56 
       ---*----*---*------*-*-----**--*-----------*-*****--***-***- 
 
PG 62  ERSAAVLVRYPFGIPMELIKELAKNDKVITIVASESQKNTVITQYTQSGVNLSNCDFIIA 121 
CA 57  EPASDVLIRYPLGIPVSLVVQLANTANVICIVSS-SQQSSAISTFTNAGVNMERVSFLNA 115 
       *----**-***-***--*---**----**-**-*-**----*---*--***-----*--* 
 
PG 122 KTDSYWTRDYTGWFAMYDTNKVGLVDFIYNRPRPNDDEFPKYEAQYLGIEMFGMKLKQTG 181 
CA 116 ATDSYWTRDYGPWFIFDGNDEYGVVDFIYNRPRPNDNLIPQVFANHFALNYYGMNLQQTG 175 
       -*********--**--------*-************---*---*--------**-*-*** 
 
PG 182 GNYMTDGYGSAVQSHIAYTENSSLSQAQVNQKMKDYLGITHHDVVQDPNGEYINHVDCWG 241 
CA 176 GNYMSDGINTAAQTTLVYTENGN-NQTNVNTKMQQYLGITNYLVMTDPNNTYIEHIDCWA 234 
       ****-**---*-*----****----*--**-**--*****---*--***--**-*-***- 
 
PG 242 KYLAPNKILIRKVPDNHPQHQALEDMAAYFAAQTCAWGTKYEVYRALATNEQPYTNSLIL 301 
CA 235 KFLAPDKVMIRSVPASHSQYNAIENAANYFATHNCAWGYPYRVYRVYTPSNEPYTNSLIL 294 
       *-***-*--**-**--*-*--*-*--*-***---****--*-***-------******** 
 
PG 302 NNRVFVPVNGPASVDNDALNVYKTAMPGYEIIGVKGASGTPWLGTDALHCRTHEVADKGY 361 
CA 295 NKKVFVPIVG-SSNDNSALQAYREAMPGYEVIGVSQISSAPWESTDALHCRTHEIPDKNM 353 
       *--****--*--*-**-**--*--******-***---*--**--**********--**-- 
 
PG 362 LYIKHYPILG-EQAGPDYKIEADVVSCANATISPVQCY--YRINGSGSFKAADMTMESTG 418 
CA 354 LNIVHTPWHSIVPVGTDIIINTEIIAHSGQPLYTDSLFVCYKVN-SGAWQRNYLQPLTRN 412 
       *-*-*-*-------*-*--*--------------------*--*-**------------- 
 
PG 419 HYTYSFTGLNKNDKVEYYISAADNSGRKETYPFIGEPDPFKF 460  
CA 413 YYTVTLNGFAYGDTIRYFIHAADQSGRSVDHPVFAALDPHLF 454 
       -**----*----*---*-*-***-***----*-----**--* 
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Identification of citrullinated peptides by tandem mass spectrometry 
A good introduction to general aspects of peptide sequencing by mass spectrometry is given 
in a recent review by Steen and Mann (Steen et al. 2004). Here, I will focus on the relevant 
information regarding identification of citrulline residues in peptides. 
Peptides can fragment in the mass spectrometer via several different pathways. Cleavage 
between the carbonyl group and the nitrogen of the peptide bond (shown in the diagram 
below) is the most important fragmentation process in collision-induced dissociation (CID) of 
peptides. The fragments produced may retain either the original carboxyl end of the peptide, 
or the original amino end. Fragments containing the original amino terminus are known as B 
ions, and fragments containing the original carboxyl-terminal end of the peptide are known as 
Y ions. If trypsin or other arg/lysine-specific proteases (such as gingipains in this project) are 
used for the generation of peptides, the formed peptides will harbour a positive charge on the 
carboxyl-terminal end. Therefore, after CID, Y type fragment ions are predominantly (but not 
exclusively) detected, as they retain the positive charge conferred by arginine/lysine at the 
carboxy-terminus. The diagram below illustrates the conventional nomenclature for peptide 
fragment ions. The residue cleaved is indicated by a superscripted number, counting from the 
appropriate end.  
 
 
 
 
The amino acid sequence of the parent ion (injected peptide) can be concluded from the mass 
difference between the Y-ion or B-ion series. Conversion of arginine to citrulline results in a 
mass increase of ~1 Da. This is done automatically by a search algorithm in the first instance, 
highlighting potential hits. Each candidate peptide is then carefully inspected to rule out 
another amino acid modification (deamidation of asparagines and glutamine residues) which 
results in the same mass increase of ~1 Da.  
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Example 
In Chapter 3, citrullination of the carboxyl terminal arginine residue of the fibrinogen-derived 
peptide ESSSHHPGIAEFPScit was identified. The first fragmentation diagram below shows 
the theoretical mass differences between the B- and Y-series ions of the arginine-containing 
peptide (ESSSHHPGIAEFPSR). In the case of a C-terminal citrulline residue (see second 
diagram below), the mass of all Y-series ions will be shifted (+1 Da) compared to the Y-
series ions of the arginine-containing peptide, beginning with the Y1 ion as this is the ion 
containing the C-terminal amino acid only. All other Y ions retain, by definition, the original 
C-terminal amino acid, and will therefore be shifted as well. The B ions contain the original 
amino-terminal end but not the original carboxy-terminal end and will therefore not be 
shifted.  
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Usually, not all possible ions of a series are detected, but the combination of the available Y- 
and B-ion data enables the deduction of the amino acid sequence of the peptide. 
 
Tandem mass spectrum of ESSSHHPGIAEFPS(Cit): 
x-axis: mass-to-charge ratio (m/z) of the detected fragments 
y-axis: frequency of the detected fragment ions in % relative to the most frequently detected 
fragment ion (100%, here y‟‟3) 
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List of peptides generated after incubation of human fibrinogen and α-
enolase with P. gingivalis 
 
Comments: 
 
The m/z ratio is the mass-to-charge ratio of the precursor peptide (before fragmentation), 
followed by the number and type of elementary charges on the ion (peptide ion charge state, 
number in brackets). The mass-to-charge ratio is a dimensionless, physical quantity of the 
peptide ions that determines their separation in the electromagnetic field of the mass 
spectrometer. The same peptide can exist in several different charge states, giving rise to 
different m/z ratios. To deduct the original mass of the peptide, the m/z ratio needs to be 
multiplied by the peptide ion charge state. 
 
The Mascot score is a probability-based score from the Mascot search engine, which is used 
to identify the source proteins based on the mass spectrometry data. The total score is the 
absolute probability that the observed match is a random event. The score is reported as -
10*LOG10(P), where P is the probability for a match to be a random effect. A probability of 
P= 0.01 thus becomes a score of 20. The higher the score, the lower is the probability that the 
match is random. The threshold value for a significant match depends on the number of 
entries of the database searched and was around 67 (p<0.05). However, the experimentally 
obtained score highly depends on the frequency of the individual detected peptides, which is 
expected to be low in a relatively complex and dilute sample such as analysed here. In this 
case, a manual and careful inspection of the raw sequence data is required, which was mainly 
performed by Dr. Robin Wait.    
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Table 1 Mass spectrometry analysis of peptides generated after incubation of 
human fibrinogen with P. gingivalis wild-type (WT) or Δppad strains.  
Amino acids that would be present in the uncleaved proteins located carboxy- and amino-
terminal to the identified peptides are indicated (separated by a full stop) to demonstrate sites 
of proteolytic cleavage. Identified citrulline residues (Cit) are underlined. 
 
Sequence
 
Protein Location  
(amino 
acids) 
Strain m/z ratio Mascot Score 
-.ADSGEGDFLAEGGGVCit.G Fibrinogen 
α-chain 
1-16  WT  
 
769.29 (+2) 
 
56 
 
-.ADSGEGDFLAEGGGVR.G     Δppad 768.77 (+2) 99 
R.GGSTSYGTGSETESPCit.N  Fibrinogen 
α-chain 
253-268 WT 546.91 (+3) 51 
R.GGSTSYGTGSETESPR.N   Δppad 786.82 (+2) 78 
R.NPGSSGTGGTATWK.P Fibrinogen 
α-chain 
290-303 WT 
 
Δppad 
660.78 (+2) 
 
660.77 (+2) 
105 
 
75 
P.GSSGTGGTATWK.P  292-303 Δppad 555.25 (+2) 77 
G.SSGTGGTATWK.P  293-303 Δppad 556.73 (+2) 72 
T.LSGIGTLDGFR.H Fibrinogen 
α-chain 
481-491 Δppad 568.28 (+2) 46 
R.HPDEAAFFDTASTGK.T Fibrinogen 
α-chain 
494-508 WT 797.32 (+2) 115 
K.ESSSHHPGIAEFPSCit.G Fibrinogen 
α-chain 
540-554 WT 819.83 (+2) 98 
S.SHHPGIAEFPSR.G  543-554 Δppad 445.54 (+3) 39 
K.MADEAGSEADHEGTHST.K Fibrinogen 
α-chain 
584-600 WT 
 
582.19 (+3) 
 
85 
K.MADEAGSEADHEGTHSTK.R  584-601 Δppad 624.90 (+3) 72 
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Sequence
 
Protein Location  
(amino 
acids) 
Strain m/z ratio Mascot Score 
A.DEAGSEADHEGTHST.K  586-600 WT 771.78 (+2) 81 
R.PAPPPISGGGYCit.A Fibrinogen 
β-chain 
31-42 WT 585.30 (+2) 26 
R.PAPPPISGGGYR.A   Δppad 584.77 (+2) 65 
K.DNENVVNEYSSELEK.H Fibrinogen 
β-chain 
134-148 WT 884.83 (+2) 
 
106 
 
   Δppad 884.86 (+2) 74 
K.GGETSEMYLIQPDSSVK.P Fibrinogen 
β-chain 
218-234 WT 
 
920.87 (+2) 106 
Y.LIQPDSSVK.P  226-234 Δppad 493.78 (+2) 48 
R.QDGSVDFGR.K Fibrinogen 
β-chain 
256-264 Δppad 490.70 (+2) 51 
K.QGFGNVATNTDGK.N Fibrinogen 
β-chain 
271-283 WT 654.74 (+2) 117 
G.FGNVATNTDGK.N  273-283 WT 562.25 (+2) 62 
K.EDGGGWWYNR.C Fibrinogen 
β-chain 
397-406 Δppad 
 
620.22 (+2) 40 
K.PNMIDAATLK.S Fibrinogen γ-
chain 
76-85 WT 537.29 (+2) 62 
K.DTVQIHDITGK.D Fibrinogen γ-
chain 
141-151 WT 
 
613.79 (+2) 99 
 
K.EGFGHLSPTGTTEFW.L Fibrinogen γ-
chain 
213-227 Δppad 883.38 (+2) 52 
R.VELEDWNGR.T Fibrinogen γ-
chain 
248-256 Δppad 559.24 (+2) 41 
F.AGGDAGDAFDGFDFGDDPSDK.F Fibrinogen γ-
chain 
282-302 Δppad 1038 (+2) 72 
R.LTIGEGQQHHLGGA.K Fibrinogen γ-
chain 
392-405 WT 
 
709.31 (+2) 71 
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Sequence
 
Protein Location  
(amino 
acids) 
Strain m/z ratio Mascot Score 
T.IGEGQQHHLGGA.K  394-405 WT 
 
Δppad 
401.84 (+3) 
 
602.28 (+2) 
74 
 
65 
 
Table 2 Mass spectrometry analysis of peptides generated after incubation of 
human α-enolase with P. gingivalis wild-type (WT) or Δppad strains. 
 
Sequence
 
Location  
(amino acids) 
Strain m/z ratio Mascot Score 
G.ASTGIYEALELR.D 39-50 Δppad 661.83 (+2) 78 
S.TGIYEALELCit.D 41-50 WT 583.30 (+2) 24 
S.TGIYEALELR.D 41.50 Δppad 582.79 (+2) 56 
K.LNVTEQEK.I 82-89 WT  
Δppad 
480.76 (+2) 
480.75 (+2) 
43 
39 
R.HIADLAGNSEVI.L 133-144 Δppad 619.81 (+2) 65 
R.HIADLAGNSEVILPVPA.F 133-149 WT 858.44 (+2) 86 
R.HIADLAGNSEVILPVPAF.N 133-150 WT  
Δppad 
931.99 (+2) 
931.98 (+2) 
26 
50 
R.HIADLAGNSEVILPVPAFN.V 133-151 WT 
Δppad 
989.02 (+2) 
988.99 (+2) 
61 
28 
K.DATNVGDEGGFAPNILEN.K 203-220 WT 
Δppad 
916.90 (+2) 
916.89 (+2) 
69 
32 
G.MDVAASEFFR.S 244-253 Δppad 586.77 (+2) 23 
K.DYPVVSIEDPFDQDDWGAWQ.K 286-305 WT 1191.49 (+2) 27 
S.IEDPFDQDDWGAWQ.K 292-305 WT 861.34 (+2) 77 
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Sequence
 
Location  
(amino acids) 
Strain m/z ratio Mascot Score 
S.AGIQVVGDDLTVTNPK.R 311-326 WT  
Δppad 
813.90 (+2) 
813.94 (+2) 
84 
62 
A.GIQVVGDDLTVTNPK.R 312-326 WT 
Δppad 
778.39 (+2) 
778.38 (+2) 
98 
98 
G.IQVVGDDLTVTNPK.R 313-326 WT 
Δppad 
749.88 (+2) 
749.89 (+2) 
106 
81 
I.QVVGDDLTVTNPK.R 314-326 Δppad 693.34 (+2) 83 
Q.VVGDDLTVTNPK.R 315-326 WT 629.33 (+2) 42 
 
Table 3 Mass spectrometry analysis of citrullinated peptides generated after 
incubation of human α-enolase with P. gingivalis Δkgp. 
 
Sequence
 
Location  
(amino acids) 
Strain m/z ratio Mascot Score 
V.EVDLFTSKGLFCit.A 21-32 Δkgp 706.85 (+2) 88 
P.SGASTGIYEALELCit.D 37-50 Δkgp 734.36 (+2) 39 
D.FKSPDDPSCit.Y 261-269 Δkgp 525.23 (+2) 28 
S.AGIQVVGDDLTVTNPKCit.I 311-327 Δkgp 892.47 (+2) 62 
R.IEEELGSKAKFAGCit.N 413-426 Δkgp 768.40 (+2) 20 
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Alignment of PPAD with Streptococcus mutans agmatine deiminase 
 
Target (PPAD) - Template (S. mutans agmatine deiminase, 2ewoA) alignment  
 
Identical (id.) residues are marked in line three of each row, with the predicted catalytic 
residues of PPAD highlighted in grey. 
 
 
 
PPAD            -RAFQETNPPAGPVRAIAE---------Y-------ERSAAVLVRYPFGIPMELIKELAK  
2ewoA           AKRIKNTTPKQDGFRXPGEFEKQKQIWXLWPWRNDNWRLGAKPAQ---KAFLEVAEAISE  
id. residues    ......T.P.....R...E..................R..A...........E.......  
 
PPAD            NDKVITIVASESQKNTVITQYTQSGVNLSNCDFIIAKTDSYWTRDYTGWFAMYDTNKVGL  
2ewoA           FEPVSLCVPP---LQYENALARVSELGSHNIRIIEXTNDDAWIRDCGPTFLVNDKGDLRA  
id. residues    ...V...V...............S.....N...I....D..W.RD....F...D......  
 
PPAD            V---------DFIYNRP-RPNDDEFPKYEAQYLGIE-MFGMKLKQTGGNYMTDGYGSAVQ  
2ewoA           VDWEFNAWGGLVDGLYFPWDQDALVARKVCEIEGVDSYKTKDFVLEGGSIHVDGEGTVLV  
id. residues    V....................D...........G............GG....DG.G....  
 
PPAD            SHI---AYTENSSLSQAQVNQKMKDYLGITHHDVVQDPNGEY----INHVDCWGKYLAPN  
2ewoA           TEXCLLHPSRNPHLTKEDIEDKLKD--YLNCVKVLWVKDGIDPYETNGHIDDVACFIRPG  
id. residues    ..........N..L.......K.KD........V.....G........H.D.......P.  
 
PPAD            KILIR-KVPDNHPQHQALEDMAAYFAAQTCAWGTKYEVYRALA---------T------N  
2ewoA           EVACIYTDDKEHPFYQEAKAAYDFLSQQTDAKGRPLKVHKXCVTKEPCYLQEAATIDYVE  
id. residues    ...........HP..Q...........QT.A.G....V......................  
 
PPAD            ----EQPYTNSLILNNRVFVPVNGPASVDNDALNVYKTAMPGYEIIGVKGASGTPWLGTD  
2ewoA           GEXAIASYLNFLIVNGGIILPQ-YGDENDQLAKQQVQEXFPDRK--VVGVRTEEIAYGGG  
id. residues    .......Y.N.LI.N.....P.......D..A........P......V.........G..  
 
PPAD            ALHCRTHEV---  
2ewoA           NIHCITQQQPAT  
id. residues    ..HC.T......  
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Vector Maps and Sequences 
 
pGEM
®
-T-Easy Vector Sequence 
 
 
 
Source: www.promega.com 
 
The pGEM(R)-T Easy Vector has been linearized with EcoRV at Base 60 of this  
sequence (indicated by an asterisk *) and a T added to both 3' -ends.  The added T is not 
included in this sequence. 
 
                
   1  GGGCGAATTG GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCGGCCGCG 
 
  51  GGAATTCGAT* ATCACTAGTG AATTCGCGGC CGCCTGCAGG TCGACCATAT 
 
 101  GGGAGAGCTC CCAACGCGTT GGATGCATAG CTTGAGTATT CTATAGTGTC 
 
 151  ACCTAAATAG CTTGGCGTAA TCATGGTCAT AGCTGTTTCC TGTGTGAAAT 
 
 201  TGTTATCCGC TCACAATTCC ACACAACATA CGAGCCGGAA GCATAAAGTG 
 
 251  TAAAGCCTGG GGTGCCTAAT GAGTGAGCTA ACTCACATTA ATTGCGTTGC 
 
 301  GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGCATTAA 
 
 351  TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCGCTCTTC 
 
 401  CGCTTCCTCG CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG 
 
 451  CGGTATCAGC TCACTCAAAG GCGGTAATAC GGTTATCCAC AGAATCAGGG 
 
 501  GATAACGCAG GAAAGAACAT GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA 
 
 551  CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC CGCCCCCCTG 
 
 601  ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA 
 
 651  GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC 
 
 701  TCCTGTTCCG ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT 
 
 751  CGGGAAGCGT GGCGCTTTCT CATAGCTCAC GCTGTAGGTA TCTCAGTTCG 
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 801  GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC CCCCCGTTCA 
 
 851  GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG 
 
 901  TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC 
 
 951  AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA 
 
1001  CTACGGCTAC ACTAGAAGAA CAGTATTTGG TATCTGCGCT CTGCTGAAGC 
 
1051  CAGTTACCTT CGGAAAAAGA GTTGGTAGCT CTTGATCCGG CAAACAAACC 
 
1101  ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC AAGCAGCAGA TTACGCGCAG 
 
1151  AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG GGGTCTGACG 
 
1201  CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA 
 
1251  AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC 
 
1301  AATCTAAAGT ATATATGAGT AAACTTGGTC TGACAGTTAC CAATGCTTAA 
 
1351  TCAGTGAGGC ACCTATCTCA GCGATCTGTC TATTTCGTTC ATCCATAGTT 
 
1401  GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG GCTTACCATC 
 
1451  TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG 
 
1501  ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT 
 
1551  CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC 
 
1601  TAGAGTAAGT AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG 
 
1651  CTACAGGCAT CGTGGTGTCA CGCTCGTCGT TTGGTATGGC TTCATTCAGC 
 
1701  TCCGGTTCCC AACGATCAAG GCGAGTTACA TGATCCCCCA TGTTGTGCAA 
 
1751  AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA AGTAAGTTGG 
 
1801  CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT 
 
1851  GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA 
 
1901  GTCATTCTGA GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT 
 
1951  CAATACGGGA TAATACCGCG CCACATAGCA GAACTTTAAA AGTGCTCATC 
 
2001  ATTGGAAAAC GTTCTTCGGG GCGAAAACTC TCAAGGATCT TACCGCTGTT 
 
2051  GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT 
 
2101  CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT 
 
2151  GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT 
 
2201  CTTCCTTTTT CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA 
 
2251  GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT AGGGGTTCCG 
 
2301  CGCACATTTC CCCGAAAAGT GCCACCTGAT GCGGTGTGAA ATACCGCACA 
 
2351  GATGCGTAAG GAGAAAATAC CGCATCAGGA AATTGTAAGC GTTAATATTT 
 
2401  TGTTAAAATT CGCGTTAAAT TTTTGTTAAA TCAGCTCATT TTTTAACCAA 
 
2451  TAGGCCGAAA TCGGCAAAAT CCCTTATAAA TCAAAAGAAT AGACCGAGAT 
 
2501  AGGGTTGAGT GTTGTTCCAG TTTGGAACAA GAGTCCACTA TTAAAGAACG 
 
2551  TGGACTCCAA CGTCAAAGGG CGAAAAACCG TCTATCAGGG CGATGGCCCA 
 
2601  CTACGTGAAC CATCACCCTA ATCAAGTTTT TTGGGGTCGA GGTGCCGTAA 
 
2651  AGCACTAAAT CGGAACCCTA AAGGGAGCCC CCGATTTAGA GCTTGACGGG 
 
 255 
2701  GAAAGCCGGC GAACGTGGCG AGAAAGGAAG GGAAGAAAGC GAAAGGAGCG 
 
2751  GGCGCTAGGG CGCTGGCAAG TGTAGCGGTC ACGCTGCGCG TAACCACCAC 
 
2801  ACCCGCCGCG CTTAATGCGC CGCTACAGGG CGCGTCCATT CGCCATTCAG 
 
2851  GCTGCGCAAC TGTTGGGAAG GGCGATCGGT GCGGGCCTCT TCGCTATTAC 
 
2901  GCCAGCTGGC GAAAGGGGGA TGTGCTGCAA GGCGATTAAG TTGGGTAACG 
 
2951  CCAGGGTTTT CCCAGTCACG ACGTTGTAAA ACGACGGCCA GTGAATTGTA 
 
3001  ATACGACTCA CTATA 
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pGEX-6P-3 Vector Sequence 
 
 
Source: www.gelifesciences.com 
GenBank Accession Number: U78874  
   1 acgttatcga ctgcacggtg caccaatgct tctggcgtca ggcagccatc ggaagctgtg 
       61 gtatggctgt gcaggtcgta aatcactgca taattcgtgt cgctcaaggc gcactcccgt 
      121 tctggataat gttttttgcg ccgacatcat aacggttctg gcaaatattc tgaaatgagc 
      181 tgttgacaat taatcatcgg ctcgtataat gtgtggaatt gtgagcggat aacaatttca 
      241 cacaggaaac agtattcatg tcccctatac taggttattg gaaaattaag ggccttgtgc 
      301 aacccactcg acttcttttg gaatatcttg aagaaaaata tgaagagcat ttgtatgagc 
      361 gcgatgaagg tgataaatgg cgaaacaaaa agtttgaatt gggtttggag tttcccaatc 
      421 ttccttatta tattgatggt gatgttaaat taacacagtc tatggccatc atacgttata 
      481 tagctgacaa gcacaacatg ttgggtggtt gtccaaaaga gcgtgcagag atttcaatgc 
      541 ttgaaggagc ggttttggat attagatacg gtgtttcgag aattgcatat agtaaagact 
      601 ttgaaactct caaagttgat tttcttagca agctacctga aatgctgaaa atgttcgaag 
      661 atcgtttatg tcataaaaca tatttaaatg gtgatcatgt aacccatcct gacttcatgt 
      721 tgtatgacgc tcttgatgtt gttttataca tggacccaat gtgcctggat gcgttcccaa 
      781 aattagtttg ttttaaaaaa cgtattgaag ctatcccaca aattgataag tacttgaaat 
      841 ccagcaagta tatagcatgg cctttgcagg gctggcaagc cacgtttggt ggtggcgacc 
      901 atcctccaaa atcggatctg gaagttctgt tccaggggcc cctgggatcc ccgaattccc 
      961 gggtcgactc gagcggccgc atcgtgactg actgacgatc tgcctcgcgc gtttcggtga 
     1021 tgacggtgaa aacctctgac acatgcagct cccggagacg gtcacagctt gtctgtaagc 
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     1081 ggatgccggg agcagacaag cccgtcaggg cgcgtcagcg ggtgttggcg ggtgtcgggg 
     1141 cgcagccatg acccagtcac gtagcgatag cggagtgtat aattcttgaa gacgaaaggg 
     1201 cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt cttagacgtc 
     1261 aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt tctaaataca 
     1321 ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat aatattgaaa 
     1381 aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt ttgcggcatt 
     1441 ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca 
     1501 gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag 
     1561 ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc tatgtggcgc 
     1621 ggtattatcc cgtgttgacg ccgggcaaga gcaactcggt cgccgcatac actattctca 
     1681 gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt 
     1741 aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct 
     1801 gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt 
     1861 aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga 
     1921 caccacgatg cctgcagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact 
     1981 tactctagct tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc 
     2041 acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga 
     2101 gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt 
     2161 agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga 
     2221 gataggtgcc tcactgatta agcattggta actgtcagac caagtttact catatatact 
     2281 ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga tcctttttga 
     2341 taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt cagaccccgt 
     2401 agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct gctgcttgca 
     2461 aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc taccaactct 
     2521 ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc ttctagtgta 
     2581 gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc tcgctctgct 
     2641 aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg ggttggactc 
     2701 aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt cgtgcacaca 
     2761 gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg agctatgaga 
     2821 aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg 
     2881 aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt atagtcctgt 
     2941 cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag gggggcggag 
     3001 cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt gctggccttt 
     3061 tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta ttaccgcctt 
     3121 tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt cagtgagcga 
     3181 ggaagcggaa gagcgcctga tgcggtattt tctccttacg catctgtgcg gtatttcaca 
     3241 ccgcataaat tccgacacca tcgaatggtg caaaaccttt cgcggtatgg catgatagcg 
     3301 cccggaagag agtcaattca gggtggtgaa tgtgaaacca gtaacgttat acgatgtcgc 
     3361 agagtatgcc ggtgtctctt atcagaccgt ttcccgcgtg gtgaaccagg ccagccacgt 
     3421 ttctgcgaaa acgcgggaaa aagtggaagc ggcgatggcg gagctgaatt acattcccaa 
     3481 ccgcgtggca caacaactgg cgggcaaaca gtcgttgctg attggcgttg ccacctccag 
     3541 tctggccctg cacgcgccgt cgcaaattgt cgcggcgatt aaatctcgcg ccgatcaact 
     3601 gggtgccagc gtggtggtgt cgatggtaga acgaagcggc gtcgaagcct gtaaagcggc 
     3661 ggtgcacaat cttctcgcgc aacgcgtcag tgggctgatc attaactatc cgctggatga 
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     3721 ccaggatgcc attgctgtgg aagctgcctg cactaatgtt ccggcgttat ttcttgatgt 
     3781 ctctgaccag acacccatca acagtattat tttctcccat gaagacggta cgcgactggg 
     3841 cgtggagcat ctggtcgcat tgggtcacca gcaaatcgcg ctgttagcgg gcccattaag 
     3901 ttctgtctcg gcgcgtctgc gtctggctgg ctggcataaa tatctcactc gcaatcaaat 
     3961 tcagccgata gcggaacggg aaggcgactg gagtgccatg tccggttttc aacaaaccat 
     4021 gcaaatgctg aatgagggca tcgttcccac tgcgatgctg gttgccaacg atcagatggc 
     4081 gctgggcgca atgcgcgcca ttaccgagtc cgggctgcgc gttggtgcgg atatctcggt 
     4141 agtgggatac gacgataccg aagacagctc atgttatatc ccgccgtcaa ccaccatcaa 
     4201 acaggatttt cgcctgctgg ggcaaaccag cgtggaccgc ttgctgcaac tctctcaggg 
     4261 ccaggcggtg aagggcaatc agctgttgcc cgtctcactg gtgaaaagaa aaaccaccct 
     4321 ggcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa tgcagctggc 
     4381 acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc 
     4441 tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa 
     4501 ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac ggattcactg 
     4561 gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgcctt 
     4621 gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgcac cgatcgccct 
     4681 tcccaacagt tgcgcagcct gaatggcgaa tggcgctttg cctggtttcc ggcaccagaa 
     4741 gcggtgccgg aaagctggct ggagtgcgat cttcctgagg ccgatactgt cgtcgtcccc 
     4801 tcaaactggc agatgcacgg ttacgatgcg cccatctaca ccaacgtaac ctatcccatt 
     4861 acggtcaatc cgccgtttgt tcccacggag aatccgacgg gttgttactc gctcacattt 
     4921 aatgttgatg aaagctggct acaggaaggc cagacgcgaa ttatttttga tggcgttgga 
     4981 att 
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pET-47b(+) Vector Sequence 
The pET-47b(+) plasmid features the ability to express fusion proteins with an N-terminal 
His•Tag® coding sequence that is cleavable with the human rhinovirus (HRV) 3C protease. 
The plasmid contains a strong T7lac promoter, an optimized RBS, the coding sequence for 
the HRV 3C protease cleavage site (LeuGluValLeuPheGlnGlyPro), and a multiple cloning 
site that contains restriction enzyme sites found in many other Novagen expression vectors to 
facilitate insert transfer. An optional C-terminal S•Tag™ coding sequence is compatible with 
purification, detection, and quantification. 
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LOCUS       pET-47b(+)  5203 bp    DNA   circular            17-MAY-2004 
DEFINITION pET-47b(+) 
SOURCE       
  ORGANISM   
COMMENT     This file is created by Vector NTI 
            http://www.informaxinc.com/ 
COMMENT     VNTDATE|333903583| 
COMMENT     VNTDBDATE|338806447| 
COMMENT     VNTNAME|pET-47b(+)| 
COMMENT     VNTAUTHORNAME|Bob Novy| 
COMMENT     VNTREPLTYPE|Plasmid 
COMMENT     VNTEXTCHREPL|Bacteria 
FEATURES             Location/Qualifiers 
     rep_origin      complement(4744..5191) 
                     /vntifkey="33" 
                     /label=f1\ori 
     misc_RNA        complement(3120..3675) 
                     /vntifkey="53" 
                     /label=RNA\II 
     rep_origin      complement(3120..3120) 
                     /vntifkey="33" 
                     /label=ColE1,\pBR\ori 
     misc_RNA        3560..3667 
                     /vntifkey="53" 
                     /label=RNA\I 
     CDS             2498..2689 
                     /vntifkey="4" 
                     /label=ROP\gene 
     CDS             844..1926 
                     /vntifkey="4" 
                     /label=lacI 
                     /note="lac repressor" 
     promoter        complement(437..453) 
                     /vntifkey="30" 
                     /label=T7\promoter 
     protein_bind    complement(412..432) 
                     /vntifkey="31" 
                     /label=lacO 
     terminator      complement(26..73) 
                     /vntifkey="43" 
                     /label=T7\terminator 
     CDS             3829..4644 
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                     /vntifkey="4" 
                     /label=Kan 
     misc_feature    complement(213..230) 
                     /vntifkey="21" 
                     /label=Thrombin\site 
     protein_bind    complement(168..212) 
                     /vntifkey="31" 
                     /label=S-Tag 
     misc_binding    complement(341..359) 
                     /vntifkey="20" 
                     /label=His-Tag 
     protein_bind    complement(310..332) 
                     /vntifkey="31" 
                     /label=3c 
     primer          complement(300..336) 
                     /vntifkey="27" 
                     /label=S-SacII/Bam\+SanDI\-dcm 
     CDS             complement(141..365) 
                     /vntifkey="4" 
                     /label=MCS\ORF 
 
 
BASE COUNT     1256 a      1328 c      1394 g      1225 t  
ORIGIN 
        1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa  
       61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt  
      121 tgtttagcag cctaggttaa ttaagcctcg agagcagcag aagtagagct gtccatgtgc  
      181 tggcgttcga atttagcagc agcggtttct ttactaccgc gtggcaccag agcgagctct  
      241 gcggccgcaa gcttgtcgac ggacgtcggg cgcgccaagg cctgtacaga attcggatcc  
      301 tggtacccgg gtccctgaaa gaggacttca agagccgcgg agtgatggtg gtggtgatgt  
      361 gccatatgta tatctccttc ttaaagttaa acaaaattat ttctagaggg gaattgttat  
      421 ccgctcacaa ttcccctata gtgagtcgta ttaatttcgc gggatcgaga tcgatctcga  
      481 tcctctacgc cggacgcatc gtggccggca tcaccggcgc cacaggtgcg gttgctggcg  
      541 cctatatcgc cgacatcacc gatggggaag atcgggctcg ccacttcggg ctcatgagcg  
      601 cttgtttcgg cgtgggtatg gtggcaggcc ccgtggccgg gggactgttg ggcgccatct  
      661 ccttgcatgc accattcctt gcggcggcgg tgctcaacgg cctcaaccta ctactgggct  
      721 gcttcctaat gcaggagtcg cataagggag agcgtcgaga tcccggacac catcgaatgg  
      781 cgcaaaacct ttcgcggtat ggcatgatag cgcccggaag agagtcaatt cagggtggtg  
      841 aatgtgaaac cagtaacgtt atacgatgtc gcagagtatg ccggtgtctc ttatcagacc  
      901 gtttcccgcg tggtgaacca ggccagccac gtttctgcga aaacgcggga aaaagtggaa  
      961 gcggcgatgg cggagctgaa ttacattccc aaccgcgtgg cacaacaact ggcgggcaaa  
     1021 cagtcgttgc tgattggcgt tgccacctcc agtctggccc tgcacgcgcc gtcgcaaatt  
     1081 gtcgcggcga ttaaatctcg cgccgatcaa ctgggtgcca gcgtggtggt gtcgatggta  
     1141 gaacgaagcg gcgtcgaagc ctgtaaagcg gcggtgcaca atcttctcgc gcaacgcgtc  
     1201 agtgggctga tcattaacta tccgctggat gaccaggatg ccattgctgt ggaagctgcc  
     1261 tgcactaatg ttccggcgtt atttcttgat gtctctgacc agacacccat caacagtatt  
     1321 attttctccc atgaagacgg tacgcgactg ggcgtggagc atctggtcgc attgggtcac  
     1381 cagcaaatcg cgctgttagc gggcccatta agttctgtct cggcgcgtct gcgtctggct  
     1441 ggctggcata aatatctcac tcgcaatcaa attcagccga tagcggaacg ggaaggcgac  
     1501 tggagtgcca tgtccggttt tcaacaaacc atgcaaatgc tgaatgaggg catcgttccc  
     1561 actgcgatgc tggttgccaa cgatcagatg gcgctgggcg caatgcgcgc cattaccgag  
     1621 tccgggctgc gcgttggtgc ggacatctcg gtagtgggat acgacgatac cgaagacagc  
     1681 tcatgttata tcccgccgtt aaccaccatc aaacaggatt ttcgcctgct ggggcaaacc  
     1741 agcgtggacc gcttgctgca actctctcag ggccaggcgg tgaagggcaa tcagctgttg  
     1801 cccgtctcac tggtgaaaag aaaaaccacc ctggcgccca atacgcaaac cgcctctccc  
     1861 cgcgcgttgg ccgattcatt aatgcagctg gcacgacagg tttcccgact ggaaagcggg  
     1921 cagtgagcgc aacgcaatta atgtaagtta gctcactcat taggcaccgg gatctcgacc  
     1981 gatgcccttg agagccttca acccagtcag ctccttccgg tgggcgcggg gcatgactag  
     2041 catgatcgtg ctcctgtcgt tgaggacccg gctaggctgg cggggttgcc ttactggtta  
     2101 gcagaatgaa tcaccgatac gcgagcgaac gtgaagcgac tgctgctgca aaacgtctgc  
     2161 gacctgagca acaacatgaa tggtcttcgg tttccgtgtt tcgtaaagtc tggaaacgcg  
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     2221 gaagtcagcg ccctgcacca ttatgttccg gatctgcatc gcaggatgct gctggctacc  
     2281 ctgtggaaca cctacatctg tattaacgaa gcgctggcat tgaccctgag tgatttttct  
     2341 ctggtcccgc cgcatccata ccgccagttg tttaccctca caacgttcca gtaaccgggc  
     2401 atgttcatca tcagtaaccc gtatcgtgag catcctctct cgtttcatcg gtatcattac  
     2461 ccccatgaac agaaatcccc cttacacgga ggcatcagtg accaaacagg aaaaaaccgc  
     2521 ccttaacatg gcccgcttta tcagaagcca gacattaacg cttctggaga aactcaacga  
     2581 gctggacgcg gatgaacagg cagacatctg tgaatcgctt cacgaccacg ctgatgagct  
     2641 ttaccgcagc tgcctcgcgc gtttcggtga tgacggtgaa aacctctgac acatgcagct  
     2701 cccggagacg gtcacagctt gtctgtaagc ggatgccggg agcagacaag cccgtcaggg  
     2761 cgcgtcagcg ggtgttggcg ggtgtcgggg cgcagccatg acccagtcac gtagcgatag  
     2821 cggagtgtat actggcttaa ctatgcggca tcagagcaga ttgtactgag agtgcaccat  
     2881 atatgcggtg tgaaataccg cacagatgcg taaggagaaa ataccgcatc aggcgctctt  
     2941 ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag  
     3001 ctcactcaaa ggcggtaata cggttatcca cagaatcagg ggataacgca ggaaagaaca  
     3061 tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcgtttt  
     3121 tccataggct ccgcccccct gacgagcatc acaaaaatcg acgctcaagt cagaggtggc  
     3181 gaaacccgac aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct  
     3241 ctcctgttcc gaccctgccg cttaccggat acctgtccgc ctttctccct tcgggaagcg  
     3301 tggcgctttc tcatagctca cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca  
     3361 agctgggctg tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta tccggtaact  
     3421 atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca gccactggta  
     3481 acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tggtggccta  
     3541 actacggcta cactagaagg acagtatttg gtatctgcgc tctgctgaag ccagttacct  
     3601 tcggaaaaag agttggtagc tcttgatccg gcaaacaaac caccgctggt agcggtggtt  
     3661 tttttgtttg caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatcctttga  
     3721 tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg attttggtca  
     3781 tgaacaataa aactgtctgc ttacataaac agtaatacaa ggggtgttat gagccatatt  
     3841 caacgggaaa cgtcttgctc taggccgcga ttaaattcca acatggatgc tgatttatat  
     3901 gggtataaat gggctcgcga taatgtcggg caatcaggtg cgacaatcta tcgattgtat  
     3961 gggaagcccg atgcgccaga gttgtttctg aaacatggca aaggtagcgt tgccaatgat  
     4021 gttacagatg agatggtcag actaaactgg ctgacggaat ttatgcctct tccgaccatc  
     4081 aagcatttta tccgtactcc tgatgatgca tggttactca ccactgcgat ccccggcaaa  
     4141 acagcattcc aggtattaga agaatatcct gattcaggtg aaaatattgt tgatgcgctg  
     4201 gcagtgttcc tgcgccggtt gcattcgatt cctgtttgta attgtccttt taacagtgat  
     4261 cgcgtatttc gtctcgctca ggcgcaatca cgaatgaata acggtttggt tgatgcgagt  
     4321 gattttgatg acgagcgtaa tggctggcct gttgaacaag tctggaaaga aatgcataaa  
     4381 cttttgccat tctcaccgga ttcagtcgtc actcatggtg atttctcact tgataacctt  
     4441 atttttgacg aggggaaatt aataggttgt attgatgttg gacgagtcgg aatcgcagac  
     4501 cgataccagg atcttgccat cctatggaac tgcctcggtg agttttctcc ttcattacag  
     4561 aaacggcttt ttcaaaaata tggtattgat aatcctgata tgaataaatt gcagtttcat  
     4621 ttgatgctcg atgagttttt ctaagaatta attcatgagc ggatacatat ttgaatgtat  
     4681 ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgaaat  
     4741 tgtaaacgtt aatattttgt taaaattcgc gttaaatttt tgttaaatca gctcattttt  
     4801 taaccaatag gccgaaatcg gcaaaatccc ttataaatca aaagaataga ccgagatagg  
     4861 gttgagtgtt gttccagttt ggaacaagag tccactatta aagaacgtgg actccaacgt  
     4921 caaagggcga aaaaccgtct atcagggcga tggcccacta cgtgaaccat caccctaatc  
     4981 aagttttttg gggtcgaggt gccgtaaagc actaaatcgg aaccctaaag ggagcccccg  
     5041 atttagagct tgacggggaa agccggcgaa cgtggcgaga aaggaaggga agaaagcgaa  
     5101 aggagcgggc gctagggcgc tggcaagtgt agcggtcacg ctgcgcgtaa ccaccacacc  
     5161 cgccgcgctt aatgcgccgc tacagggcgc gtcccattcg cca  
 
Source: http://www.merck-chemicals.co.uk/ 
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pET-48b(+) Vector Sequence 
The pET-48b(+) vector is designed for cloning and high-level expression of target proteins 
fused with the 109aa Trx•Tag™ thioredoxin protein that is cleavable with the human 
rhinovirus (HRV) 3C protease. Cloning sites are available for producing fusion proteins also 
containing a cleavable N- terminal His•Tag® sequence for detection and purification. The 
plasmid contains a strong T7lac promoter, optimized RBS, the coding sequence for the 
rhinovirus 3C protease cleavage site (LeuGluValLeuPheGlnGlyPro) for N-terminal fusion 
tag removal and a multiple cloning site that contains restriction enzyme sites found in many 
other Novagen expression vectors to facilitate insert transfer. An optional C-terminal 
S•Tag™ coding sequence is compatible with purification, detection, and quantification. 
 
Thioredoxin: A ubiquitous protein with two redox-active half-cysteine residues. Functions as 
a general disulfide reductant. Works efficiently on model compounds (e.g. Ellman‟s reagent) 
and protein disulfides. Plays an essential role in cellular protection against oxidative stress 
and cell death. Inhibits apoptosis in Jurkat T cells and human PBL. 
 
Here: E.coli thioredoxin (trxA, SwissProt accession number P0AA27) (LaVallie et al. 1993). 
 
>sp|P0AA27|THIO_ECO57 
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVA
KLNIDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA 
 
Thioredoxin is highly conserved amongst bacteria. The active domain is similar to some 
human proteins, such as mitochondrial thioredoxin (see alignment below) and protein 
disulfide isomerise. (Alignment created with uniprot alignment). 
 
First line: E. coli Trx (P0AA27) 
Second line: Human mitochondrial thioredoxin (Q99757) 
 
M A Q R L L L R R F L A S V I S R K P S Q G Q W P P L T S R A L Q T P Q C S P G G L T V T P N P A R T I Y T T R I S L T   6 0  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S D K   4       
                                                        : *  .  
 
T F N I Q D G P D F Q D R V V N S E T P V V V D F H A Q W C G P C K I L G P R L E K M V A K Q H G K V V M A K V D I D D   1 2 0  
I I H L T D D S - F D T D V L K A D G A I L V D F W A E W C G P C K M I A P I L D E I A D E Y Q G K L T V A K L N I D Q   6 3      
 : : :  * . .  * :   * : : : :  . : : * * *  * : * * * * * * : : . *  * : : : .  :  : * * : . : * * : : * * :  
 
H T D L A I E Y E V S A V P T V L A M K N G D V V D K F V G I K D E D Q L E A F L K K L I G   1 6 6  
N P G T A P K Y G I R G I P T L L L F K N G E V A A T K V G A L S K G Q L K E F L D A N L A   1 0 9     
: . .  *  : *  :  . : * * : *  : * * * : * .  .  * *   . : . * * :  * * .   : .  
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LOCUS       pET-48b(+)   5605 bp    DNA   circular            17-MAY-2004 
DEFINITION  pET-48b(+) 
SOURCE       
  ORGANISM   
COMMENT     This file is created by Vector NTI 
            http://www.informaxinc.com/ 
COMMENT     VNTDATE|333905404| 
COMMENT     VNTDBDATE|338806447| 
COMMENT     VNTNAME|pET-48b(+)| 
COMMENT     VNTAUTHORNAME|Bob Novy| 
COMMENT     VNTREPLTYPE|Plasmid 
COMMENT     VNTEXTCHREPL|Bacteria 
FEATURES             Location/Qualifiers 
     rep_origin      complement(5146..5593) 
                     /vntifkey="33" 
                     /label=f1\ori 
     misc_RNA        complement(3522..4077) 
                     /vntifkey="53" 
                     /label=RNA\II 
     rep_origin      complement(3522..3522) 
                     /vntifkey="33" 
                     /label=ColE1,\pBR\ori 
     misc_RNA        3962..4069 
                     /vntifkey="53" 
                     /label=RNA\I 
     CDS             2900..3091 
                     /vntifkey="4" 
                     /label=ROP\gene 
     CDS             1246..2328 
                     /vntifkey="4" 
                     /label=lacI 
                     /note="lac repressor" 
     promoter        complement(839..855) 
                     /vntifkey="30" 
                     /label=T7\promoter 
     protein_bind    complement(814..834) 
                     /vntifkey="31" 
                     /label=lacO 
     protein_bind    complement(342..359) 
                     /vntifkey="31" 
                     /label=His-Tag 
     terminator      complement(26..73) 
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                     /vntifkey="43" 
                     /label=T7\terminator 
     CDS             4231..5046 
                     /vntifkey="4" 
                     /label=Kan 
     misc_feature    complement(213..230) 
                     /vntifkey="21" 
                     /label=Thrombin\site 
     protein_bind    complement(168..212) 
                     /vntifkey="31" 
                     /label=S-Tag 
     CDS             complement(441..767) 
                     /vntifkey="4" 
                     /label=Trx-Tag 
     protein_bind    complement(310..332) 
                     /vntifkey="31" 
                     /label=3c 
     primer          complement(300..336) 
                     /vntifkey="27" 
                     /label=S-SacII/Bam\+SanDI\-dcm 
     misc_feature    complement(234..315) 
                     /vntifkey="21" 
                     /label=MCS 
     primer          complement(374..421) 
                     /vntifkey="27" 
                     /label=S-Tag\Spacer-Spe\I 
 
BASE COUNT     1355 a      1434 c      1492 g      1324 t  
ORIGIN 
        1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa  
       61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt  
      121 tgtttagcag cctaggttaa ttaagcctcg agagcagcag aagtagagct gtccatgtgc  
      181 tggcgttcga atttagcagc agcggtttct ttactaccgc gtggcaccag agcgagctct  
      241 gcggccgcaa gcttgtcgac ggacgtcggg cgcgccaagg cctgtacaga attcggatcc  
      301 tggtacccgg gtccctgaaa gaggacttca agagccgcgg agtgatggtg atggtgatga  
      361 ccagaaccac tagatggagt aggagtagga ggattgttat tagaaccgcc accaccacta  
      421 gtatggccag aaccagaacc ggccaggtta gcgtcgagga actctttcaa ctgaccttta  
      481 gacagtgcac ccactttggt tgccgccact tcaccgtttt tgaacagcag cagagtcggg  
      541 ataccacgga tgccatattt cggcgcagtg ccagggtttt gatcgatgtt cagttttgca  
      601 acggtcagtt tgccctgata ttcgtcagcg atttcatcca gaatcggggc gatcattttg  
      661 cacggaccgc accactctgc ccagaaatcg acgaggatcg ccccgtccgc tttgagtaca  
      721 tccgtgtcaa aactgtcgtc agtcaggtga ataattttat cgctcatatg tatatctcct  
      781 tcttaaagtt aaacaaaatt atttctagag gggaattgtt atccgctcac aattccccta  
      841 tagtgagtcg tattaatttc gcgggatcga gatcgatctc gatcctctac gccggacgca  
      901 tcgtggccgg catcaccggc gccacaggtg cggttgctgg cgcctatatc gccgacatca  
      961 ccgatgggga agatcgggct cgccacttcg ggctcatgag cgcttgtttc ggcgtgggta  
     1021 tggtggcagg ccccgtggcc gggggactgt tgggcgccat ctccttgcat gcaccattcc  
     1081 ttgcggcggc ggtgctcaac ggcctcaacc tactactggg ctgcttccta atgcaggagt  
     1141 cgcataaggg agagcgtcga gatcccggac accatcgaat ggcgcaaaac ctttcgcggt  
     1201 atggcatgat agcgcccgga agagagtcaa ttcagggtgg tgaatgtgaa accagtaacg  
     1261 ttatacgatg tcgcagagta tgccggtgtc tcttatcaga ccgtttcccg cgtggtgaac  
     1321 caggccagcc acgtttctgc gaaaacgcgg gaaaaagtgg aagcggcgat ggcggagctg  
     1381 aattacattc ccaaccgcgt ggcacaacaa ctggcgggca aacagtcgtt gctgattggc  
     1441 gttgccacct ccagtctggc cctgcacgcg ccgtcgcaaa ttgtcgcggc gattaaatct  
     1501 cgcgccgatc aactgggtgc cagcgtggtg gtgtcgatgg tagaacgaag cggcgtcgaa  
     1561 gcctgtaaag cggcggtgca caatcttctc gcgcaacgcg tcagtgggct gatcattaac  
     1621 tatccgctgg atgaccagga tgccattgct gtggaagctg cctgcactaa tgttccggcg  
     1681 ttatttcttg atgtctctga ccagacaccc atcaacagta ttattttctc ccatgaagac  
     1741 ggtacgcgac tgggcgtgga gcatctggtc gcattgggtc accagcaaat cgcgctgtta  
     1801 gcgggcccat taagttctgt ctcggcgcgt ctgcgtctgg ctggctggca taaatatctc  
     1861 actcgcaatc aaattcagcc gatagcggaa cgggaaggcg actggagtgc catgtccggt  
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     1921 tttcaacaaa ccatgcaaat gctgaatgag ggcatcgttc ccactgcgat gctggttgcc  
     1981 aacgatcaga tggcgctggg cgcaatgcgc gccattaccg agtccgggct gcgcgttggt  
     2041 gcggacatct cggtagtggg atacgacgat accgaagaca gctcatgtta tatcccgccg  
     2101 ttaaccacca tcaaacagga ttttcgcctg ctggggcaaa ccagcgtgga ccgcttgctg  
     2161 caactctctc agggccaggc ggtgaagggc aatcagctgt tgcccgtctc actggtgaaa  
     2221 agaaaaacca ccctggcgcc caatacgcaa accgcctctc cccgcgcgtt ggccgattca  
     2281 ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc gcaacgcaat  
     2341 taatgtaagt tagctcactc attaggcacc gggatctcga ccgatgccct tgagagcctt  
     2401 caacccagtc agctccttcc ggtgggcgcg gggcatgact agcatgatcg tgctcctgtc  
     2461 gttgaggacc cggctaggct ggcggggttg ccttactggt tagcagaatg aatcaccgat  
     2521 acgcgagcga acgtgaagcg actgctgctg caaaacgtct gcgacctgag caacaacatg  
     2581 aatggtcttc ggtttccgtg tttcgtaaag tctggaaacg cggaagtcag cgccctgcac  
     2641 cattatgttc cggatctgca tcgcaggatg ctgctggcta ccctgtggaa cacctacatc  
     2701 tgtattaacg aagcgctggc attgaccctg agtgattttt ctctggtccc gccgcatcca  
     2761 taccgccagt tgtttaccct cacaacgttc cagtaaccgg gcatgttcat catcagtaac  
     2821 ccgtatcgtg agcatcctct ctcgtttcat cggtatcatt acccccatga acagaaatcc  
     2881 cccttacacg gaggcatcag tgaccaaaca ggaaaaaacc gcccttaaca tggcccgctt  
     2941 tatcagaagc cagacattaa cgcttctgga gaaactcaac gagctggacg cggatgaaca  
     3001 ggcagacatc tgtgaatcgc ttcacgacca cgctgatgag ctttaccgca gctgcctcgc  
     3061 gcgtttcggt gatgacggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc  
     3121 ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg  
     3181 cgggtgtcgg ggcgcagcca tgacccagtc acgtagcgat agcggagtgt atactggctt  
     3241 aactatgcgg catcagagca gattgtactg agagtgcacc atatatgcgg tgtgaaatac  
     3301 cgcacagatg cgtaaggaga aaataccgca tcaggcgctc ttccgcttcc tcgctcactg  
     3361 actcgctgcg ctcggtcgtt cggctgcggc gagcggtatc agctcactca aaggcggtaa  
     3421 tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc  
     3481 aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc  
     3541 ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat  
     3601 aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc  
     3661 cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct  
     3721 cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg  
     3781 aaccccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc  
     3841 cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga  
     3901 ggtatgtagg cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa  
     3961 ggacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta  
     4021 gctcttgatc cggcaaacaa accaccgctg gtagcggtgg tttttttgtt tgcaagcagc  
     4081 agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg  
     4141 acgctcagtg gaacgaaaac tcacgttaag ggattttggt catgaacaat aaaactgtct  
     4201 gcttacataa acagtaatac aaggggtgtt atgagccata ttcaacggga aacgtcttgc  
     4261 tctaggccgc gattaaattc caacatggat gctgatttat atgggtataa atgggctcgc  
     4321 gataatgtcg ggcaatcagg tgcgacaatc tatcgattgt atgggaagcc cgatgcgcca  
     4381 gagttgtttc tgaaacatgg caaaggtagc gttgccaatg atgttacaga tgagatggtc  
     4441 agactaaact ggctgacgga atttatgcct cttccgacca tcaagcattt tatccgtact  
     4501 cctgatgatg catggttact caccactgcg atccccggca aaacagcatt ccaggtatta  
     4561 gaagaatatc ctgattcagg tgaaaatatt gttgatgcgc tggcagtgtt cctgcgccgg  
     4621 ttgcattcga ttcctgtttg taattgtcct tttaacagtg atcgcgtatt tcgtctcgct  
     4681 caggcgcaat cacgaatgaa taacggtttg gttgatgcga gtgattttga tgacgagcgt  
     4741 aatggctggc ctgttgaaca agtctggaaa gaaatgcata aacttttgcc attctcaccg  
     4801 gattcagtcg tcactcatgg tgatttctca cttgataacc ttatttttga cgaggggaaa  
     4861 ttaataggtt gtattgatgt tggacgagtc ggaatcgcag accgatacca ggatcttgcc  
     4921 atcctatgga actgcctcgg tgagttttct ccttcattac agaaacggct ttttcaaaaa  
     4981 tatggtattg ataatcctga tatgaataaa ttgcagtttc atttgatgct cgatgagttt  
     5041 ttctaagaat taattcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat  
     5101 aggggttccg cgcacatttc cccgaaaagt gccacctgaa attgtaaacg ttaatatttt  
     5161 gttaaaattc gcgttaaatt tttgttaaat cagctcattt tttaaccaat aggccgaaat  
     5221 cggcaaaatc ccttataaat caaaagaata gaccgagata gggttgagtg ttgttccagt  
     5281 ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt  
     5341 ctatcagggc gatggcccac tacgtgaacc atcaccctaa tcaagttttt tggggtcgag  
     5401 gtgccgtaaa gcactaaatc ggaaccctaa agggagcccc cgatttagag cttgacgggg  
     5461 aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc  
     5521 gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc  
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     5581 gctacagggc gcgtcccatt cgcca  
 
Source: http://www.merck-chemicals.co.uk/ 
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pET-49b(+) Vector Sequence 
 
The pET-49b(+) vector is designed for cloning and high-level expression of target proteins 
fused with the 220 aa schistosomal glutathione-S-transferase (GST•Tag™) protein that is 
cleavable with the human rhinovirus (HRV) 3C protease. Schistosomal glutathione-S-
transferase (GST) is commonly used as a fusion partner when expressing proteins in E. coli. 
The GST•Tag sequence has been reported to enhance the production and in some cases the 
solubility of its fusion partners. When expressed in a soluble, properly folded form, GST•Tag 
fusion proteins can be purified with immobilized glutathione. Gentle elution is achieved with 
buffers containing reduced glutathione. Quantification of soluble GST fusions is also possible 
by assaying the glutathione-S-transferase activity. Cloning sites are available for producing 
fusion proteins also containing a cleavable N- terminal His•Tag® sequence for detection and 
purification. The plasmid contains a strong T7lac promoter, optimized RBS, the coding 
sequence for the HRV 3C protease cleavage site (LeuGluValLeuPheGlnGlyPro) for N-
terminal fusion tag removal and a multiple cloning site that contains restriction enzyme sites 
found in many other Novagen expression vectors to facilitate insert transfer. An optional C-
terminal S•Tag™ coding sequence is compatible with purification, detection, and 
quantification. 
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LOCUS       pET-49b(+)   5926 bp    DNA   circular            17-MAY-2004 
DEFINITION  pET-49b(+). 
SOURCE       
  ORGANISM   
COMMENT     This file is created by Vector NTI 
            http://www.informaxinc.com/ 
COMMENT     VNTDATE|333905385| 
COMMENT     VNTDBDATE|338806447| 
COMMENT     VNTNAME|pET-49b(+)| 
COMMENT     VNTAUTHORNAME|Bob Novy| 
COMMENT     VNTREPLTYPE|Plasmid 
COMMENT     VNTEXTCHREPL|Bacteria 
FEATURES             Location/Qualifiers 
     rep_origin      complement(5467..5914) 
                     /vntifkey="33" 
                     /label=f1\ori 
     misc_RNA        complement(3843..4398) 
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                     /vntifkey="53" 
                     /label=RNA\II 
     rep_origin      complement(3843..3843) 
                     /vntifkey="33" 
                     /label=ColE1,\pBR\ori 
     misc_RNA        4283..4390 
                     /vntifkey="53" 
                     /label=RNA\I 
     CDS             3221..3412 
                     /vntifkey="4" 
                     /label=ROP\gene 
     CDS             1567..2649 
                     /vntifkey="4" 
                     /label=lacI 
                     /note="lac repressor" 
     promoter        complement(1160..1176) 
                     /vntifkey="30" 
                     /label=T7\promoter 
     protein_bind    complement(1135..1155) 
                     /vntifkey="31" 
                     /label=lacO 
     CDS             complement(429..1088) 
                     /vntifkey="4" 
                     /label=GST 
     protein_bind    complement(342..359) 
                     /vntifkey="31" 
                     /label=His-Tag 
     terminator      complement(26..73) 
                     /vntifkey="43" 
                     /label=T7\terminator 
     CDS             4552..5367 
                     /vntifkey="4" 
                     /label=Kan 
     misc_feature    complement(213..230) 
                     /vntifkey="21" 
                     /label=Thrombin\site 
     protein_bind    complement(168..212) 
                     /vntifkey="31" 
                     /label=S-Tag 
     protein_bind    complement(310..332) 
                     /vntifkey="31" 
                     /label=3c 
     primer          complement(300..336) 
                     /vntifkey="27" 
                     /label=S-SacII/Bam\+SanDI\-dcm 
     primer          complement(374..421) 
                     /vntifkey="27" 
                     /label=S-Tag\Spacer-Spe\I 
BASE COUNT     1485 a      1486 c      1520 g      1435 t  
ORIGIN 
        1 atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa  
       61 ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt  
      121 tgtttagcag cctaggttaa ttaagcctcg agagcagcag aagtagagct gtccatgtgc  
      181 tggcgttcga atttagcagc agcggtttct ttactaccgc gtggcaccag agcgagctct  
      241 gcggccgcaa gcttgtcgac ggacgtcggg cgcgccaagg cctgtacaga attcggatcc  
      301 tggtacccgg gtccctgaaa gaggacttca agagccgcgg agtgatggtg atggtgatga  
      361 ccagaaccac tagatggagt aggagtagga ggattgttat tagaaccgcc accaccacta  
      421 gttgaaccat ccgattttgg aggatggtcg ccaccaccaa acgtggcttg ccagccctgc  
      481 aaaggccatg ctatatactt gctggatttc aagtacttat caatttgtgg gatagcttca  
      541 atacgttttt taaaacaaac taattttggg aacgcatcca ggcacattgg gtccatgtat  
      601 aaaacaacat caagagcgtc atacaacatg aagtcaggat gggttacatg atcaccattt  
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      661 aaatatgttt tatgacataa acgatcttcg aacattttca gcatttcagg tagcttgcta  
      721 agaaaatcaa ctttgagagt ttcaaagtct ttactatatg caattctcga aacaccgtat  
      781 ctaatatcca aaaccgctcc ttcaagcatt gaaatctctg cacgctcttt tggacaacca  
      841 cccaacatgt tgtgcttgtc agctatataa cgtatgatgg ccatagactg tgttaattta  
      901 acatcaccat caatataata aggaagattg ggaaactcca aacccaattc aaactttttg  
      961 tttcgccatt tatcaccttc atcgcgctca tacaaatgct cttcatattt ttcttcaaga  
     1021 tattccaaaa gaagtcgagt gggttgcaca aggcccttaa ttttccaata acctagtata  
     1081 ggggacatat gtatatctcc ttcttaaagt taaacaaaat tatttctaga ggggaattgt  
     1141 tatccgctca caattcccct atagtgagtc gtattaattt cgcgggatcg agatcgatct  
     1201 cgatcctcta cgccggacgc atcgtggccg gcatcaccgg cgccacaggt gcggttgctg  
     1261 gcgcctatat cgccgacatc accgatgggg aagatcgggc tcgccacttc gggctcatga  
     1321 gcgcttgttt cggcgtgggt atggtggcag gccccgtggc cgggggactg ttgggcgcca  
     1381 tctccttgca tgcaccattc cttgcggcgg cggtgctcaa cggcctcaac ctactactgg  
     1441 gctgcttcct aatgcaggag tcgcataagg gagagcgtcg agatcccgga caccatcgaa  
     1501 tggcgcaaaa cctttcgcgg tatggcatga tagcgcccgg aagagagtca attcagggtg  
     1561 gtgaatgtga aaccagtaac gttatacgat gtcgcagagt atgccggtgt ctcttatcag  
     1621 accgtttccc gcgtggtgaa ccaggccagc cacgtttctg cgaaaacgcg ggaaaaagtg  
     1681 gaagcggcga tggcggagct gaattacatt cccaaccgcg tggcacaaca actggcgggc  
     1741 aaacagtcgt tgctgattgg cgttgccacc tccagtctgg ccctgcacgc gccgtcgcaa  
     1801 attgtcgcgg cgattaaatc tcgcgccgat caactgggtg ccagcgtggt ggtgtcgatg  
     1861 gtagaacgaa gcggcgtcga agcctgtaaa gcggcggtgc acaatcttct cgcgcaacgc  
     1921 gtcagtgggc tgatcattaa ctatccgctg gatgaccagg atgccattgc tgtggaagct  
     1981 gcctgcacta atgttccggc gttatttctt gatgtctctg accagacacc catcaacagt  
     2041 attattttct cccatgaaga cggtacgcga ctgggcgtgg agcatctggt cgcattgggt  
     2101 caccagcaaa tcgcgctgtt agcgggccca ttaagttctg tctcggcgcg tctgcgtctg  
     2161 gctggctggc ataaatatct cactcgcaat caaattcagc cgatagcgga acgggaaggc  
     2221 gactggagtg ccatgtccgg ttttcaacaa accatgcaaa tgctgaatga gggcatcgtt  
     2281 cccactgcga tgctggttgc caacgatcag atggcgctgg gcgcaatgcg cgccattacc  
     2341 gagtccgggc tgcgcgttgg tgcggacatc tcggtagtgg gatacgacga taccgaagac  
     2401 agctcatgtt atatcccgcc gttaaccacc atcaaacagg attttcgcct gctggggcaa  
     2461 accagcgtgg accgcttgct gcaactctct cagggccagg cggtgaaggg caatcagctg  
     2521 ttgcccgtct cactggtgaa aagaaaaacc accctggcgc ccaatacgca aaccgcctct  
     2581 ccccgcgcgt tggccgattc attaatgcag ctggcacgac aggtttcccg actggaaagc  
     2641 gggcagtgag cgcaacgcaa ttaatgtaag ttagctcact cattaggcac cgggatctcg  
     2701 accgatgccc ttgagagcct tcaacccagt cagctccttc cggtgggcgc ggggcatgac  
     2761 tagcatgatc gtgctcctgt cgttgaggac ccggctaggc tggcggggtt gccttactgg  
     2821 ttagcagaat gaatcaccga tacgcgagcg aacgtgaagc gactgctgct gcaaaacgtc  
     2881 tgcgacctga gcaacaacat gaatggtctt cggtttccgt gtttcgtaaa gtctggaaac  
     2941 gcggaagtca gcgccctgca ccattatgtt ccggatctgc atcgcaggat gctgctggct  
     3001 accctgtgga acacctacat ctgtattaac gaagcgctgg cattgaccct gagtgatttt  
     3061 tctctggtcc cgccgcatcc ataccgccag ttgtttaccc tcacaacgtt ccagtaaccg  
     3121 ggcatgttca tcatcagtaa cccgtatcgt gagcatcctc tctcgtttca tcggtatcat  
     3181 tacccccatg aacagaaatc ccccttacac ggaggcatca gtgaccaaac aggaaaaaac  
     3241 cgcccttaac atggcccgct ttatcagaag ccagacatta acgcttctgg agaaactcaa  
     3301 cgagctggac gcggatgaac aggcagacat ctgtgaatcg cttcacgacc acgctgatga  
     3361 gctttaccgc agctgcctcg cgcgtttcgg tgatgacggt gaaaacctct gacacatgca  
     3421 gctcccggag acggtcacag cttgtctgta agcggatgcc gggagcagac aagcccgtca  
     3481 gggcgcgtca gcgggtgttg gcgggtgtcg gggcgcagcc atgacccagt cacgtagcga  
     3541 tagcggagtg tatactggct taactatgcg gcatcagagc agattgtact gagagtgcac  
     3601 catatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgct  
     3661 cttccgcttc ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat  
     3721 cagctcactc aaaggcggta atacggttat ccacagaatc aggggataac gcaggaaaga  
     3781 acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt  
     3841 ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggt  
     3901 ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgtgc  
     3961 gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa  
     4021 gcgtggcgct ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct  
     4081 ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta  
     4141 actatcgtct tgagtccaac ccggtaagac acgacttatc gccactggca gcagccactg  
     4201 gtaacaggat tagcagagcg aggtatgtag gcggtgctac agagttcttg aagtggtggc  
     4261 ctaactacgg ctacactaga aggacagtat ttggtatctg cgctctgctg aagccagtta  
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     4321 ccttcggaaa aagagttggt agctcttgat ccggcaaaca aaccaccgct ggtagcggtg  
     4381 gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt  
     4441 tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg  
     4501 tcatgaacaa taaaactgtc tgcttacata aacagtaata caaggggtgt tatgagccat  
     4561 attcaacggg aaacgtcttg ctctaggccg cgattaaatt ccaacatgga tgctgattta  
     4621 tatgggtata aatgggctcg cgataatgtc gggcaatcag gtgcgacaat ctatcgattg  
     4681 tatgggaagc ccgatgcgcc agagttgttt ctgaaacatg gcaaaggtag cgttgccaat  
     4741 gatgttacag atgagatggt cagactaaac tggctgacgg aatttatgcc tcttccgacc  
     4801 atcaagcatt ttatccgtac tcctgatgat gcatggttac tcaccactgc gatccccggc  
     4861 aaaacagcat tccaggtatt agaagaatat cctgattcag gtgaaaatat tgttgatgcg  
     4921 ctggcagtgt tcctgcgccg gttgcattcg attcctgttt gtaattgtcc ttttaacagt  
     4981 gatcgcgtat ttcgtctcgc tcaggcgcaa tcacgaatga ataacggttt ggttgatgcg  
     5041 agtgattttg atgacgagcg taatggctgg cctgttgaac aagtctggaa agaaatgcat  
     5101 aaacttttgc cattctcacc ggattcagtc gtcactcatg gtgatttctc acttgataac  
     5161 cttatttttg acgaggggaa attaataggt tgtattgatg ttggacgagt cggaatcgca  
     5221 gaccgatacc aggatcttgc catcctatgg aactgcctcg gtgagttttc tccttcatta  
     5281 cagaaacggc tttttcaaaa atatggtatt gataatcctg atatgaataa attgcagttt  
     5341 catttgatgc tcgatgagtt tttctaagaa ttaattcatg agcggataca tatttgaatg  
     5401 tatttagaaa aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctga  
     5461 aattgtaaac gttaatattt tgttaaaatt cgcgttaaat ttttgttaaa tcagctcatt  
     5521 ttttaaccaa taggccgaaa tcggcaaaat cccttataaa tcaaaagaat agaccgagat  
     5581 agggttgagt gttgttccag tttggaacaa gagtccacta ttaaagaacg tggactccaa  
     5641 cgtcaaaggg cgaaaaaccg tctatcaggg cgatggccca ctacgtgaac catcacccta  
     5701 atcaagtttt ttggggtcga ggtgccgtaa agcactaaat cggaacccta aagggagccc  
     5761 ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag ggaagaaagc  
     5821 gaaaggagcg ggcgctaggg cgctggcaag tgtagcggtc acgctgcgcg taaccaccac  
     5881 acccgccgcg cttaatgcgc cgctacaggg cgcgtcccat tcgcca  
 
Source: http://www.merck-chemicals.co.uk/ 
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Construct sequences 
Mature PPAD in pET48b (mPPAD/pET48) 
 
Forward 
M1-F_pET48-F      ATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGGCATTCC 60 
PPAD              -----------------------------------------------------GCATTCC 7 
                                                                       *******  
 
M1-F_pET48-F      AGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAACGCTCTGCAG 119 
PPAD              AGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAACGCTCTGCAG 67 
                  ************************************************************ 
 
M1-F_pET48-F      CCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAGCTGGCCAAGA 179 
PPAD              CCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAGCTGGCCAAGA 127 
                  ************************************************************ 
 
M1-F_pET48-F      ACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTTATAACCCAGT 239 
PPAD              ACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTTATAACCCAGT 187 
                  ************************************************************ 
 
M1-F_pET48-F      ACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAAACTGACTCTT 299 
PPAD              ACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAAACTGACTCTT 247 
                  ************************************************************ 
 
M1-F_pET48-F      ACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAAGTAGGTCTCG 359 
PPAD              ACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAAGTAGGTCTCG 307 
                  ************************************************************ 
 
M1-F_pET48-F      TGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAATACGAAGCAC 419 
PPAD              TGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAATACGAAGCAC 367 
                  ************************************************************ 
 
M1-F_pET48-F      AATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGCAACTACATGA 479 
PPAD              AATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGCAACTACATGA 427 
                  ************************************************************ 
 
M1-F_pET48-F      CGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAACTCCTCTCTGT 539 
PPAD              CGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAACTCCTCTCTGT 487 
                  ************************************************************ 
 
M1-F_pET48-F      CTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACATCATGATGTGG 599 
PPAD              CTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACATCATGATGTGG 547 
                  ************************************************************ 
 
M1-F_pET48-F      TACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAGTATTTGGCAC 659 
PPAD              TACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAGTATTTGGCAC 607 
                  ************************************************************ 
 
M1-F_pET48-F      CGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCCCTGGAAG 719 
PPAD              CGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCCCTGGAAG 667 
                  ************************************************************ 
 
M1-F_pET48-F      ATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTACGAGGTATATC 779 
PPAD              ATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTACGAGGTATATC 727 
                  ************************************************************ 
 
M1-F_pET48-F      GCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAACAACAGGGTAT 839 
PPAD              GCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAACAACAGGGTAT 787 
                  ************************************************************               
 
M1-F_pET48-F      TTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACGTCTATAAGACGG 899 
PPAD              TTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACGTCTATAAGACGG 847 
                  ************************************************************                                                         
 
M1-F_pET48-F      CAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACA------------  946 
PPAD              CAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACACCTTGGTTAGGA  906 
                  *********************************************************** 
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Reverse 
                                                                               
M1-R_pET48-R      -----------------------CAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCC 28 
PPAD              TTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCC 660 
                                         *************************************                                                             
 
M1-R_pET48-R      CTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTACGAG 88 
PPAD              CTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTACGAG 720 
                  ************************************************************                                   
 
M1-R_pET48-R      GTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAACAAC 148 
PPAD              GTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAACAAC 780 
                  ************************************************************ 
 
M1-R_pET48-R      AGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACGTCTAT 208 
PPAD              AGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACGTCTAT 840 
                  ************************************************************ 
 
M1-R_pET48-R      AAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACACCTTGG 268 
PPAD              AAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACACCTTGG 900 
                  ************************************************************ 
 
M1-R_pET48-R      TTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTATCTCTAT 328 
PPAD              TTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTATCTCTAT 960 
                  ************************************************************ 
 
M1-R_pET48-R      ATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAAGCAGAT 388 
PPAD              ATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAAGCAGAT 1020 
                  ************************************************************ 
 
M1-R_pET48-R      GTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATCAATGGT 448 
PPAD              GTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATCAATGGT 1080 
                  ************************************************************ 
 
M1-R_pET48-R      TCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATACTTATAGC 508 
PPAD              TCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATACTTATAGC 1140 
                  ************************************************************ 
 
M1-R_pET48-R      TTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGACAATAGT 568 
PPAD              TTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGACAATAGT 1200 
                  ************************************************************ 
 
M1-R_pET48-R      GGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACGTGTATG 628 
PPAD              GGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACGTGTATG 1260 
                  ************************************************************ 
 
M1-R_pET48-R      AACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATGGTTCAAC 688 
PPAD              AACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATGGTTCAAC 1320 
                  ************************************************************ 
 
M1-R_pET48-R      GCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATATCGGATA 748 
PPAD              GCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATATCGGATA 1380 
                  ************************************************************ 
 
M1-R_pET48-R      AAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTAGCAGGG 808 
PPAD              AAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTAGCAGGG 1440 
                  ************************************************************ 
 
M1-R_pET48-R      ACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTGGTTGTT 868 
PPAD              ACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTGGTTGTT 1500 
                  ************************************************************                                       
 
M1-R_pET48-R      GAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTCTGGTGCCA 928 
PPAD              GAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA------------------ 1542 
                                            ****************************************** 
 
 
  
 276 
Full PPAD in pET48b (PPAD/pET48) 
 
Forward 
 
PPAD               ----------------------------------------------------------AA 2 
F16-F_pET48-F      TCACCATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGAA 60 
                                                                             **   
 
PPAD               AAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAAT 62 
F16-F_pET48-F      AAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAAT 120 
                   ************************************************************ 
 
PPAD               CGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCA 122 
F16-F_pET48-F      CGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCA 180 
                   ************************************************************ 
 
PPAD               ACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGA 182 
F16-F_pET48-F      ACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGA 240 
                   ************************************************************ 
 
PPAD               ACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGA 242 
F16-F_pET48-F      ACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGA 300 
                   ************************************************************ 
 
PPAD               GCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGT 302 
F16-F_pET48-F      GCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGT 360 
                   ************************************************************ 
 
PPAD               TATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAA 362 
F16-F_pET48-F      TATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAA 420 
                   ************************************************************ 
 
PPAD               AACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAA 422 
F16-F_pET48-F      AACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAA 480 
                   ************************************************************ 
 
PPAD               AGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAA 482 
F16-F_pET48-F      AGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAA 540 
                   ************************************************************ 
 
PPAD               ATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGG 542 
F16-F_pET48-F      ATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGG 600 
                   ************************************************************ 
 
PPAD               CAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAA 602 
F16-F_pET48-F      CAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAA 660 
                   ************************************************************ 
 
PPAD               CTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACA 662 
F16-F_pET48-F      CTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACA 720 
                   ************************************************************ 
 
PPAD               TCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAA 722 
F16-F_pET48-F      TCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAA 780 
                   ************************************************************ 
 
PPAD               GTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCA 782 
F16-F_pET48-F      GTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCA 840 
                   ************************************************************ 
 
PPAD               AGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTA 842 
F16-F_pET48-F      AGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTA 900 
                   ************************************************************                                                            
 
PPAD               CGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 901 
F16-F_pET48-F      CGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 960 
                   ***********************************************************                                                             
 
PPAD               ACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAAC 961 
F16-F_pET48-F      ACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACA-------------- 1004 
                   ********************************************* 
 
 
 
 
 277 
Reverse 
 
F16-R_pET48-R      -----------------------------------------TGACAATCACCCTCAGCA 18 
PPAD               AAGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCA 779 
                                                             ***************** 
 
F16-R_pET48-R      CCAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAA 78 
PPAD               CCAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAA 839 
                   ************************************************************ 
 
F16-R_pET48-R      GTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCT 138 
PPAD               GTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCT 899 
                   ************************************************************ 
 
F16-R_pET48-R      GAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAA 198 
PPAD               GAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAA 959 
                   ************************************************************ 
 
F16-R_pET48-R      CGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAAC 258 
PPAD               CGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAAC 1019 
                   ************************************************************ 
 
F16-R_pET48-R      ACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTA 318 
PPAD               ACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTA 1079 
                   ************************************************************ 
 
F16-R_pET48-R      TCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGA 378 
PPAD               TCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGA 1139 
                   ************************************************************ 
 
F16-R_pET48-R      AGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTAT 438 
PPAD               AGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTAT 1199 
                   ************************************************************ 
 
F16-R_pET48-R      CAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATAC 498 
PPAD               CAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATAC 1259 
                   ************************************************************ 
 
F16-R_pET48-R      TTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGA 558 
PPAD               TTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGA 1319 
                   ************************************************************ 
 
F16-R_pET48-R      CAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTAC 618 
PPAD               CAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTAC 1379 
                   ************************************************************ 
 
F16-R_pET48-R      GTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATG 678 
PPAD               GTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATG 1439 
                   ************************************************************ 
 
F16-R_pET48-R      GTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATA 738 
PPAD               GTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATA 1499 
                   ************************************************************ 
 
F16-R_pET48-R      TCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGT 798 
PPAD               TCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGT 1559 
                   ************************************************************ 
 
F16-R_pET48-R      AGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCT 858 
PPAD               AGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCT 1619 
                   ************************************************************ 
 
F16-R_pET48-R      GGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTCT 918 
PPAD               GGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA----------- 1668 
                   *************************************************                                                  
 
 
  
 278 
Full PPAD in pET47b (PPAD/pET47) 
 
Forward                                                                             
 
Ppad-F_T7       CATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGAAAAAGCTTTTA 120 
PPAD            ------------------------------------------------AAAAAGCTTTTA 12 
                                                                ************ 
 
Ppad-F_T7       CAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATCGCCCAAACG 180 
PPAD            CAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATCGCCCAAACG 72 
                ************************************************************ 
 
Ppad-F_T7       CAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAACGAGCATTC 240 
PPAD            CAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAACGAGCATTC 132 
                ************************************************************ 
 
Ppad-F_T7       CAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAACGCTCTGCA 300 
PPAD            CAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAACGCTCTGCA 192 
                ************************************************************ 
 
Ppad-F_T7       GCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAGCTGGCCAAG 360 
PPAD            GCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAGCTGGCCAAG 252 
                ************************************************************ 
 
Ppad-F_T7       AACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTTATAACCCAG 420 
PPAD            AACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTTATAACCCAG 312 
                ************************************************************ 
 
Ppad-F_T7       TACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAAACTGACTCT 480 
PPAD            TACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAAACTGACTCT 372 
                ************************************************************ 
 
Ppad-F_T7       TACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAAGTAGGTCTC 540 
PPAD            TACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAAGTAGGTCTC 432 
                ************************************************************ 
 
Ppad-F_T7       GTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAATACGAAGCA 600 
PPAD            GTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAATACGAAGCA 492 
                ************************************************************ 
 
 
Ppad-F_T7       CAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGCAACTACATG 660 
PPAD            CAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGCAACTACATG 552 
                ************************************************************ 
 
Ppad-F_T7       ACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAACTCCTCTCTG 720 
PPAD            ACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAACTCCTCTCTG 612 
                ************************************************************ 
 
 
Ppad-F_T7       TCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACATCATGATGTG 780 
PPAD            TCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACATCATGATGTG 672 
                ************************************************************ 
 
Ppad-F_T7       GTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAGTATTTGGCA 840 
PPAD            GTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAGTATTTGGCA 732 
                ************************************************************ 
 
Ppad-F_T7       CCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCCCTGGAA 900 
PPAD            CCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAAGCCCTGGAA 792 
                ************************************************************ 
 
 
 
  
 279 
Reverse 
 
Ppad-R_s-tag-rev      CGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAAC 363 
PPAD                  CGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAAC 1019 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      ACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTA 423 
PPAD                  ACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTA 1079 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      TCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGA 483 
PPAD                  TCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGA 1139 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      AGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTAT 543 
PPAD                  AGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTAT 1199 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      CAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATAC 603 
PPAD                  CAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATAC 1259 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      TTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGA 663 
PPAD                  TTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGA 1319 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      CAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTAC 723 
PPAD                  CAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTAC 1379 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      GTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATG 783 
PPAD                  GTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATG 1439 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      GTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATA 843 
PPAD                  GTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATA 1499 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      TCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGT 903 
PPAD                  TCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGT 1559 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      AGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCT 963 
PPAD                  AGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCT 1619 
                      ************************************************************ 
 
Ppad-R_s-tag-rev      GGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTCT 1023 
PPAD                  GGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA----------- 1668 
                      *************************************************            
  
 280 
Mutated PPADs in pET48b 
 
C351A 
 
Forward 
 
C351_D-F_pET-48-F      CACCATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGAAA 60 
PPAD                   ------------------------------------------------------ATGAAA 6 
                                                                              ***** 
 
C351_D-F_pET-48-F      AAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATC 120 
PPAD                   AAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATC 66 
                       ************************************************************ 
 
C351_D-F_pET-48-F      GCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAA 180 
PPAD                   GCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAA 126 
                       ************************************************************ 
 
C351_D-F_pET-48-F      CGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAA 240 
PPAD                   CGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAA 186 
                       ************************************************************ 
 
C351_D-F_pET-48-F      CGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAG 300 
PPAD                   CGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAG 246 
                       ************************************************************ 
 
C351_D-F_pET-48-F      CTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTT 360 
PPAD                   CTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTT 306 
                       ************************************************************ 
 
C351_D-F_pET-48-F      ATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAA 420 
PPAD                   ATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAA 366 
                       ************************************************************ 
 
C351_D-F_pET-48-F      ACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAA 480 
PPAD                   ACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAA 426 
                       ************************************************************ 
 
C351_D-F_pET-48-F      GTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAA 540 
PPAD                   GTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAA 486 
                       ************************************************************ 
 
C351_D-F_pET-48-F      TACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGC 600 
PPAD                   TACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGC 546 
                       ************************************************************ 
 
C351_D-F_pET-48-F      AACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAAC 660 
PPAD                   AACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAAC 606 
                       ************************************************************ 
 
C351_D-F_pET-48-F      TCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACAT 720 
PPAD                   TCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACAT 666 
                       ************************************************************ 
 
C351_D-F_pET-48-F      CATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAG 780 
PPAD                   CATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAG 726 
                       ************************************************************ 
 
C351_D-F_pET-48-F      TATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAA 840 
PPAD                   TATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAA 786 
                       ************************************************************ 
 
C351_D-F_pET-48-F      GCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTAC 900 
PPAD                   GCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTAC 846 
                       ************************************************************ 
 
C351_D-F_pET-48-F      GAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAAC 960 
PPAD                   GAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAAC 906 
                       ************************************************************ 
 
 
 281 
Reverse 
 
C351_D-RevCom      AAGTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATT 100 
PPAD               AAGTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATT 900 
                   ************************************************************ 
 
C351_D-RevCom      CTGAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTG 160 
PPAD               CTGAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTG 960 
                   ************************************************************ 
 
C351_D-RevCom      AACGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGA 220 
PPAD               AACGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGA 1020 
                   ************************************************************ 
 
C351_D-RevCom      ACACCTTGGTTAGGAACAGATGCCCTGCATGCCCGTACTCACGAGGTAGCGGATAAGGGC 280 
PPAD               ACACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGC 1080 
                   ******************************   *************************** 
 
C351_D-RevCom      TATCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATC 340 
PPAD               TATCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATC 1140 
                   ************************************************************ 
 
C351_D-RevCom      GAAGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGT 400 
PPAD               GAAGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGT 1200 
                   ************************************************************ 
 
C351_D-RevCom      ATCAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTAT 460 
PPAD               ATCAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTAT 1260 
                   ************************************************************ 
 
C351_D-RevCom      ACTTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCT 520 
PPAD               ACTTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCT 1320 
                   ************************************************************ 
 
C351_D-RevCom      GACAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTT 580 
PPAD               GACAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTT 1380 
                   ************************************************************ 
 
C351_D-RevCom      ACGTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCA 640 
PPAD               ACGTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCA 1440 
                   ************************************************************ 
 
C351_D-RevCom      TGGTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACA 700 
PPAD               TGGTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACA 1500 
                   ************************************************************ 
 
C351_D-RevCom      TATCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTA 760 
PPAD               TATCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTA 1560 
                   ************************************************************ 
 
C351_D-RevCom      GTAGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTT 820 
PPAD               GTAGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTT 1620 
                   ************************************************************ 
 
C351_D-RevCom      CTGGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCT 880 
PPAD               CTGGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA--------- 1671 
                   ***************************************************          
 
 
  
 282 
N297A 
 
Forward 
 
N297_1_F.       ---ACCATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGA 57 
PPAD.           -----------------------------------------------------------A 1 
                                                                           * 
 
N297_1_F.       AAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAA 117 
PPAD.           AAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAA 61 
                ************************************************************ 
 
N297_1_F.       TCGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGC 177 
PPAD.           TCGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGC 121 
                ************************************************************ 
 
N297_1_F.       AACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACG 237 
PPAD.           AACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACG 181 
                ************************************************************ 
 
N297_1_F.       AACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAG 297 
PPAD.           AACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAG 241 
                ************************************************************ 
 
N297_1_F.       AGCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCG 357 
PPAD.           AGCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCG 301 
                ************************************************************ 
 
N297_1_F.       TTATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGA 417 
PPAD.           TTATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGA 361 
                ************************************************************ 
 
N297_1_F.       AAACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACA 477 
PPAD.           AAACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACA 421 
                ************************************************************ 
 
N297_1_F.       AAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCA 537 
PPAD.           AAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCA 481 
                ************************************************************ 
 
N297_1_F.       AATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTG 597 
PPAD.           AATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTG 541 
                ************************************************************ 
 
N297_1_F.       GCAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGA 657 
PPAD.           GCAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGA 601 
                ************************************************************ 
 
N297_1_F.       ACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC 717 
PPAD.           ACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC 661 
                ************************************************************ 
 
N297_1_F.       ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCA 777 
PPAD.           ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCA 721 
                ************************************************************ 
 
N297_1_F.       AGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACC 837 
PPAD.           AGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACC 781 
                ************************************************************ 
 
N297_1_F.       AAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGT 897 
PPAD.           AAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGT 841 
                ************************************************************ 
 
N297_1_F.       ACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGGCCTCTCTGATTCTGA 957 
PPAD.           ACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 901 
                ********************************************   ************* 
 
N297_1_F.       ACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACG 1017 
PPAD.           ACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACG 961 
                *********************************************                
 
  
 283 
Reverse 
 
N297_1_F.           -----------------AGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCAC 43 
PPAD.               AACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCAC 659 
                                      ***************************************** 
 
N297_1_F.           ACATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGG 103 
PPAD.               ACATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGG 718 
                    *********************************************************** 
 
N297_1_F.          GCAAGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGC 163 
PPAD.              GCAAGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGC 778 
                   ************************************************************ 
 
N297_1_F.          ACCAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGA 223 
PPAD.              ACCAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGA 838 
                   ************************************************************ 
 
N297_1_F.          AGTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGGCCTCTCTGATTC 283 
PPAD.              AGTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTC 898 
                   ***********************************************  *********** 
 
N297_1_F.          TGAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGA 343 
PPAD.              TGAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGA 958 
                   ************************************************************ 
 
N297_1_F.          ACGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAA 403 
PPAD.              ACGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAA 1018 
                   ************************************************************ 
 
N297_1_F.          CACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCT 463 
PPAD.              CACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCT 1078 
                   ************************************************************ 
 
N297_1_F.          ATCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCG 523 
PPAD.              ATCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCG 1138 
                   ************************************************************ 
 
N297_1_F.          AAGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTA 583 
PPAD.              AAGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTA 1198 
                   ************************************************************ 
 
N297_1_F.          TCAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATA 643 
PPAD.              TCAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATA 1258 
                   ************************************************************ 
 
N297_1_F.          CTTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTG 703 
PPAD.              CTTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTG 1318 
                   ************************************************************ 
 
N297_1_F.          ACAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTA 763 
PPAD.              ACAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTA 1378 
                   ************************************************************ 
 
N297_1_F.          CGTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCAT 823 
PPAD.              CGTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCAT 1438 
                   ************************************************************ 
 
N297_1_F.          GGTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACAT 883 
PPAD.              GGTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACAT 1498 
                   ************************************************************ 
 
N297_1_F.          ATCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAG 943 
PPAD.              ATCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAG 1558 
                   ************************************************************ 
 
N297_1_F.          TAGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTC 1003 
PPAD.              TAGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTC 1618 
                   ************************************************************ 
 
N297_1_F.          TGGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTC 1063 
PPAD.              TGGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA---------- 1668 
                   **************************************************           
 
 284 
H236A 
 
Forward 
 
H236_1_F.       ------ATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGA 54 
PPAD.           -----------------------------------------------------------A 1 
                                                                           * 
 
H236_1_F.       AAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAA 114 
PPAD.           AAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAA 61 
                ************************************************************ 
 
H236_1_F.       TCGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGC 174 
PPAD.           TCGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGC 121 
                ************************************************************ 
 
H236_1_F.       AACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACG 234 
PPAD.           AACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACG 181 
                ************************************************************ 
 
H236_1_F.       AACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAG 294 
PPAD.           AACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAG 241 
                ************************************************************ 
 
H236_1_F.       AGCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCG 354 
PPAD.           AGCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCG 301 
                ************************************************************ 
 
H236_1_F.       TTATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGA 414 
PPAD.           TTATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGA 361 
                ************************************************************ 
 
H236_1_F.       AAACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACA 474 
PPAD.           AAACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACA 421 
                ************************************************************ 
 
H236_1_F.       AAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCA 534 
PPAD.           AAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCA 481 
                ************************************************************ 
 
H236_1_F.       AATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTG 594 
PPAD.           AATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTG 541 
                ************************************************************ 
 
H236_1_F.       GCAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGA 654 
PPAD.           GCAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGA 601 
                ************************************************************ 
 
H236_1_F.       ACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC 714 
PPAD.           ACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC 661 
                ************************************************************ 
 
H236_1_F.       ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACGCCGTGGACTGTTGGGGCA 774 
PPAD.           ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCA 721 
                *****************************************   **************** 
 
H236_1_F.       AGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACC 834 
PPAD.           AGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACC 781 
                ************************************************************ 
 
H236_1_F.       AAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGT 894 
PPAD.           AAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGT 841 
                ************************************************************ 
 
H236_1_F.       ACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 954 
PPAD.           ACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 901 
                ************************************************************ 
 
 
  
 285 
Reverse 
 
H236_1_R_Com.      ---------------------------GGCGAATATATCAACGCCGTGGACTGTTGGGGC 33 
PPAD.              CATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGC 720 
                                              ***************   *************** 
 
H236_1_R_Com.      AAGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCAC 93 
PPAD.              AAGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCAC 780 
                   ************************************************************ 
 
H236_1_R_Com.      CAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAG 153 
PPAD.              CAAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAG 840 
                   *********************** ************************************ 
 
H236_1_R_Com.      TACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTG 213 
PPAD.              TACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTG 900 
                   ************************************************************ 
 
H236_1_R_Com.      AACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAAC 273 
PPAD.              AACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAAC 960 
                   ************************************************************ 
 
H236_1_R_Com.      GTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACA 333 
PPAD.              GTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACA 1020 
                   ************************************************************ 
 
H236_1_R_Com.      CCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTAT 393 
PPAD.              CCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTAT 1080 
                   ************************************************************ 
 
H236_1_R_Com.      CTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAA 453 
PPAD.              CTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAA 1140 
                   ************************************************************ 
 
H236_1_R_Com.      GCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATC 513 
PPAD.              GCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATC 1200 
                   ************************************************************ 
 
H236_1_R_Com.      AATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATACT 573 
PPAD.              AATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATACT 1260 
                   ************************************************************ 
 
H236_1_R_Com.      TATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGAC 633 
PPAD.              TATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGAC 1320 
                   ************************************************************ 
 
H236_1_R_Com.      AATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACG 693 
PPAD.              AATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACG 1380 
                   ************************************************************ 
 
H236_1_R_Com.      TGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATGG 753 
PPAD.              TGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATGG 1440 
                   ************************************************************ 
 
H236_1_R_Com.      TTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATAT 813 
PPAD.              TTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATAT 1500 
                   ************************************************************ 
 
H236_1_R_Com.      CGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTA 873 
PPAD.              CGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTA 1560 
                   ************************************************************ 
 
H236_1_R_Com.      GCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTG 933 
PPAD.              GCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTG 1620 
                   ************************************************************ 
 
H236_1_R_Com.      GTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTCTG 993 
PPAD.              GTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA------------ 1668 
                   ************************************************             
 
 
  
 286 
D130A 
 
Forward  
 
D130_1_F.       CTCACCATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGA 60 
PPAD.           -----------------------------------------------------------A 1 
                                                                           * 
 
D130_1_F.       AAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAA 120 
PPAD.           AAAAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAA 61 
                ************************************************************ 
 
D130_1_F.       TCGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGC 180 
PPAD.           TCGCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGC 121 
                ************************************************************ 
 
D130_1_F.       AACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACG 240 
PPAD.           AACGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACG 181 
                ************************************************************ 
 
D130_1_F.       AACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAG 300 
PPAD.           AACGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAG 241 
                ************************************************************ 
 
D130_1_F.       AGCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCG 360 
PPAD.           AGCTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCG 301 
                ************************************************************ 
 
D130_1_F.       TTATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGA 420 
PPAD.           TTATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGA 361 
                ************************************************************ 
 
D130_1_F.       AAACTGACTCTTACTGGACACGCGCCTATACCGGTTGGTTCGCAATGTACGATACGAACA 480 
PPAD.           AAACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACA 421 
                ************************ *********************************** 
 
D130_1_F.       AAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCA 540 
PPAD.           AAGTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCA 481 
                ************************************************************ 
 
D130_1_F.       AATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTG 600 
PPAD.           AATACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTG 541 
                ************************************************************ 
 
D130_1_F.       GCAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGA 660 
PPAD.           GCAACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGA 601 
                ************************************************************ 
 
D130_1_F.       ACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC 720 
PPAD.           ACTCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACAC 661 
                ************************************************************ 
 
D130_1_F.       ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCA 780 
PPAD.           ATCATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCA 721 
                ************************************************************ 
 
D130_1_F.       AGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACC 840 
PPAD.           AGTATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACC 781 
                ************************************************************ 
 
D130_1_F.       AAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGT 900 
PPAD.           AAGCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGT 841 
                ************************************************************ 
 
D130_1_F.       ACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 960 
PPAD.           ACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGA 901 
                ************************************************************ 
 
D130_1_F.       ACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACG 1019 
PPAD.           ACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACG 961 
                ************************************************************ 
  
 
 287 
Reverse 
 
 
D130_1_R.       GTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCT 256 
PPAD.           GTACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCT 899 
                ************************************************************ 
 
D130_1_R.       GAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAA 316 
PPAD.           GAACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAA 959 
                ************************************************************ 
 
D130_1_R.       CGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAAC 376 
PPAD.           CGTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAAC 1019 
                ************************************************************ 
 
D130_1_R.       ACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTA 436 
PPAD.           ACCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTA 1079 
                ************************************************************ 
 
D130_1_R.       TCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGA 496 
PPAD.           TCTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGA 1139 
                ************************************************************ 
 
D130_1_R.       AGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTAT 556 
PPAD.           AGCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTAT 1199 
                ************************************************************ 
 
D130_1_R.       CAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATAC 616 
PPAD.           CAATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATAC 1259 
                ************************************************************ 
 
D130_1_R.       TTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGA 676 
PPAD.           TTATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGA 1319 
                ************************************************************ 
 
D130_1_R.       CAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTAC 736 
PPAD.           CAATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTAC 1379 
                ************************************************************ 
 
D130_1_R.       GTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATG 796 
PPAD.           GTGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATG 1439 
                ************************************************************ 
 
D130_1_R.       GTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATA 856 
PPAD.           GTTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATA 1499 
                ************************************************************ 
 
D130_1_R.       TCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGT 916 
PPAD.           TCGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGT 1559 
                ************************************************************ 
 
D130_1_R.       AGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCT 976 
PPAD.           AGCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCT 1619 
                ************************************************************ 
 
D130_1_R.       GGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTCT 1036 
PPAD.           GGTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA----------- 1668 
                *************************************************            
 
 
 
  
 288 
D238A 
 
Forward  
 
D238_1_F.       -ACCATCACCATCACTCCGCGGCTCTTGAAGTCCTCTTTCAGGGACCCGGGTACCTGAAA 59 
PPAD.           ---------------------------------------------------------AAA 3 
                                                                         *** 
 
D238_1_F.       AAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATC 119 
PPAD.           AAGCTTTTACAGGCTAAAGCCTTGATTCTGGCATTGGGACTCTTCCAACTGCCCGCAATC 63 
                ************************************************************ 
 
D238_1_F.       GCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAA 179 
PPAD.           GCCCAAACGCAAATGCAAGCAGACCGAACAAACGGTCAATTTGCAACAGAAGAGATGCAA 123 
                ************************************************************ 
 
D238_1_F.       CGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAA 239 
PPAD.           CGAGCATTCCAGGAAACGAATCCCCCTGCAGGTCCTGTGCGTGCTATCGCTGAGTACGAA 183 
                ************************************************************ 
 
D238_1_F.       CGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAG 299 
PPAD.           CGCTCTGCAGCCGTTTTGGTACGCTACCCGTTCGGTATCCCGATGGAATTGATCAAAGAG 243 
                ************************************************************ 
 
D238_1_F.       CTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTT 359 
PPAD.           CTGGCCAAGAACGACAAGGTGATTACCATTGTGGCGAGTGAAAGCCAAAAAAACACCGTT 303 
                ************************************************************ 
 
D238_1_F.       ATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAA 419 
PPAD.           ATAACCCAGTACACCCAAAGCGGTGTGAATCTCTCTAATTGCGATTTCATCATTGCGAAA 363 
                ************************************************************ 
 
D238_1_F.       ACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAA 479 
PPAD.           ACTGACTCTTACTGGACACGCGACTATACCGGTTGGTTCGCAATGTACGATACGAACAAA 423 
                ************************************************************ 
 
D238_1_F.       GTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAA 539 
PPAD.           GTAGGTCTCGTGGACTTTATTTATAACCGCCCTCGTCCTAACGATGATGAATTCCCCAAA 483 
                ************************************************************ 
 
D238_1_F.       TACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGC 599 
PPAD.           TACGAAGCACAATATCTGGGCATCGAGATGTTCGGGATGAAGCTCAAGCAGACCGGTGGC 543 
                ************************************************************ 
 
D238_1_F.       AACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAAC 659 
PPAD.           AACTACATGACGGACGGATATGGATCCGCTGTGCAGTCACATATCGCATATACGGAGAAC 603 
                ************************************************************ 
 
D238_1_F.       TCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACAT 719 
PPAD.           TCCTCTCTGTCTCAAGCTCAAGTAAATCAAAAGATGAAAGACTATCTCGGCATCACACAT 663 
                ************************************************************ 
 
D238_1_F.       CATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGCCTGTTGGGGCAAG 779 
PPAD.           CATGATGTGGTACAAGATCCGAACGGCGAATATATCAACCATGTGGACTGTTGGGGCAAG 723 
                ********************************************** ************* 
 
D238_1_F.       TATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAA 839 
PPAD.           TATTTGGCACCGAACAAAATCCTCATCAGGAAAGTGCCTGACAATCACCCTCAGCACCAA 783 
                ************************************************************ 
 
D238_1_F.       GCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTAC 899 
PPAD.           GCCCTGGAAGATATGGCAGCCTACTTCGCAGCACAGACCTGCGCATGGGGAACGAAGTAC 843 
                ************************************************************ 
 
D238_1_F.       GAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAAC 959 
PPAD.           GAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTGAAC 903 
                ************************************************************ 
 
D238_1_F.       AACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTG--------------------- 998 
PPAD.           AACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAACGTC 963 
                ***************************************                      
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Reverse 
 
D238_1_R.       TACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTG 219 
PPAD.           TACGAGGTATATCGCGCTTTGGCCACCAATGAACAACCGTACACGAACTCTCTGATTCTG 900 
                ************************************************************ 
 
D238_1_R.       AACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAAC 279 
PPAD.           AACAACAGGGTATTTGTTCCTGTCAATGGCCCCGCCTCCGTGGACAACGATGCTCTGAAC 960 
                ************************************************************ 
 
D238_1_R.       GTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACA 339 
PPAD.           GTCTATAAGACGGCAATGCCCGGTTACGAAATTATAGGTGTCAAAGGGGCTTCAGGAACA 1020 
                ************************************************************ 
 
D238_1_R.       CCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTAT 399 
PPAD.           CCTTGGTTAGGAACAGATGCCCTGCATTGTCGTACTCACGAGGTAGCGGATAAGGGCTAT 1080 
                ************************************************************ 
 
D238_1_R.       CTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAA 459 
PPAD.           CTCTATATCAAGCACTACCCGATACTGGGCGAACAGGCAGGCCCTGATTATAAGATCGAA 1140 
                ************************************************************ 
 
D238_1_R.       GCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATC 519 
PPAD.           GCAGATGTCGTCTCATGCGCCAATGCTACTATCTCGCCGGTACAATGTTACTATCGTATC 1200 
                ************************************************************ 
 
D238_1_R.       AATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATACT 579 
PPAD.           AATGGTTCCGGTAGCTTTAAGGCTGCTGATATGACGATGGAATCAACAGGTCACTATACT 1260 
                ************************************************************ 
 
D238_1_R.       TATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGAC 639 
PPAD.           TATAGCTTTACAGGTCTTAACAAGAATGATAAGGTAGAATACTATATCTCTGCCGCTGAC 1320 
                ************************************************************ 
 
D238_1_R.       AATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACG 699 
PPAD.           AATAGTGGTCGCAAAGAGACTTATCCCTTTATCGGCGAACCTGATCCTTTCAAGTTTACG 1380 
                ************************************************************ 
 
D238_1_R.       TGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATGG 759 
PPAD.           TGTATGAACGAAACCAATACATGTACTGTGACCGGAGCTGCCAAAGCTCTTCGTGCATGG 1440 
                ************************************************************ 
 
D238_1_R.       TTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATAT 819 
PPAD.           TTCAACGCCGGTCGTTCAGAACTGGCTGTTTCGGTAAGTTTGAATATTGCCGGCACATAT 1500 
                ************************************************************ 
 
D238_1_R.       CGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTA 879 
PPAD.           CGGATAAAGCTTTATAACACCGCAGGAGAAGAAGTCGCTGCAATGACCAAGGAATTAGTA 1560 
                ************************************************************ 
 
D238_1_R.       GCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTG 939 
PPAD.           GCAGGGACGAGTGTCTTCAGTATGGATGTGTATTCTCAGGCTCCGGGCACATATGTTCTG 1620 
                ************************************************************ 
 
D238_1_R.       GTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAAGAGCTCGCTCTG 999 
PPAD.           GTTGTTGAAGGAAATGGAATCCGTGAGACAATGAAAATTCTCAAATAA------------ 1668 
                ************************************************             
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Synovial Fluid Is a Site of Citrullination of Autoantigens in
Inflammatory Arthritis
Andrew Kinloch,1 Karin Lundberg,1 Robin Wait,1 Natalia Wegner,1 Ngee Han Lim,1
Albert J. W. Zendman,2 Tore Saxne,3 Vivianne Malmstro¨m,4 and Patrick J. Venables1
Objective. To examine synovial fluid as a site for
generating citrullinated antigens, including the candi-
date autoantigen citrullinated -enolase, in rheumatoid
arthritis (RA).
Methods. Synovial fluid was obtained from 20
patients with RA, 20 patients with spondylarthritides
(SpA), and 20 patients with osteoarthritis (OA). Sam-
ples were resolved using sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, followed by staining
with Coomassie blue and immunoblotting for citrulli-
nated proteins, -enolase, and the deiminating enzymes
peptidylarginine deiminase type 2 (PAD-2) and PAD-4.
Proteins from an RA synovial fluid sample were sepa-
rated by 2-dimensional electrophoresis, and each pro-
tein was identified by immunoblotting and mass spec-
trometry. Antibodies to citrullinated -enolase peptide
1 (CEP-1) and cyclic citrullinated peptide 2 were mea-
sured by enzyme-linked immunosorbent assay.
Results. Citrullinated polypeptides were detected
in the synovial fluid from patients with RA and patients
with SpA, but not in OA samples. Alpha-enolase was
detected in all of the samples, with mean levels of 6.4
ng/l in RA samples, 4.3 ng/l in SpA samples, and
<0.9 ng/l in OA samples. Two-dimensional electro-
phoresis provided evidence that the -enolase was cit-
rullinated in RA synovial fluid. The citrullinating en-
zyme PAD-4 was detected in samples from all 3 disease
groups. PAD-2 was detected in 18 of the RA samples, in
16 of the SpA samples, and in none of the OA samples.
Antibodies to CEP-1 were found in 12 of the RA samples
(60%), in none of the SpA samples, and in 1 OA sample.
Conclusion. These results highlight the impor-
tance of synovial fluid for the expression of citrullinated
autoantigens in inflammatory arthritis. Whereas the
expression of citrullinated proteins is a product of
inflammation, the antibody response remains specific
for RA.
Antibodies to citrullinated proteins (ACPAs) are
highly specific for rheumatoid arthritis (RA) and are a
powerful tool for its diagnosis and for prediction of
disease severity. In addition, the study of ACPAs en-
ables incorporation of risk factors, including smoking
and presence of the shared epitope, into a common
etiopathogenic model in which citrullination and the
generation of antibodies play an intimate role in the
pathogenesis of RA (for review, see ref. 1).
Citrullinated proteins are formed when arginine
residues are deiminated by peptidylarginine deiminase
(PAD). Five PADs have been identified in humans (2),
of which PAD-2 and PAD-4 are found in rheumatoid
synovial fluid cells (3) and in synovial membrane (4,5).
PADs are calcium dependent (2), and are thus more
likely to be active in the extracellular compartment,
where calcium concentrations are higher. Cell death may
result in increased PAD activity, because the loss of
membrane integrity will both increase intracellular cal-
cium concentration and enable extracellular leakage of
PAD enzymes.
Citrullinated proteins have been detected in the
synovial membrane of patients with various forms of
arthritis (6) and in other inflamed tissues (7), suggesting
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that, whereas citrullination is associated with inflamma-
tion in general, the development of ACPAs is specific to
RA. In patients with RA, ACPA-producing plasma cells
have been detected in the synovial membrane (8), and
higher concentrations of ACPAs in the rheumatoid joint
compared with the serum have also been reported (8,9).
This suggests that synovial citrullinated proteins are
driving a local production of antibodies, and that the
resulting immune complexes contribute to the chronic
inflammation in the rheumatoid joint.
Previous studies of citrullinated antigens have
tended to focus on synovial membrane (10–12). In the
present study we investigated synovial fluid as a site of
extracellular deimination, focusing on the candidate
autoantigen citrullinated -enolase (13). We recently
mapped the autoantibody response to an immunodom-
inant peptide, which we have termed citrullinated
-enolase peptide 1 (CEP-1). Antibodies to CEP-1 are
closely correlated with antibodies to cyclic citrullinated
peptide 2 (CCP-2), are highly specific for RA, and have
a diagnostic sensitivity of 50% depending on the
cohort of patients studied (14). Having identified a
major epitope, we now have reagents to study the
distribution of native and citrullinated -enolase and its
antibodies in clinical samples. In addition, CEP-1 is
derived from a real protein, as opposed to the purely
artificial peptides that comprise the CCP-2 assay, and, as
such, may reflect the pathologic processes occurring in
the joints of patients with RA.
PATIENTS AND METHODS
Patient samples. Synovial fluid was removed from the
knees of patients at the time of therapeutic arthrocentesis.
Samples were obtained, following the patients’ provision of
informed consent and approval from the local ethics commit-
tee, from 20 patients with RA and 20 patients with spondylar-
thritides (SpA). These patients were attending the Rheuma-
tology Clinic at Karolinska University Hospital (Stockholm,
Sweden). Synovial fluid samples from 20 patients with osteo-
arthritis (OA), selected for the absence of cellularity and thus
serving as noninflammation controls, were obtained from the
knees of patients attending the Department of Rheumatology
at Lund University Hospital (Lund, Sweden), following the
provision of informed consent and approval from the local
ethics committee. For 2-dimensional electrophoresis, an addi-
tional rheumatoid synovial fluid sample was obtained from the
knee of a patient attending Charing Cross Hospital in London,
UK.
After centrifugation to remove cells, the synovial fluid
samples were stored at 70°C until used. After thawing, the
samples were digested with hyaluronidase type IV-S (50 g/ml;
Sigma, St. Louis, MO), vortexed, and passed through a 0.2-m
Ministart filter unit (Sartorius, Hannover, Germany). Protease
inhibitor cocktail (Sigma) and EDTA were added to final
concentrations of 10 l/ml and 50 mM, respectively, and the
samples were stored at 20°C.
Generation of rabbit anti–CEP-1 antibodies. A rabbit
polyclonal anti–CEP-1 antibody was generated at Cambridge
Research Biochemicals (Ely, UK). Briefly, 2 rabbits were
immunized subcutaneously every 2 weeks, for 10 weeks, with
200 g keyhole limpet hemocyanin (KLH)–conjugated CEP-1
(peptide:KLH ratio 1:1) in Freund’s incomplete adjuvant per
booster. Blood was collected 7 days after each injection, and
sera were analyzed for the presence of anti–CEP-1 antibodies
by enzyme-linked immunosorbent assay (ELISA) (14).
When antibody titers had reached significant levels,
animals were killed and blood samples were harvested. The
crude antisera were depleted of cross-reactive antibodies by
chromatography on a thiopropyl-Sepharose column conju-
gated to a control peptide in which the citrulline residues had
been replaced with arginine residues. The unbound fraction
was affinity purified on a second thiopropyl-Sepharose col-
umn, conjugated to CEP-1. Anti–CEP-1–specific antibodies
were eluted and further depleted of nonspecific antibodies in 3
subsequent passages through the depleting column. Bound
antibodies were eluted from the column with 27 ml of 0.1M
glycine/HCl, pH 2.5, and the flow-through was collected as the
unbound fraction.
Both antibody fractions demonstrated similar preferen-
tial reactivity for citrullinated -enolase, with the glycine eluate
having a greater sensitivity for citrullinated -enolase (as demon-
strated by immunoblotting of uncitrullinated and in vitro citrulli-
nated -enolase at the same dilution, 1:400 [data not shown]).
Both fractions were stored at 20°C until further used.
Cloning and expression of recombinant enolase. The
full-length human -enolase coding sequence was amplified,
by polymerase chain reaction (PCR), from the complementary
DNA of HL60 cells differentiated with vitamin D3 (13). The
PCR forward and reverse primers contained the Bam HI and
Xho I restriction sites, respectively (AGTTGGATCCTCTAT-
TCTCAAGATCCATGCCA and ATCCTCGAGTTACTTG-
GCCAAGGGRTTTCTGAAGTTCCTG, respectively). The
PCR product was ligated in-frame into the multiple cloning
site of the plasmid expression vector pGEX 6P3 (GE Health-
care, Bucks, UK), 3 to the glutathione S-transferase (GST)
coding site.
Expression of GST -enolase was induced in the
protease-deficient BL21 strain of Escherichia coli. Briefly, the
bacteria were grown at 28°C. Once an optical density at 600 nm
(OD600 nm) of 0.6–0.8 had been reached, IPTG was added to
the culture to a final concentration of 0.1 M to induce GST
-enolase expression. Cultures were incubated for a further 18
hours, and fusion protein was purified from bacterial lysates
according to the plasmid manufacturer’s instructions. PreScis-
sion Protease (GE Healthcare), used to cleave the GST from
the -enolase, was pelleted with the excised GST, using
glutathione–Sepharose 4B (GE Healthcare). Purified
-enolase, as determined by Coomassie blue staining and
tandem electrospray mass spectrometry (MS), was dialyzed
against phosphate buffered saline (PBS), and the protein
concentration was measured by bicinchoninic acid assay
(Pierce, Rockford, IL).
Immunoblotting. Citrullinated proteins were identified
using an Anti–Modified Citrulline (AMC) detection kit (Up-
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state Biotechnology, Lake Placid, NY) according to the man-
ufacturer’s instructions. Rabbit anti–-enolase (H300; Santa
Cruz Biotechnology, Santa Cruz, CA), rabbit anti–PAD-2
(Abcam, Cambs, UK), and goat anti–PAD-4 (Abcam) were
used at 1:200 in incubations overnight at 4°C.
Synovial fluid proteins were resolved by sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
using 10-well 4–12% Bis-Tris precast gels (Invitrogen, Paisley,
UK). Gels were either stained with Coomassie blue or trans-
ferred to nitrocellulose membranes for immunoblotting. Fol-
lowing incubations with primary and secondary antibodies, the
membranes were blocked in 5% milk in PBS/0.1% Tween,
blotted with antibodies diluted in blocking buffer, and washed
in PBS/0.1% Tween. The preparations were then developed
using enhanced chemiluminescence. Anti-goat and anti-rabbit
secondary antibodies conjugated to horseradish peroxidase
(Dako, Glostrup, Denmark) were diluted to 1:5,000 and
1:3,000, respectively, and reacted with membranes for 1 hour at
room temperature.
To prevent masking by abundant comigrating proteins,
synovial fluid samples were depleted of albumin and IgG, using
the Proteoextract Albumin/IgG Removal Kit (Calbiochem,
Notts, UK), prior to immunoblotting for the quantification of
-enolase and the detection of PAD-2 and PAD-4. Briefly,
synovial fluid, diluted 1:9 in the supplied binding buffer, was
added at 560 l per column. Proteins in the flow-through were
immunoblotted for -enolase without concentration or were
immunoblotted at a 10-fold concentration, attained using a
0.5-ml concentrator with a molecular weight cutoff of 10,000
kd (Vivascience, Stonehouse, UK). Proteins in the flow-
through were also immunoblotted for PAD-2 or PAD-4.
Poly-His–tagged recombinant human PAD-2 and PAD-4 (each
50 ng/well) (3) were used as positive controls. In addition,
nondepleted synovial fluid samples (diluted 1:30 in PBS) from
20 patients with RA, 20 patients with SpA, and 20 patients with
OA were applied directly (2 l/dot) onto a single nitrocellulose
membrane for detection of citrullinated proteins. Immunoblot-
ting was performed using the AMC detection kit in accordance
with the manufacturer’s instructions.
Measurement of synovial fluid soluble -enolase con-
centration. Synovial fluid samples depleted of IgG and albu-
min and boiled in 2 Laemmli buffer were loaded in duplicate
onto 15-well 4–12% Bis-Tris precast gels (Invitrogen). On each
gel, a range of purified -enolase standards was also loaded.
Following SDS-PAGE and electrotransferesis, nitrocellulose
membranes were blocked in 5% milk/PBS/0.1% Tween over-
night, incubated in rabbit anti–-enolase, diluted 1:200 in
blocking buffer, washed in PBS/0.1% Tween, incubated with
anti-rabbit secondary antibodies (Dako), washed in PBS/0.1%
Tween, and developed using enhanced chemiluminescence.
Concentrations of -enolase were calculated by densitometry.
Films (Amersham Hyperfilm; GE Healthcare) were
scanned using a scanning densitometer (GS-710 Calibrated
Imaging Densitometer; Bio-Rad, Hercules, CA). Fifty-
kilodalton bands were quantified for total pixel volumes (cor-
responding to total amounts of -enolase) using Phoretix
software (Nonlinear Dynamics, Ltd., Newcastle, UK). Pixel
volumes of bands at 50 kd in lanes containing recombinant
-enolase were used to create a standard curve of total
-enolase levels relative to pixel volume, achieved using Prism
software (GraphPad Software, San Diego, CA). From this
curve, total -enolase levels in each of the wells loaded with
synovial fluid samples were deduced, and a mean -enolase
level for each patient sample was calculated from duplicate
lanes. This assay was performed for each individual 15-well gel,
to avoid generation of artefacts resulting from intergel and
interfilm variation. Each gel was loaded with 4 samples, added
in duplicate. Because of the dilutions and volumes of the
synovial fluid samples, the concentration of -enolase in the
fluid was multiplied by 1.5. Thus, the densitometric value
representing the lowest value on the standard curve, 0.6 ng/l,
equated to 0.9 ng/l of -enolase in the synovial fluid.
Liquid-phase isoelectric focusing (IEF). To character-
ize citrullinated proteins by tandem MS, an RA synovial fluid
sample with an abundance of citrullinated proteins was frac-
tionated by liquid-phase IEF (Zoom IEF; Invitrogen). Briefly,
synovial fluid was mixed with 40 l carrier ampholytes (Invitro-
gen) and 80 l of 1M dithiothreitol, and made up to a volume
of 4 ml in IEF buffer, giving a final concentration of 0.5 mg/ml
protein. Polyacrylamide Zoom disks (Invitrogen), each with
the appropriate pH, were added to the assembly, to yield 5
liquid-phase protein fractions (pH 3.0–4.5, 4.6–5.3, 5.4–6.1,
6.2–6.9, and 7.0–10.0). Anode (pH 2.5–2.9) and cathode (pH
3.0–10.0) buffers were added to their respective electrodes at a
volume of 17.5 ml. Samples were added to each of the
chambers (650 l/chamber), and IEF was performed according
to the manufacturer’s guidelines, consisting of 100V for 20
minutes, 200V for 80 minutes, and 800V for 80 minutes. Each
fraction was further separated by SDS-PAGE, followed by
either staining with Coomassie blue or immunoblotting.
Coomassie blue–stained proteins were excised, di-
gested with trypsin, and characterized by tandem MS as
previously described (13). For these experiments, semipurified
-enolase (Hytest, Turku, Finland), with or without prior
digestion with PAD, was used as the positive control.
ELISA. Ninety-six–well plates (Maxisorp; Nunc, Rosk-
ilde, Denmark) were coated with CEP-1 (CKIHA-X-EIFDS-
X-GNPTVEC, where X represents citrulline) or the arginine-
containing control peptide (CKIHAREIFDSRGNPTVEC) at
10 g/ml (diluted in a 50-mM carbonate buffer, pH 9.6), or
with 2% bovine serum albumin (BSA) in carbonate buffer, and
incubated overnight at 4°C. Wells were washed with PBS/
0.05% Tween and blocked with 2% BSA (diluted in PBS) for
3 hours at room temperature. Sera were diluted 1:100 in
radioimmunoassay (RIA) buffer (10 mM Tris, 1% BSA, 350
mM NaCl, 1% Triton-X, 0.5% sodium deoxycholate, 0.1%
SDS), added in duplicate, and incubated for 1.5 hours at room
temperature. Plates were washed as described above and
incubated for 1 hour at room temperature with peroxidase-
conjugated mouse anti-human IgG (Hybridoma Reagent Lab-
oratory, Baltimore, MD), diluted 1:1,000 in RIA buffer.
After a final wash (PBS/0.05% Tween), bound antibod-
ies were detected with tetramethylbenzidine substrate (KPL,
Gaithersburg, MD). The reaction was stopped by the addition
of 1M H2SO4, and absorbance was measured at 450 nm in a
Multiscan Ascent microplate reader (ThermoLabsystems, Hel-
sinki, Finland). A control serum was included on all plates to
correct for plate-to-plate variation.
For each serum tested, background OD450 nm values (i.e.,
in wells coated with 2%BSA in carbonate buffer) were subtracted
from peptide OD450 nm values. OD values higher than 0.2 were
considered to be peptide positive. Anti-CCP antibody status was
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analyzed using the CCP-2 kit (Eurodiagnostica, Malmo, Sweden)
according to the manufacturer’s instructions.
RESULTS
Increased levels of citrullinated proteins and
-enolase in synovial fluid from patients with inflam-
matory arthritis. Immunoblotting with the AMC detec-
tion kit demonstrated that both the RA samples and the
SpA samples contained citrullinated proteins across the
entire range of molecular mass, although none were
detected in the OA samples (individual immunoblotting
results are available upon request from the correspond-
ing author). These findings were also confirmed by
dot-blot analysis of synovial fluid samples from all
patients (Figure 1), assessed on a single membrane to
eliminate possible variability between separate mem-
branes. Citrullinated proteins were detected by dot-blot
in 19 of 20 RA samples, in 17 of 20 SpA samples, and in
only 2 OA specimens.
Immunoblotting demonstrated the presence of
-enolase in both the RA samples and the SpA samples;
however, -enolase was barely detectable in the OA
samples (Figure 2). We used densitometry and a stan-
dard curve of recombinant protein to quantify the
-enolase in all 60 samples. As shown in Figures 2 and 3,
higher levels of -enolase were detected in samples from
both the patients with RA (mean 6.4 ng/l, range
1.2–15.4) and the patients with SpA (mean 4.3 ng/l,
range 1.1–9.2) as compared with the OA controls (0.9
ng/l in all samples).
RA specificity of increased levels of antibodies to
CEP-1 in synovial fluid. Antibodies to CEP-1 were
detected in 12 of the 20 RA synovial fluid samples (60%)
but in only 1 OA sample (5%) and in none of the SpA
samples (Figure 4). None of the RA patients had
antibodies to the arginine-containing control peptide,
while 1 OA synovial fluid sample and 1 from a patient
Figure 1. Dot-blots of synovial fluid samples from the 3 different
disease groups (n  20 per group), showing citrullinated proteins on a
single membrane. “No SF” refers to a spot to which no synovial fluid
was added. RA  rheumatoid arthritis; SpA  spondylarthritides;
OA  osteoarthritis.
Figure 2. Immunoblots of synovial fluid samples from the 3 different
disease groups (n  20 per group), showing higher levels of -enolase
in synovial fluid from patients with RA (lanes I and II) and patients
with SpA (lanes III and IV) compared with patients with OA (lanes
V–VIII); standard curves of recombinant -enolase are also shown.
The OA synovial fluid required longer exposures to demonstrate the
much lower levels of the reactive polypeptide. Results from represen-
tative duplicate samples are shown. See Figure 1 for definitions.
Figure 3. Levels of -enolase in synovial fluid samples from the 3
different disease groups (n 20 per group), as measured using immuno-
blotting and densitometry analyses. Broken line indicates the cutoff for
positivity; solid lines indicate the mean. See Figure 1 for definitions.
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with SpA were positive for the control peptide. All 12
RA patients who were anti–CEP-1 positive were also
anti–CCP-2 positive.
Characterization of citrullinated proteins in syno-
vial fluid from a patient with RA. To characterize the
citrullinated proteins present in rheumatoid synovial
fluid, we selected an RA synovial fluid sample contain-
ing heavily citrullinated proteins. This sample was re-
solved by liquid-phase IEF, followed by SDS-PAGE.
Bands from Coomassie blue–stained gels were identified
by tandem MS (Figure 5a). Immunoblotting with the
AMC antibody demonstrated the presence of citrulli-
nated proteins with molecular masses between 35 kd and
250 kd (Figure 5b). The concentration of these proteins
was greatest in the more acidic fractions, particularly
between pH 3.0 and pH 4.6, whereas Coomassie blue–
stained material was most abundant in fractions with a
pH higher than 5.5. This is consistent with the acidic
shift associated with deimination of arginine.
We identified -enolase with 2 different antibod-
ies: the rabbit anti–-enolase H300, which reacted with
purified -enolase equally in its uncitrullinated and
citrullinated forms, and the anti–CEP-1 antibody, which
preferentially reacted with the in vitro citrullinated form.
The H300 antibody reacted with a 50-kd polypeptide,
which was most abundant in the IEF fractions with pH
of 6.2–6.9 and 7.0–10.0 (Figure 5c). This is consistent
with the characteristics of native -enolase, which has a
calculated pH of 6.9. The reactivity of the anti–CEP-1
antibody showed a shift toward more acidic forms of the
molecule, including a stronger reaction with the 5.4–6.1
fraction and a weaker reaction with the 7.0–10.0 fraction
(Figure 5d), compared with the reactions with the H300
antibody. This is consistent with the presence of some
partially citrullinated -enolase.
All bands visible by Coomassie blue staining were
excised and digested in gel with trypsin, and the resulting
peptides were sequenced by tandem MS; the proteins
identified are shown in Figure 5a. No citrulline residues
were observed with the use of tandem MS in peptides
derived from any of the synovial fluid proteins, whereas
peptides containing deiminated arginine residues were
readily detected in a PAD-treated sample of -enolase
analyzed in parallel, suggesting that the stoichiometry of
in vivo citrullination is relatively low.
Presence of PAD-2 and PAD-4 in synovial fluid
from RA, SpA, and OA patients. We investigated the
presence of enzymes capable of deimination of arginine,
using antibodies against PAD-2 and PAD-4 in immuno-
blots of synovial fluid cultures that had been depleted of
IgG and albumin and subsequently concentrated. Prom-
inent bands were seen when blotting for PAD-4 in all of
the synovial fluid samples. However, reactivity was gen-
Figure 4. Antibodies to citrullinated -enolase peptide 1 (anti–
CEP-1) and cyclic citrullinated peptide 2 (anti–CCP-2) in synovial fluid
(SF) samples from the 3 different disease groups (n  20 per group),
with elevated levels specifically observed in the synovial fluid from
patients with RA compared with the patients with SpA and patients
with OA. There was no reaction with the arginine-containing control
peptide in the RA samples, confirming that the anti–CEP-1 reaction is
citrulline-specific. Broken line indicates the cutoff for positivity; solid
lines indicate the mean. OD450  optical density at 450 nm; AU 
arbitrary units (see Figure 1 for other definitions).
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erally lower in the OA samples. In comparison, reactivity
with the anti–PAD-2 antibody was detectable in 18 of 20
RA samples, in 16 of 20 SpA samples, and in none of the
OA samples. Both PAD-2 and PAD-4 migrated at a
molecular weight similar to the 75-kd molecular weight
standard, just below the recombinant PAD-2– and PAD-
4–positive controls, the difference in mass being ac-
counted for by the poly-His tag (Figure 6).
Although the antibodies showed good specificity
for their respective controls, there were widespread
cross-reactions with other proteins in the synovial fluid.
Some of the samples (see OA sample 3 in Figure 6)
showed a reaction of the PAD-2 antibody with a
polypeptide that migrated just above the 75-kd marker
and the positive control. This was interpreted as not
being PAD-2, because of the increased molecular mass.
There was no reaction with the conjugate controls
(results not shown). These findings are consistent with
the notion that the extracellular compartment of syno-
vial fluid in patients with inflammatory arthritis is a site
for generation of citrullinated proteins by either or both
of these enzymes.
Figure 5. Resolution and identification of synovial fluid proteins by 2-dimensional electrophoresis. A synovial fluid sample from a patient with
rheumatoid arthritis was analyzed by liquid-phase isoelectric focusing (without Zoom disks [pre] or with Zoom disks at 5 liquid-phase protein
fractions of pH 3.0–4.5, 4.6–5.3, 5.4–6.1, 6.2–6.9, and 7.0–10) followed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. a, Proteins
were identified by tandem electrospray mass spectrometry (MS) on Coomassie blue–stained gels: 1 albumin, 2 inter–-trypsin inhibitor H-chain,
3  1-antitrypsin, 4  fibronectin, 5  fibrinogen -chain, 6  ceruplasmin, 7  IgM H-chain, 8  haptoglobin, 9  IgM1 H-chain, 10 
2-macroglobulin, 11  major histocompatibility complex factor B, 12  gelsolin, 13  IgM3 H-chain, 14  M1/M2 pyruvate kinase, 15 
apolipoprotein, 16  native -enolase (eno), 17  citrullinated -enolase (c-eno), 18  IgM3, and 19  1-acid glycoprotein. Only in vitro
citrullinated -enolase could be demonstrated to contain citrulline residues byMS. b, Immunoblotting of Zoom fractions with the anti–modified citrulline
antibody (AMC) demonstrated that citrullinated proteins were present in all Zoom fractions, but were more abundant in the most acidic ones. c,
Immunoblotting for -enolase with the H300 anti–-enolase antibody, which reacts equally with native -enolase and citrullinated -enolase, demonstrated
that -enolase was most abundant in the 2 most basic fractions. d, Immunoblotting with the citrullinated -enolase peptide 1 antibody (anti–CEP-1), which
reacts preferentially with citrullinated -enolase, showed reactivity with a 50-kd polypeptide that was relatively abundant in more acidic fractions, indicating
that a proportion of the -enolase is citrullinated in rheumatoid synovial fluid. MW indicates the molecular weight standard.
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DISCUSSION
In this study we have demonstrated that synovial
fluid from patients with RA and from patients with SpA
is characterized by an abundance of citrullinated pro-
teins. The presence of abundant citrullinated proteins in
synovial fluid from patients with SpA and patients with
RA, compared with a lack of citrullinated proteins in
OA synovial fluid, suggests that, similar to that in the
synovial membrane, the presence of elevated levels of
citrullinated proteins may be characteristic of inflamma-
tion, and not restricted to RA.
Our identification of -enolase as a candidate
citrullinated antigen in synovial fluid suggests that this
previously neglected compartment of the rheumatoid
joint is a site of expression of autoantigens. This obser-
vation is consistent with the findings from previous
studies, which have demonstrated the presence of citrul-
linated fibrin in synovial fluid from patients with RA, but
not in OA synovial fluid (15,16), and is consistent with a
recent description of mutated and citrullinated vimentin
in RA synovial fluid (17), although in that report, the
material included lysed cells. We also found that the
mean -enolase levels in rheumatoid synovial fluid were
increased at least 6-fold in the samples from RA pa-
tients, and increased at least 4-fold in the SpA synovial
fluid. Because the levels in the OA samples fell below
the lowest concentration of recombinant -enolase on
the standard curve, it may be that the ratio of concen-
trations in the 2 types of inflammatory arthritis tested
herein may be even higher in comparison with OA.
The higher levels of anti–CEP-1 antibodies found
in RA patients (60% of the RA synovial fluid samples)
compared with the controls supports the concept that
expression of citrullinated proteins is a product of
inflammation, whereas the antibody response remains
specific to RA. In this study we did not examine the
relative concentration of anti–CEP-1 antibodies in syno-
vial fluid compared with that in the serum. A highly
significant enrichment has already been demonstrated
for anti–CEP-1 and other ACPAs in more than 300
paired serum and synovial fluid samples in a separate
study (Snir O, et al: unpublished observations).
We demonstrated reactivity with the anti–CEP-1
antibody in acidic fractions containing proteins with pH
below the calculated pH of unmodified -enolase. Re-
activity with the AMC detection antibody was also
evident in the more acidic fractions. This is consistent
with some of the -enolase being citrullinated in vivo,
and therefore gaining acidity. However, we were unable
to demonstrate specific citrullinated residues in synovial
fluid -enolase by tandem MS.
Similar findings were obtained for other abun-
Figure 6. Representative immunoblots of peptidylarginine deiminase type 2 (PAD-2) and PAD-4 in synovial fluid of patients with rheumatoid
arthritis (RA), patients with spondylarthritides (SpA), and patients with osteoarthritis (OA). PAD-2 was detected in all 3 RA samples and in 2 of
the SpA samples (SpA1 and SpA2), but in none of the OA samples. PAD-4 was found in all of the synovial fluid samples. His-tagged PAD-2 and
PAD-4 were used to confirm specific reactivity of the anti-PAD antibodies. Note that the recombinant His–tagged PAD-2 and PAD-4, used as
positive controls, migrated at a slightly higher apparent mass because of the 6 histidine residues in the tag. Both antibodies reacted with higher and
lower molecular weight polypeptides, indicating cross-reactivity with other unidentified proteins. Immunoblotting with anti-goat and anti-rabbit
antibodies, without primary antibodies, confirmed that the synovial fluid proteins were not reacting directly with the secondary antibodies (results
not shown).
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dant proteins, mainly well-documented serum proteins,
in which citrullination was demonstrated in comigrating
polypeptides, as revealed by staining with the AMC
antibody. The only sample in which deiminated argi-
nines were demonstrable by MS was the in vitro citrul-
linated -enolase, in which every arginine was deimi-
nated, as observed both in this study and in our previous
report (13). The failure to detect citrulline residues in
the deiminated synovial fluid proteins is probably due to
partial deimination, to the low stoichiometry of in vivo
citrullination, and to the distribution of the modification
over different arginines in different molecules. This is
entirely consistent with the findings from another recent
study, in which deimination was detected in synovial
membrane proteins by both electrophoretic shift assay
and staining with the AMC antibody, but not by MS,
even in relatively abundant proteins such as citrullinated
fibrinogen (12).
This is the first report demonstrating the pres-
ence of extracellular PAD-2 and PAD-4 in the synovial
fluid, although it required removal of the abundant
serum proteins, and subsequent concentration, to dem-
onstrate the enzymes clearly. The anti–PAD-4 antibody
reacted unequivocally at the appropriate molecular
weight with all of the synovial fluid samples, with fainter
bands visible in the OA samples, which again supports
the hypothesis that synovial fluid is a site of active
deimination in the presence of inflammation. In com-
parison, reactivity with the anti–PAD-2 antibody was
only detectable in the RA and SpA samples. Therefore,
it cannot be discounted that PAD-2 is also present in the
OA samples, but was below the levels of detection used
in this study. If both PAD-2 and citrullinated proteins
are indeed absent in OA samples, the hypothesis can
justly be made that it is the PAD-2 that is responsible for
the deimination of the extracellular citrullination of
synovial fluid proteins.
The presence of polypeptides of other molecular
weights that was detected with both the anti–PAD-2 and
anti–PAD-4 antibodies raises questions regarding the
specificity of these reagents. Therefore, caution should
be taken when using these reagents in assay systems such
as immunohistochemistry, since there is no control for
molecular weight, and therefore, there is the possibility
of false-positive results.
In the present study we have provided evidence
that the synovial fluid from patients with inflammatory
arthritis is a site of expression of citrullinated proteins
and up-regulation of -enolase. The presence of PAD-2
and PAD-4, in which the extracellular environment
would favor activation of the enzymes, supports the
hypothesis that the synovial fluid may be an important
site of expression of citrullinated proteins in inflamma-
tory arthritis. The restriction of the immune response to
patients with RA may help explain the chronic auto-
immune response in the rheumatoid joint, characteristic
of this disease.
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Antibodies to Citrullinated -Enolase Peptide 1 Are Specific
for Rheumatoid Arthritis and Cross-React With
Bacterial Enolase
Karin Lundberg,1 Andrew Kinloch,1 Benjamin A. Fisher,1 Natalia Wegner,1 Robin Wait,1
Peter Charles,1 Ted R. Mikuls,2 and Patrick J. Venables1
Objective. To map the antibody response to hu-
man citrullinated -enolase, a candidate autoantigen in
rheumatoid arthritis (RA), and to examine cross-
reactivity with bacterial enolase.
Methods. Serum samples obtained from patients
with RA, disease control subjects, and healthy control
subjects were tested by enzyme-linked immunosorbent
assay (ELISA) for reactivity with citrullinated
-enolase peptides. Antibodies specific for the immuno-
dominant epitope were raised in rabbits or were purified
from RA sera. Cross-reactivity with other citrullinated
epitopes was investigated by inhibition ELISAs, and
cross-reactivity with bacterial enolase was investigated
by immunoblotting.
Results. An immunodominant peptide, citrulli-
nated -enolase peptide 1, was identified. Antibodies to
this epitope were observed in 37–62% of sera obtained
from patients with RA, 3% of sera obtained from disease
control subjects, and 2% of sera obtained from healthy
control subjects. Binding was inhibited with homolo-
gous peptide but not with the arginine-containing con-
trol peptide or with 4 citrullinated peptides from else-
where on the molecule, indicating that antibody binding
was dependent on both citrulline and flanking amino
acids. The immunodominant peptide showed 82% ho-
mology with enolase from Porphyromonas gingivalis, and
the levels of antibodies to citrullinated -enolase pep-
tide 1 correlated with the levels of antibodies to the
bacterial peptide (r2  0.803, P < 0.0001). Affinity-
purified antibodies to the human peptide cross-reacted
with citrullinated recombinant P gingivalis enolase.
Conclusion. We have identified an immunodomi-
nant epitope in citrullinated -enolase, to which anti-
bodies are specific for RA. Our data on sequence
similarity and cross-reactivity with bacterial enolase
may indicate a role for bacterial infection, particularly
with P gingivalis, in priming autoimmunity in a subset of
patients with RA.
Rheumatoid arthritis (RA) is a chronic inflam-
matory joint disorder that is considered to be auto-
immune, although the autoantigens that trigger and
sustain the immune response remain unknown. Over the
last 10 years, investigations have shown that an essential
feature of many autoantigens in RA is the posttransla-
tional conversion of peptidyl arginine to peptidyl citrul-
line. Anti–citrullinated protein antibodies (ACPAs) are
highly specific (98%) and sensitive (up to 80%) for RA
(1,2), making citrullinated proteins strong candidates for
driving the autoimmune response in this disease (for
review, see ref. 3). Kuhn et al, for example, recently
demonstrated that administration of anti–citrullinated
fibrinogen antibodies enhanced disease severity in an
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experimental mouse model of arthritis (4). In the ma-
jority of patients with RA, the presence of ACPAs
antedates disease onset (5,6), and ACPA-positive pa-
tients present with a more severe and erosive form of
arthritis (7–16). A commercial enzyme-linked immu-
nosorbent assay (ELISA) based on cyclic citrullinated
peptides (CCPs) detects ACPAs and is now routinely
used in the diagnosis of RA.
Citrullination has a physiologic role in the gener-
ation of structural tissue such as skin, hair follicles, and
the myelin sheaths of nerve fibers. In addition, the
accumulation of citrullinated proteins has been de-
scribed at sites of inflammation, including the joints of
patients with all forms of arthritis (17), the brains of
patients with multiple sclerosis (18) or Alzheimer’s
disease (19), and in the muscle fibers of patients with
myositis (20). Hence, citrullinated proteins are present
in the setting of both health and disease, while tolerance
to citrullinated proteins appears to be selectively lost in
patients with RA. Thus, in RA, it is the antibody
response rather than the expression of antigen that is
specific to the disease.
Genes and the environment interact in the devel-
opment of this complex and heterogeneous disorder.
Recent studies have demonstrated that the HLA–DRB1
shared epitope (SE) alleles, the best known genetic risk
factor for RA, are associated with only anti-CCP
antibody–positive RA, not anti-CCP antibody–negative
RA, indicating that HLA SE alleles may be a specific
risk factor for the production of ACPAs rather than the
for RA itself (21,22). Furthermore, a strong gene–
environment interaction between HLA SE alleles and
cigarette smoking is present in anti-CCP antibody–
positive patients but not in anti-CCP antibody–negative
patients (21,23). Infectious agents, both bacterial and
viral, have also been proposed as potential environmen-
tal stimuli (24–27), although to date, no single organism
has survived as a compelling candidate for the etiology
of the disease. Given that citrullinated proteins are
target autoantigens in RA, the pathogen Porphyromonas
gingivalis, which expresses the citrullinating enzyme pep-
tidyl arginine deiminase (PAD) (28), could be an envi-
ronmental trigger of RA in a manner similar to that
proposed for smoking (21).
It is not clear which proteins harbor the epitopes
targeted by ACPAs, although several candidates, includ-
ing citrullinated fibrinogen (29), vimentin (30), and type
II collagen (31), have been suggested, and we recently
identified citrullinated -enolase as another potential
autoantigen (32). Alpha-enolase is abundantly expressed
in the rheumatoid joint, antibodies targeting only the
citrullinated form of the protein are specific for the
disease, and our group recently demonstrated the pres-
ence in vivo of citrullinated -enolase in synovial fluid
from patients with RA (33). The molecule is also highly
conserved throughout eukaryotes and prokaryotes and
could therefore be a candidate for molecular mimicry
between bacterial and host proteins (34). In the present
study, we mapped the epitope of this anti–citrullinated
-enolase antibody response, using several citrullinated
-enolase peptides (CEPs), with the aim of examining
cross-reactivity with bacterial enolase, which could
prime autoimmunity in a subset of patients with RA.
PATIENTS AND METHODS
Serum samples from patients and control subjects.
Serum samples were obtained, with informed consent and
ethics approval from the Regional Research Ethics committee,
from 102 consecutive patients with RA who were attending the
Rheumatology Clinic at Charing Cross Hospital, London. The
disease control group comprised 110 patients with other
rheumatic diseases, including systemic lupus erythematosus
(n  32), Sjo¨gren’s syndrome (n  31), Behc¸et’s syndrome
(n  18), psoriatic arthritis (n  5), and miscellaneous other
rheumatic diseases (n  24). Ninety-two control serum sam-
ples were obtained from healthy volunteers. Serum samples
from 20 patients with spondylarthritides who were attending
the Rheumatology Clinic at the Karolinska University Hospital
in Stockholm, Sweden, were also collected, with informed
consent and local ethics approval. In addition, serum samples
were collected from an independent US cohort of 81 patients
with RA obtained at baseline in clinical trials conducted by the
Rheumatoid Arthritis Investigational Network (RAIN; coor-
dinating center, University of Nebraska, Omaha) and from 82
age- and sex-matched healthy volunteers. All US samples were
obtained with ethics approval from the local institutional
review board. All patients with RA met the American College
of Rheumatology (formerly, the American Rheumatism Asso-
ciation) 1987 revised criteria for the classification of RA (35).
Peptides. Fifteen cyclic 15–23-mer peptides were syn-
thesized at Cambridge Research Biochemicals (Billingham,
Cleveland, UK). The peptide sequences corresponded to
amino acid sequences in human -enolase (Swiss-Prot acces-
sion no. P06733) or P gingivalis enolase (Swiss-Prot accession
no. AAQ66821), with the addition of cysteine residues at the
amino and carboxy termini and the exchange of arginine for
citrulline residues at certain positions (Table 1).
ELISAs. Ninety-six–well plates (MaxiSorp; Nunc,
Roskilde, Denmark) were coated with -enolase peptides at 10
g/ml (diluted in a 50-mM carbonate buffer, pH 9.6) or with
carbonate buffer alone and incubated overnight at 4°C. Wells
were washed with phosphate buffered saline (PBS)–Tween
(0.05%) and blocked with 2% bovine serum albumin (BSA)
diluted in PBS for 3 hours at room temperature. Sera were
diluted 1:50 in radioimmunoassay (RIA) buffer (10 mM Tris,
1% BSA, 350 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate) supplemented
with 10% fetal calf serum (FCS), added in duplicates, and
incubated for 1.5 hours at room temperature. Plates were
washed as described above and incubated with peroxidase-
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conjugated mouse anti-human IgG (Hybridoma Reagent Lab-
oratory, Baltimore, MD) (diluted 1:1,000 in RIA buffer, 10%
FCS) for 1 hour at room temperature. After a final wash
(PBS–Tween, 0.05%), bound antibodies were detected with
tetramethylbenzidine substrate (KPL, Gaithersburg, MD). The
reaction was stopped by the addition of 1M H2SO4, and
absorbance was measured at 450 nm in a Multiscan Ascent
microplate reader (Thermolab Systems, Franklin, MA). A
control serum was included on all plates to correct for plate-
to-plate variation. The value for background optical density at
450 nm (OD450) (wells coated with carbonate buffer alone)
was subtracted from the peptide OD450 value. OD values
above 0.1 were considered to be positive. ELISA of the serum
samples obtained from the US cohort was performed in a
similar manner but with 2% BSA in carbonate buffer as
background and with an OD450 cutoff of 0.2 for positive
samples. Anti-CCP antibody status was analyzed using the
CCP2 kit (Eurodiagnostica, Malmo, Sweden), according to the
manufacturer’s instructions.
Inhibition assays. Inhibition experiments were per-
formed in liquid phase using serum samples obtained from 6
anti–CEP-1–positive patients with RA or in solid phase using
serum samples obtained from 9 double-positive (anti–CEP-1
positive and CCP positive) patients with RA. Sera were
preincubated for 2 hours in RIA buffer containing increasing
concentrations (0, 1, 10, and 100 g/ml) of CEP-1, control
peptide 1D, peptide 11, 4, or 9 (representing the second, third,
and fourth most reactive peptides), or peptide 7 (representing
the peptide with the lowest degree of reactivity). Alternatively,
serum specimens were preabsorbed on plates coated with
CEP-1 or carbonate buffer alone or were preabsorbed on
commercial CCP2 plates. The liquid phase mixtures were
centrifuged at 16,200g for 15 minutes before the supernatants
were transferred to CEP-1–coated plates and assessed as
described above for ELISAs. Inhibition of binding to CEP-1,
for serum samples preabsorbed to CCP, was calculated in
relation to the maximum inhibition, which by definition was set
to 100% for samples preincubated with CEP-1.
Generation of anti–CEP-1 antibodies. A rabbit poly-
clonal anti–CEP-1 antibody was generated at Cambridge Re-
search Biochemicals. Briefly, 2 rabbits were immunized subcu-
taneously every 2 weeks, for 10 weeks, with 200 g keyhole
limpet hemocyanin–conjugated peptide 1A in Freund’s incom-
plete adjuvant per boost. Blood was collected 7 days after each
injection, and sera were analyzed for the presence of anti–
CEP-1 antibodies. When antibody titers reached significant
levels, the animals were killed and their blood was harvested.
The crude antisera were depleted of cross-reactive antibodies
by chromatography on a thiopropyl–Sepharose column conju-
gated to peptide 1D. The unbound fraction was affinity-
purified on a second thiopropyl–Sepharose column conjugated
to peptide 1A. Anti–CEP-1–specific antibodies were eluted
and further depleted of nonspecific antibodies by 3 subsequent
passages through the depleting column. Human anti–CEP-1
antibodies from a patient with RA were purified with high
titers of anti–CEP-1 antibodies. The serum was passed through
a thiopropyl–Sepharose column conjugated to peptide 1A.
Bound antibodies were eluted, after repeated PBS washes,
using 3M GuHCl, and dialyzed against PBS. Purified rabbit
anti–CEP-1 antibodies (0.39 mg/ml) and human anti–CEP-1
antibodies (0.6 g/ml) were stored at20°C until used further.
ELISA to assess CEP-1 specificity of affinity-purified
anti–CEP-1 antibodies. Affinity-purified anti–CEP-1 antibod-
ies (rabbit and human) were tested for their anti–CEP-1
specificity in serial dilutions (starting at 1:50 for the rabbit
anti–CEP-1 antibody and at 1:2 for the human anti–CEP-1
antibody) on plates coated with peptide 1A or peptide 1D and
assayed as described above for ELISAs.
Cloning and expression of human and bacterial eno-
lase. Full-length human enolase and P gingivalis enolase were
amplified by polymerase chain reaction (PCR), from vitamin
D3–differentiated HL-60 cells and P gingivalis strain W83 (no.
Table 1. Alpha-enolase peptide sequences and the antibody response to these peptides in patients with
RA and controls*
Peptide name Sequence
RA
(n  102)
Disease controls
(n  110)
Healthy controls
(n  92)
1A (CEP-1) ckiha-X-eifds-X-gnptvec 37 3† 2
1A P gingivalis ckiig-X-eilds-X-gnptvec 34 1† ND
1B ckiha-R-eifds-X-gnptvec 40 ND ND
1C ckiha-X-eifds-R-gnptvec 20 ND ND
1D ckiha-R-eifds-R-gnptvec 5 2 3
2 cvdlftskglf-X-aavpsgc 10 0 2
3 cyealel-X-dndkt-X-ymgkgvskc 15 2 0
4 cekgvply-X-hiadlagnsec 16 2 2
5 cnf-X-eam-X-igaevyhnlknc 11 4 3
6 cf-X-sgkydldfkspddps-X-yc 12 5 0
7 cangwgvmvsh-X-sgetedtc 4 2 2
8 cakynqll-X-ieeelgskac 7 4 0
9 ckfag-X-nf-X-nplakc 15 1 1
10 ciqvvgddltvtnpk-X-iakac 6 ND 1
11 cnpk-X-iakavnekscncllc 18 ND 0
* Values are the percent positive, using an optical density at 450 nm cutoff value of 0.1. RA rheumatoid
arthritis; X  citrulline; R  arginine; ND  not done.
† A total of 130 disease controls were screened for reactivity with human and Porphyromonas gingivalis
citrullinated -enolase peptide 1 (CEP-1).
NEW MODEL FOR BACTERIAL INFECTION PRIMING THE AUTOIMMUNE RESPONSE IN RA 3011
BAA-308D-5; American Type Culture Collection, Rockville,
MD), respectively. PCR products were ligated between Bam
HI and Xho I restriction sites in a pGEX 6P3 expression vector
(GE Healthcare, Bucks, UK), 3 to the glutathione transferase
(GST) coding site. GST–enolase protein expression was in-
duced by isopropyl thiogalactose in the protease-deficient
BL21 strain of Escherichia coli. Protein was purified using
glutathione–Sepharose 4B (GE Healthcare), and the GST
moiety was cleaved using PreScission Protease (GE Health-
care). Purified enolase, as determined by Coomassie staining
and tandem mass spectometry analysis, was dialyzed against
PBS and stored at 20°C until used further.
In vitro deimination. Recombinant human enolase and
bacterial enolase were diluted to a concentration of 0.3 mg/ml
in PAD buffer (0.1M Tris HCl, pH 7.6, 10 mM CaCl2, 5 mM
dithiothreitol) and incubated with rabbit skeletal PAD (Sigma,
St. Louis, MO) at a concentration of 7 units/mg protein, for 3
hours at 50°C. Citrullination was terminated by the addition of
20 mM EDTA. Control proteins were treated similarly, apart
from the addition of PAD. All samples were stored at 20°C
until used further.
Silver staining and immunoblotting. Recombinant hu-
man enolase and P gingivalis enolase were electrophoresed on
4–12% NuPAGE Bis-Tris gels (Invitrogen, Paisley, UK) be-
fore silver staining, using a standard protocol, or before
transfer to nitrocellulose membranes for immunoblotting.
Briefly, membranes were blocked with 5% nonfat milk and
incubated with rabbit anti–CEP-1 antibody (diluted 1:25) or
human anti–CEP-1 antibody, diluted 1:2. Proteins were de-
tected using peroxidase-conjugated secondary antibody (goat
Figure 1. A, IgG response to citrullinated -enolase peptides in patients with rheumatoid arthritis (RA; n  102),
disease controls (n  110), and healthy controls (n  92). B, Antibody response to the immunodominant peptides
1A, 1B, 1C, and 1D in patients with RA. The response to peptide 1A is dependent on the presence of citrulline, as
demonstrated by the low antibody levels to the arginine-containing control peptide 1D. The second citrulline
residue, rather than the first, is more important for antibody binding (compare peptides 1B and 1C). IgG was
measured by enzyme-linked immunosorbent assay, and data are presented as the peptide optical density at 450 nm
(OD450) value with the background (carbonate buffer) OD450 value subtracted. Each dot represents the reactivity
of 1 serum sample with the indicated peptide. Bars indicate the mean.   P  0.01;   P  0.0001. ND  not
done.
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anti-rabbit IgG, diluted 1:2,000; Dako, Glostrup, Denmark) or
mouse anti-human IgG, diluted 1:500 (Hybridoma Reagent
Laboratory, Baltimore, MD). Membranes were developed
using the enhanced chemiluminescence technique (Amersham
Biosciences, Little Chalfont, UK). Citrullinated proteins were
detected using the Anti-Citrulline (Modified) Detection Kit
(Upstate Biotechnology, Lake Placid, NY), in accordance with
the manufacturer’s instructions.
Statistical analysis. All statistical analyses were per-
formed using the Mann-Whitney U test for independent
groups.
RESULTS
Detection of a disease-specific antibody response
to CEPs in patients with RA. Eleven citrullinated pep-
tides (peptides 1–11) (Table 1), covering 15 of the 17
arginine residues within -enolase, were selected on the
basis of containing 1 potential citrulline residue within
a 20–amino acid sequence, or by the demonstration (by
mass spectrometry) in our previous study (32) that
arginines had been deiminated to citrulline in vitro (32).
Each peptide synthesized was tested for reactivity in 102
patients with RA, 110 disease control subjects, and 92
healthy control subjects. The results showed that 64% of
patients with RA and 15% of the control subjects had
IgG antibodies to 1 or several CEPs. The pattern of
reactivity in patients with RA varied, with the majority
of patients having an antibody response to multiple
CEPs. In contrast, the antibody response in the control
subjects was mainly restricted to one of the peptides, and
the IgG antibody levels were significantly lower than
those observed in patients with RA (Figure 1A).
Identification of an immunodominant B cell
epitope within citrullinated -enolase. Peptide 1 (1A)
was the immunodominant peptide, which reacted with
37% of the RA serum samples compared with 2% of the
healthy control samples and 3% of the disease control
samples (Table 1). To map the antibody epitope further
and to investigate the citrulline dependence of this
antibody response, another 3 peptides (peptides 1B, 1C,
and 1D) were synthesized (Table 1). The low reactivity
of control peptide 1D, which does not contain any
citrulline residues, confirms the importance of citrulline
in this epitope (Figure 1B). The proportion of patients
with RA whose sera reacted with peptide 1B (40%) was
similar to the proportion whose sera reacted with pep-
tide 1A but was higher than the proportion whose sera
reacted with peptide 1C (20%). This, together with the
higher antibody levels to peptides 1A and 1B compared
with peptide 1C (Figure 1B), indicates that it is the
second citrulline residue, rather than the first, that is
more important for antibody recognition. Peptide 1A,
containing both citrullinated residues, was chosen for
further study and is referred to as CEP-1.
Anti-CCP antibodies in the same serum samples
gave a diagnostic sensitivity of 71%, with a specificity of
98%. Seven (23%) of the anti-CCP antibody–negative
patients with RA had positive results on the anti–CEP-1
ELISA (data not shown). Hence, combining the anti-
CCP with the anti–CEP-1 ELISA results increased the
overall sensitivity of ACPAs in this cohort to 78%.
Confirmation of the diagnostic sensitivity and
specificity of the anti–CEP-1 ELISA in an independent
cohort of patients with RA. To confirm that the high
levels of antibodies to CEP-1 were not a peculiarity of
the patients in our study, we used the anti–CEP-1
antibody ELISA to test 81 patients with RA and 82
healthy control subjects from a US cohort. To compare
the data with the UK cohort, the OD value for the
ninety-eighth percentile of control subjects was used as
the cutoff point for positive samples. The sensitivity was
increased to 62% in the US RA population, with a
specificity of 98% (Figure 2). Disease controls were not
examined in this part of the study.
Anti–CEP-1–specific as well as CCP cross-
reactive antibodies in patients with RA. The epitope
specificity of the anti–CEP-1 antibody response was
tested in 2 separate inhibition assays. In the first exper-
iment, inhibition of binding to CEP-1 was evaluated in
sera from 6 anti–CEP-1–positive patients with RA, using
Figure 2. Anti–citrullinated -enolase peptide 1 antibodies in the US
cohort. Data were generated by enzyme-linked immunosorbent assay
and are presented as the peptide optical density at 450 nm (OD450)
value with the background OD450 value subtracted. Broken line
indicates the cutoff value for positive samples, based on the OD value
for the ninety-eighth percentile of control subjects. Bar indicates the
mean. RA  rheumatoid arthritis.
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Figure 3. A–F, No cross-reaction of anti–citrullinated -enolase peptide 1 (anti–CEP-1) antibodies with other citrullinated
-enolase epitopes. A dose-dependent decrease in binding to CEP-1–coated plates was seen in 6 anti–CEP-1–positive serum
samples from patients with rheumatoid arthritis (RA), preincubated with increasing concentrations (0, 1, 10, and 100 g/ml)
of CEP-1 (A), while preincubation with the control peptide 1D (B), peptide 4 (C), peptide 7 (D), peptide 9 (E), or peptide 11
(F) did not result in decreased antibody binding. G, Differing degrees of cross-reactivity with cyclic citrullinated peptide (CCP)
in individual serum specimens from 9 double-positive (anti–CEP-1 positive and anti-CCP positive) patients with RA following
preincubation with CCP (shaded bars), as demonstrated by a reduction in CEP-1 reactivity that ranged from 0% to 53%.
Results are expressed as the percentage of maximum inhibition, which by definition was set to 100% for preincubation with
CEP-1 (solid bars). OD450  optical density at 450 nm.
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liquid phase. There was a dose-dependent inhibition by
the homologous peptide, while there was no inhibition
by the arginine-containing control peptide 1D or by the
nonreactive citrullinated -enolase peptide 7. Also,
there was no inhibition when using citrullinated
-enolase peptides representing other reactive epitopes
on the molecule, i.e., peptides 4, 9, and 11 (Figures
3A–F). In the second experiment, in which we examined
cross-reactivity to CCP, it was necessary to use the
commercially available CCP2 plates in a solid phase
assay, because the sequences of the peptides used in the
assay have not been published. In 9 double-positive
(anti–CEP-1 positive and anti–CCP positive) RA sam-
ples, preabsorption on CCP plates showed inhibition of
anti–CEP-1 binding, varying from 0% in 2 of the sera
and increasing to a maximum of 53% in 1 sample,
suggesting variable cross-reactivity of the antibodies
(Figure 3G).
High sequence similarity between human and
bacterial CEP-1. Human enolase and P gingivalis (Swiss-
Prot accession no. AAQ66821) enolase were 51% iden-
tical at the amino acid level, across the whole protein.
However, when comparing the sequence for peptide 1
(amino acids 5–21), the sequence identity increased to
82%, and the 9 amino acids spanning the immunodom-
inant epitope on peptide 1 (amino acids 13–21) were
100% identical.
Antibodies to P gingivalis CEP-1 in patients with
RA, and cross-reaction of purified anti–CEP-1 antibod-
ies with bacterial enolase. We tested the 102 RA
patients from the UK cohort for reactivity with the P
gingivalis version of CEP-1, and 34% had positive results
(Table 1); IgG antibody levels were similar to those
observed for the human version of this peptide (data not
shown). Sera from the 110 disease control subjects and
from 20 patients with spondylarthritides were also tested
for reactivity with P gingivalis CEP-1, and only 1 was
positive (Table 1). In addition, serum samples from the
US cohort were analyzed for anti–P gingivalis CEP-1
reactivity, and 54% of the patients with RA and 2% of
the healthy control subjects had positive results. This
antibody response correlated strongly (r2  0.803, P 
0.0001) with the antibody response directed to the
human version of CEP-1 (Figure 4).
To investigate whether antibodies directed to the
immunodominant epitope of human -enolase also rec-
ognized epitopes in P gingivalis enolase, recombinant P
gingivalis enolase was in vitro treated with rabbit skeletal
PAD or was left untreated, before immunoblotting with
affinity-purified anti–CEP-1 antibodies. These antibod-
ies were generated in rabbits or purified from RA sera,
and their specificity for CEP-1 was analyzed by ELISA.
Serial dilutions of the rabbit polyclonal antibody (Figure
5A) showed a higher CEP-1 specificity than affinity-
purified human immunoglobulins (Figure 5B), which
also showed reactivity with the arginine-containing con-
trol peptide.
Silver staining (Figure 5C) demonstrated that P
gingivalis enolase migrated at a slightly lower molecular
weight than human -enolase, consistent with the theo-
retical molecular weights of 45.8 kd for P gingivalis
enolase and 47.2 kd for human -enolase.
Western blots, using the Anti-Citrulline (Modi-
fied) Detection Kit, also confirmed that P gingivalis
enolase had been successfully citrullinated in vitro by
eukaryotic PAD (Figure 5D). The purified anti–CEP-1
antibodies demonstrated cross-reactivity with citrulli-
nated P gingivalis enolase. Both the rabbit (Figure 5E)
and the human (Figure 5F) anti–CEP-1 antibody pref-
erentially bound the citrullinated form of the protein but
also showed cross-reactivity to the noncitrullinated
form. Control blots, using goat anti-rabbit IgG, mouse
anti-human IgG, the anti–modifed citrulline antibody on
partially modified membranes, or the goat anti-rabbit
IgG secondary on modified membranes were all nega-
tive (data not shown).
Figure 4. IgG antibodies to the Porphyromonas gingivalis version of
CEP-1 in patients with RA (n  81) and healthy control subjects (n 
82), as measured by enzyme-linked immunosorbent assay. Fifty-four
percent of patients with RA were positive for anti–P gingivalis CEP-1
antibodies (circles), compared with 2% of healthy controls (dia-
monds). The antibody response to P gingivalis CEP-1 (y-axis) corre-
lates strongly with the antibody response to the human version of this
peptide (x-axis) (r2  0.803, P  0.0001). See Figure 3 for definitions.
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DISCUSSION
In this report, we describe the identification of a
dominant B cell epitope in citrullinated -enolase,
CEP-1, which is reactive with 37–62% of RA sera and
2% of healthy control sera. This epitope shows high
sequence identity to bacterial enolase, and affinity-
purified antibodies, specific for this epitope, react with
both human and bacterial forms of the molecule. These
data provide a new model for bacterial infection priming
the autoimmune response in RA.
RA is diagnosed according to a set of clinical
criteria and probably comprises different disease enti-
ties, with different pathogenic pathways leading to a
similar clinical outcome. For example, 2 subgroups can
clearly be distinguished based on the presence or ab-
sence of ACPAs (36). It is also possible that there is a
Figure 5. A and B, Enzyme-linked immunosorbent assays. A, CEP-1 specificity for the rabbit polyclonal antibody and B,
cross-reactivity with the control peptide for the affinity-purified human antibody were demonstrated. IgG responses to CEP-1
(solid circles) and to the control peptide (open circles) were measured in serial dilutions. C–F, Silver staining and
immunoblotting. C, Silver staining showed recombinant Porphyromonas gingivalis enolase (lanes 1 and 2) migrating at a
slightly lower molecular weight than recombinant human -enolase (lanes 3 and 4). D, Successful in vitro citrullination by
rabbit skeletal peptidyl arginine deiminase (PAD) was demonstrated for P gingivalis enolase (lane 1) and human -enolase
(lane 3). E and F, Noncitrullinated P gingivalis enolase (lane 2) and human -enolase (lane 4) were run in parallel as negative
controls. Affinity-purified rabbit and human anti–CEP-1 antibodies cross-reacted with citrullinated P gingivalis enolase (lane
1), while a lower degree of reactivity was seen with the noncitrullinated form of the protein (lane 2). Citrullinated (lane 3)
and noncitrullinated (lane 4) human -enolase served as controls. Proteins were subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis.   P  0.01. AMC  anti–modified citrulline (see Figure 3 for other definitions).
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range of disease-driving antigens within the ACPA-
positive group of patients with RA (37). In a previous
study, we characterized citrullinated -enolase as one
such candidate (32). Using immunoblotting of whole
protein, we observed that serum samples from 46% of
patients with RA reacted with citrullinated -enolase, of
which 7 samples (13%) also recognized the noncitrulli-
nated protein. Sera from 15% of healthy control subjects
reacted with both forms of the molecule, and we spec-
ulated that this was attributable to reactivity with non-
citrullinated epitopes. In the present study, we at-
tempted to identify RA-specific antibodies by testing
cyclic peptides consisting of -enolase sequences sur-
rounding citrulline residues. In doing so, we have iden-
tified a dominant epitope, CEP-1, with a diagnostic
sensitivity of 37% and a specificity of 98%.
To confirm that this sensitivity and high specific-
ity were not a peculiarity of the sera used at our
institution, we also tested 81 RA samples and 82 healthy
control samples obtained from a separate unit and found
that the sensitivity was higher (62%), with a specificity of
98%. This difference may be attributable to the fact that
the US cohort was derived from patients participating in
clinical trials; therefore, patients in the US cohort may
have had more active disease than did patients in the UK
cohort, which was derived from patients attending a
regular clinic, many of whom were receiving treatment.
Antibodies to native -enolase have also been demon-
strated in patients with SLE and those with Behc¸et’s
disease (38,39), although in our study, patients with
these diagnoses were uniformly negative for anti–CEP-1
antibodies, again supporting the concept that this
epitope has specificity for patients with RA.
The importance of citrulline in the anti–CEP-1
antibody response was demonstrated by the low degree
of reactivity to the arginine-containing control peptide.
However, it was also clear that neighboring amino acids
constitute important antigenic determinants, because
the response to the other citrullinated -enolase pep-
tides was much weaker. The 2 amino acids, serine and
glycine, flanking the second citrulline residue in CEP-1
have previously been reported to enhance ACPA recog-
nition and binding (37,40). Thus, it was not surprising to
observe that peptide 1B, containing the Ser-Cit-Gly
motif, had a higher sensitivity than peptide 1C, which
lacks this motif. Our inhibition experiments demonstrate
that anti–CEP-1 antibodies do not cross-react with other
immunoreactive citrullinated -enolase peptides. This
suggests that antibodies to citrullinated -enolase react
independently with multiple epitopes, which character-
izes an antigen-driven immune response. This in turn
supports the concept that citrullinated -enolase is a
true autoantigen in RA. The concordance between
anti–CEP-1 and anti-CCP antibodies, as well as the
results from our inhibition experiments showing a vari-
able degree of cross-reactivity between the 2 antigens,
suggests that citrullinated -enolase may be one of a
family of citrullinated autoantigens, for which antibodies
are screened, at least in part, by the anti-CCP assay.
At this stage, we do not claim that the anti–
CEP-1 ELISA is a new diagnostic assay for RA. Modi-
fication of coating conditions, the use of different con-
figurations of peptides, and a standard curve to ensure
accurate quantification and reproducibility may increase
the sensitivity of the assay. These refinements, together
with further analysis of large cohorts, may show that
antibodies to CEP-1 define a specific clinical or immu-
nogenetic subset of RA. Thus far, our data using 2
independent cohorts of RA patients and appropriate
normal controls and disease controls support the con-
cept that citrullinated -enolase is a true autoantigen,
and that the sequence of the immunodominant peptide
representing CEP-1 may be important in the pathogen-
esis of the disease in the proportion of patients who have
the antibody.
In light of the hypothesis that RA may be precip-
itated by infection, it was intriguing to observe that the
sequence of 9 amino acids spanning the immunodomi-
nant epitope on CEP-1 was 100% identical to that
encoded by P gingivalis. P gingivalis is a gram-negative
bacterium that causes adult periodontitis. Like RA,
adult periodontitis is a chronic inflammatory disorder in
which the accumulation of immune cells leads to local
production of proinflammatory cytokines such as tumor
necrosis factor  and interleukin-1, metalloproteinases,
and prostaglandins, which results in tissue swelling and
degradation (for review, see refs. 41 and 42). RA is 4
times more common in patients with periodontitis than
in the normal population (43), and higher levels of
antibodies to P gingivalis (44), as well as a higher
prevalence of advanced forms of periodontal destruc-
tion, have also been reported in patients with RA
compared with control subjects. Finally, both rheuma-
toid factor production and anti-CCP antibody produc-
tion have been associated with periodontal disease
(41,45).
These data could imply a common underlying
dysregulation of the host immune response in adult
periodontitis and RA. However, there is also a striking
genetic similarity between the 2 diseases in that both are
associated with the HLA SE alleles (46,47). This, to-
gether with the fact that P gingivalis is the only bacterium
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known to synthesize its own PAD enzyme (28), lends
support to another hypothesis: that P gingivalis may be
the “septic stimulus” in RA, as proposed by Rosenstein
et al (42). Therefore, individuals with periodontal infec-
tion may already be exposed to citrullinated antigens,
including citrullinated bacterial enolase, generated by
host PAD during the inflammatory response or by
bacterial PAD produced as a virulence factor to evade
host defense (28). In the genetic context of the HLA SE
alleles, and in the presence of danger signals, this could
result in a pathologic immune response, with the forma-
tion of ACPAs. A subclinical arthritis could develop at a
later time point, perhaps due to trauma or a viral
infection, resulting in citrullination of synovial proteins.
Under normal circumstances, this arthritis would be
self-limiting. However, the presence of anti–CEP-1 an-
tibodies could lead to cross-reactivity with citrullinated
proteins in the joint and amplification of the inflamma-
tory process, with progression to chronic RA.
We were, in fact, able to demonstrate such anti-
body cross-reactivity between human and bacterial eno-
lase. Not only did patients with RA have antibodies
reactive with the P gingivalis version of CEP-1, but
anti–CEP-1 antibodies (raised in rabbits or purified
from a patient with RA) bound to the immunodominant
epitope in P gingivalis enolase. Hence, based on our
data, we hypothesize that autoimmunity in the subset of
RA patients with a humoral immune response to CEP-1
could be primed by bacterial infection, and that toler-
ance could be broken by citrullinated bacterial enolase.
Cross-reactivity with citrullinated human -enolase
within the joint could then lead to the chronic destruc-
tive inflammation that characterizes RA.
ACKNOWLEDGMENTS
We wish to acknowledge Professor Dorian Haskard,
Imperial College London, for providing serum samples from
patients with Behc¸et’s syndrome, and Dr. Vivianne Malmstrom
and Professor Lars Klareskog, Karolinska Institutet, Stock-
holm, Sweden, for providing serum samples from patients with
spondylarthritides. We would also like to thank James R.
O’Dell, MD, as well as investigators and patients from the
RAIN Network, for their contributions.
AUTHOR CONTRIBUTIONS
Dr. Lundberg had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy of the
data analysis.
Study design. Lundberg Kinloch, Venables.
Acquisition of data. Lundberg, Kinloch, Fisher, Wegner, Wait,
Charles, Mikuls, Venables.
Analysis and interpretation of data. Lundberg, Kinloch, Fisher, Wait,
Venables.
Manuscript preparation. Lundberg, Kinloch, Mikuls, Venables.
Statistical analysis. Lundberg.
REFERENCES
1. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH,
Hazes JM, Breedveld FC, et al. The diagnostic properties of
rheumatoid arthritis antibodies recognizing a cyclic citrullinated
peptide. Arthritis Rheum 2000;43:155–63.
2. Van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/
peptide antibody and its role in the diagnosis and prognosis of
early rheumatoid arthritis. Neth J Med 2002;60:383–8.
3. Kinloch A, Lundberg K, Venables P. The pathogenic role of
antibodies to citrullinated proteins in rheumatoid arthritis. Exp
Rev Clin Immunol 2006;2:365–75.
4. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP,
Robinson WH, et al. Antibodies against citrullinated proteins
enhance tissue injury in experimental autoimmune arthritis. J Clin
Invest 2006;116:961–73.
5. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ,
van der Horst-Bruinsma IE, de Koning MH, et al. Specific
autoantibodies precede the symptoms of rheumatoid arthritis: a
study of serial measurements in blood donors. Arthritis Rheum
2004;50:380–6.
6. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G,
Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated
peptide and IgA rheumatoid factor predict the development of
rheumatoid arthritis. Arthritis Rheum 2003;48:2741–9.
7. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B.
Prediction of radiological outcome in early rheumatoid arthritis in
clinical practice: role of antibodies to citrullinated peptides (anti-
CCP). Ann Rheum Dis 2004;63:1090–5.
8. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van
der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value
of anti-cyclic citrullinated peptide antibodies in early arthritis.
J Rheumatol 2003;30:1691–5.
9. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP
antibody test predicts the disease course during 3 years in early
rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis
2004;63:1085–9.
10. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chales G,
Le Henaff C, et al. Value of antibodies to citrulline-containing
peptides for diagnosing early rheumatoid arthritis. J Rheumatol
2003;30:2535–9.
11. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J,
Pesakova V, et al. Autoantibodies can be prognostic markers of an
erosive disease in early rheumatoid arthritis. Ann Rheum Dis
2003;62:427–30.
12. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den
Hoogen FH, van ’t Hof M, et al. The prognostic value of
anti–cyclic citrullinated peptide antibody in patients with recent-
onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831–5.
13. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A,
Dubois A, et al. Anticitrullinated protein/peptide antibody assays
in early rheumatoid arthritis for predicting five year radiographic
damage. Ann Rheum Dis 2003;62:120–6.
14. Tamai M, Kawakami A, Uetani M, Takao S, Tanaka F, Nakamura
H, et al. The presence of anti-cyclic citrullinated peptide antibody
is associated with magnetic resonance imaging detection of bone
marrow oedema in early stage rheumatoid arthritis. Ann Rheum
Dis 2006;65:133–4.
15. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U,
Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated
3018 LUNDBERG ET AL
peptide antibodies compared with rheumatoid factor isotypes in
rheumatoid arthritis. Ann Rheum Dis 2004;63:1079–84.
16. Van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM,
Breedveld FC, Zanelli E, et al. Association between HLA class II
genes and autoantibodies to cyclic citrullinated peptides (CCPs)
influences the severity of rheumatoid arthritis. Arthritis Rheum
2004;50:2113–21.
17. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij
WJ, Tak PP. The presence of citrullinated proteins is not specific
for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485–94.
18. Moscarello MA, Wood DD, Ackerley C, Boulias C. Myelin in
multiple sclerosis is developmentally immature. J Clin Invest
1994;94:146–54.
19. Ishigami A, Ohsawa T, Hiratsuka M, Taguchi H, Kobayashi S,
Saito Y, et al. Abnormal accumulation of citrullinated proteins
catalyzed by peptidylarginine deiminase in hippocampal extracts
from patients with Alzheimer’s disease. J Neurosci Res 2005;80:
120–8.
20. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren
AK, Klareskog L, et al. Citrullination is an inflammation depen-
dent process. Ann Rheum Dis 2006;65:1219–22.
21. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C,
Grunewald J, et al, and the Epidemiological Investigation of
Rheumatoid Arthritis Study Group. A new model for an etiology
of rheumatoid arthritis: smoking may trigger HLA–DR (shared
epitope)–restricted immune reactions to autoantigens modified by
citrullination. Arthritis Rheum 2006;54:38–46.
22. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huiz-
inga TW, Toes RE, de Vries RR. The HLA–DRB1 shared epitope
alleles are primarily a risk factor for anti–cyclic citrullinated
peptide antibodies and are not an independent risk factor for
development of rheumatoid arthritis. Arthritis Rheum 2006;54:
1117–21.
23. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A,
Wohlfahrt J, et al. Environmental risk factors differ between
rheumatoid arthritis with and without auto-antibodies against
cyclic citrullinated peptides. Arthritis Res Ther 2006;8:R133.
24. Origuchi T, Eguchi K, Kawabe Y, Yamashita I, Mizokami A, Ida
H, et al. Increased levels of serum IgM antibody to staphylococcal
enterotoxin B in patients with rheumatoid arthritis. Ann Rheum
Dis 1995;54:713–20.
25. Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, et
al. Human parvovirus B19 as a causative agent for rheumatoid
arthritis. Proc Natl Acad Sci U S A 1998;95:8227–32.
26. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-
Borst M. Epstein-Barr virus infection in peripheral blood mono-
nuclear cells, synovial fluid cells, and synovial membranes of
patients with rheumatoid arthritis. J Rheumatol 2000;27:866–73.
27. Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J.
Persistence of B19 parvovirus in synovial membranes of patients
with rheumatoid arthritis. Rheumatol Int 1992;12:147–51.
28. McGraw WT, Potempa J, Farley D, Travis J. Purification, charac-
terization, and sequence analysis of a potential virulence factor
from Porphyromonas gingivalis, peptidylarginine deiminase. Infect
Immun 1999;67:3248–56.
29. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L,
Vincent C, Senshu T, et al. The major synovial targets of the
rheumatoid arthritis-specific antifilaggrin autoantibodies are de-
iminated forms of the - and -chains of fibrin. J Immunol
2001;166:4177–84.
30. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora
M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibod-
ies target citrullinated vimentin. Arthritis Res Ther 2004;6:
R142–50.
31. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR,
Holmdahl R. Humoral immune response to citrullinated collagen
type II determinants in early rheumatoid arthritis. Eur J Immunol
2005;35:1643–52.
32. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P,
et al. Identification of citrullinated -enolase as a candidate
autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:
R1421–9.
33. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman
AJ, et al. Synovial fluid is a site of citrullination of autoantigens in
inflammatory arthritis. Arthritis Rheum 2008;58:2287–95.
34. Albert LJ, Inman RD. Molecular mimicry and autoimmunity.
N Engl J Med 1999;341:2068–74.
35. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 1988;31:315–24.
36. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van
Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid
arthritis phenotype based on specificity of the HLA–DRB1 shared
epitope for antibodies to citrullinated proteins. Arthritis Rheum
2005;52:3433–8.
37. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte
LB, van Venrooij WJ. Citrulline is an essential constituent of
antigenic determinants recognized by rheumatoid arthritis-specific
autoantibodies. J Clin Invest 1998;101:273–81.
38. Pratesi F, Moscato S, Sabbatini A, Chimenti D, Bombardieri S,
Migliorini P. Autoantibodies specific for -enolase in systemic
autoimmune disorders. J Rheumatol 2000;27:109–15.
39. Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, et al.
Human -enolase from endothelial cells as a target antigen of
anti–endothelial cell antibody in Behcet’s disease. Arthritis
Rheum 2003;48:2025–35.
40. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M,
Vincent C, et al. The epitopes targeted by the rheumatoid
arthritis-associated antifilaggrin autoantibodies are posttransla-
tionally generated on various sites of (pro)filaggrin by deimination
of arginine residues. J Immunol 1999;162:585–94.
41. Mercado FB, Marshall RI, Bartold PM. Inter-relationships be-
tween rheumatoid arthritis and periodontal disease: a review.
J Clin Periodontol 2003;30:761–72.
42. Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G.
Hypothesis: the humoral immune response to oral bacteria pro-
vides a stimulus for the development of rheumatoid arthritis.
Inflammation 2004;28:311–8.
43. Mercado F, Marshall RI, Klestov AC, Bartold PM. Is there a
relationship between rheumatoid arthritis and periodontal dis-
ease? J Clin Periodontol 2000;27:267–72.
44. Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum
antibodies to oral anaerobic bacteria in patients with rheumatoid
arthritis. MedGenMed 2005;7:2.
45. Havemose-Poulsen A, Westergaard J, Stoltze K, Skjodt H, Dan-
neskiold-Samsoe B, Locht H, et al. Periodontal and hematological
characteristics associated with aggressive periodontitis, juvenile
idiopathic arthritis, and rheumatoid arthritis. J Periodontol 2006;
77:280–8.
46. Katz J, Goultschin J, Benoliel R, Brautbar C. Human leukocyte
antigen (HLA) DR4: positive association with rapidly progressing
periodontitis. J Periodontol 1987;58:607–10.
47. Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec
P. The association between periodontal disease and joint destruc-
tion in rheumatoid arthritis extends the link between the HLA-DR
shared epitope and severity of bone destruction. Ann Rheum Dis
2006;65:905–9.
NEW MODEL FOR BACTERIAL INFECTION PRIMING THE AUTOIMMUNE RESPONSE IN RA 3019
The International Journal of Biochemistry & Cell Biology 41 (2009) 390–397
Contents lists available at ScienceDirect
The International Journal of Biochemistry
& Cell Biology
journa l homepage: www.e lsev ier .com/ locate /b ioce l
Review
Evolutionarily conserved antigens in autoimmune disease: Implications for an
infective aetiology
Natalia Wegner, Robin Wait, Patrick J. Venables ∗
Kennedy Institute of Rheumatology Division, Imperial College London, 65 Aspenlea Road, London W6 8LH, UK
a r t i c l e i n f o
Article history:
Available online 24 September 2008
Keywords:
Autoimmune disease
Conserved epitopes
Molecular mimicry
Infection
Rheumatoid
Evolution
Enolase
a b s t r a c t
The immune system has evolved to eliminate or inactivate infectious organisms. An inappropriate
response against self-components (autoantigens) can result in autoimmune disease. Here we examine
the hypothesis that some evolutionarily conserved proteins, present in pathogenic and commensal organ-
isms and their hosts, provide the stimulus that initiates autoimmune disease in susceptible individuals.
We focus on seven autoantigens, of which at least four, glutamate decarboxylase, pyruvate dehydroge-
nase, histidyl-tRNA synthetase and alpha enolase, have orthologs in bacteria. Citrullinated alpha-enolase,
a target for autoantibodies in 40% of patients with rheumatoid arthritis, is our main example. The major
epitope is highly conserved, with over 90% identity to human in some bacteria. We propose that this reac-
tivity of autoantibodies to shared sequences provides a model of autoimmunity in rheumatoid arthritis,
which may well extend to other autoimmune disease in humans.
© 2008 Elsevier Ltd. All rights reserved.
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1. Introduction
The adaptive immune system provides an important line of
defence against infectious agents and has evolved an array of toler-
ance mechanisms, which prevent inappropriate responses against
Abbreviations: ANCA, anti-neutrophil cytoplasmic antigens; 2-OADC, 2-oxo-acid
dehydrogenase complex; BLAST, basic local alignment search tool; CCP, cyclic citrul-
linated peptide; GABA, -aminobutyric acid; GAD, glutamate decarboxylase; HisRS,
histidyl-tRNA synthetase; LPS, lipopolysaccharide;MS,multiple sclerosis; PAD, pep-
tidyl arginine deiminase; PDC-E2, pyruvate dehydrogenase complex E2 component;
PR3, proteinase 3; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
∗ Corresponding author. Tel.: +44 20838334444.
E-mail address: p.venables@imperial.ac.uk (P.J. Venables).
self-(auto) antigens. Because the discrimination between self- and
nonself-reactive lymphocytes is imperfect, some self-reactive lym-
phocytes may mature and, in the presence of danger signals from
the innate immune system, become activated and cause autoim-
mune disease.
Autoimmune diseases are increasingly diagnosed by their asso-
ciated autoantibodies. Traditionally, such antibodies are detected
with immunological assays such as indirect immunoﬂuorescence,
which deﬁne antibodies targeting tissues including the thyroid,
pancreas and gastric parietal cells. Using cell lines, antibodies to
subcellular components, for example nuclei, nucleoli, ribosomes
and mitochondria, can also be identiﬁed. The need for more
disease-speciﬁc tests has driven the search for the actualmolecules
that are targeted by these antibodies, and has resulted in the dis-
1357-2725/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.biocel.2008.09.012
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Table 1
Organ-speciﬁc and non-organ-speciﬁc autoimmune diseases and their antigens.
+Signiﬁes existence of bacterial orthologs.
aBocquet N, Prado de Carvalho L, Cartaud J, Neyton J, Le Poupon C, Taly A, Grutter T, Changeux J-P, Corringer P-J. A prokaryotic proton-gated ion channel from the nicotinic
acetylcholine receptor family. Nature 2007;445:116–9.
bHilf RJC, Dutzler R. X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature 2008;452:375–9.
cCalamitaG, BishaiWR, PrestonGM,GugginoWB, Agre P.Molecular cloning and characterization of AqpZ, awater channel from Escherichia coli. J Biol Chem1995;270:29063–6.
dForterre P, Gribaldo S, Gadelle D, Serre M-C. Origin and evolution of DNA topoisomerases. Biochimie 2007;89:427–46.
covery of autoantigens within the nucleus and other organelles,
for which the autoantibody response is exquisitely antigen- and,
in many cases, disease-speciﬁc. In parallel, there is accumulating
evidence that some antigens are directly involved in pathogenesis.
Most autoimmune diseases have only a small number of asso-
ciated autoantigens; some examples are shown in Table 1. While
no doubt others will be discovered, the repertoire of human
autoantibodies is relatively small (no more than a few hun-
dred autoantigens) compared to around 21,000 genome-encoded
proteins, implying considerable selectivity of the autoimmune
response. Many autoantigens are members of evolutionarily con-
served protein families which originated before the divergence of
the prokaryotic and eukaryotic lineages. In this review we consider
those autoantigens for which antibodies are diagnostically and/or
392 N. Wegner et al. / The International Journal of Biochemistry & Cell Biology 41 (2009) 390–397
pathologically signiﬁcant, rather than targetsof autoantibodies that
are present in healthy people. We have not addressed the issue of
mechanisms, such as the evolution of the benign to a pathologi-
cal autoimmune response, nor do we discuss T cell epitopes. We
focus speciﬁcally on the stimulus that causes breakdown of toler-
ance and initiates or potentiates autoimmune disease. We propose
that this stimulus is due tomolecular similarities betweenprokary-
otic and eukaryotic molecules, which in some cases may be due to
evolutionary conservation.
2. Autoantigens and disease
For the purposes of this review, we use the accepted distinc-
tion between organ- and non-organ-speciﬁc autoimmunity, but
have extended it to encompass a spectrum ranging from purely
organ-speciﬁc to completely systemic (Table 1). In organ-speciﬁc
autoimmunity, the antigens are usually hormones, enzymes or
receptors largely restricted to a particular organ, often an endocrine
or exocrine gland. The purest examples are Hashimoto’s thy-
roiditis and Grave’s disease, where both the autoantigens and
the pathology are almost exclusively conﬁned to the thyroid.
Other important examples are type I diabetes, autoimmune gas-
tritis and celiac disease. In non-organ-speciﬁc autoimmunity, the
antigens are more widely distributed and may include nucleic
acids, nucleoproteins, ribonucleoproteins, intracellular enzymes,
membrane phospholipids, and plasma proteins. Most diseases
in this group can loosely be deﬁned as systemic autoimmune
rheumatic disease. Systemic lupus erythematosus is the proto-
type, with antibodies directed to ubiquitous cellular antigens
and involvement of multiple organs. Exceptions to this pattern
are organ-speciﬁc diseases with ubiquitous autoantigens, such as
polymyositis and primary biliary cirrhosis. Polymyositis is char-
acterised by inﬂammation of muscle, but the main autoantigen
(histidyl-tRNA synthetases) can be found in every human cell
type. The same applies to primary biliary cirrhosis, an inﬂam-
matory liver disease, where the major autoantigen (pyruvate
dehydrogenase complex E2 component) is present throughout the
body.
Most of the speciﬁc antigens listed in Table 1 have only been
described in the last decade and have enabled deﬁnitive classiﬁca-
tion of their respective diseases as truly autoimmune. A notable
exception is multiple sclerosis (MS), where a number of candi-
date autoantibodies have been proposed, but none have been
convincingly demonstrated to be disease-speciﬁc targets for the
autoimmune response. It has even been argued that autoimmu-
nity in MS may be entirely T-cell driven. The similarity of MS to
rare diseases such as neuromyelitis optica (Devic’s disease), for
which the target antigen aquaporin-4 was reported as recently as
2005 (Lennon et al., 2005), may imply that there is a true B cell
autoantigen in MS, which remains to be described. Other com-
mon chronic inﬂammatory diseases omitted from Table 1 include
Crohn’s disease and ulcerative colitis. Both exhibit many charac-
teristics of autoimmune disease and may prove to have their own
speciﬁc autoantigens.
3. Evolutionarily conserved proteins and autoimmune
disease
3.1. Thyroid peroxidase and myeloperoxidase
Hashimoto’s thyroiditis is probably the commonest autoim-
mune syndrome in humans. The disease is characterised by a T
cell-mediated destruction of thyroid follicular cells, resulting in
hypothyroidism. Antibodies to the main autoantigen, thyroid per-
oxidase, are found in up to 20% of adult females, though many
subjects are asymptomatic (Prentice et al., 1990).
Thyroid peroxidase, a dimeric glycoprotein located on the sur-
face of thyroid follicular cells, is responsible for the hydrogen
peroxide-mediated oxidation of iodide to iodine for incorporation
into tyrosine residues of thyroglobulin and subsequent production
of the hormones thyroxine and triiodothyronine. It is a member
of the myeloperoxidase superfamily of peroxidases which catalyse
hydrogen peroxide-mediated oxidations and, among other func-
tions, detoxify reactive oxygen species.
Some of the anti-neutrophil cytoplasmic antibodies (ANCA)
associated with various types of systemic vasculitis, particularly
microscopic polyangiitis (see below), turned out to target another
family member, myeloperoxidase, a lysosomal enzyme abundant
in the azurophilic granules of neutrophils, which catalyzes the pro-
duction of bactericidal compounds during the respiratory burst.
A second peroxidase superfamily (Passardi et al., 2007) com-
prises proteins present in plants, fungi, many bacteria and
some protists, which show very low levels of sequence sim-
ilarity to myeloperoxidase family members. This similarity is
too weak to establish an evolutionary relationship between the
two families, but available X-ray structures indicate considerable
similarity in the overall topology of the catalytic and heme bind-
ing regions and the disposition of helices (Picot et al., 1994),
suggesting a conserved structure in spite of their divergent
sequences.
The myeloperoxidase family was originally thought to be con-
ﬁned to mammals, but relatives were subsequently discovered
in arthropods, Caenorhabditis elegans and bacteria, speciﬁcally an
open reading frame from Pseudomonas alcaligenes, located in the
Xcp-secretion gene cluster, which showed sequence similarity to
themyeloperoxidase family, including conservation of the histidine
residues involved in haem binding in myeloperoxidase (Daiyasu
and Toh, 2000). We have detected a number of other poten-
tial myeloperoxidase family members in prokaryotes, including
Pseudomonas putida and the marine organism Planctomyces maris
(present authors, unpublished observations).
Recently, local sequence similarities have been reported
between thyroid autoantigens (including the conserved haem
binding region of thyroid peroxidase) and proteins from Yersinia
pseudotuberculosis and Borrelia burgdorferi (Benvenga et al., 2006).
Interestingly, infectionswithB. burgdorferiandYersinia specieshave
both been associatedwith autoimmune thyroid disease (Tomer and
Davies, 1993; Vaccaro et al., 2002).
3.2. Proteinase 3
Anti-neutrophil cytoplasmic autoantibodies are associatedwith
another form of vasculitis, Wegeners granulomatosis, but in this
case the ANCA are primarily directed to proteinase 3 (PR3;
also known as myeloblastin), a serine protease of the S1 family
expressed in azurophilic granules of neutrophils. Related proteins
present in these granules include neutrophil elastase, cathepsin G
and the proteolytically inactive azurocidin. PR3 is able to degrade
extracellular matrix components including elastin, ﬁbronectin,
laminin, vitronectin, and collagen types I, III and IV, thus facili-
tating migration of neutrophils through basement membranes. It
also has microbicidal properties, which may be independent of its
proteolytic activity, and may have a role in the release of surface-
associated tumour necrosis factor alpha.
The major immunodominant linear epitopes are ATVQLPQ
(residues 108–114) and RVGAHDP (residues 132–148) which,
according to the crystal structure, are located within a relatively
mobile, and thus possibly accessible, region towards the middle of
the sequence (Fujinaga et al., 1996).
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Orthologs of neutrophil serine proteases have been detected in
bony ﬁsh (Wernersson et al., 2006), and tBLAST analysis of the col-
lectionof currently availablemicrobial genomes retrieves anumber
of sequences with about 50% similarity and 30% identity, which
appear to correspond to S1 proteases, including examples from
Myxococcus xanthus, Pseudoalteromonas tunicata, and Vibrio species
(present authors, unpublished observations).
There is some evidence for a bacterial role in Wegener’s granu-
lomatosis, as carriage of Staphylococcus aureus appears to increase
the risk of relapse, which may be reduced by prophylactic antibi-
otic treatment (Kallenberg, 2008). However, there is no ortholog of
PR3 in any of the 12 strains of S. aureus which have been com-
pletely sequenced, nor in S. epidermidis or S. haemolyticus. One
hypothesis is that the effect is mediated via bacterial superanti-
gens, which are potent antigen-independent T cell stimulators,
though this would not explain the generation of speciﬁc anti-
PR3 antibodies. An alternative theory is based on the observation
that antibodies to peptides translated from the antisense strand of
PR3, as well as anti-PR3 antibodies, are present in sera from some
patients with Wegener’s granulomatosis (Pendergraft et al., 2004).
It was proposed that the antibody response to these complemen-
tary peptides could generate anti-idiotypic antibodies capable of
cross-reactions to PR3 sense peptides, leading to autoimmunity.
The complementary peptides could either be endogenous tran-
scripts of the antisense PR3 DNA or microbial proteins containing
regions of local similarity to complementary PR3 peptides. While
this intriguing hypothesis remains unproven, it suggests a mech-
anism that could potentially increase the likelihood of microbial
exposure leading to autoimmunity, as the repertoire of potentially
mimetic exogenous sequences would be increased.
3.3. Pyruvate dehydrogenase complex
Primary biliary cirrhosis, a chronic liver disease leading to pro-
gressive destruction of intrahepatic bile ducts, and eventually to
liver cirrhosis, is characterised by the presence of high-titre antim-
itochondrial antibodies. The major autoantigen, present in more
than 90% of patients, has been identiﬁed as the E2 component
of the pyruvate dehydogenase complex (PDC-E2). The pyruvate
dehydrogenase complex is located within the matrix of the inner
mitochondrial membrane, and in common with other 2-oxo-acid
dehydrogenase complexes, consists of multiple copies of three
enzymes. These are a thiamine pyrophosphate-dependent decar-
boxylase (E1), a coenzyme A-dependent acyltransferase (E2), and a
dihydrolipoyl dehydrogenase (E3).
TheE2 component is highly conservedbetweenprokaryotes and
humans, both in terms of amino acid sequence (typically about 40%
identity and 55% similarity) and its overall fold. The immunodom-
inant B and T cell epitopes on PDC-E2 are located around the inner
lipoic acid domain (Shimoda et al., 1995; Van de Water et al., 1988).
This region is exposed on the surface of the molecule, which may
explain its dominant antigenicity (Howard et al., 1998).
Because of the similarity of prokaryotic and human PDC-E2,
and because some studies have shown antibody and T cell cross-
reactivity between them, an infectious aetiology for PBC has
been suggested via molecular mimicry. Candidates have included
mycobacterial and enterobacterial infections, but these associa-
tions have not been conﬁrmed in all studies. For a review see
Haydon and Neuberger (2000).
Recently, Novosphingobium aromaticivorans (formerly Sphin-
gomonas aromaticivorans) has been suggested as a potential
aetiological agent (Kaplan, 2004; Selmi et al., 2003), since the lipoyl
domain of its PDC-E2 ortholog was claimed to be more similar to
the human enzyme than that from other prokaryotes, and reactiv-
itywith sera frompatientswith primary biliary cirrhosiswasmuch
higher than observed with E. coli. However, comparison of both full
length human PDC-E2 and its conserved lipoylated motif against
988 partial and complete microbial genomes using tBLAST found
at least 70 prokaryotes in which the conserved lipoic acid attach-
ment region was as, or more, similar to the human enzyme than to
that from N. aromaticivorans (present authors; unpublished obser-
vations). This, together with the fact that Selmi et al. were unable
to show any differences in carriage rates between PBC patients
and controls might suggests that N. aromaticivorans is one among
several possible candidates present in the human microbial ﬂora.
However, members of the Sphingomonodaceae, including N. aro-
maticivorans, areunusual amongGramnegativebacteria, in thatnot
only do they lack lipopolysaccharide (LPS), but their cell walls are
rich in glycosphingolipids, which can bind to CD1d in the lysosomal
compartement, leading to speciﬁc recognition by, and activation of,
CD1d restricted NKT cells. An interesting recent study (Mattner et
al., 2008) demonstrated that infection of mice with N. aromaticivo-
rans induced an inﬂammatory liver pathology and anti-PDC-E2 IgG
antibodies in a CD1 dependentmanner. T cells were able to transfer
the inﬂammation to naïve mice, in the absence of NKT cells, CD1d
or bacterial infection.
3.4. Glutamic acid decarboxylase (GAD)
Glutamic acid decarboxylase is a pyridoxal 5′ phosphate depen-
dent enzyme which catalyses the decarboxylation of glutamic acid
to -aminobutyric acid, an inhibitory neurotransmitter in higher
animals. Two GAD enzymes are present in mammals, GAD67 (or
GAD1) and GAD65 (or GAD2), which in humans are respectively
encoded by genes on chromosome 2 and chromosome 10. GAD67 is
thought to be constitutively active and responsible for maintaining
basal levels of GABA. This is reﬂected in the more severe pheno-
type of Gad1 null mice, which have low GABA levels and die at
birth,whereasGAD2−/− animalshavenearnormalGABAandappear
healthy when born, though subsequently are prone to anxiety and
seizures.
GAD occurs predominantly in the brain, but both enzymes are
also present in pancreatic beta cells, where their function is uncer-
tain. GAD65, but not GAD 67, is an important autoantigen in type
1 diabetes and latent autoimmune diabetes of adults (Baekkeskov
et al., 1990; Fenalti and Rowley, 2008), and autoantibodies can be
detected long before the onset of overt symptoms. The sequences
of both enzymes are very similar, except for the ﬁrst 100 amino
terminal residues, which are divergent. Interestingly, most of the
epitopes which have been partially characterised do not seem to
be associatedwith the divergent N-terminal region but rather clus-
ter towards the C-terminus, though in areas of local dissimilarity,
which, a recently published crystal structure (Fenalti et al., 2007)
suggests, may be relatively mobile.
GAD is widely distributed (Ueno, 2000) and bacterial orthologs
of about 30% similarity and 50% identity to humanGAD65 are read-
ily found, and include proteins from a number of pathogens, for
example Coxiella burnetti, Yersinia pestis and Vibrio species. A previ-
ous report (GarciaandLopez, 1995) suggested that theenzyme from
Streptococcus pneumoniae was more similar to human GAD65 than
examples from other prokaryotes, but this was probably an artefact
of the limited number of bacterial sequences available at the time,
since alignment of currently available sequences reveal many that
are as, or more, closely related. The absence of a convincing asso-
ciation of diabetes mellitus (one of the most intensively studied of
humanautoimmunediseases)with any speciﬁcprecedingbacterial
infection tends to argue against epitope mimicry as a pathogenic
mechanism.
Possible associations between type I diabetes and Coxsackie B
virus infection have been frequently reported over the last 30 years.
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Fig. 1. Rooted phylogenetic tree for enolase from representative eukaryotic, archaeal and bacterial species. The tree was constructed using Clustal X version 2.0
(ftp://ftp.ebi.ac.uk/pub/software/clustalw2/) with the neighbour joining method. Peptidyl arginine deiminase from Porphymonas gingivalis was used as outgroup. Protein
sequences in FASTA format were retrieved from UniProt. The tips are labelled with the corresponding accession numbers and SwissProt identiﬁers. (Key: red=bacteria;
green=archaea; blue = eukaryotes; cyan=outgroup (P. gingivalis peptidyl arginine deiminase).) Branches are labelled with bootstrap values obtained from 1000 replicates.
Trees with similar topology were also obtained using parsimony and maximum likelihood methods. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of the article.)
However, a recent systematic review of controlled studies of the
relationship between Coxsackie virus serology and type 1 diabetes
incidence concluded that existing epidemiological datadidnot pro-
vide convincing evidence for or against such an association (Green
et al., 2004).
3.5. Histidyl-tRNA synthetase
Aminoacyl-tRNA synthetases catalyse the attachment of amino
acids to their cognate tRNA molecules during protein translation.
Being part of the basal machinery of protein synthesis, individual
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Fig. 2. Sequence alignment of the ﬁrst 60 residues of mammalian and bacterial and archael enolases showing the high degree of conservation of the immunodominant
epitope CEP-1 (KIHAREIFDSRGNPTVE; indicated by the red line). The alignment was created using Clustal X version 2.0. The sequences were obtained from UniProt. P06733
(H. sapiens); P17182 (Mus musculus); Q7MTV8 (P. gingivalis); Q9CHS7 (Lactococcus lactis); P0A6P9 (E. coli); Q9HJT (Thermoplasma acidophilum). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
aminoacyl-tRNA synthetases are highly conserved and are present
in archaea, bacteria, and eucarya. Recently, four aminoacyl-tRNA
synthetases were detected in Acanthamoeba polyphaga mimi virus
(Abergel et al., 2005), though phylogenetic analysis suggests that
they were possibly the result of complex lateral gene transfer from
ancient hosts, rather than being survivors of a now lost viral protein
translation apparatus (Abergel et al., 2007).
Aminoacyl-synthetases are structurally diverse, but can be clas-
siﬁed into classes I and II, on the basis of conserved signaturemotifs
and the differing folds of their active site regions (Arnez and Moras,
1997).
Autoantibodies to aminoacyl-tRNAsynthetases occur in approx-
imately 25% of patients with myositis, for a review seeMimori et al.
(2007). Cytoplasmic histidyl-tRNA synthetase (HisRS) is the major
target, but antibodies to glycyl-, alanyl-, isoleucyl-, threonyl-, and
asparaginyl-tRNA synthase have also been reported.
Most of anti-HisRS antibodies in myositis patient sera bind to
sites within the conserved N-terminal sequence of the enzyme
(residues 1–47) near the catalytic domain, the predominant anti-
genic region being surface-exposed, and predicted to forma coiled-
coil (Raben et al., 1994; Ramsden et al., 1989). This region, however,
is absent from bacterial HisRS, which otherwise share about 25%
identity and 40% similarity to human HisRS, which argues against
a mechanism involving infection and epitope mimicry. Consistent
with this, mysositis autoantibodies are reported to recognise only
histidyl-tRNA synthetase fromhigher eukaryotes. Interestingly, the
amino terminal domain contains a highly conserved 32 amino acid
motif which is shared by other class I and class II tRNA aminoacyl
synthetases from both eukaryotes and prokaryotes, including bac-
terial seryl-tRNA synthetases (Raben et al., 1994). Whether this has
implications for the aetiology of the disease is unclear.
Encephalomyocarditis virus (EMCV) infection has been associ-
atedwithmyositis, as it is able toproducedisease symptomssimilar
to myositis in mice. It has been reported that the VP1 component
of the viral polyprotein has some regions of local similarity with
HisRS, though the resemblance is presumably fortuitous and not
evidence of a common ancestor (Walker and Jeffrey, 1988).
3.6. Enolase
Enolase catalyses the interconversion of phosphoenolpyruvate
and 2-phosphoglycerate, the penultimate step in glycolysis. Glycol-
ysis is an ancientmetabolic pathway and its key enzymes are highly
conserved (Pancholi, 2001).
Enolase from higher eukaryotes is a dimeric protein composed
of three isoenzymes (, , ), of which the most abundant is
-enolase. Unlike the other autoantigens discussed so far, the
presence of antibodies to -enolase is not disease-speciﬁc. Anti--
enolase antibodies have been implicated in autoimmune diseases
including post-streptococcal syndromes, Behc¸et’s disease, sys-
temic lupus erythematosus (SLE), ulcerative colitis, Crohn’s disease,
autoimmune hepatitis and lymphocytic hypophysitis, reviewed in
Pratesi et al. (2000). Despite the high sequence similarity between
enolases from different species, bacterial aetiology has only been
studied for post-streptococcal autoimmune disease (Dale et al.,
2006; Fontan et al., 2000). The fact that cell-surface exposed eno-
lase is found not only in mammalian cells but also in prokaryotic
and eukaryotic pathogens (e.g. Streptococci, Pneumococci, S. aureus,
Candida albicans, Pneumocystis carini, and Leishmania mexicana)
makes it a prime candidate for the generation of cross-reactive
autoantibodies.
3.7. Citrullinated ˛-enolase
The familyof peptidyl argininedeiminase (PAD)enzymesdeimi-
natepositively chargedarginine residues inproteins to formneutral
citrulline residues. It was ﬁrst appreciated that citrullinated pro-
teins were the dominant autoantigens in rheumatoid arthritis (RA)
over a decade ago, when it was shown that serum samples from a
panel of patientswithRApreferentially bound to synthetic peptides
containing citrulline, compared with serum from healthy controls
(Schellekens et al., 1998). This observation led to the development
of a newdiagnostic test for RA, using randomly generated synthetic
peptides of unpublished sequence, optimised for highest speci-
ﬁcity (98%) and sensitivity (80%) for the diagnosis of RA. This test,
known as anti-CCP2, predicts severe disease and may occur years
before the onset of clinical symptoms. There is increasing evidence
that these antibodies are directly involved in disease pathogenesis
(Clavel et al., 2008; Kinloch et al., 2006) (Fig. 1).
Citrullinated-enolasewas ﬁrst described by our group in 2005
as a candidate member of the family of citrullinated proteins tar-
geted by autoantibodies in RA (Kinloch et al., 2005). Since then it
has gained acceptance as a novel disease-speciﬁc autoantigen with
distinctive immunogenetic association with HLA DRB1*0401 (Snir
et al., 2008).We have identiﬁed a sequence (KIHAREIFDSRGNPTVE)
near the amino terminus as the immunodominant epitope, and
have shown that the citrullination of the second argininemakes the
greatest contribution to its immunogenicity. This sequence, desig-
nated citrullinated enolase peptide-1 (CEP-1), is highly conserved
between eukaryotes and prokaryotes as illustrated by the multiple
sequence alignment in Fig. 2.
Western blot analysis using afﬁnity-puriﬁed antibodies from
RA sera showed cross-reactivity between citrullinated human
-enolase and citrullinated recombinant enolase from the peri-
odontal pathogen Porphyromonas gingivalis (Lundberg et al., 2008).
There is evidence that P. gingivalis expresses a PAD-like enzyme
which can deiminate C-terminal arginine residues (McGraw et al.,
1999), but, alternatively, human PAD enzymes, which are secreted
in response to inﬂammation, could be responsible for citrullination
of both human and bacterial enolase.
4. Conclusion
Why particular proteins elicit autoantibodies, while others do
not, is unknown, but the example of GAD suggests that the reasons
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are subtle, since GAD67 and GAD65 are closely related and present
in the target tissue, but autoantibodies aremainly produced against
GAD65. Certain intrinsic structural features seem to be necessary
to trigger autoantibody formation, including surface chargedensity,
and the presence of repetitive surface elements. Epitopes targeted
by autoantibodies tend to be surface accessible, often in coiled-coil
domains, and relatively mobile.
The evolutionary distances between humans and prokaryotes
are enormous, so that even proteins subject to extreme functional
constraints, such as those responsible for fundamental processes of
protein synthesis and energy metabolism, may exhibit substantial
sequence divergence. Thus, in most cases, the likelihood of linear
epitopes inmicrobial proteins retaining sufﬁcient similarity to trig-
ger an autoimmune response is probably quite small.Moreover, the
presence of microbial epitopes mimicking host proteins is proba-
bly a necessary rather than a sufﬁcient condition for production
of autoantibodies, which may require, in addition, an underlying
genetic or other susceptibility in the host, and possibly some form
of co-stimulation from the environment or the infecting microbe.
The presence of glycosphingolipids able to bind CD1d in N. aro-
maticivorans, or the modiﬁcation of arginine to citrulline, could be
examplesof the latter. The requirement for a conjunctionof all these
factors is likely to dramatically reduce the number of proteins able
to induce an autoimmune response.
Of the seven major autoantigens examined in this review,
four (glutamate decarboxylase, pyruvate dehydrogenase complex
E2, histidyl-tRNA synthetase and alpha-enolase) have well con-
served prokaryotic orthologs, most with signiﬁcant regions of local
identity. In the case of -enolase, the immunodominant epitope
is the most highly conserved and therefore potentially a true
molecular mimic in genetic, functional and immunological terms.
When Damian coined the term “molecular mimicry” (Damian,
1965), he focussed on the conservation of sequences as a con-
sequence of the selective pressure exerted on the pathogen by
immune surveillance.We conclude thatmolecularmimicry leading
to autoimmunitymay be another unwelcome effect of evolutionary
conservation.
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Summary: Rheumatoid arthritis (RA) is now clearly a true autoimmune
disease with accumulating evidence of pathogenic disease-specific
autoimmunity to citrullinated proteins. Citrullination, also termed
deimination, is a modification of arginine side chains catalyzed by pepti-
dylarginine deiminase (PAD) enzymes. This post-translational modifica-
tion has the potential to alter the structure, antigenicity, and function of
proteins. In RA, antibodies to cyclic citrullinated peptides are now well
established for clinical diagnosis, though we argue that the identification
of specific citrullinated antigens, as whole proteins, is necessary for
exploring pathogenic mechanisms. Four citrullinated antigens, fibrino-
gen, vimentin, collagen type II, and a-enolase, are now well established,
with others awaiting further characterization. All four proteins are
expressed in the joint, and there is evidence that antibodies to citrullinat-
ed fibrinogen and collagen type II mediate inflammation by the forma-
tion of immune complexes, both in humans and animal models.
Antibodies to citrullinated proteins are associated with HLA ‘shared
epitope’ alleles, and autoimmunity to at least one antigenic sequence, the
CEP-1 peptide from citrullinated a-enolase (KIHAcitEIFDScitGNPTVE),
shows a specific association with HLA-DRB1*0401, *0404, 620W
PTPN22, and smoking. Periodontitis, in which Porphyromonas gingivalis is a
major pathogenic bacterium, has been linked to RA in epidemiological
studies and also shares similar gene ⁄ environment associations. This is
also the only bacterium identified that expresses endogenous citrullinated
proteins and its own bacterial PAD enzyme, though the precise molecular
mechanisms of bacterial citrullination have yet to be explored. Thus, both
smoking and Porphyromonas gingivalis are attractive etiological agents for
further investigation into the gene ⁄ environment ⁄ autoimmunity triad of
RA.
Keywords: rheumatoid, enolase, autoimmune, etiology, smoking, periodontitis
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
of unknown etiology, affecting 0.5–1.0% of the adult popula-
tion worldwide. It is a complex, multifactorial disease in
which chronic inflammation of synovial joints and erosion of
bone result in joint destruction, pain, disability, and a reduced
life expectancy. Genetic influences are estimated to be respon-
sible for around 50–60% of the risk of developing RA (1),
with environmental factors explaining the remainder. The
recent characterization of citrullinated proteins as the main
targets for the autoimmune attack in RA has enabled the inves-
tigation of the paradigm that the pathology of the disease is
mediated by specific autoantibodies, which themselves are
induced by the interaction of genetic risk factors and the envi-
ronment (Fig. 1). This triad of factors – autoantibodies, genes,
and environment – is of course a gross simplification of the
diverse and complex pathways that underlie the clinical
manifestations seen in RA. Nevertheless, it serves as a useful
template for addressing a fundamental issue, namely, what
actually causes the disease.
Autoimmunity in RA
In contrast to many other autoimmune diseases, where the
major autoantigens and their involvement in disease patho-
logy have been characterized at a molecular level several
decades ago, the autoantigens in RA are only just beginning to
be evaluated. Historically, rheumatoid factor (RF), an anti-
body reactive with the Fc portion of IgG, has been the main
serological marker for the diagnosis of RA and is still used as
one of the criteria for the classification of the disease (2).
Therefore, it has been suggested that IgG is the autoantigen in
RA. However, RFs also occur in other autoimmune diseases,
infections, and in 5% of the healthy population, and thus may
simply be a consequence of polyclonal B-cell activation. Given
the lack of disease specificity of RFs, it is difficult to substanti-
ate the concept that IgG is the specific antigen driving the
destructive inflammatory response that characterizes RA.
Interest has focused recently on citrullinated proteins as the
true autoantigens in RA. A prototype assay was described over
40 years ago as the anti-perinuclear factor test; though at the
time, it was not known that it was detecting anti-citrullinated
protein antibodies. Human buccal mucosa cells were used as
the substrate, and antibodies reactive with granular structures
around the nucleus were detected by indirect immunofluores-
cence (3). The assay had a high diagnostic specificity for RA
but with variable sensitivity (reviewed in 4). This drawback,
combined with the cumbersome nature of the assay, precluded
its use for routine diagnosis. An antibody reactive with the
keratinized layer of rat esophagus was subsequently reported
as the so-called ‘anti-keratin antibody’ (5) and correlated
strongly with the anti-perinuclear factor. More recently, it was
shown that both anti-perinuclear and anti-keratin antibodies
reacted with mature filaggrin (6–8), and a crucial discovery
was that this reactivity was citrulline-specific (9, 10). Nowa-
days, enzymatic assays using cyclic citrullinated peptides
(CCP) as surrogate target antigens are routinely used in RA
diagnosis. The first generation anti-CCP assay (anti-CCP1) was
based on citrulline-containing peptides from the filaggrin
sequence (10, 11). This test had a diagnostic sensitivity of
approximately 70% with a disease-specificity of 96% (11).
Because filaggrin, a protein which is involved in epidermal dif-
ferentiation and hydration, is found only in epithelial cells but
not in the joint (12), it was concluded that citrullinated filag-
grin acted as a surrogate antigen and that other citrullinated
proteins were more likely to be driving the autoimmune
response in RA (reviewed in 13). To improve the diagnostic
sensitivity and specificity of the anti-CCP1 test, the anti-CCP2
assay was developed and is now widely used in diagnostic lab-
oratories. The substrates for this test were selected from a large
panel of randomly generated citrulline-containing peptides
that were tested against RA and control serum, with the
sequences giving the best discrimination in diagnostic sensitiv-
ity and specificity being adopted for a commercial assay. Using
an enzyme-linked immunosorbent assay (ELISA), anti-CCP2
antibodies have a diagnostic sensitivity that is at least equiva-
lent to that of RF (up to 82%) and a specificity that is much
higher (98%) (reviewed in 14). Anti-CCP antibodies have
been detected prior to the development of clinically apparent
RA and are associated with more severe and erosive disease
(15–19). The high diagnostic specificity and predictive value
of these antibodies has stimulated interest in their involvement
in the pathophysiology of RA.
Physiological and pathological consequences of protein
citrullination
Citrulline, in the context of a peptide backbone, is a non-
standard amino acid that results from post-translational
modification of arginine residues. This conversion, termed
citrullination or deimination, reduces the net charge of the
protein by the loss of a positive charge per citrulline residue
Gene Environment
Specific 
autoantibody
Disease
Fig. 1. Schematic representation of the hypothesis for the gene ⁄ envi-
ronment ⁄ autoimmunity triad in the etiology of rheumatoid arthritis
and other chronic autoimmune diseases.
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(Fig. 2). Citrullination is catalyzed by a family of calcium-
dependent peptidylarginine deiminase (PAD) enzymes, which
are activated by higher Ca2+ concentrations [>10)6 M, varies
with the source of PAD enzyme and in vitro substrate (20, 21)]
than that present in intact cells [estimates range from 10)9 to
10)7 (22)]. Five members of the PAD family (PAD1, PAD2,
PAD3, PAD4, and PAD6) with different tissue distribution,
sub-cellular localization and substrates have been found in
humans (23). Of particular relevance to RA are PAD2 and
PAD4, as their expression has been demonstrated in rheuma-
toid synovial membrane (21, 24–26), synovial fluid cells
(27), and extracellularly in synovial fluid (28).
Arginine residues within polypeptides often play a central
role in the structural integrity of a protein, due to their ability
to participate in ionic interactions with negatively charged
amino acid side chains, substrates, and cofactors, and to form
multiple hydrogen bonds to both the peptide backbone and
other amino acid side chains (29). Arginine has also got the
most polar of all the common amino acid side chains and is
therefore the amino acid that is most likely to be found on the
surface of proteins in an aqueous environment (29). Citrullina-
tion would be expected to destroy the ionic interactions, inter-
fere with hydrogen bonds, and create new interactions. Hence,
the conversion of arginine into citrulline may result in an
altered three-dimensional structure and function of a protein.
In healthy physiology, citrullinated proteins are present in a
variety of cells and tissues. Citrullination of keratin and filag-
grin in the skin enables proteolytic cleavage and cross-linking
during the final stages of keratinocyte differentiation, which
plays an important role in the cornification of the epidermis
(30, 31). Trichohyalin, the major structural protein of the hair
follicle, and S100A3, a protein involved in the maturation of
hair cuticle cells, are also PAD substrates and citrullination
of these proteins is important in the formation of rigid
structures (32). In the nervous system, physiological citrulli-
nation of myelin basic protein (MBP) is important in ensuring
electrical insulation of the myelin sheaths. Pathological citrul-
lination of MBP results in a more open conformation
(reviewed in 33), increasing its susceptibility to cleavage by
cathepsin D (34). Thus, citrullination of MBP is important in
the investigation of demyelinating diseases such as multiple
sclerosis.
At a cellular level, citrullination affects cytoskeletal stability.
Inagaki et al. (20) have demonstrated that in vitro citrullination
of murine vimentin filaments results in the disassembly of the
filaments and explained this finding as a mechanism for non-
reversible filament modulation taking place under pathologi-
cal conditions, where the cell membrane disintegrates and
allows for elevated intracellular Ca2+ concentrations. Similar
results were also obtained for the other intermediate filament
proteins desmin and glial fibrillary acidic protein (GFAP) (20,
35). Several studies suggest that citrullination of histones may
be involved in transcriptional regulation (36–44) and in the
decondensation of chromatin when forming neutrophil extra-
cellular traps, as an innate response to infectious and inflam-
matory stimuli (45, 46).
Citrullination, as part of the inflammatory process, is only
just beginning to be explored. Stimulation of peripheral blood
mononuclear cells with IFN-c and a synthetic dsRNA causes
citrullination of the chemokines CXCL8 (47) and CXCL10
(48), with fundamental effects on their receptor usage,
proteolytic processing, and biological activities. Furthermore,
thrombin-catalyzed fibrinogen polymerization is defective
when fibrinogen is citrullinated (49), due to citrullination at
the thrombin cleavage site (arginine-16 in the a chain and
arginine-14 in b chain) (50). The physiological role of this is
unclear, but it might be an anti-inflammatory response
to tissue inflammation and a negative regulator of fibrin
deposition. Excessive fibrin deposition, with a potential
pro-inflammatory role, is a common feature within RA joints
(51), suggesting inefficient fibrinolysis. Hence, the fibrino-
lytic process, where plasmin degrades fibrin clots, may also be
Fig. 2. Enzymatic conversion of peptidylarginine into peptidylcitrulline, catalyzed by the family of peptidylarginine deiminase enzymes. The
positively charged arginine guanidino group is converted into the neutral citrulline ureido group in the presence of water, yielding ammonia and a
hydrogen ion as by-products. The possible consequences on the protein structure are shown schematically.
Wegner et al Æ Citrullination and the etiology of RA
36  2009 John Wiley & Sons A/S • Immunological Reviews 233/2010
defective as a result of fibrin citrullination, as arginine residues
are part of the cleavage sites.
In RA, the effects of citrullination are of particular impor-
tance with regard to the potential change in antigenicity of
the proteins. The unfolding of certain proteins upon citrulli-
nation was reported to be similar to that observed in the pres-
ence of high concentrations of urea (>4.5 M) (30) and could
clearly expose new epitopes to the immune system, either
directly as a result of the changed three-dimensional structure
or indirectly due to altered proteolytic processing and MHC
class II presentation. Citrullination of rat serum albumin
(RSA), for example, has been shown to break immune toler-
ance in rats in the presence of adjuvant. Animals immunized
with citrullinated RSA developed an antibody response to both
citrullinated and native RSA, while control animals immu-
nized with native RSA did not (52). As we discuss below, the
mere substitution of a single arginine by citrulline in a small
peptide can fundamentally alter the binding of the peptide to
both antibodies and to MHC class II molecules. Thus, the pres-
ence of citrullinated proteins as autoantigens and their distri-
bution in inflamed tissues are of critical importance in our
understanding of the pathogenesis of RA.
Citrullinated proteins in disease
Pathological protein citrullination is associated with inflam-
mation, not just in RA but also in other forms of inflammatory
arthritis (53–55) and unrelated inflammatory diseases, such as
multiple sclerosis (56), glaucoma (57), myositis (54), and
Alzheimer’s disease (58). In psoriasis, citrullination is down-
regulated in keratinocytes, possibly reflecting their failure to
undergo terminal differentiation in the formation of the
cornified layer of the skin (59). In inflammatory arthritis,
including RA, it is assumed that inflammation and the result-
ing release of pro-inflammatory stimuli and increased cell
death, allowing PAD activation in a calcium-rich environment,
might account for the accumulation of citrullinated proteins.
We have shown that the synovial fluid is an extracellular com-
partment within the joint with particularly abundant expres-
sion of citrullinated proteins (28). In a study of 60 cell-free
synovial fluids (20 rheumatoid, 20 spondylarthropathies, and
20 osteoarthropathies), we found citrullinated proteins in 34
out of the 40 inflammatory fluids (i.e. RA and spondyloarthr-
opathies) but none or markedly reduced levels of citrullinated
proteins in the osteoarthritis controls. The deiminating
enzyme PAD4 was detected in all three disease groups, while
detection of PAD2 was mainly restricted to the inflammatory
synovial fluids. This provides some evidence that the extra-
cellular (and therefore Ca2+-rich) environment is able to
support the activity of PADs and that PAD2 may be inducible
by inflammation. However, intracellular citrullinated proteins
in inflammatory arthritides were also observed by a number
of investigators (12, 24, 60–63) and might result from a
controlled increase of intracellular Ca2+ concentrations, for
example in response to specific ion pump activation.
Autoantibodies to specific citrullinated proteins in RA
As accumulation of citrullinated proteins occurs in a variety of
inflammatory conditions, it is now accepted that it is the anti-
body response rather than the presence of citrullinated pro-
teins in general that characterizes RA. The question is,
therefore, which specific antigens drive the immune response
in RA? The cyclic citrullinated peptides used in the CCP2 test
do not correspond to in vivo generated citrullinated proteins
and are therefore of limited use for understanding the disease
etiology and pathogenesis. However, four citrullinated candi-
date antigens, present in the joint, are now well established:
citrullinated fibrinogen ⁄fibrin (63), vimentin (64), collagen
type II (65), and a-enolase (66).
Citrullinated fibrinogen
Fibrinogen is the precursor of fibrin, and citrullinated fibrin-
(ogen) is one of the best-established specific autoantigens in
RA. The antigen, mainly as citrullinated fibrin, is abundantly
expressed in inflammatory joints of humans (53, 55, 63, 67,
68) and experimental animals (69). It was originally identi-
fied by its cross-reaction with anti-citrullinated filaggrin
antibodies, which were affinity-purified from RA serum.
By immunoblotting, these antibodies reacted mainly with the
a-and b-chains of fibrin (63). Later studies utilized the more
convenient, soluble (citrullinated) fibrinogen for further
characterization of the reactivity.
One large study of established RA suggested that antibodies
to whole citrullinated fibrinogen are equal, in terms of diag-
nostic sensitivity and specificity, to the anti-CCP2 assay (70),
though a more recent study of early RA found that the sensi-
tivity of antibodies to citrullinated fibrinogen was slightly
lower (66%) compared with the CCP2 test (72%) (71). In
both studies, there was a close correlation but by no means
exclusive relationship between anti-citrullinated fibrinogen
and anti-CCP2 antibodies.
The most extensive study aimed at identifying the major
immunodominant B-cell epitopes in human fibrin(ogen) was
published by Sebbag et al. (72). Using 71 linear peptides
derived from the a- and b-chains of fibrinogen (residues
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36–644 and 45–491, respectively), five peptides containing
immunodominant epitopes, out of a total of 18 reactive
peptides, were identified by ELISA: four from the a-chain
(36GPcitVVEcitHQSACKDS50; 171VDIDIKIcitSCcitGSCS185;
501SGIGTLDGFcitHcitHPD515; 621citGHAKScitPVcitGIHTS635)
and one from the b-chain (60citPAPPPISGGGYcitAcit74).
Although each of the 20 RA serum samples showed reactivity
to a limited number of peptides (between two and seven), an
overall inter-individual variability in reactivity profiles was
observed. As the authors stated, conformation-dependent
epitopes which are only formed in the context of the whole
molecule might not have been detected using the applied
technique, and it is not clear whether the identified epitopes
exist in vivo. Assuming citrullination in the joint occurs after
fibrinogen processing into fibrin, some peptides might be
absent from mature fibrin. In another study, Nakayama-
Hamada et al. (21) investigated in vitro citrullination of fibrino-
gen after incubation with recombinant human PAD2 or PAD4.
They observed citrullination in protein regions corresponding
to three of the peptide epitopes identified by Sebbag et al.
(a-chain peptides 36–50 and 501–515 and b-chain peptide
60–74) but not to the other two. However, Nakayama-
Hamada et al. used whole fibrinogen, which may well expose
different protein regions to PAD than those corresponding to
the peptides used by Sebbag et al.
The expression of antigen in the joint and the detection of
disease-specific antibodies in the serum make citrullinated
fibrinogen an attractive antigen for mediating the immuno-
pathology of RA. This possibility was recently explored in an
in vitro model system (73). Clavel et al. (73) found that
human monocyte-derived macrophages produced TNF-a
when incubated with immobilized immune complexes
containing citrullinated fibrinogen and that the effect was
mediated by Fcc receptor IIa. Fibrinogen-containing immune
complexes were demonstrated in serum samples from about
50% of anti-CCP-positive RA patients, and there was indirect
evidence of complement component 3 (C3)-binding
immune complexes colocalizing with fibrin(ogen) in the
pannus tissue (74). These findings go a long way towards
explaining the mechanisms of how immune complexes, con-
taining citrullinated fibrinogen, might be important in the
pathogenesis of RA by driving inflammation via Fcc and
complement receptors, resulting in inflammatory cytokine
release (75).
An arthritogenic role for citrullinated fibrinogen was
recently reported by Hill et al. (60), using C57B6 mice trans-
genic for human HLA-DRB1*0401. Transgenic and wildtype
mice were immunized with unmodified or citrullinated
human fibrinogen. Approximately 35% of transgenic mice
immunized with citrullinated fibrinogen but none of those
immunized with unmodified fibrinogen developed marked
swelling of the hind paws, which was followed by ankylosis.
The histological changes were not entirely typical of human
RA. There was synovial hyperplasia, but only a mild lympho-
cytic infiltrate and a notable absence of neutrophil infiltration.
Importantly, wildtype mice immunized with either form of
fibrinogen did not develop arthritis, nor did mice, including
the transgenic immunized with murine unmodified or citrulli-
nated fibrinogen. These data indicate the importance of both
the human MHC II genotype, in this case DRB1*0401, and
citrullination of the antigen, in this case the human antigen,
in mediating pathology.
We would argue that this model, although not perfect, is
the first prototype for true RA as opposed to other models,
such as collagen-induced arthritis, which are more representa-
tive of inflammatory arthritis as a whole. Other studies have
shown that immunization of several wildtype mice with
citrullinated human fibrinogen together with adjuvant breaks
tolerance, with an antibody response to both citrullinated and
unmodified fibrinogen, but this procedure does not induce
arthritis (76, 77). However, this observation does not exclude
the possibility that antibodies to citrullinated fibrinogen are
important in downstream pathogenic events in other mouse
models. For example, co-administration of a murine mono-
clonal antibody binding to citrullinated human fibrinogen
with a sub-optimal dose of anti-collagen II antibodies exacer-
bated arthritis, compared with administration of anti-collagen
II antibodies alone (78).
Citrullinated vimentin
Vimentin is an abundant intermediate filament protein,
involved in the dynamic organization of the cytoskeleton, with
a vital function in organelle transport, cell migration, and
proliferation. Citrullinated vimentin was first described as the
Sa antigen, detected by immunoblotting using placenta and
spleen extracts (79). Anti-Sa antibodies were detected in
approximately 40% of rheumatoid serum samples and were
predictive of a more severe disease (80). The identity of the Sa
antigen was subsequently suggested (81) and later confirmed
(64) to be citrullinated vimentin. Citrullinated vimentin is
expressed in vitro in macrophage-like cells after ionophore-
induced Ca2+ influx (27, 82). As these ionophores and the
concomitant Ca2+ influx cause apoptosis, it was suggested that
citrullination of vimentin is associated with apoptosis. Later,
two independent groups (83, 84) demonstrated the presence
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of citrullinated vimentin in the inflamed joint. In one of these
studies, citrullinated isoforms lacking the amino-terminal
region were detected in synovial tissue of patients with various
arthritides (83). These particular isoforms could be the result
of caspase-3 cleavage, as it is known that vimentin is cleaved
by various caspases during apoptosis (85, 86) and that the
amino-terminal cleavage products promote apoptosis (86). In
the other study, Bang et al. (84) reported various citrullinated
and mutated isoforms of vimentin in cellular synovial fluid
from RA patients and their reactivity with serum antibodies by
immunoblotting. Mass-spectrometry analysis demonstrated
that the vimentin isoforms contained certain amino acid muta-
tions and modifications, in particular mutations of glycine resi-
dues into arginine residues at positions 16, 59, 145, and 147,
and citrullination of a number of arginine residues. Based on
these findings, recombinant human vimentin was expressed,
mutated at positions glycine-16 and glycine-59 into arginine
and at arginine-50 into histidine, and citrullinated in vitro. The
commercial test using this antigen is known as the anti-modi-
fied citrullinated vimentin (anti-MCV) assay and was found to
be of superior diagnostic sensitivity (82%) compared with the
anti-CCP2 assay (72%), without loss of specificity (84). A sim-
ilar difference in sensitivity was also found in patients with
early RA (anti-MCV: 70.7% versus anti-CCP2: 57.9%) (87),
while another study reported that anti-CCP2 was superior
(88). In a systematic review of 14 studies comparing the two
assays (89), the authors concluded that the anti-MCV assay
could be used as an alternative to the anti-CCP2 assay for
diagnosis, though importantly, all studies found a handful of
samples which were positive for anti-MCV but negative for
anti-CCP2 or vice versa. This means that it is best to adopt one of
the assays as a ‘gold standard’ for the purposes of epidemiolog-
ical studies, and, for most, this choice has tended to be anti-
CCP2.
The high diagnostic sensitivity and specificity of anti-MCV
as well as its predictive value for erosive disease provide
indirect evidence for citrullinated vimentin as an important
molecule for driving the pathological immune response in
RA. A vimentin peptide (65SAVRAcitSSVPGVR77), derived
from human vimentin with leucine-69 replaced by alanine,
was shown to bind HLA-DRB1*0401 with higher affinity in
its citrullinated (at position 70) than in its native form. Immu-
nization of HLA-DRB1*0401 transgenic mice with the citrulli-
nated but not the native peptide induced a CD4+ T-cell
response (90). The substitution of a leucine for alanine was
designed to lock the adjacent arginine ⁄ citrulline in a stable
position in the P4 pocket of the HLA-DRB1*0401 groove,
though unpublished results showed that the leucine-contain-
ing peptide produced very similar results (David Bell, personal
communication). These experiments demonstrate that at least
one citrullinated peptide, but not its arginine-containing
counterpart, can drive a T-cell response in the context of the
HLA-DRB1*0401 molecule. However, unlike citrullinated
fibrinogen, citrullinated vimentin has yet to be demonstrated
to be arthritogenic in an in vivo animal model.
Given the fact that human and murine vimentin are highly
conserved (97.4% sequence identity), animal models using
antibodies to human citrullinated vimentin could provide
important insights into the pathogenicity of these auto-
antibodies. Furthermore, a potential role for vimentin in the
pathology of RA is beginning to emerge from studies of extra-
cellular vimentin in inflammation. A recent study showed that
extracellular vimentin mediates TGF-b activation (91), and
Mor-Vaknin et al. (92) reported that during the inflammatory
response to bacteria, cell-surface expression and secretion of
vimentin in monocyte-derived macrophages was enhanced by
TNF-a stimulation and mediated killing of internalized E. coli.
Other studies have shown extracellular vimentin fragments on
endothelial cells (91, 93) and on inflammatory cells, includ-
ing apoptotic T cells (94), neutrophils (95), activated platelets
(96), and macrophages (92, 93). Interestingly, various bacte-
ria use cell-surface vimentin as an attachment receptor (97–
99). Taken together, the extracellular location and the data
demonstrating in vivo citrullination of vimentin support a role
for citrullinated vimentin in pathogenesis and, in the presence
of additional risk factors such as bacterial infection, possibly
priming of an autoantibody response.
Citrullinated collagen type II
Collagen type II is a fibrillar protein and the major component
of articular cartilage. Antibodies reactive with citrullinated
collagen type II were originally reported in patients with early
RA (65). Using an immunodominant citrullinated peptide
from collagen type II, C1III (359AcitGLTGcitPGDA369), the
diagnostic sensitivity for RA was 40% (65, 71), and it remains
an attractive antigen because it is likely to be present in
degraded cartilage. Antibodies to unmodified collagen type II
can also be found in RA patient serum, though at a lower fre-
quency (around 15–25%), and are also present in other
inflammatory and autoimmune diseases (65, 100–103). In a
rat model of collagen-induced arthritis, Lundberg et al. (52)
found that citrullinated rat collagen type II was more arthrito-
genic than the native form of the molecule. A more recent
study demonstrated that monoclonal antibodies to the
citrullinated C1III peptide bound cartilage and inflamed
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synovial tissue and induced or enhanced arthritis in mice
(104). Importantly, the same study demonstrated in vivo citrul-
linated collagen peptides in synovial fluid from patients with
RA. These data lend powerful support for citrullinated colla-
gen type II being important in mediating pathology in both
human RA and murine arthritis, though whether citrullinated
collagen or a related molecule can break tolerance and induce
autoimmunity remains unknown.
Citrullinated a-enolase
a-enolase was first described as a candidate autoantigen
reactive with 25% of early RA sera, using human placenta and
epithelial cell line extracts, by Saulot et al. (105). However,
using recombinant a-enolase as the substrate, only eight of the
36 previously positive samples showed reactivity, strongly
suggesting the presence of crucial post-translational modifica-
tions of a-enolase from the placental ⁄ cell line tissue extracts.
We independently described the citrullinated form of a-eno-
lase as a polypeptide in deiminated lysates of HL-60 cells
reactive with serum from patients with RA (66). a-enolase was
abundantly expressed in the synovial membrane, and anti-
bodies reacting only with the citrullinated form of the mole-
cule were specific for RA (sensitivity approximately 40%),
compared with healthy serum. More recently, using cyclic cit-
rullinated a-enolase peptides covering 15 out of 17 arginine
residues present in human a-enolase, we identified a peptide
containing immunodominant B-cell epitope(s) (106). This
region comprised amino acids 5–21 of a-enolase, with argi-
nine-9 and arginine-15 replaced by citrulline (5KIHAcitEIF-
DScitGNPTVE21). Carboxy- and amino-terminal cysteine
residues were added to enable the peptide to adopt a cyclic
conformation, and the resultant peptide is referred to as citrul-
linated a-enolase peptide-1 (CEP-1). Using mass spectrome-
try, we have confirmed that both arginine-9 and arginine-15
can be citrullinated in vitro (66). A three-dimensional represen-
tation of the human a-enolase protein shows that the CEP-1
peptide is present near the amino-terminus on a pole of the
molecule, comprising the first and part of the second b strand,
and is surface-accessible (Fig. 3A-C). Arginine-15, which is the
crucial amino acid in CEP-1, is located in the loop region
between the first and the second b strand. Taken together,
these observations could explain why CEP-1 might be
a dominant epitope and why a cyclic version of the peptide
may be required for the detection of antibodies. In our studies
of over 300 serum samples, antibodies to CEP-1 were found in
37% of RA patients, 3% of disease controls, and 2% of healthy
controls (106). Similar frequencies of anti-CEP-1 antibodies
(41%) were found in a large cohort of Swedish patients with
RA (71). A much lower frequency of antibodies (13.9%) to a
linear peptide from the same region of a-enolase (amino acids
5–20), shortened by one amino acid and without added
amino- and carboxy-terminal cysteine residues, was found in a
separate study (107). We suggest that it is the linear rather
than the cyclic version of the peptide that explains these differ-
ences, as only a proportion of linear peptides will adopt a con-
formation similar to the original epitope (11). Other factors
may explain differences in autoantibody frequencies. For
example, in our original description of anti-CEP-1, we were
surprised to find a much higher frequency of anti-CEP-1 anti-
bodies (62%) in a cohort of sera derived from the US (106).
We have no explanation for this discrepancy, though it may
have been related to different genetic backgrounds or different
smoking habits (see below), details which were not available
in this cohort. In addition, as the patients in the US cohort
were participating in clinical trials, they may have had more
active RA, resulting in a higher frequency of antibodies.
The prevalence of anti-CEP-1 antibodies may not necessarily
represent the true frequency of anti-citrullinated a-enolase
antibodies as a whole. Using recombinant whole human
a-enolase protein citrullinated in vitro, we found that detection
of antibodies by immunoblotting increased to 70% in RA
compared with 5% in healthy controls (A. Kinloch, K. Lund-
berg, P.J. Venables, unpublished data) (Fig. 5). In this study,
we used highly purified recombinant human a-enolase,
which may explain the higher frequency than that found in
our first report (40%) (66), in which a semi-purified, com-
mercially available rabbit a-enolase was used. Using purified
recombinant human a-enolase, the healthy controls reacted to
non-citrullinated and citrullinated alpha-enolase with an equal
frequency (5%) (Fig. 5), suggesting that antibodies to non-
citrullinated epitopes on the molecule could occur in a
substantial proportion of the population. This finding is in
accordance with studies reporting anti-a-enolase antibodies in
cancer and a whole range of other inflammatory diseases,
among which Behc¸et’s syndrome and autoimmune hypo-
physitis are particularly prominent (103–112).
Similar to other established antigens in human autoimmune
diseases, enolase is a highly conserved and ubiquitous protein
(reviewed in 113). Mammals express three enolase isotypes
(a, b, and c), which form homodimers (Fig. 3) or hetero-
dimers. a-enolase is the most ubiquitous isotype and is
expressed in a variety of tissues, while b-enolase is exclusively
found in muscle tissues and c-enolase in neuronal and neuro-
endocrine tissues. Enolase is a multifunctional protein: it catal-
yses the penultimate step in glycolysis but also plays a role in
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various processes, such as hypoxia tolerance, growth control,
and in fibrinolysis, extracellular matrix remodeling and cell
migration, due its ability to bind plasminogen on the cell
surface of various eukaryotic cells (110, 112, 114–117) and a
number of bacteria (118–125), fungi (126), and parasites
(127–129). Using human cell lines and a monoclonal anti-
body directed towards the plasminogen-binding region of
a-enolase, Lopez-Alemany et al. (117) showed that a-enolase,
despite being responsible for only around 15–20% of the total
plasminogen binding, accounts for up to 90% of plasminogen
activation on the cell surface. It was also reported that plas-
minogen upregulates a-enolase gene expression in fibroblasts
and peripheral blood mononuclear cells (130), supporting an
important physiological role of a-enolase in the plasminogen
system. A recent study by Wygrecka et al. (116) demonstrated
a role for cell-surface a-enolase in inflammatory cell recruit-
ment. They showed that cell-surface expression of a-enolase
is upregulated in monocytes upon lipopolysaccharide stimula-
tion, and enhances plasmin generation, monocyte cell migra-
tion, and matrix invasion in inflamed lungs (116).
The multifunctional nature of the molecule, involving inter-
actions with both cells of the immune system and infectious
agents or their products, provides the basis for a hypothesis of
its involvement as an autoantigen in the etiology and patho-
genesis of RA. We have already demonstrated increased
expression of a-enolase in synovial membrane from patients
with RA compared with OA (Fig. 4) and more recently shown
that a-enolase is upregulated in cell-free synovial fluid in
inflammatory arthritis (28). Using synovial fluid sample from
a patient with RA, a shift towards a more acidic isoelectric
point (pI) in the two-dimensional electrophoretic migration
of alpha-enolase was observed (28). This relative ‘acidic shift’
towards the anode is a characteristic of protein citrullination
due to the resulting decreased net positive charge. Taken
together, these data provide some evidence that a-enolase is
involved in the pathogenesis of RA, though animal model
data, such as that already available for citrullinated fibrinogen
and collagen, are awaited.
Given the multitude of physiological roles in which
a-enolase is involved, an obvious question is as to what the
possible consequences of citrullination on the structure and
function of this protein are. A number of arginine residues on
a-enolase, including the ones located within the CEP-1
epitope, can be citrullinated in vitro using rabbit PAD2 and
a-enolase from HL-60 cell lysates (66). Citrullination is likely
to change the conformation of the enolase monomer and
could influence the non-covalent interactions involved in the
formation of the enolase dimer. This might result in an altered
glycolytic activity and plasminogen-binding potential. As the
plasminogen-binding sites are located on the surface of the
molecule [residues 250–256 and carboxy-terminal lysine
residues (131)], autoantibodies could interfere with the
coagulation pathway. Given the fact that excessive fibrin depo-
sition is a common feature of RA joints (51) and that mice
defective of fibrinolysis exhibit an exacerbated arthritis (132),
we could speculate that citrullination of cell-surface a-enolase
abrogates its plasminogen-binding and -activating function
and contributes to the decreased fibrinolysis seen in RA joints.
Other potential citrullinated antigens
It is apparent that the targets of anti-citrullinated protein
antibodies extend beyond the four listed above. For example,
in the study that led us to identify citrullinated a-enolase as a
candidate autoantigen in RA, we also identified a number of
other citrullinated proteins in in vitro deiminated HL-60 cell
lysates. Some of these also reacted specifically with rheuma-
toid serum, including elongation factor 1a (EF1a) and adenyl
cyclase-associated protein 1 (CAP1) (66). In a more recent
study, Goeb et al. (133) performed similar experiments, using
A B C
Fig. 3. Molecular representation of the human a-enolase dimer (A, B) and monomer (C). (A) Ribbon diagram. The immunodominant B-cell
epitope (CEP-1) is highlighted in red. Secondary structure elements (helices, light blue; strands, dark blue; loops, grey) are labeled. Bound magnesium
and sulphate ions are not depicted. (B) Molecular surface model. CEP-1 is highlighted in red, with the two arginines in orange. (C) Molecular surface
model of the monomer, looking onto the dimer interface. Color coding as in (B). This figure was generated using the software DeepView v4.0
(http://spdbv.vital-it.ch/) and is based on the X-ray crystal structure published by Kang et al. (132).
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HL-60 cell lysates with no additional in vitro deimination step,
where they identified a number of citrullinated glycolytic
enzymes and molecular chaperons as potential targets. Citrulli-
nated a-enolase was confirmed as a specific autoantigen in
RA, but also novel citrullinated candidates such as citrullinated
aldolase, phosphoglycerate kinase 1 (PGK1), calreticulin, heat
shock protein 60 (HSP 60) and far upstream element-binding
proteins 1 and 2 (FUSE-BPs), were described.
To determine which citrullinated proteins are generated
and targeted in the rheumatoid synovium, Matsuo et al.
(67) blotted synovial tissue extract from an RA patient with
a pool of RA serum and in parallel with an anti-modified
citrulline antibody. Eight citrullinated candidate antigens
were reported: asporin, cathepsin D, b-actin, F-actin cap-
ping protein a-1 subunit (CapZa-1), albumin, histamine
receptor, protein disulfide-isomerase ER60 precursor, glu-
cose-regulated protein, and mitochondrial aldehyde dehy-
drogenase (ALDH2). Importantly, (citrullinated) fibrinogen
was also detected, which could be seen as a proof of con-
cept result for the method. However, the study did not
provide convincing evidence that the peptides identified by
MALDI-TOF MS contained citrulline residues. The presence
of autoantibodies to recombinant citrullinated and non-cit-
rullinated CapZa-1 was then investigated using an ELISA
with serum samples from 30 RA patients, 28 OA patients,
19 with SLE, and 31 healthy controls. The results showed
reactivity to citrullinated CapZa-1, which was increased in
RA patients (53%) versus OA (7%), SLE (5%), and healthy
controls (6%), but also to the non-citrullinated protein (RA
36%; OA 10%; SLE 5%; healthy controls 6%). More
detailed analyses of individual samples revealed that citrul-
line-specific reactivity (i.e. antibodies to the citrullinated
but not the unmodified protein) was observed in 16% of
RA patients, in one OA patient (3%), and in none of the
other controls.
Using a different approach, Okazaki et al. (134) performed
immunoscreening of human chondrocyte cDNA expression
libraries modified by PAD4. A citrullinated fragment of
eukaryotic translation initiation factor 4G1 (eIF4G1) was
identified. With ELISA and Western blot, they demonstrated
that 48 out of 100 RA patients had autoantibodies to the
citrullinated eIF4G1 fragment, nine out of 100 had autoanti-
bodies to the native form, while no reactivity was detected in
44 healthy controls.
Confirmatory data in large-scale cohorts as well as studies
where (i) the citrulline specificity, (ii) the disease specificity,
and (iii) the in vivo demonstration of these new candidates are
investigated will determine whether they represent ‘true’
autoantigens in RA or not. Screening strategies using anti-
citrullinated protein antibodies purified from RA serum and
synovium-derived citrullinated proteins in their native
conformation should help to establish the repertoire of true
citrullinated autoantigens in RA.
Antibodies to citrullinated proteins in RA: citrulline
specific, peptide specific, or antigen specific?
Citrulline specific?
The identification of at least four good candidate citrullinated
antigens in RA, with potential others awaiting further charac-
terization, could suggest that it is merely the presence of
citrulline that confers antigenicity and that the molecule on
which the residue is found is irrelevant. This view is widely
held, which has led to terms such as ‘anti-citrulline auto-
immunity’. In one study (107), ‘anti-Sa’ antibodies in an
ELISA were detected not using citrullinated vimentin but
Fig. 4. Expression of a-enolase (stained brown) in synovial membranes from a patient with osteoarthritis (OA) and a patient with rheumatoid
arthritis (RA). Strongest staining was observed in the subsynovial layer in RA sections and in vascular endothelial cells in OA sections. Cell nuclei are
counterstained in blue.
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in vitro citrullinated MBP. This was justified on the basis that
commercially available MBP was less expensive than vimentin
and that it was a valid substitute based on the fact that it had a
similar proportion of arginines. It was suggested that antibod-
ies detected with citrullinated MBP by ELISA closely correlated
with positive results obtained in the original anti-Sa test,
detected using immunoblotting on human placenta extracts
(135), although no data in support of this were shown. In
contrast, our recent preliminary study of several purified anti-
gens showed that only two out of 50 RA serum samples
reacted weakly with citrullinated MBP (Fig. 5). It could be
argued that the low frequency of this reactivity, as detected by
Western blotting, was due to technical factors or to the pres-
ence of largely conformational epitopes detected by ELISA in
the study described above. We would counter this by propos-
ing that most true autoantibodies react with multiple epitopes
on the same molecule, both linear and conformational. For
example, in the same cohort, antibodies to citrullinated fibrin-
ogen and a-enolase were readily detected by this method in a
significant proportion of the serum samples (Fig. 5). Further
evidence for the importance of more than just a citrulline resi-
due comes from studies showing that not all proteins become
targets for anti-citrulline antibodies after in vitro citrullination
[for example, citrullinated bovine albumin (9) and citrullinat-
ed fibrinogen c chain (63)].
Peptide specific?
Another concept, which is widely held and which has more
evidence in its support, is that the autoantibody response in
RA is determined by the presence of citrulline residues
in association with certain flanking amino acids that facilitate
antibody binding. In the first study of sequences derived from
filaggrin (10), it was shown that peptides containing citrulline
flanked by neutral and relatively flexible residues, such as
glycine and serine, showed greater sensitivity for the diagnosis
of RA than those which contained strongly charged residues
or imposed a rigid structural conformation, such as proline.
In the case of CEP-1 from a-enolase, there are two citrulline
residues, the second of which at position 15 is flanked by a
serine and glycine. Girbal-Neuhauser et al. (9) demonstrated
that two citrulline-containing peptides from filaggrin harbor
epitopes recognized by RA serum. Both peptides contained a
citrulline residue flanked by a serine and a histidine residue
(9). Evidence for the importance of structural homology of
the surrounding amino acid residues on immunodominant
epitopes from different antigens comes from a subsequent
study, where Sebbag et al. (72) used five fillagrin-derived
peptides, including the two described above, in inhibition
studies, showing that these peptides can inhibit RA serum
reactivity towards citrullinated fibrinogen. As the identified
immunodominant B-cell epitopes on fibrinogen do not share
sequence homology with the filaggrin peptides, it was
concluded that structural homology of surrounding amino
acids is the crucial factor. Thus, it could be argued that the
antibody response in RA is entirely dependent on the presence
of citrulline residues with appropriate surrounding amino
acids with structural homology and that the candidate anti-
gens are no more than molecules which happen to possess
these sequences.
Fig. 5. Percentage of serum samples from RA patients (red bars) and healthy controls (grey bars) that are seropositive for the respective native
or citrullinated antigens. Serum samples from 50 patients with RA and 45 healthy controls were screened by immunoblotting for IgG reactivity to
aldolase-A (Ald), fibrinogen (Fbg), total histones (His), myelin basic protein (MBP), and a-enolase (Eno), either in their native or in vitro citrullinated
form (C-). Significant reactivity in RA serum was observed with aldolase-A, fibrinogen, histones, and a-enolase, though increased reactivity with the
citrullinated form of the proteins was observed only for fibrinogen and a-enolase.
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Antigen specific?
More recent data support the concept that it is the whole mole-
cule that drives the autoimmune response rather than specific
citrulline-containing epitopes. Using absorption experiments,
we showed that a given serum sample reacting with citrullinat-
ed a-enolase peptides reacted independently with different epi-
topes on the molecule (106). Similar results were also found
for citrullinated fibrinogen by Sebbag et al. (72) and in a study
of different citrullinated antigens by Snir et al. (71). Anti-CEP-1
reactivity was not inhibited by absorption with a citrullinated
collagen type II peptide, though complete inhibition occurred
with the CEP-1 peptide. While this result might be due to suffi-
cient dissimilar structural homology between the CEP-1 and
collagen type II peptides, the occurrence of independent anti-
body reactivities to different (non-cross-reactive) epitopes on a
handful of antigens strongly suggests that the ACPA response is
antigen-specific. Absorption of serum with whole citrullinated
fibrinogen, which potentially contains a large number of citrul-
linated peptide epitopes, had little effect on binding to peptides
from the other antigens (a-enolase and collagen type II) tested.
This study provided evidence that at least three citrullinated
molecules, fibrinogen, collagen type II, and a-enolase, could
justifiably be termed ‘specific citrullinated antigens’. A heat
map was constructed to visually compare autoantibody reactiv-
ities to CCP2, citrullinated vimentin peptide (residues 60–75),
citrullinated fibrinogen (whole protein), CEP-1, and citrulli-
nated collagen type II peptide (residues 359–369) within indi-
vidual rheumatoid serum samples (Fig. 6). The majority of the
serum samples reacted with more than one antigen, though
each serum had its own pattern of reactivity and most fell
within the anti-CCP2 positive population. These findings are in
accordance with the concept that disease-specific autoimmu-
nity is characterized by reactivity to a ‘family’ of anatomically
or functionally related antigens (113).
Genes and autoimmunity to specific citrullinated
antigens
Autoimmune diseases are polygenic, with each gene conferring
a relatively small risk but when added together producing an
interacting profile leading to an enhanced probability for a
common phenotype (reviewed in 136). In most autoimmune
diseases, the MHC class II provides the strongest risk, with indi-
vidual alleles often showing more association with specific
autoantibodies than with the disease itself. For example, in
a cohort of 157 patients with systemic lupus erythematosus,
the well-established association with HLA-DR3-containing
haplotypes was confirmed, with an odds ratio (OR) of 2.5,
though in the small subset of patients positive for anti-La anti-
bodies (13%) the OR rose to an astonishing 71 (137). Analo-
gous results were also published in relationship to polymyositis
(138). Again, DR3 showed an association with the disease as a
whole, but a marked increased risk was seen in patients with
antibodies to PM ⁄ Scl. In the same cohort, a group with
antibodies to U1 RNP all possessed at least one copy of DR4.
It is now beginning to emerge that a similar pattern of sus-
ceptibility, namely that MHC class II alleles are more associ-
ated with autoantibody-specificities than with disease, also
applies to RA. The major susceptibility alleles for RA are pres-
ent in HLA-DR4, -DR1, and -DR10, principally DRB1*0101,
*0102, *0401, *0404, *0405, *0408, *1001, and *1402. All
share variants of the EQKRAA motif, present in the third
hypervariable region of the DRB chain, which constitutes part
of the peptide binding cleft of the class II molecule. These
alleles are collectively known as the ‘shared epitope’ (SE),
implying that any of these alleles confer risk for RA (139).
The universality of the SE hypothesis has been challenged by
the findings that DR1 alleles (DRB1*0101 and DRB1*0102)
Fig. 6. Clustering of IgG RA-associated antibodies. IgG reactivity to
CCP2, a citrullinated vimentin peptide (aa 60–75) (Cit Vim), citrullinat-
ed full-length fibrinogen (Cit Fbg), the immunodominant epitope
(CEP-1) of citrullinated a-enolase (Cit Eno), and the triple helical peptide
of the CII C1-epitope (aa 359-369) (CitCII) was measured in serum from
291 RA patients. Each row represents one patient. The color scale shows
the relative degree of antibody reactivity, from low reactivity (green) to
high reactivity (light red). The order of the columns is according to their
relationship with each other and anti-CCP.
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tend to associate with milder disease (reviewed in 140).
Thus, when analyzing DRB1*SE susceptibility to individual
autoantibodies, it is important to consider the DR1 and DR4
haplotypes separately.
In RA, it is now well established that the SE primarily deter-
mines the presence of anti-CCP antibodies rather than the dis-
ease itself (141, 142). Not surprisingly, given that anti-CCP
antibodies predict more severe disease, this association is the
strongest for DR4 alleles. The link with DR4 has also been
confirmed with antibodies to specific citrullinated antigens,
including antibodies to a citrulline-containing peptide from
vimentin (60VYATcitSSAVcitLcitSSVP75) (143), CEP-1 from
a-enolase, and, to a lesser extent, the collagen type II peptide
already described above (71). Discrepant results have been
obtained in relationship to fibrinogen. Using a peptide
(6NEEGFFSAcitGHcitPLDKK22) from the fibrinogen b chain as
antigen, there was no association with the SE (143), whereas
using the whole molecule citrullinated in vitro, an association
was shown both with SE in general and DR4 in particular
(71). These results could indicate that the initial autoimmune
response, determined by the MHC class II, was directed
against a fibrinogen epitope on a different part of the mole-
cule or that antibodies to citrullinated fibrinogen may be more
of a downstream event in pathogenesis, resulting from epi-
tope spreading. However, it should be emphasized that in the
animal model of citrullinated fibrinogen-induced arthritis
(60), only mice transgenic for human HLA-DRB1*0401
developed arthritis, whereas wildtype controls did not. This
study provides some evidence that HLA-DRB1*0401 is
required for an immune response to citrullinated fibrinogen.
Citrullinated a-enolase and vimentin appear to be the most
promising candidates for priming an MHC class II-determined
autoimmune response, though a direct interaction between
peptide and HLA-DRB1*SE alleles has yet to be demonstrated
for a-enolase. Nevertheless, there is indirect evidence for
epitopes within citrullinated a-enolase being important in
relation to the SE. We have recently studied three large
cohorts, of approximately 1000 RA cases, and demonstrated
that the HLA-DRB1*SE association is considerably stronger for
anti-CCP positive patients that also have antibodies to CEP-1,
compared with anti-CCP positive patients that do not have
these antibodies (144).
Genome-wide association studies have contributed signifi-
cantly to the identification of other gene loci in polygenic
diseases (reviewed in 137), and the following loci have now
been confirmed to associate with RA in several large cohorts:
TRAF1-C5, STAT4, REL, TNFAIP3, CTLA, and CD40. Of relevance
to citrullination, TRAF1-C5 has been associated with anti-CCP
positive disease (145), as have polymorphisms of the PAD4
gene in Japanese and Korean populations but notably not in
those derived from Western Europeans (reviewed in 137). In
one large case–control study, at least three loci, the MHC, the
PTPN22, and variants around IL2RA (chromosome 10p15),
were associated with RA, with several other SNPs being identi-
fied as candidates for further investigation (146).
In spite of the discovery of increasing numbers of suscepti-
bility genes, it is MHC that consistently provides the strongest
genetic risk, which, as discussed above, has already enjoyed
more that 30 years of investigation. Polymorphisms of PTPN22
have also already been described as a risk factor, not only for
RA (147) but also for other autoimmune diseases (137), and
may well be a risk factor for autoimmunity in general. The
gene encodes a tyrosine phosphatase involved in T and B-cell
signaling, and the susceptibility allele 620W of PTPN22, which
is present in approximately 17% of healthy controls and in
28% of individuals with RA, disrupts the proline-rich motif of
the protein that is important for its normal function as a nega-
tive regulator of T and B-cell activation (147). Like the SE, the
risk allele of PTPN22 is more related to the anti-CCP positive
subset of RA than to the disease as a whole, and when com-
bined in an additive analysis as a ‘gene ⁄ gene interaction’ with
the SE, produces an even higher OR than either gene alone
(148). In our recent study, we dissected this effect further by
showing that the combined effect of the two genes conferred
a higher risk for the anti-CEP-1 positive ⁄ anti-CCP positive
population (OR = 17.8) compared with the anti-CEP-1
negative ⁄ anti-CCP positive (OR = 4.6) (143). In this study,
we did not investigate the possibility that other antibodies to
other citrullinated antigens would show the same powerful
associations with interacting risk genes. Given the data
published on HLA-DRB1*SE interactions (144), it might be
predicted that antibodies to citrullinated vimentin peptides
may show a similar effect. Preliminary studies suggest that this
is the case (Renne Toes, personal communication), though
this kind of analysis in large cohorts of patients has yet to be
published.
In our study discussed above, we also found an association
between CEP-1-positive disease and polymorphism in the
bromodomain-containing 2 (Brd2) gene. Brd2 has not previ-
ously been linked to RA or any other autoimmune condition.
A substantial literature exists on genetic polymorphism in Brd2
in association with idiopathic generalized epilepsy (reviewed
in 149). Brd2, situated within the MHC region, encodes
a ubiquitously expressed protein kinase, associated with tran-
scription complexes and acetylated chromatin during mitosis.
It has been implicated in fundamental cellular processes, such
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as cell-cycle regulation and transcriptional regulation (150,
151). Mice deficient in Brd2 do not complete embryogenesis
and neurogenesis (152), while constitutive expression of
Brd2 was shown to cause malignancy in mice, similar to
human diffuse large B-cell lymphoma (151). The association
between Brd2 and CEP-1-positive RA needs to be confirmed
in other cohorts, and further studies will determine the
functional consequences of variants of the gene and their
relationship with autoantibody specificities in RA.
Environmental factors in the development of
autoimmunity to specific citrullinated proteins
Smoking
Cigarette smoking is today the best known environmental
risk factor for the development of RA. The link to smok-
ing was first recognized in 1987 (153), as an unexpected
finding in a study investigating the association between
RA and the use of oral contraceptive, and later confirmed
in a number of case-control and cohort studies. Perhaps,
the most striking results were presented from the Arthritis
and Rheumatism Council Twin Study, where 13 pairs of
monozygotic twins, discordant for RA and smoking, were
identified, and in 12 out of 13 cases the RA patient was
also the smoker (154).
Cigarette smoking constitutes more of a specific risk for
RF-positive (155–160) and most notably anti-CCP-positive
RA (141, 161–163). Furthermore, this risk is strongly
dependent on the presence of HLA-DRB1*SE alleles, and
evidence exists for a biological gene–environment interac-
tion (142, 161–164). More recently, we have found that
smoking and HLA-DRB1*SE is primarily associated with
the anti-CEP-1-positive subset of anti-CCP-positive RA
(144). In a large case–control study, comprising 1000 RA
cases and 872 matched healthy controls, we compared the
anti-CEP-1-positive ⁄ -CCP-positive population with the anti-
CEP-1 negative ⁄ -CCP-positive population. In the subset
with antibodies to CEP-1, we could demonstrate an
impressive OR of 37 for smokers with the SE and the
susceptibility allele of PTPN22 compared with an OR of
six in the corresponding subset negative for anti-CEP-1
(Fig. 7). These data strongly suggest that CEP-1 is at least
one peptide from a specific autoantigen which links
smoking to HLA–DRB1*SE in the development of RA.
It is currently not known how smoking may contribute to
the development of CEP-1-positive ⁄CCP-positive RA. Cigarette
smoke contains thousands of potential toxic compounds that
may cause tissue damage and inflammation (165). Recruit-
ment and activation of immune cells, levels of CRP, matrix
metalloproteinases, IL-6, IL-1b, TNF-a, and serum levels of
fibrinogen, as well as the expression of Fas on T and B cells,
have been reported to be elevated in response to cigarette
smoke (reviewed in 166). In support of the hypothesis linking
smoking-induced inflammation and citrullination are data
demonstrating higher levels of both PAD2 and citrullinated
proteins in the lungs of smokers as compared with non-smok-
ers (142, 167). The presence of IgA anti-CCP in approximately
60% of the IgG anti-CCP-positive patients (168) also points to
the involvement of mucosal surfaces, such as the lung, in
generating or sustaining autoantibodies to citrullinated
proteins. Furthermore, the occurrence of IgA anti-CCP has
been reported to be associated with smoking (169). However,
A
B
Fig. 7. Single and combined effects of the three risk factors HLA-
DRB1*SE (SE), the W620 allele of PTPN22 (PTPN22) and cigarette
smoking (smoke), for the two anti-CCP positive RA subsets.
(A) CEP-1+ ⁄ CCP+ and (B) CEP-1) ⁄ CCP+. Odds ratios (OR) were
calculated by means of logistic regression in a case-control analysis (1000
RA cases and 872 healthy controls), where adjustments for age, residen-
tial area and gender were made. Both the single and the combined effects
of the three risk factors were strongest for the CEP-1+ ⁄ CCP+ subset.
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not all anti-CEP-1-positive ⁄ anti-CCP-positive and HLA-
DRB1*SE-positive patients are past or current smokers, and the
interaction between smoking and HLA-DRB1*SE could not be
confirmed in three North American cohorts (170). Other fac-
tors, such as air pollution, silica dust exposure, or interstitial
lung disease could have masked the effect of smoking. Alterna-
tively, the generation of citrullinated antigens and an antibody
response could occur, in a similar fashion as hypothesized for
smoking, at another site in response to other inflammatory
stimuli, such as infection.
Infection: Porphyromonas gingivalis
Infection as a contributory or even sole etiological factor
in RA has been suggested and discussed for decades (171,
172). Here, we focus on a possible role of infection with
Porphyromonas (P.) gingivalis in the development of autoimmunity
to citrullinated proteins, based on its expression of a bacterial
PAD enzyme (173) with the potential to generate citrullinated
epitopes both on bacterial antigens and human autoantigens.
This bacterium plays a significant role in the progression of
chronic periodontitis (174) and has been proposed as an
environmental risk factor for the development of RA (106,
175–182).
The oral cavity is a diverse ecological reservoir for a large
number of bacterial species, with an estimated 500 colonizing
species (183). P. gingivalis is a Gram-negative bacterium and is
the most extensively studied of all major periodontopathogen-
ic organisms (reviewed in 184). It is commonly present in
periodontitis patients as a biofilm in the gingival crevice and
intracellularly in oral epithelial cells but can also be found in
periodontally healthy subjects, although at lower numbers
(185–187). P. gingivalis produces an array of virulence factors,
most notably extracellular cysteine proteases called gingipains,
to support its adherence, growth, tissue invasion and degrada-
tion, and to evade and subvert the immune system (184,
188–192).
Analogous to RA, periodontitis is a chronic inflammatory
disease characterized by erosion of bone. The prevalence of
periodontitis in the American population was reported to be
4.2% (193), although this varies depending on the definition
criteria of periodontitis and the applied examination protocol,
among other factors. Periodontitis usually begins with a
self-sustaining inflammation as a result of plaque accumulation
(i.e. gingivitis) and then progresses into a chronic, erosive dis-
ease mediated by TNF-a, IL-1b, prostaglandins E2, and
metalloproteinases. With progressing inflammation, lympho-
cytes and monocytes accumulate, and more degradative and
pro-inflammatory molecules are released, leading to erosion of
adjacent bone.
Studies in our laboratory have recently shown that P. gin-
givalis contains a range of endogenous bacterial citrullinated
proteins (N. Wegner, K. Lundberg, P.J Venables, unpub-
lished data). Citrullination of a human protein, fibrinogen,
by P. gingivalis has been stated (177) and recently repeatedly
cited (175, 178, 194, 195), despite the fact that experi-
mental proof supporting these claims has never been pub-
lished, including the referenced article which is cited in
these publications.
The citrullination of bacterial and ⁄or host proteins by an
external PAD enzyme in the infectious context of chronic
gingival inflammation could prime autoimmunity to citrulli-
nated proteins in individuals with additional susceptibility
factors. Two small-scale studies have found slightly higher
than expected rates of anti-CCP antibodies in patients with
periodontitis. Two out of 27 (196) and two out of 49 (174)
periodontitis patients, who had no history or current manifes-
tations of RA, were found to be anti-CCP positive. We have
previously shown by Western blotting that autoantibodies to
CEP-1, affinity-purified from an RA patient, cross-react with in
vitro citrullinated recombinant P. gingivalis enolase (106).
Whether P. gingivalis enolase is an in vivo target of bacterial PAD
has yet to be demonstrated. Both bacterial enolase (Fig. 8) and
PAD (173) are present on the cell surface of P. gingivalis. In
addition, exposure of neutrophils, epithelial cells, and
platelets to P. gingivalis has been shown to increase intracellular
Fig. 8. Western blot showing the presence of extracellular enolase in
the cell membrane fraction of Porphyromonas gingivalis. Enolase was
detected using an antibody raised against a conserved peptide from the
amino-terminus of human a-enolase.
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Ca2+ concentrations in these cells via cleavage and activation
of human proteinase-activated receptor-2 (PAR-2) (197–
202), which might lead to intracellular activation of human
PAD enzymes. Hence, human PAD enzymes could also contri-
bute to the citrullination of proteins at the site of gingival
inflammation. Very little is known about the enzymatic and
functional properties of bacterial PAD, which might generate
different epitopes than the human PAD enzymes, and hence
needs to be addressed in future studies.
There is also epidemiological evidence linking periodonti-
tis and RA (reviewed in 178) and some evidence of a com-
mon pattern of genetic susceptibility and environmental risk
factors. Genetic influences account for around 50% of the
total risk for developing chronic periodontitis (203). Gene
polymorphisms associated with periodontitis were reported
for a number of genes encoding cytokines, Fc receptors,
and, notably, MHC class II (reviewed in 204, 205). Suscep-
tibility to periodontitis has been linked to the same HLA-
DRB1 alleles which predispose to RA, specifically the *0401
allele. In a study of 48 patients with severe periodontitis,
Bonfil et al. (206) found that HLA-DRB1 subtypes *0401,
*0404, *0405, and *0408 are more frequent in patients
with severe periodontitis compared with healthy controls.
Other studies (207–211) also demonstrated an increased
frequency of HLA-DR4 in patients with various forms of
periodontitis.
Smoking, now established as an environmental risk factor
for RA, has also been linked to periodontitis with an OR
in the order of 2–6 (reviewed in 212), and there is a
dose–response relationship between the number of ciga-
rettes smoked per day and the odds of developing disease
(213). Smokers have more severe periodontitis, as mea-
sured by the degree of alveolar bone erosion and ⁄or loss.
In a large study of 1361 subjects, smokers were at greater
risk for severe bone loss than non-smokers, with odds
ratios of 3.25 and 7.28 for light and heavy smokers,
respectively (214). Levels of cotinine, the principle metab-
olite of nicotine, have been shown to correlate directly
with periodontal destruction (215, 216). The direct role of
smoking in the pathogenesis of periodontitis is uncertain,
but studies have shown increased levels of TNF-a in gingi-
val crevicular fluid of smoking as compared with non-
smoking periodontitis patients (217–219). As discussed
previously, cigarette smoke has been demonstrated to have
several pro-inflammatory properties (reviewed in 166).
Using various in vitro systems and compounds to mimic
smoking, a trend towards functionally compromised phe-
notypes in phagocytic cells, B, and T lymphocytes has been
observed (reviewed in 212, 220). However, it is important
to bear in mind that in vitro smoking studies use different
compounds, cells, and experimental setups to mimic smok-
ing and therefore afford only a limited reproducibility of
the true short- and long-term physiological events accom-
panying tobacco smoking.
The direct association between smoking and both peri-
odontitis and RA also points out an important confounding
factor for epidemiological studies on the association
between periodontitis and RA. Some studies (195, 221)
included statistical adjustment for smoking in their analysis;
however, these were based on questionnaires, often con-
taining inadequate documentation of smoking variables,
with the potential to inflate the incidence of RA in individ-
uals with periodontitis (222). In spite of these limitations,
it can be concluded that periodontitis and RA have similar
genetic and environmental risk factors leading to analogous
patterns of pathology. A definitive causative role for P. gin-
givalis requires much larger and appropriately adjusted epi-
demiological studies and more molecular work on the
targets for its PAD enzyme and the mechanisms for the
generation of potential autoantigens.
Conclusion
We have summarized evidence that antibodies to specific
citrullinated antigens can be traced to the immune response
genes, HLA-DRB1*0401 and HLA-DRB1*0404, with the
PTPN22 gene and the novel gene BRD2 conferring additional
risk to subsets of the autoimmune response in RA. Smoking
and P. gingivalis are attractive environmental risk factors,
because both are likely to be associated with citrullination of
autoantigens in vivo, though the mechanisms involved require
further elucidation. Whether, in the presence of susceptibility
genes, citrullination itself, through exposure of new self-
epitopes, or citrullination by the bacterial PAD in an infectious
context are enough to break tolerance has yet to be investi-
gated. An alternative hypothesis, suggested by the identifica-
tion of citrullinated enolase as at least one disease-specific
autoantigen that is conserved in prokaryotes, raises the possi-
bility that an immune response to the bacterial form of the
protein could trigger autoimmunity through molecular mim-
icry. Whatever the mechanisms involved, both epidemiology
and molecular immunology point to specific citrullinated pro-
tein antigens as being key factors that link genes and environ-
ment to the etiology of RA. We propose that further
investigation of these mechanisms could lead us towards the
cause of the disease.
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Peptidylarginine Deiminase From Porphyromonas gingivalis
Citrullinates Human Fibrinogen and -Enolase
Implications for Autoimmunity in Rheumatoid Arthritis
Natalia Wegner,1 Robin Wait,1 Aneta Sroka,2 Sigrun Eick,3 Ky-Anh Nguyen,4 Karin Lundberg,1
Andrew Kinloch,1 Shauna Culshaw,5 Jan Potempa,6 and Patrick J. Venables1
Objective. To investigate protein citrullination by
the periodontal pathogen Porphyromonas gingivalis as a
potential mechanism for breaking tolerance to citrulli-
nated proteins in rheumatoid arthritis (RA).
Methods. The expression of endogenous citrulli-
nated proteins was analyzed by immunoblotting of cell
extracts from P gingivalis and 10 other oral bacteria. P
gingivalis–knockout strains lacking the bacterial pepti-
dylarginine deiminases (PADs) or gingipains were cre-
ated to assess the role of these enzymes in citrullination.
Citrullination of human fibrinogen and -enolase by P
gingivalis was studied by incubating live wild-type and
knockout strains with the proteins and analyzing the
products by immunoblotting and mass spectrometry.
Results. Endogenous protein citrullination was
abundant in P gingivalis but lacking in the other oral
bacteria. Deletion of the bacterial PAD gene resulted in
complete abrogation of protein citrullination. Inactiva-
tion of arginine gingipains, but not lysine gingipains, led
to decreased citrullination. Incubation of wild-type P
gingivalis with fibrinogen or -enolase caused degrada-
tion of the proteins and citrullination of the resulting
peptides at carboxy-terminal arginine residues, which
were identified by mass spectrometry.
Conclusion. Our findings demonstrate that
among the oral bacterial pathogens tested, P gingivalis is
unique in its ability to citrullinate proteins. We further
show that P gingivalis rapidly generates citrullinated
host peptides by proteolytic cleavage at Arg-X peptide
bonds by arginine gingipains, followed by citrullination
of carboxy-terminal arginines by bacterial PAD. Our
results suggest a novel model where P gingivalis–
mediated citrullination of bacterial and host proteins
provides a molecular mechanism for generating anti-
gens that drive the autoimmune response in RA.
Rheumatoid arthritis (RA) is characterized by
disease-specific autoimmunity to citrullinated proteins.
Citrullination is a posttranslational modification of argi-
nine residues that is mediated by the family of peptidy-
larginine deiminases (PADs). Citrullinated fibrin(ogen)
and -enolase are 2 of the physiologic proteins that are
targeted by anti–citrullinated protein antibodies in RA
(1–5). Fibrinogen is the precursor of fibrin, and autoan-
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tibodies to citrullinated fibrin(ogen) are found in up to
66% of patients with RA (6). Alpha-enolase is an
evolutionarily conserved, multifunctional protein (7)
that is best known for its role in glucose metabolism and,
more recently, as a plasminogen-binding protein on the
surface of various mammalian and prokaryotic cell types
(8,9). Autoantibodies to citrullinated -enolase can be
found in 40–60% of patients with RA (4–6). The
pathogenicity of these autoantibodies may be mediated
by the formation of immune complexes with citrullinated
host proteins in the joint and by activation of down-
stream inflammatory pathways via complement fixation
and Fc receptor activation (10–13).
It is not yet known which factors trigger the
breakdown of tolerance to citrullinated proteins. Protein
citrullination is part of healthy physiology, with citrulli-
nated filaggrin having been identified in healthy skin
(14), and is part of the inflammatory response in general
(15), whereas the formation of autoantibodies to citrul-
linated proteins is largely restricted to RA (16). Deposits
of citrullinated fibrin have been found in a variety of
inflammatory joint conditions without an accompanying
autoantibody response (17,18). Additional environmen-
tal and genetic risk factors are therefore likely to be
required.
To date, tobacco exposure and the presence of
certain alleles in the HLA–DRB1 locus with a common
peptide-binding motif, collectively known as the shared
epitope, have been identified as susceptibility factors for
the development of autoantibodies to citrullinated pro-
teins (19,20), -enolase and vimentin in particular (21),
but these do not explain the total risk. Additional
etiologic pathways require consideration, with the peri-
odontal pathogen Porphyromonas gingivalis being a
prime candidate for investigation.
Periodontitis, in which P gingivalis is a major
causative agent, is a chronic inflammatory disease of the
supporting tissues of the teeth, with an estimated prev-
alence of 4.2% in the US population (22). P gingivalis
can be detected in 80–90% of periodontitis patients and
in 10–30% of healthy subjects (23,24). The bacterium
has recently attracted interest based on epidemiologic
links between RA and periodontitis (25) and the de-
scription of a novel bacterial PAD (26) (hereinafter
called PPAD), suggesting a potential etiologic role of P
gingivalis in RA through the generation of citrullinated
antigens.
The pathophysiologic mechanisms of periodonti-
tis are similar to those of RA. The condition is charac-
terized by the resorption of the supporting bony struc-
ture around the teeth and is mediated by a variety of
proinflammatory molecules, including tumor necrosis
factor , interleukin-1, prostaglandin E2, and matrix
metalloproteinases (27). A number of studies have indi-
cated a positive association between the prevalence of
periodontitis and RA (25,28), even when adjusted for
smoking, which is a major risk factor for both diseases.
We have shown that RA-specific autoantibodies to
citrullinated -enolase peptide 1, the immunodominant
B cell epitope of human -enolase, cross-react with in
vitro–citrullinated enolase from P gingivalis (5), raising
the possibility of molecular mimicry between epitopes
from citrullinated bacterial and human enolases. P gin-
givalis is the only prokaryote described to date that
expresses a functional bacterial PAD, though its physi-
ologic substrates are unknown, as are the molecular
mechanisms of citrullination.
PPAD displays no amino acid sequence similarity
to the human PAD enzymes, and a previous study
indicated that it might preferentially target carboxy-
terminal arginine residues (26). This is in contrast to the
human enzymes, which efficiently deiminate internal
arginine residues (29). Citrullination of bacterial and
host proteins and peptides by P gingivalis PAD could
therefore create new epitopes and, given the infectious
context providing endogenous and exogenous danger
signals, trigger a latent antibody response to citrullinated
bacterial and host proteins in susceptible individuals.
In the present study, we aimed to elucidate the
molecular requirements for bacterial and human protein
citrullination by P gingivalis PAD and thus advance our
understanding of the potential underlying mechanisms
for the generation of citrullinated antigens and the
induction of autoimmunity in RA.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Porphyromo-
nas gingivalis wild-type strain (W83), P gingivalis clinical iso-
lates obtained from patients with severe periodontitis (MaRL,
D243, JH16, and J430), and P gingivalis mutants (ppad,
ppad, rgp, kgp, and rgpkgp) were grown in Schaedler
anaerobe broth (Oxoid), supplemented with 5% sheep blood,
at 37°C in an anaerobic chamber (90% N2, 5% CO2, and 5%
H2). Erythromycin or tetracycline was used at 5 g/ml or 1
g/ml, respectively, on solid media. The concentrations were
doubled for selective growth in liquid culture.
Other anaerobic oral bacteria (Prevotella intermedia
H13 [clinical isolate], Prevotella oralis [ATCC 33269], Capno-
cytophaga gingivalis [ATCC 33624], and Capnocytophaga ochra-
cea [ATCC 27872]) were grown in Schaedler anaerobe broth,
supplemented with 2.5 g/liter of vitamin K, at 37°C in an
anaerobic chamber (90% N2, 5% CO2, and 5% H2). Fusobac-
terium nucleatum (ATCC 10953) was grown in Schaedler
anaerobe broth at 37°C in an anaerobic chamber (80% N2,
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10% CO2, and 10% H2). Aggregatibacter actinomycetemcomi-
tans (ATCC 43718) was grown in tryptic soy broth (Sigma),
supplemented with 6% yeast extract and 8% glucose, at 37°C in
an atmosphere consisting of 5% CO2. Aerobic bacteria (Strep-
tococcus constellatus [ATCC 27823], Streptococcus gordonii
[ATCC 10558], Streptococcus sanguinis [ATCC 10556], and
Streptococcus salivarius [ATCC 7073]) were grown on Colum-
bia agar plates, supplemented with 8% defibrinated sheep
blood or brain/heart infusion broth.
Construction of P gingivalis mutant strain ppad. A 1-kb
region 3 to the P gingivalis ppad gene (GenBank accession no.
2552184; locus tag PG1424) was amplified by polymerase chain
reaction (PCR; primers 5-GCTCTAGATGGAATCCGTGA-
GACAATG and 5-TAAGCATGCGATATTTGTCGGAA-
GGACTC) for insertion into the Xba I and Sph I sites of the
pUC19 plasmid (New England BioLabs). An erythromycin
resistance cassette ermF/ermAM from plasmid pVA2198 was
amplified and inserted into the Sma I and Xba I sites of the
modified pUC19 plasmid. The resultant plasmid was modified
further by incorporating an amplified 1-kb region 5 to the
ppad gene (primers 5-AAGAGCTCAAGCACGTAATAAG-
GACAATGA and 5-TTATCCCGGGTGTTCCTGAACAT-
ATGATAAGATCT) into the Sac I and Sma I sites to create
the deletional inactivation plasmid construct (pppad) or by
incorporating the entire ppad gene and a 1-kb region 5 to the
gene (primers 5-AAGAGCTCAAGCACGTAATAAGGAC-
AATGA and 5-TTATCCCGGGTGTCTACCTGAGGAGT-
ATTCT) into the Sac I and Sma I sites to create the control
mutant construct (pppad) to control for possible polar effects.
The correct placement and orientation of the DNA
segments were confirmed by sequencing. The modified plas-
mid constructs were integrated into the P gingivalis W83
genome by a double-crossover recombination event by electro-
poration using standard protocols (30). Erythromycin-resistant
clones were subcultured on selective plates, and genomic
integration was confirmed by PCR using primers from outside
of the cloned regions surrounding the ppad gene.
Construction of P gingivalis mutant strains rgp and
kgp. The general procedure for construction of the rgp and
kgp mutants has been described elsewhere (30). Homologous
recombination of the ‚kgp plasmid into the P gingivalis ‚rgp
mutant genome resulted in a kgp-rgp–deficient mutant
(rgpkgp). The respective phenotypes were confirmed by
enzymatic assays and Western blot analysis.
Preparation of bacterial whole-cell extracts. Bacterial
cultures were grown in liquid media until the early stationary
phase. Twenty milliliters of the culture was centrifuged at
10,000g for 15 minutes at 4°C, and the resulting bacterial pellet
was resuspended in phosphate buffered saline (PBS). The
optical density (OD) at 600 nm was measured and adjusted to
1.0 with PBS, and the suspension was sonicated on ice. Sodium
azide (final concentration 0.02% volume/volume) was added to
all samples as a preservative.
Sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE). Protein samples were mixed with re-
ducing 4 lithium dodecyl sulfate (LDS) sample buffer (In-
vitrogen), heated for 10 minutes at 70°C, and resolved on 12%
NuPAGE Bis-Tris gels (Invitrogen) using MOPS running
buffer. After electrophoresis, proteins were stained with the
Coomassie-based stain InstantBlue (Triple Red) or transferred
to nitrocellulose membranes for immunoblotting. For analysis
of fibrinogen/enolase-derived peptides, 10–20% Tricine gels,
2 Tricine sample buffer, and Tricine SDS running buffer (all
from Invitrogen) were used, and protein bands were visualized
using a standard silver staining protocol.
Detection of citrullinated proteins by immunoblotting
and dot-blotting. Citrullinated proteins were detected using
an anticitrulline (modified) detection kit (Upstate/Millipore)
in accordance with the manufacturer’s instructions. For dot-
blotting, 10 l of sample was spotted onto an equilibrated
nitrocellulose membrane (0.1-m Protran membrane; What-
man) and allowed to dry before proceeding with the standard
Western blotting protocol. Controls were performed in which
the modification step or the primary antibody was omitted to
control for nonspecific binding by the primary antibody to
structures other than modified citrulline side chains or for
binding of the secondary antibody to proteins other than the
primary antibody, respectively.
Analysis of fibrinogen and -enolase citrullination by
live P gingivalis. P gingivalis was cultured as described above,
and the OD600 nm was measured. Bacterial cells were pelleted,
washed in ice-cold PBS, and resuspended in assay buffer (10
mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.5, and 10 mM
L-cysteine) to a final OD600 nm of 1.0. Purified fibrinogen was
purchased from Sigma-Aldrich (catalog no. F3879), and re-
combinant human -enolase was expressed in Escherichia coli
as previously described (31). The proteins were diluted in
HEPES buffer at a concentration of 0.5 mg/ml. Equal volumes
of protein solution and bacterial cell suspension were mixed,
and an aliquot was immediately withdrawn (corresponds to
time point of 1 minute). The cultures were then incubated at
37°C on a shaking platform, and further aliquots were with-
drawn after 1.5 hours, 3 hours, and 6 hours. Bacterial cells were
immediately removed from all aliquots by centrifugation. The
resulting supernatant was used for analysis on SDS-PAGE gels
and immunoblotting as described above and for protein pre-
cipitation with 15% meta-phosphoric acid, leaving small pep-
tides in solution, and subsequent analysis by high-performance
liquid chromatography (HPLC). HPLC peak fractions were
collected and subjected to peptide analysis by mass spectrom-
etry.
HPLC analysis. HPLC was performed with a Shi-
madzu VP series chromatograph equipped with a Supelcosil
LC-318 reverse-phase column measuring 25 cm  4.6 mm
(Sigma-Aldrich). Samples (100 l) were injected and eluted
with a gradient of H2O/0.1% trifluoroacetic acid (TFA) (solu-
tion A) and 80% acetonitrile/0.08% TFA (solution B) and
were monitored at 215 nm with a Shimadzu SPD-10A UV-Vis
detector. Peaks were collected manually and freeze-dried prior
to analysis by mass spectrometry.
In-gel digestion of proteins for mass spectrometry.
Protein bands were excised with a scalpel, and in-gel digestion
was performed using a robotic system (Investigator ProGest;
Genomic Solutions). The bands were washed in 100 mM
ammonium bicarbonate buffer and dehydrated in 100% ace-
tonitrile. Cysteine residues were reduced with 10 mM DTT,
then carboamidomethylated with 55 mM iodoacetamide. Di-
gestion was performed for 6 hours at 37°C by the addition of
modified porcine trypsin (10 l at 6.5 ng/l in 25 mM
ammonium bicarbonate), and peptides were recovered by
sequential extraction with 25 mM ammonium bicarbonate
buffer, 5% formic acid, and acetonitrile. Extracts were pooled,
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lyophilized, and redissolved in 0.1% formic acid prior to
performing mass spectrometry.
Analysis by mass spectrometry. Tandem electrospray
mass spectra were recorded with a Q-Tof hybrid quadrupole/
orthogonal acceleration time-of-flight spectrometer (Waters)
interfaced to a CapLC chromatograph. Freeze-dried peptide
samples were redissolved in 0.1% formic acid, and 6 l was
injected onto a PepMap C18 column (300 m  0.5 cm; LC
Packings) and eluted with an acetonitrile/0.1% formic acid
gradient at a flow rate of 1 l/minute. The capillary voltage was
set to 3,500V, and data-dependent product ion scans were
performed on precursor ions with charge states of 2, 3, or 4
over a survey mass range of m/z 400 to 1,400. The raw spectra
were smoothed, deisotoped, transformed onto a singly charged
mass/charge (m/z) axis using a maximum entropy method as
implemented in the peptide auto module of MassLynx (Wa-
ters), and then saved in the peaklist (pkl) format prior to
database searching.
Proteins were identified by correlation of uninter-
preted spectra to entries in the Swiss-Prot/TrEMBL database
using the ProteinLynx Global Server (version 1.1; Waters) and
a local installation of Mascot, version 2.2 (www.matrixscience-
.com). The database used was a FASTA format composite
constructed in-house by merging Swiss-Prot, TrEMBL, and
associated splice variants (release date May 26, 2009; 8,413,758
sequences). Searches were run in error-tolerant mode, and no
mass or taxomic constraints were applied. The initial enzyme
specificity was set to trypsin, but subsequent searches of the P
gingivalis digestions of fibrinogen and enolase were repeated
with no enzyme specificity in order to match peptides resulting
from the combination of gingipain activity with other enzymes,
such as aminopeptidases and carboxypeptidases. All spectra
matching citrullinated peptides were reviewed manually by
interpretation of sequence-specific fragment ions to confirm
the presence and location of the citrulline residue and to
exclude other modifications, such as deamidation of aspartic
acid, which also result in a mass increase of 1 dalton.
RESULTS
Expression of endogenous citrullinated proteins
is unique for P gingivalis. In order to test whether P
gingivalis citrullinates its own endogenous proteins, cul-
tures of P gingivalis, comprising reference strain W83
and 4 clinical isolates from patients with periodontal
disease, were grown to stationary phase, and whole-cell
lysates were analyzed by immunoblotting using anti–
modified citrulline (AMC) antibody. We observed
strong, distinct bands, with a similar pattern of citrulli-
nated proteins in all strains tested (Figure 1A). The gene
encoding PPAD was detected in all P gingivalis strains
tested, including the clinical isolates, as determined by
PCR (data not shown). Subcellular fractionation of the
wild-type strain further showed that the majority of
citrullinated proteins were associated with the periplasm
and the outer and inner membrane fractions (data not
shown), which is a typical feature of bacterial virulence
factors and antigens.
To examine whether endogenous citrullination is
a unique ability of P gingivalis within the community of
oral pathogens, we tested whole cell lysates of 10 other
Figure 1. Expression of endogenous citrullinated proteins is ubiquitous in Porphyromonas gingi-
valis, but not in 10 other oral bacteria. A, Protein citrullination in total cell extracts of the P gingivalis
wild-type reference strain W83 (lane 3) and in 4 clinical isolates (lanes 4–7, corresponding to strains
MaRL, D243, JH16, and J430) was analyzed by immunoblotting with anti–modified citrulline
(AMC) antibody. Controls in which the modification step (lane 1) or the secondary antibody (lane
2) had been omitted were run in parallel. Molecular mass markers are shown on the left. B, Total
cell extracts of 10 other prominent oral bacteria were tested for endogenous protein citrullination
using the AMC antibody. Background signals were confirmed to stem from nonspecific binding of
the primary antibody (control). Pg  Porphyromonas gingivalis; Fn  Fusobacterium nucleatum;
Aa  Aggregatibacter actinomycetemcomitans; Pi  Prevotella intermedia; Po  Prevotella oralis;
Cg  Capnocytophaga gingivalis; Co  Capnocytophaga ochracea; Sc  Streptococcus constellatus;
Sg  Streptococcus gordonii; Sn  Streptococcus sanguinis; Sl  Streptococcus salivarius.
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oral organisms for the presence of citrullinated proteins.
None were detected except in P gingivalis (Figure 1B),
suggesting that functional PAD enzymes are absent
from the other strains tested. Weak bands were notice-
able in a number of strains, but were the result of
nonspecific antibody binding (see controls in Figure 1B).
Endogenous protein citrullination is dependent
on the bacterial PAD enzyme in cooperation with pro-
tein cleavage by arginine gingipains. To confirm that the
observed endogenous protein citrullination in P gingiva-
lis is due to the enzymatic activity of PPAD, and to rule
out the possibility of a second, uncharacterized, bacterial
PAD enzyme, we created a P gingivalis W83–knockout
strain (ppad) by replacement of the entire ppad-
encoding DNA sequence with an antibiotic cassette. A
strain in which the antibiotic cassette was inserted
behind the ppad gene was used as a control against polar
effects from genetic manipulations (ppad). Immuno-
blotting for citrullinated proteins showed that ppad
entirely lacked endogenous citrullinated proteins, while
the wild-type strain and the control strain (ppad)
showed a similar pattern and intensity of citrullinated
proteins (Figure 2A). These data demonstrated that
PPAD is essential for citrullination of endogenous pro-
teins in P gingivalis and that it possesses only 1 peptidy-
larginine deiminase.
We then examined how citrullination depends on
the activity of the major virulence factors in P gingivalis,
which are called gingipains (32,33). Gingipains are po-
tent proteases and cleave various proteins/peptides after
either arginine residues (i.e., arginine gingipain [Rgp])
or lysine residues (i.e., lysine gingipain [Kgp]), resulting
in peptides with carboxy-terminal arginine or lysine
residues. The reported preference of native PPAD for
carboxy-terminal arginine residues in vitro (26) could be
mediated through the activity of arginine gingipains, and
as such, this would have important consequences for
the type of citrullinated peptides that can be generated
by P gingivalis. Hence, we studied P gingivalis mutants
lacking functional arginine (rgp), lysine (kgp), or both
(rgpkgp) types of gingipains for endogenous citrulli-
nation. Immunoblotting of whole-cell lysates showed a
significantly decreased level, but not complete abroga-
tion, of citrullinated proteins in the rgp and rgpkgp
strains, but not in the kgp strain (Figure 2B), confirm-
ing that arginine gingipains play a role in protein citrul-
lination, probably by generating proteins with carboxy-
terminal arginine residues that are subsequently
citrullinated by PPAD. The residual citrullinated pro-
teins seen in the rgp and rgpkgp strains might be due
to the presence of proteins that naturally contain a
carboxy-terminal arginine residue, which had not been
proteolytically processed, and therefore appeared at
different molecular weights as compared with the wild-
type.
P gingivalis rapidly generates citrullinated fibrin-
ogen and -enolase peptides by proteolytic cleavage at
Arg-X peptide bonds, followed by citrullination of
carboxy-terminal arginines. Having found that citrulli-
nation of endogenous P gingivalis proteins depends on
the presence of PPAD and is influenced by arginine
gingipains, the question arose whether the same princi-
ples apply to human proteins. We initially chose human
fibrinogen for this study, since it is a major RA autoan-
tigen in its citrullinated form (2,3,34) and a major part of
the inflammatory response in general because of its
function in the coagulation and platelet aggregation
cascade. Fibrinogen is also involved in the pathogenesis
of periodontitis, where it is abundantly found in the
periodontal lesion, being an established target protein
of gingipains (35). We investigated the potential of P
gingivalis to citrullinate human fibrinogen using intact,
live wild-type, ppad-knockout, and rgp-knockout strains.
Fibrinogen was rapidly cleaved by wild-type P
gingivalis (Figure 3A), which is consistent with previous
Figure 2. Citrullination in Porphyromonas gingivalis depends on the
bacterial peptidylarginine deiminase (PPAD) and is influenced by
arginine gingipain–mediated proteolytic cleavage of substrate proteins.
A, A P gingivalis mutant strain lacking the PPAD gene (ppad) was
constructed, and total cell extracts were analyzed for the presence of
citrullinated proteins by immunoblotting with anti–modified citrulline
(AMC) antibody or by staining with the Coomassie-based stain
InstantBlue. A control mutant containing the entire ppad gene and the
antibiotic cassette (ppad) was created to control for possible polar
effects. The P gingivalis wild-type (WT) strain W83 was used as positive
control. Molecular mass markers are shown on the left. B, P gingivalis
mutant strains lacking arginine gingipain (rgp), lysine gingipain
(kgp), or both (rgpkgp) proteolytic activities were analyzed for the
presence of citrullinated proteins by immunoblotting with AMC
antibody or by staining with the Coomassie-based stain InstantBlue.
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reports (36). A similar degradation pattern was observed
with the ppad strain, indicating that citrullination of
substrate proteins, including gingipains themselves, is
not essential to the proteolytic potency of gingipains. As
expected, fibrinogen samples incubated with the rgp
strain showed considerably decreased proteolytic cleav-
age and a different pattern of cleaved peptides, with the
residual proteolytic activity being mainly due to cleavage
by lysine gingipains and other proteinases and pepti-
dases from P gingivalis (37–40). Our analysis of the
identity of the protein bands by mass spectrometry
confirmed that the majority were derived from any of
the 3 fibrinogen chains (Figure 3A). To exclude cleavage
of protein by plasma-derived proteases, which may con-
taminate fibrinogen, we further performed control reac-
tions in which protein alone was incubated in assay
buffer, and no such cleavage was detected.
Next, we examined whether the cleaved fibrino-
gen fragments had been citrullinated by P gingivalis.
Immunoblotting of all samples that contained protein
bands (see Figure 3A) detected 2 citrullinated peptide
bands at8.5 kd, mapping to the amino-terminal region
of the fibrinogen -chain, in samples incubated with P
gingivalis wild-type, but not ppad or rgp (Figure 3B),
confirming that Arg-X proteolytic cleavage of fibrinogen
is a prerequisite for subsequent citrullination by PPAD.
We further observed a weak positive signal in fibrinogen
samples taken before incubation with P gingivalis and in
the rgp sample taken at 1 minute, while the corre-
sponding controls (the modification and the conjugate
controls) were negative (Figure 3B), suggesting that
purified human fibrinogen, as used in these experiments,
is already endogenously citrullinated by human PADs.
The fact that the majority of fibrinogen had been
degraded within minutes and that only 2 citrullinated
proteins/peptides could be detected by immunoblotting
suggested that the majority of generated peptides was
smaller than the size limit of the peptide gels (3 kd)
used for this analysis. Thus, we applied a dot-blot
technique, which confirmed that the wild-type P gingiva-
lis cells rapidly degraded and citrullinated fibrinogen
into small citrullinated peptides (Figure 3C) and that
both arginine gingipains and PPAD were required, since
no positive signals were observed with the ppad and
rgp strains.
We then aimed to identify the amino acid se-
quence of the citrullinated fibrinogen peptides and
determine the position of the citrulline residue. To this
end, we fractionated the peptides derived from the
wild-type and ppad strains by HPLC and analyzed the
eluted peak fractions by liquid chromatography tandem
mass spectrometry. We identified a total of 30 peptides
derived from fibrinogen (results not shown). The major-
ity of the identified peptides were the product of pro-
teolytic cleavage after either an arginine residue or a
lysine residue, which is consistent with the results de-
Figure 3. Porphyromonas gingivalis rapidly cleaves human fibrinogen through arginine gingipain activity, and the
resulting peptides are citrullinated at the carboxy-terminus by bacterial peptidylarginine deiminase (PAD). A,
Fibrinogen fragments were incubated for 1 minute, 1.5 hours, 3 hours, or 6 hours with P gingivalis wild-type (WT)
strain or with mutant strains lacking bacterial PAD (ppad) or arginine gingipain (rgp), resolved by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, and visualized using silver staining. A fibrinogen sample prior
to incubation with P gingivalis (pre) served as a control. Protein bands were analyzed by mass spectrometry. Bands
labeled , , and  indicate the , , and  chains of fibrinogen. B, All samples with visible protein bands from
the experiments shown in A were tested for citrullination by immunoblotting with anti–modified citrulline (AMC).
Controls for the preincubation sample were performed in which the modification step (pre ctrl1) or the secondary
antibody (pre ctrl2) was omitted. C, All samples from the experiments shown in A were analyzed for the presence
of citrullinated peptides by dot-blotting. Areas on the membrane where samples were not applied are marked as .
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scribed above, but further proteolytic processing by
other peptidases, particularly at the amino-terminus
after glycine, alanine, and serine residues, was also
evident. In samples incubated with P gingivalis wild-type,
but not ppad, we found 4 peptides that contained a
carboxy-terminal citrulline residue (Figure 4): 1ADS-
Figure 4. Sequences of citrullinated peptides from human fibrinogen generated after incubation with Porphyromonas
gingivalis. Amino acid sequences of human fibrinogen -chain (Fib A; Swiss-Prot entry P02671) and fibrinogen -chain
(Fib B; Swiss-Prot entry P02675) are shown. Peptides were detected using liquid chromatography tandem mass
spectrometry. Citrullinated peptides detected after incubation of fibrinogen with P gingivalis wild-type strain are
underlined. Fibrinopeptides A and B and the thrombin cleavage sites are indicated. Cit  citrulline.
Table 1. Mass spectrometry of citrullinated peptides generated after incubation of human fibrinogen or
-enolase with Porphyromonas gingivalis wild-type strain and their respective arginated peptides generated
with the ppad strain*
Protein,
sequence
Amino acid
positions
P gingivalis
strain m/z ratio
Mascot
score
Fibrinogen -chain
.ADSGEGDFLAEGGGVCit.G 1–16 Wild type 769.29 (2) 56
.ADSGEGDFLAEGGGVR.G 1–16 ppad 768.77 (2) 99
Fibrinogen -chain
R.GGSTSYGTGSETESPCit.N 253–268 Wild type 546.91 (3) 51
R.GGSTSYGTGSETESPR.N 253–268 ppad 786.82 (2) 78
Fibrinogen -chain
K.ESSSHHPGIAEFPSCit.G 540–554 Wild type 819.83 (2) 98
S.SHHPGIAEFPSR.G 543–554 ppad 445.54 (3) 39
Fibrinogen -chain
R.PAPPPISGGGYCit.A 31–42 Wild type 585.30 (2) 26
R.PAPPPISGGGYR.A 31–42 ppad 584.77 (2) 65
-enolase
S.TGIYEALELCit.D 41–50 Wild type 583.30 (2) 24
S.TGIYEALELR.D 41–50 ppad 582.79 (2) 56
* Amino acids in the uncleaved proteins located carboxy–terminal and amino–terminal to the identified
peptides are indicated to demonstrate the sites of proteolytic cleavage. Citrulline (Cit) residues that were
identified are underlined. For the mass/charge (m/z) ratio, the numbers in parentheses are the peptide ion
charge state.
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GEGDFLAEGGGVCit16, 31PAPPPISGGGYCit42,
253GGSTSYGTGSETESPCit268, and 540ESSSHHPGIA-
EFPSCit554. Carboxy-terminal arginine-containing pep-
tides were detected only in the ppad, but not the
wild-type, strain (Table 1), suggesting that citrullination
of fibrinogen is tightly linked to cleavage by arginine
gingipains. The combined data support the concept that
target proteins such as human fibrinogen are cleaved
by arginine gingipains, generating suitable peptide sub-
strates for subsequent citrullination at the exposed
carboxy-terminal arginine residue by P gingivalis PAD.
To further test this concept, we performed anal-
ogous experiments using recombinant human -enolase.
Similar to the findings with fibrinogen, -enolase was
rapidly degraded by the wild-type and ppad strains and
less so by the rgp strain (Figure 5A). Using immuno-
blotting on peptide SDS-PAGE gels (Figure 5B) as well
as dot-blotting (Figure 5C), no citrullination could be
detected. Analysis of the samples derived from the
wild-type and ppad strains by mass spectrometry re-
vealed only 1 citrullinated peptide in the wild-type
(41TGIYEALELCit50) (Figure 5D and Table 1), among
a total of 17 peptides detected. The arginine-containing
counterpart of this citrullinated peptide was detected in
the samples incubated with ppad. Analogous to fibrin-
ogen, no peptides with carboxy-terminal arginine were
detected in the wild-type samples. The proportion of
peptides cleaved at residues other than arginine and
lysine was higher than that found in fibrinogen, suggest-
ing extensive cleavage by non–arginine/lysine-specific
peptidases. Combined with the higher relative number
of lysine residues in -enolase (8.8% versus 6.9% in
fibrinogen), this might result in the generation of short
peptides, some of which might be citrullinated but would
be too short to be detected using these methods. We
therefore incubated P gingivalis kgp with -enolase
(Figures 5A–C) and detected 5 citrullinated peptides by
mass spectrometry (Figure 5D), confirming that PPAD
is able to citrullinate -enolase peptides. Using the
AMC antibody dot-blot, which relies on long peptides
that are hydrophobic enough to bind to the membrane,
we observed weak positive signals with the kgp strain,
which decreased with time (Figure 5C), again suggesting
extensive proteolytic degradation by other proteinases.
DISCUSSION
In the present study, we found evidence that the
periodontal pathogen Porphyromonas gingivalis is an
alternative source in the human host for generating
citrullinated proteins and peptides. The underlying
mechanism—proteolytic cleavage and subsequent citrul-
Figure 5. Human -enolase is rapidly cleaved by Porphyromonas gingivalis gingipains, and citrullinated
peptides are detectable by mass spectrometry. A, Analogous to the experiments with fibrinogen shown in
Figure 3, human -enolase was incubated for 1 minute, 1.5 hours, 3 hours, or 6 hours with P gingivalis
wild-type (WT) strain or with mutant strains lacking bacterial peptidylarginine deiminase (ppad),
arginine gingipain (rgp), or lysine gingipain (kgp), resolved by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, and visualized using silver staining. An -enolase sample prior to incubation with P
gingivalis (pre) served as a control. B, All samples with visible protein bands from the experiments shown
in A were tested for citrullination by immunoblotting with anti–modified citrulline (AMC). C, All samples
from the experiments shown in A were analyzed for the presence of citrullinated peptides by dot-blotting.
Areas on the membrane where samples were not applied are marked as . D, Citrullinated peptides
detected by mass spectrometry after incubation of enolase with P gingivalis wild-type and kgp are
underlined with a continuous line and with a dashed line, respectively. The amino acid sequence of human
-enolase (Swiss-Prot entry P06733) is shown. Cit  citrulline.
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lination at carboxy-terminal arginine residues—differs
from that of the human PAD enzymes, which citrullinate
internal arginine residues in whole proteins the most
efficiently. This finding suggests that protein citrullina-
tion by the bacterial PAD has the potential to generate
epitopes to which immunologic tolerance does not exist,
not only due to the presence of foreign citrullinated
proteins from the bacterium, but also through a foreign
mode of proteolytic processing and posttranslational
modification of host antigens. It also indicates that
citrullination of bacterial proteins at internal arginines,
as a potential mechanism for triggering autoantibodies
via molecular mimicry (5), is more likely to be due to the
action of human PAD enzymes that are present at the
site of inflammation.
Of the 11 oral bacterial species tested, endoge-
nous citrullinated proteins were detected exclusively in P
gingivalis, indicating that a bacterial PAD gene is ex-
pressed or is active only in this bacterium among those
tested. To substantiate this finding, we performed simi-
larity searches using BLAST and PSI-BLAST (41). This
revealed numerous ortholog distantly related to PPAD
among prokaryotes, including several of the oral organ-
isms we tested. Most share the predicted conserved
catalytic residues of PPAD and other members of the
guanidino group–modifying enzyme superfamily, al-
though they most likely possess agmatine iminohydro-
lase or arginine deiminase, rather than peptidylarginine
deiminase activity (42).
Using fibrinogen as a model antigen, we showed
that P gingivalis rapidly generated small fibrinogen pep-
tides with carboxy-terminal citrulline residues. Fibrino-
peptide A, which normally results from thrombin cleav-
age of the fibrinogen -chain after arginine-16, was also
detected in its citrullinated form (1ADSGEGDFLAE-
GGGVcit16) in samples incubated with P gingivalis wild-
type, but only in the native, arginine-containing form
in the ppad samples. It is known that P gingivalis
gingipain–mediated degradation of human fibrinogen
inhibits fibrinogen polymerization and results in the
localized bleeding tendency that is typical of chronic
periodontitis (35). A recent study showed that in intact
fibrinogen, internal citrullination at arginine-16 by mam-
malian PAD impairs thrombin-catalyzed cleavage and
fibrin polymerization (43), indicating at least 2 possible
pathogenic roles of citrullinated fibrinogen in RA: serv-
ing as an autoantigen and disturbing the coagulation
cascade and linked pathways.
The pathophysiologic role of fibrinogen peptides
with carboxy-terminal citrulline residues, which are gen-
erated by the concerted action of gingipain and PPAD,
is as yet unknown, thus opening up a novel area for
future investigations. Similarly, it is known that P gingi-
valis arginine gingipains cleave a number of other hu-
man proteins, releasing biologically active peptides with
important roles in immunity and inflammation, such as
C5a (44) and bradykinin (45,46), and simultaneous
citrullination of these peptides by P gingivalis PAD might
have a previously unappreciated role in human disease.
The lower levels of detectable citrullination of
-enolase peptides with the P gingivalis wild-type strain
are likely to be the result of a combination of physiologic
and technical factors. Enolase has a lower percentage of
arginine residues (3.9%) as compared with fibrinogen
(5.2%) and a higher percentage of lysine residues (eno-
lase 8.8% versus fibrinogen 6.9%). It also appears to be
more extensively cleaved by non-Arg/Lys peptidases. In
combination, this would result in fewer suitable PPAD
substrates, and very small peptides overall, which would
not be detected with the methods used in the present
study. Thus, lower levels of detectable citrullination may
simply be due to a relative paucity of the substrate and
technical shortcomings with the detection of short pep-
tides.
Herein, we have demonstrated that P gingivalis
efficiently citrullinates its own proteins and peptides
from host fibrinogen and, to a lesser extent, -enolase.
The 2 major findings of this study—that proteolytic
processing is required for citrullination by P gingivalis
and that host peptides with exclusively carboxy-terminal
citrulline residues are generated—provides a strong
basis for future in vivo studies aimed at identifying
citrullinated peptides at the site of gingival inflammation
and exploring their potency for triggering a T cell and/or
B cell response. Citrullinated host peptides generated
by P gingivalis are likely to expose epitopes previously
hidden from immune surveillance, which in the context
of bacterial infection in a genetically susceptible host,
may trigger an immune response. The slightly increased
prevalence of anticitrullinated protein antibodies re-
ported in patients with periodontitis as compared with
healthy controls (47,48) supports this concept, but the
lower frequency and titer than are found in RA patients
suggest that P gingivalis infection is not sufficient on its
own for the mature autoimmune response. However,
once tolerance is breached, we predict that exposure to
host proteins in the inflamed joint, which have been
citrullinated by human PADs (31), leads to intra- and
intermolecular epitope spreading to additional peptides
from the initiating proteins and other autoantigens.
We therefore propose a “two-hit” model of RA,
based first on the breakdown of tolerance to specific
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citrullinated peptides generated by P gingivalis at the site
of gingival inflammation and followed by epitope-
spreading to other host citrullinated proteins in the
inflamed joint. This self-sustaining immune response
would then result in the chronic and destructive inflam-
mation that typifies RA. The unique nature of the
bacterial deiminase, along with its location on the cell
surface of the bacterium (26), provides a target for
treatment designed to prevent this otherwise incurable
disease.
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Introduction
Arginine is a positively charged, hydrophilic amino acid 
that is often found on the surface of proteins, where it 
participates in ionic interactions with other amino acid 
side chains and forms stabilizing hydrogen bonds with 
both the peptide backbone and amino acid side chains. 
Th ese characteristics make it a key amino acid in the 
three-dimensional organization of proteins and in the 
interaction with other biological molecules. Hence, post-
translational modiﬁ cation of arginine can alter the three-
dimensional protein structure and function and poten-
tially expose previously hidden epitopes to the immune 
system. Deimination (citrullination) of arginine side 
chains (peptidylarginine) to form peptidylcitrulline is one 
of many recognized post-translational modiﬁ cations of 
this amino acid. Th is post-translational conversion is 
catalyzed by the family of peptidylarginine deiminase 
(PAD) enzymes. Th e process of protein citrullination plays 
a vital role in normal physiology, in which it is involved in 
the formation of rigid structures such as hair, skin, and 
myelin sheaths [1]. Aberrant citrullination has been 
observed in diseases of the skin and nervous system and 
in inﬂ ammatory arthritides, of which rheumatoid arthritis 
(RA) is one example [1]. Despite the ubiquity of citrul li-
nated proteins, the autoantibody response to citrullinated 
proteins is largely restricted to RA [2]. Th e switch that 
leads to the generation of antibodies to citrullinated pep-
tides and thus loss of immune tolerance to citrullinated 
proteins is likely to involve a complex interplay of indivi-
dual genetic and environmental factors.
Citrullination by human and bacterial 
peptidylarginine deiminases
In humans, a family of ﬁ ve PAD enzymes (PAD1 to 4 and 
PAD6), encoded by ﬁ ve genes clustered on chromosome 
1p35-36, has been described [3]. Apart from PAD4, 
which can translocate to the nucleus, PAD enzymes are 
typically found in the cytoplasm of various cell types and 
show a characteristic tissue distribution. Th e localization 
and functions of each of the human PAD enzymes are 
summarized in Table 1. Homologous amino acid sequences 
for some or all of these PADs exist in other eukaryotic 
species, such as the mouse, chicken, frog, and bony ﬁ sh. 
Among prokaryotic species, PAD activity has, to date, been 
described in Porphyromonas gingivalis only [4]. P. gingivalis
is a major pathogen in periodontitis, a disease that (akin to 
RA) is a chronic inﬂ ammatory dis order characterized by 
pro-inﬂ ammatory cytokine production and erosion of bone.
As protein citrullination in the joint is not speciﬁ c to 
RA [5] and auto antibodies to citrullinated proteins 
precede the clinical signs of RA [6], it has been proposed 
that oral citrullination of human and bacterial proteins 
by P. gingivalis PAD (PPAD) in an infectious context prior 
to the onset of RA could break tolerance and trigger a 
latent antibody response against citrullinated protein [7]. 
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Once tolerance is breached, citrullination of host proteins 
by human PADs perpetuates the immune response 
through epitope spreading and cross-reactivity, resulting 
in chronic inﬂ ammatory disease (Figure 1). Citrullination 
by both human and bacterial PAD enzymes may thus 
provide a target for inhibiting the immune response at an 
early stage in the inﬂ ammatory pathway of RA.
Th e best-established autoantigens in RA include α-
enolase, ﬁ brinogen, vimentin, and type II collagen 
(reviewed in [1]) and all are eﬃ  ciently deiminated by 
mammalian PADs. In theory, citrullinated peptides from 
these antigens could also be generated by PPAD, although 
this has yet to be demonstrated experimentally. Alpha-
enolase is of particular interest in this respect because it 
is highly conserved among eukaryotes and prokaryotes. 
A sequence of nine amino acids (Asp-Ser-Arg-Gly-Asn-
Pro-Th r-Val-Glu) spanning the immunodominant epi-
tope on the peptide known as citrullinated enolase 
peptide-1 (CEP-1) is 100% identical to the corresponding 
region in P. gingivalis enolase, and aﬃ  nity-puriﬁ ed anti-
bodies to CEP-1 react with recombinant enolase 
citrullinated in vitro from both humans and P. gingivalis 
[8], providing an attractive target for molecular mimicry 
between human and bacterial species.
Etiological association between periodontitis and 
rheumatoid arthritis
Th e rationale for considering both human and P. gingivalis 
PADs in the etiology and pathology of RA is also based 
on epidemiological data suggesting an asso ciation 
between the two diseases (reviewed in [9]). Periodontitis 
and RA are chronic inﬂ ammatory disorders characterized 
by erosion of bone and production of pro-inﬂ ammatory 
cytokines. Th e reported prevalence of periodontitis is 
highly variable; in one large study of the American 
population, the prevalence was 4.2% [10]. Epidemiological 
studies have shown that RA is more prevalent among 
patients with periodontal disease (3.95%) than in the 
general population (1%) [11]. In addition, patients with 
RA have a higher frequency of advanced periodontal 
disease than the general population [12]. P. gingivalis, 
Treponema denticola, and Tannerella forsythia are some 
of the major Gram-negative bacteria that exist as part of 
a complex bacterial bioﬁ lm in the gingival crevice and are 
linked to the development and progression of 
periodontitis but can also be found in lower numbers in 
periodontally healthy subjects [13]. Long-term plaque 
accumulation and an interplay of host and bacterial 
factors result in chronic inﬂ ammation and tissue damage. 
Destruction of the adjacent bone and periodontal 
ligament attachment may eventually lead to tooth loss 
[14]. P. gingivalis antibody levels have been shown to 
correlate with anti-CCP (anti-cyclic citrulli nated peptide) 
antibody titres [15], making this periodontopathic oral 
bacterium an attractive candidate environmental trigger 
in the development of RA.
Several research groups have reported an increased 
variety and number of oral bacterial DNA and antibodies 
targeting these bacteria in serum and synovial ﬂ uid of 
patients with RA and other inﬂ ammatory joint diseases 
compared with controls (non-inﬂ ammatory arthritides 
or healthy donors) [15-19]. Oral bacterial DNA could 
Table 1. Localization and function of human peptidylarginine deiminase enzymes
Localization Function Reference
PAD1 Epidermis, hair follicles, arrector pili muscles, and 
sweat glands
Citrullination of fi laggrin and keratin, facilitating proteolysis and 
crosslinking of the proteins and contributing to skin cornifi cation. 
Maintains hydration of stratum corneum and epidermis barrier 
function.
Diff erentiation of hair follicles.
[66-68]
PAD2 Brain astrocytes, sweat glands, arrector pili muscles, 
skeletal muscle, spleen, macrophages, monocytes, 
epidermis, synovial tissue, and synovial fl uid
Citrullination of myelin basic protein in the brain and spinal cord, 
promoting electrical insulation of myelin sheaths.
Citrullination of vimentin in apoptotic monocytes and macrophages.
[45,46,66,67,69-73]
PAD3 Upper layers of epidermis and hair follicles Citrullination of trichohyalin, contributing to directional hair growth. [66-68]
PAD4 Hematopoietic cells and infl amed rheumatoid 
synovium
Citrullination of transcriptional coactivator p300 and histones H2A, 
H3, and H4, regulating gene expression by chromatin remodelling.
Citrullination of fi brin, contributing to chronic infl ammation in 
rheumatoid arthritis.
P53-dependent citrullination of proteins following DNA damage, 
translocation of histone chaperone nucleophosmin, and p53-
mediated inhibition of tumor cell growth.
[35,44,45,74]
PAD6 Ovary and testis tissue and peripheral blood 
leukocytes
Amino acids known to be conserved in PAD enzymatic activity are 
not conserved in PAD6. Function and enzymatic activity remain 
unclear.
[3,73]
PAD, peptidylarginine deiminase.
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reach the joint as free DNA or intracellularly in immune 
cells. Owing to the stringent growth requirements of live 
oral bacteria, their presence in the joint is unlikely, and no 
viable organisms have been obtained from synovial ﬂ uid 
[19]. However, these observations need to be interpreted 
with caution since many bacterial antibody assays using 
whole-bacterium lysates are of questionable speciﬁ city, 
and the same applies to polymerase chain reaction-based 
detection and DNA-DNA hybridization using a complex 
nucleic acid mixture containing an excess of human DNA. 
A number of antibiotics used in the treatment of 
periodontitis, such as tetracyclines and clarithromycin, are 
eﬃ  cacious in the treatment of RA [20-24], although to 
date there has been no direct evidence that this therapeutic 
eﬀ ect is due to their anti-bacterial activity. For example, 
minocycline has anti-inﬂ am matory and anti-apoptotic 
eﬀ ects that are separate from its anti-bacterial role and 
that are mediated by inhibition of nitric oxide synthase 
[25], matrix metallo proteinases [26], and caspases [27]. As 
will be discussed below, minocycline and other tetracycline 
derivatives may also be direct inhibitors of human PAD4 
[28] and P.  gingivalis arginine-gingipains [29], which are 
potent proteinases and major virulence factors in perio-
dontal disease.
Human peptidylarginine deiminases in disease
In normal physiology, PAD enzymes are involved in 
regulatory processes such as epidermal diﬀ erentiation, 
maturation of hair follicles, insulation of nerve ﬁ bers, and 
epigenetic regulation. Aberrant citrullination contributes 
Figure 1. Simplifi ed model illustrating the hypothesis that Porphyromonas gingivalis-mediated citrullination triggers anti-citrulline 
autoimmunity in rheumatoid arthritis. Citrullination by P. gingivalis peptidylarginine deiminase (PAD) in the infl ammatory context of periodontitis 
produces bacterial and host-derived citrullinated peptides to which the immune system mounts a humoral immune response with the production 
of peptidylcitrulline antibodies. Infl ammation-induced citrullination by human PAD enzymes in the gingiva is also possible (dashed arrow). Tissue 
injury and infl ammation in the joint lead to activation of human PAD enzymes and citrullination of host proteins, such as α-enolase, vimentin, 
fi brin(ogen), and collagen type II. Peptidylcitrulline antibodies bind citrullinated host and bacterial peptides, which may show molecular mimicry, 
and in genetically susceptible individuals (presence of the certain HLA alleles), intra- and intermolecular epitope spreading leads to a sustained 
immune response with the formation of high-affi  nity antibodies to host citrullinated proteins.
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to skin diseases such as psoriasis and neurological dis-
orders such as multiple sclerosis, Alzheimer disease, and 
prion disease [30-32]. Citrullination of histones and other 
nuclear proteins by PAD4 is involved in transcriptional 
regulation and response to cellular stresses and contri-
butes to the innate immune response through the forma-
tion of neutrophil extracellular traps [33-36]. Recently, 
citrullination of various chemokines has been shown to 
have functional roles in receptor binding and signalling, 
proteolytic cleavage, and extravasation of neutrophils 
[37,38]. Furthermore, citrullination appears to play a role 
in the coagulation system and associated pathways, and 
this is supported by the ﬁ ndings that in vitro citrullinated 
ﬁ brinogen shows impaired thrombin-catalyzed ﬁ brin 
polymerization [39] and in vitro citrullination of anti-
thrombin with PAD4 abolishes its thrombin-inhibitory 
activity [40]. Both citrullinated ﬁ brin(ogen) and citrulli-
nated antithrombin were detected in patients with 
inﬂ am matory arthritis [40,41].
Citrullination is thus a widespread phenomenon in 
normal physiology and inﬂ ammation, although targeting 
citrullinated proteins for an autoimmune response is 
relatively restricted to RA as shown by the high speciﬁ city 
of anti-citrullinated peptide antibodies for RA [2]. Th ere-
fore, it is important to consider which of the deiminases 
are used for generating the antigens that drive this auto-
immunity. On the transcriptional level, various single-
nucleotide polymorphisms in the PADI4 gene have been 
associated with RA in Asian but not in Caucasian popula-
tions (reviewed in [42]). Suzuki and colleagues [43] 
showed that the presence of the disease-associated 
PADI4 haplotype led to a more stable mRNA, which they 
suggested increased PAD4 expression and thus levels of 
citrullinated proteins. However, as PAD inhibitors would 
work on the post-transcriptional level, we will focus on 
the expression of PAD enzymes. PAD2 and PAD4 expres-
sion has been demonstrated in rheumatoid synovium 
[44] and synovial ﬂ uid cells [45] and extracellularly in 
synovial ﬂ uid [46]. PAD4 diﬀ ers from other PAD isotypes 
in its capacity to undergo nuclear translocation due to 
the presence of a nuclear localization sequence and this 
translocation has been shown to be induced by tumor 
necrosis factor-alpha in murine and human oligo dendro-
glial cell lines [47]. PAD expression in the synovial tissue 
is not speciﬁ c to RA. It occurs in a variety of inﬂ amma-
tory synovitides [41] and diseases such as inﬂ ammatory 
bowel disease, polymyositis, and interstitial pneumonia 
[48]. While PAD2 is expressed in the synovia of both 
patients with inﬂ ammatory arthritis and osteoarthritis 
(OA), PAD4 is predominantly expressed in the synovia of 
patients with inﬂ ammatory arthritides rather than OA 
[44]. Th e converse was observed in the extracellular 
compartment, where Kinloch and colleagues [46] showed 
the presence of PAD4 in the synovial ﬂ uid of patients 
with RA, spondyloathropathies, and OA, while PAD2 
expression was found in both groups of patients with 
inﬂ ammatory arthritis but was notably absent in those 
with OA. PAD2 and PAD4 expression in the synovium 
correlates with inﬂ ammatory cell inﬁ ltration, synovial 
lining thickness, and vascularity of the deep synovium 
[44]. Foulquier and colleagues [44] demonstrated PAD2 
and PAD4 in close proximity to citrullinated ﬁ brin 
deposits, although simultaneous detection of the two 
enzymes in the same area was rare.
Bacterial peptidylarginine deiminase
P. gingivalis, considered a primary pathogen in chronic 
periodontitis, is a Gram-negative, non-motile anaerobic 
bacterium that is the only prokaryote described to date to 
express a functional endogenous PAD enzyme [4]. To 
date, investigations of bacterial deiminases have focused 
mainly on enzymes that use free, non-peptidyl arginine 
or arginine derivatives such as arginine deiminase (ADI). 
ADIs are enzymes that catalyze the deimination of free 
arginine to citrulline, releasing ammonia. Th ey are key 
enzymes in the widespread anaerobic pathway of arginine 
degradation and many pathogenic microorganisms use 
this pathway for energy production. Since ADIs are 
missing in higher eukaryotes, the enzyme constitutes a 
potential anti-parasitic and anti-bacterial drug target 
[49]. Th e other group of structurally and functionally 
related enzymes produced by most bacterial species 
consists of agmatine deiminases (agmatine iminohydro-
lases, or AIHs). AIHs deiminate agmatine (a decarboxy-
lation product of arginine) to N-carbamoylputrescine 
and ammonia.
On the amino acid sequence level, PPAD shows no 
relation to eukaryotic PAD; instead, position-speciﬁ c 
iterative-basic local alignment search tool (PSI-BLAST) 
search connects PPAD to the AIH family (Figure 2). 
Although the molecular structure of PPAD is unknown, 
its sequence similarity to AIHs with conservation of key 
catalytic and guanidino-binding residues indicates that 
the catalytic domain shares the common α/β-propeller 
fold of the guanidine-group modifying enzyme (GME) 
superfamily, which includes human PADs, microbial 
ADI, aminotransferases, dimethylarginine dimethyl-
amino hydrolases, and AIH [50]. Of note, the database 
annotation of AIH is confusing since these enzymes are 
often referred to as ‘Porphyromonas-type peptidyl-argi-
nine deiminases’ although they most likely do not possess 
PPAD activity. Th e three-dimensional structure of PPAD 
was predicted to consist of the amino-terminal catalytic 
α/β-propeller domain, followed by an immunoglobulin-
like β sandwich. In comparison, the published structure 
of human PAD4 is composed of two amino-terminal 
immunoglobulin-like β sandwich domains, followed by 
the catalytic α/β-propeller domain [51].
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Unlike mammalian enzymes, PPAD is able to deiminate 
both free arginine and peptidylarginine ([4] and our own 
unpublished observations) and preferentially targets 
carboxy-terminal arginine, although internal citrulli-
nation cannot be excluded. Furthermore, deimination by 
human PAD is calcium-dependent in contrast to that by 
PPAD, which does not appear to require any speciﬁ c 
cofactors ([4,52] and our own unpublished observations). 
P. gingivalis has been shown, however, to increase intra-
cellular calcium concentrations by cleavage of proteinase-
activated receptor 2 (PAR 2), a G protein-coupled 
receptor found on the neutrophil surface, which may in 
turn promote human PAD activation [53].
Th e physiological role of PPAD is unclear. It was 
suggested that production of ammonia during deimina tion 
enhances the survival of P. gingivalis within the periodontal 
pocket [4]. Indeed, ADI- and AIH-catalyzed ammonium 
production among bacterial species is known to act as a 
virulence factor, promoting the survival of microbial 
pathogens in the host environment. Ammonia neutralizes 
acidic en viron ments and thereby optimizes gingipain and 
PPAD function, inactivates hemagglutinins, promotes ATP 
produc tion, and has negative eﬀ ects on neutrophil func-
tion [4,54]. Furthermore, it can be speculated that PPAD 
acts as a virulence factor by generating citrullinated 
peptides, which may assist the bacterium in spreading and 
circumventing the humoral immune response. However, 
the requirements for citrullination by PPAD have not been 
well investigated to date and it is unknown whether the 
citrullinated peptides are immunogenic.
Th us, we conclude that PPAD may be more relevant to 
the initiation of autoimmunity at a site distant from the 
joint, such as the gingiva, and that PAD2 and PAD4 are 
important in generating autoantigens that perpetuate 
autoimmunity in RA once tolerance is breached. Further 
work is required to identify the regulation and substrate 
speciﬁ city of each enzyme in order to establish a more 
precise role in the autoimmune response.
Figure 2. Alignment of amino acid sequence of catalytic domains of Porphyromonas gingivalis PAD (PPAD) (residues 86 to 363), AIH from 
Dyadobacter fermentans DSM 18053 (locus Dfer_2630, residues 60 to 352), and human PAD4 (residues 306 to 556). Residues identical in 
PPAD and AIH and/or PAD4 are highlighted. Guanidino-binding (#) and catalytic residues (*) that are conserved in all families of guanidino-group 
modifying enzyme superfamily are indicated. The amino-terminal sequence of each enzyme is unique. In PAD4, the amino-terminal portion is 
folded into two consecutive immunoglobulin-like β-sandwich domains preceding the catalytic domain harboring the α/β-propeller fold [51]. A 
long 200-residue carboxy-terminal extension of PPAD is predicted to adopt an immunoglobulin-like β-sandwich structure [50]. AIH, agmatine 
iminohydrolase; PAD, peptidylarginine deiminase.
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Therapeutic peptidylarginine deiminase blockade 
in rheumatoid arthritis
Although PAD4 has been most extensively studied as a 
potential therapeutic target in RA (mainly based on the 
availability of a crystal structure [51]), PAD2 may also be 
important. It is proposed that selective inhibition of PAD 
would reduce the levels of citrullinated proteins and 
consequently suppress the humoral immune response 
directed to citrullinated antigens in RA. Because PAD4 
has an important physiological role in regulating gene 
expression and PAD4 translocates into the nucleus from 
the cytosol, potential inhibitors may need to be selective 
for the extracellular compartment or other PAD isotypes 
to avoid unwanted eﬀ ects on gene transcription. It is, 
however, not known whether intracellular or extracellular 
PAD is important in the pathophysiology of RA.
Paclitaxel is a chemotherapeutic agent that was initially 
derived from the bark of the Paciﬁ c yew tree. It inhibits 
angiogenesis by interfering with microtubule function in 
cell mitosis, migration, chemotaxis, and intracellular 
transport [55]. In addition, in the millimolar range (half-
maximal inhibitory concentration [IC50] = approximately 
5  mM), paclitaxel inhibits PAD isolated from bovine 
brain [56]. It has been shown to prevent the induction of 
collagen-induced arthritis (CIA) and cause signiﬁ cant 
regression of existing CIA [57]. An open-label multi-
center phase II study of paclitaxel in patients with RA 
was completed in July 2008, although results of this are 
still pending [58].
Other PAD inhibitors include F-amidine [N-α-benzoyl-
N5-(2-ﬂ uoro-1-iminoethyl)-l-ornithine amide], Cl-amidine 
[N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-l-ornithine 
amide], and 2-chloroacetamidine, of which Cl-amidine 
was reported to be the most potent (IC50 = 5.9 μM) [59]. 
Ex vivo studies with F-amidine and Cl-amidine, using a 
cell line and an assay measuring PAD4-mediated citrulli-
nation of a nuclear protein and the resulting enhance-
ment in binding to another protein, indicated that these 
inhibitors are bioavailable [59,60]. F-amidine irreversibly 
inhibits PAD4 via the speciﬁ c modiﬁ cation of Cys 645, an 
active-site residue that is critical for enzyme catalysis. 
Cys 645 acts as a nucleophile to form a thiouronium 
intermediate that is hydrolyzed to form citrulline. Cl-
amidine and 2-chloroacetamidine are thought to act via a 
similar mechanism [59,61]. Inactivation by F-amidine 
and Cl-amidine is calcium-dependent [60]. In vitro 
studies with PAD4 have shown that calcium binding 
leads to a conformational change that moves Cys 645 and 
His 471 into positions that are competent for catalysis 
[51] and presumably reactive with F-amidine and Cl-
amidine. Th is is of therapeutic importance as these com-
pounds would therefore be expected to inhibit PAD4 in 
its activated state only at sites of inﬂ ammatory activity 
such as the synovium and not the inactive enzyme at 
other sites in the body, limiting toxicity [59]. Willis and 
colleagues [62] recently showed that Cl-amidine treat-
ment in CIA is able to inhibit clinical disease activity 
scores by 55%, 53%, and 42% in the 50, 10, and 1 mg/kg 
per day groups, respectively. Histological severity scores 
and complement C3 deposition scores paralleled the 
decreases in disease activity. In addition, mice receiving 
Cl-amidine showed reduced epitope spreading by peptide 
microarray, especially to citrullinated joint antigens. 
Interestingly, there were no changes in the percentages of 
T-cell, B-cell, or monocyte populations in treated mice 
compared with controls [62]. Th ese results suggest that 
Cl-amidine may represent a novel class of RA thera-
peutics that speciﬁ cally target citrullination.
Bhattacharya and colleagues [63] demonstrated that 
human astrocytes subject to pressure showed elevated 
PAD2 levels, increased intracellular calcium concentra-
tions, and increased citrullination. Treatment with the 
cell-permeable calcium chelating agent BAPTA-AM 
(1,2-bis-(o-Aminophenoxy)-ethane-N,N,N’,N’-tetra acetic 
acid tetraacetoxymethyl ester) resulted in decreased 
intra cellular calcium concentration and PAD2 levels. 
Th ese results suggest that calcium modulation may be an 
alternative therapeutic strategy in modulating PAD 
activity and citrullination, although we would argue that 
this mechanism is too broad to be applicable in practice.
On the basis of the therapeutic use of tetracyclines in 
RA [23], Knuckley and colleagues [28] screened tetra-
cycline derivatives (minocycline, doxycycline, tetracy-
cline, and chlortetracycline) for their potential to inhibit 
PAD4 activity. Chlortetracycline was identiﬁ ed as the 
most potent inhibitor (IC50 = 100 μM) and was suggested 
to bind to a region distal from the active site [28]. 
Streptomycin, an aminoglycoside antibiotic, was also 
tested because of its two guanidinium groups that could 
act as inhibitors of PAD4. Streptomycin was found to 
inhibit PAD4, though with a lower potency (IC50 = 
approximately 1.8 mM), and was suggested to bind within 
or in close proximity to the active site. Th e data suggest 
that these compounds could provide a valuable scaﬀ old 
for engineering inhibitors with greater potency and 
selectivity.
Porphyromonas gingivalis peptidylarginine 
deiminase as a target for treatment in rheumatoid 
arthritis
Th e unique nature of PPAD in terms of its diﬀ erent 
amino acid sequence, cofactor requirement, and domain 
organization compared with human PADs (Figure 2), 
along with its location on the bacterial cell surface [4], 
would make this enzyme a potential target in the 
treatment of RA provided that its possible involvement in 
disease etiology or pathology is substantiated in future 
studies. Development of therapeutics targeting PPAD is 
Mangat et al. Arthritis Research & Therapy 2010, 12:209 
http://arthritis-research.com/content/12/3/209
Page 6 of 9
further encouraged by advances in design and synthesis 
of inhibitors against parasite-derived ADI with potentials 
to be used as anti-parasitic agents [64]. Since ADI, PADs, 
and PPAD are likely to use the same catalytic machinery 
to deiminate (peptidyl)arginine (Figure 2), a similar 
chemistry may be applied to develop PPAD inhibitors. 
Th e calcium-independent deimination of carboxy-ter-
minal arginine residues speciﬁ c to PPAD can be explored 
to develop highly selective compounds with little or no 
cross-reactivity with host enzymes.
McGraw and colleagues [4] reported that native PPAD, 
puriﬁ ed from the bacterial culture supernatant, was 
missing the N-terminus inferred from the DNA sequence 
because of proteolysis at the Arg43-Ala44 peptide bond. 
Th is might have been an artifact caused by the potent 
proteases, arginine-gingipains, which co-puriﬁ ed with 
PAD at the initial stages of protein puriﬁ cation, or might 
have true biological signiﬁ cance (for example, arising 
during export of the enzyme from the cell to form the 
mature protein). A recent paper on PPAD reported that 
the full-length, uncleaved form was unstable and had 
only 40% activity when compared with the truncated 
form of the enzyme [52]. Future studies aimed at 
identifying the mature, in vivo form of PPAD and its 
enzymology are required in order to pin down the 
biologically relevant form of the enzyme and as such the 
more appropriate target for therapeutic blockade.
As the PPAD enzyme is not well studied, there are no 
published studies on possible therapeutic inhibitors. To 
gain insight into the catalytic mode of PPAD, McGraw 
and colleagues [4] tested various compounds that might 
interfere with the catalytic cysteine residue (Cys 351) or 
substrate binding. Th ey reported that the serine- and 
cysteine-protease inhibitor leupeptin is able to com-
pletely inhibit PPAD at millimolar levels (5 mM), with 
other inhibitors such as thiourea, thio-l-citrulline, and 
the serine- and cysteine-protease inhibitor TLCK (N-
alpha-p-tosyl-l-lysine chloromethyl ketone) being inhi bi-
tory at higher concentrations (12.5 to 50 mM) [4]. Apart 
from the relatively low inhibitory potency, these 
compounds are either toxic (thiourea) or unselective 
(thio-l-citrulline is a potent inhibitor of nitric oxide 
synthase) [65] but nonetheless provide a basis for the 
development of more potent, speciﬁ c inhibitors.
Conclusions
We have summarized a possible role for PPAD in 
breaking tolerance to citrullinated proteins, with human 
PAD2 or PAD4 or both maintaining the generation of 
citrullinated antigens in the joint. However, the evidence 
remains speculative and clearly requires further investi-
gation of the mechanisms of activity of the enzymes 
involved and how the apparently unique PAD encoded by 
P. gingivalis could generate immunogenic peptides. If 
these hypotheses are further substantiated, PAD blockade 
has the potential to switch oﬀ  auto immunity at the point 
of initiation and inhibit the maintenance of the pathology 
in RA. Th us, inhibition of bacterial and human PADs 
could become the ﬁ rst treatment targeting the generation 
of the actual antigens that drive the disease.
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Introduction
the etiological paradigm of rheumatoid 
arthritis (ra) is that an environmental agent 
triggers an autoimmune reaction in a geneti-
cally predisposed individual. the discovery 
of citrulline-specific autoimmunity could 
be the key to our understanding of these 
gene–environment interactions and hence 
to the cause(s) of ra.1,2 Citrullination is the 
enzymatic conversion of peptidylarginine 
to peptidylcitrulline, a post- translational 
modifica tion catalyzed by a family of 
 calcium-dependent peptidylarginine de i-
minases (PaDs). although physiological 
citrul lination of specific substrates occurs in 
a variety of cells and tissues in healthy indivi-
duals, and pathological citrullination seems 
to be a general phenomenon associated with 
inflammation, tolerance to citrullinated pro-
teins is selectively lost in patients with ra. 
Hence, the role of citrulline-specific auto-
immunity in ra has led to the suggestion 
(first proposed by rosenstein et al.3), that the 
bacterium Porphyromonas gingivalis, which 
expresses an enzyme with PaD-activity 
(denoted PPaD) and is a major cause of 
perio dontitis,4 is also involved in the etiology 
of ra. in this Perspectives article, we propose 
that the association between ra and perio-
dontitis is causative, based on the hypothesis 
that infection with P. gingivalis reduces toler-
ance to citrullinated antigens, and that one 
antigen in particular, citrullinated α-enolase, 
is central to the initiation of the pathogenic 
pathway leading to ra (Figure 1).
Links between RA and periodontitis
a number of studies have demonstrated an 
association between ra and perio dontitis 
and have been reviewed elsewhere.3,5–7 ra 
is more prevalent in individuals with perio-
dontitis and vice versa in comparison to the 
general population, and one study showed 
that patients with ra were more likely 
than individuals without ra to be eden-
tulous and to have periodontitis, indepen-
dent of age, sex, ethnicity and smoking 
habits.8 in addition to an epidemiological 
link between ra and periodontitis, the two 
diseases have a similar pathobiology.5 the 
chronic inflammation associated with both 
diseases is characterized by a dominance 
of pro inflammatory cytokines, notably 
tumor necrosis factor (tnF), leading to the 
upregulation of matrix metalloproteinases 
that cause tissue destruction and erosion of 
peri articular bone and periodontal bone, 
respectively.2,5,6 this similarity between ra 
and perio dontitis could arise from shared 
susceptibility genes and environ ment al 
factors leading to a comparable dy sregulation 
of the host immune response.
notwithstanding the similarities in their 
pathophysiology, the two diseases probably 
differ in their inflammatory effector mecha-
nisms. Periodontitis can be thought of as an 
infectious disease caused by a network of 
interacting oral pathogens, dominated by 
P. gingivalis. However, since periodontitis 
has a strong genetic background,9 it can also 
be considered as an inflammatory disease, 
resulting from an abnormal host defense 
in response to infection. By contrast, evi-
dence is accumulating that ra is a true 
autoimmune disease where, in the major-
ity of patients, inflammation is driven by 
pathogenic autoantibodies to citrullinated 
proteins.1 tissue damage is thought to be 
mediated by immune complexes binding to 
Fcγ receptors, leading to tnF secretion.2
Risk factors for RA and periodontitis
Genetic factors are thought to contribute 
considerably (~50%) to the etiology of both 
ra and periodontitis.9,11 well-established risk 
factors for ra, such as HLA-DRB1 shared 
epitope (se) alleles, the 620w poly morphism 
of the protein tyrosine phosphatase, non-
receptor type 22 gene (PTPN22), and ciga-
rette smoking, are found predominantly 
in the subset of patients with antibodies to 
citrullinated proteins.1 these antibodies are 
commonly detected using a commercial 
enzyme-linked immunosorbent assay based 
on synthetic cyclic citrullinated peptides 
(CCPs), with high diagnostic specificity (98%) 
for ra.1 However, CCPs are not physio logical 
autoantigens, and the peptides used in the 
CCP assay do not show sequence homology 
with any known human protein. this assay is 
simply a generic test for the presence of anti-
bodies to a number of possible citrullinated 
proteins present in vivo. at least four citrul-
linated autoantigens in ra have now been 
defined—citrullinated fibrinogen, vimentin, 
collagen type ii, and α-enolase, with many 
others awaiting full characterization.2
we have shown that approximately half of 
the anti-CCP-positive patients with ra have 
antibodies to citrullinated α-enolase peptide 1 
(CeP-1).10 in a case–control analysis of 1,000 
opinion
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patients with ra and 872 healthy controls, 
we compared the CeP-1+/CCP+ group with 
the CeP-1–/CCP+ subset, and demonstrated 
that HLA-DRB1 se alleles, 620w PTPN22, 
and cigarette smoking, each constitute a risk 
for the development of antibodies to CeP-1, 
rather than to CCP.12 the combined effect of 
these three risk factors showed an odds ratio 
of 39.0 (95% Ci 15.6–98.0) for the develop-
ment of CeP-1+/CCP+ disease, compared 
with an odds ratio of 4.3 (95% Ci 2.2–8.6) 
for CeP-1–/CCP+ disease.12
By contrast, less-definitive evidence has 
come from genetic association studies of 
patients with periodontitis. several cytokine 
and Fcγ receptor gene variants have been 
identified, each of which confers a relatively 
small risk of periodontitis, although no con-
sensus on the risk of these variants has been 
reached to date.13 the HLA-DRB1 se alleles 
have been associated with periodontitis;14–16 
however, the relevant studies were small 
in scale and larger cohorts, using uniform 
disease classification criteria, are needed 
before this genetic link can be confirmed. 
Cigarette smoking is another risk factor 
common to both ra and perio dontitis. 
smokers have a greater risk of developing 
severe periodontitis and bone loss compared 
with nonsmokers.17 importantly, evidence 
exists that the association between ra and 
periodontitis is independent of smoking,8 
although few studies have adjusted for this 
confounding factor.
P. gingivalis and citrullination
the Gram-negative bacterium P. gingivalis is 
commonly present, together with other oral 
bacteria, as a biofilm in the gingival crevice 
and intracellularly in oral epithelial cells. 
notably, periodontitis is not always caused 
by P. gingivalis, and conversely, P. gingivalis 
infection does not always result in perio-
dontitis. However, higher numbers of bac-
teria are present in the gingival crevice of 
patients with periodontitis than in indivi-
duals without periodontitis.18 P. gin givalis 
produces an array of virulence factors, par-
ticularly extracellular cysteine proteases 
called gingipains, to support its adherence, 
growth, tissue invasion and tissue degra-
dation, and to evade and subvert the host 
immune system.19
the most striking feature of this bacte-
rium, in the context of autoimmunity in 
ra, is that P. gingivalis expresses its own 
unique citrullinating enzyme, PPaD.4 PPaD 
has no sequence homology with human 
PaDs, and seems to differ in substrate-
specificity by showing a marked preference 
for the citrul lination of carboxy-terminal 
ar ginines.4 studies in our laboratory have 
shown that P. gingivalis contains a range of 
endogenous citrullinated proteins that are 
not present in other common oral patho-
gens.20 we have also, for the first time to our 
know ledge, demonstrated citrullination of 
human fibrino gen and human α-enolase 
by P.  gingivalis.20 Citrullination of these 
proteins was dependent on PPaD, but also 
on  arginine-gingipains, which proteo-
lytically cleave proteins at arginine residues, 
thus generating short peptides containing 
 carboxy-terminal arginine residues that are 
subsequently citrul linated by PPaD.20
The enolase connection
we first identified citrullinated α-enolase as 
a candidate autoantigen by immuno blotting 
Hl60 cell lysates with serum samples from 
patients with ra, and sequencing a reactive 
47 kDa band by mass spectro metry.21 in a 
subsequent study,10 we screened serum from 
102 patients with ra, 110 patients with other 
rheumatic diseases and 92 healthy controls 
for reactivity with 11 cyclic CePs, cover ing 15 
of the 17 arginine residues within α-enolase. 
we went on to map the immuno dominant 
B-cell epitope(s) to the CeP-1 peptide, 
which corresponds to amino acids 5–21 in 
the full-length protein. CeP-1 contains two 
arginine residues replaced by citrul line, and 
we demon strated that the second of these 
(citrul line 15) was most important for anti-
body recognition.10 reactivity against the 
arginine-containing control peptide was 
similarly low in patients and controls. a 
quantitative enzyme-linked immunosorbent 
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Figure 1 | Schematic illustration of the etiological hypothesis for P. gingivalis and citrullinated 
α‑enolase involvement in RA. a | infection by P. gingivalis leads to citrullination in the gingiva of 
bacterial and/or human proteins (by either PPAD, human PAD, or both). in the presence of danger 
signals, such as LPS and DNA, pathogenic T cells are activated by APcs (citrullinated antigen in 
the context of HLA-DRB1 Se). T‑cell‑mediated activation of pathogenic B cells results in the 
production of antibodies specific for citrullinated proteins. b | A second inflammatory event 
occurs in the joint, leading to citrullination of joint proteins and the formation of immune 
complexes in the joint (through epitope spreading, cross‑reactivity with citrullinated joint proteins, 
or both). The resulting perpetuation of the inflammatory process eventually causes chronic RA. 
Abbreviations: AcPA, anti‑citrullinated protein/peptide antibody; APc, antigen presenting cell; 
LPS, lipopolysaccharide; P. gingivalis, Porphyromonas gingivalis; PAD, peptidylarginine deiminases; 
PPAD, P. gingivalis PAD; RA, rheumatoid arthritis; Se, shared epitope.
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assay using CeP-1 has now become the 
basis of several published studies of over 
3,000 serum samples, which have demon-
strated an anti-CeP-1 antibody frequency 
of approximately 40% in patients with ra, 
and a  disease-specificity of 97%.10,12,22
although CeP-1 could possibly act as a 
surrogate marker for similar (linear) epitopes 
in other candidate autoantigens already pro-
posed as being involved in the pathogenesis 
of ra, no significant sequence similarity was 
found with any other human protein outside 
the enolase family (α, β, and γ isoenzymes). 
However, several hits mapped to bacterial 
enolases, specifically P. gingivalis enolase.10,23 
although full-length human α-enolase and 
P. gingivalis enolase are 51% identical, they 
have 82% sequence identity at the region 
corresponding to CeP-1 (Figure 2a). in 
addition, the nine amino acids at positions 
13–21, which surround the second citrul-
line residue at position 15, are 100% iden-
tical. Furthermore, in patients with ra, the 
antibody response to the P. gingivalis version 
of CeP-1 correlated strongly with that to 
human CeP-1 (r 2 = 0.8, P <0.0001).10 more 
intriguing was the observation that anti-
CeP-1 anti bodies, affinity-purified from a 
patient with ra, cross-reacted with in vitro 
citrullinated recombinant P. gingivalis enolase 
(Figure 2b),10 thus suggesting an etiological 
hypothesis based on molecular mimicry.
Etiological hypothesis
expression of anti-CCP antibodies precedes 
the onset of clinical ra by several years.24 in 
a study of 15 ‘pre-ra’ serum samples selected 
on the basis of HLA-DRB1 se alleles and anti-
CCP antibodies being present, we detected 
anti-CeP antibodies in nine samples, five of 
which were directed towards CeP-1.25 this 
finding suggests that the initial breakdown 
of immunological tolerance to citrullinated 
proteins, including α-enolase, might occur 
as a consequence of an inflammatory event 
outside the joint. Furthermore, the presence 
of iga CCP and iga CeP-122 might indicate 
the involvement of mucosal surfaces, such 
as the gingiva. Hence, we hypothesize that 
anti-CeP-1 antibodies can be generated, 
as a consequence of P. gingivalis-induced 
citrullination of enolase, in the gingiva of 
genetical ly susceptible individuals.
we have demonstrated the presence of 
citrullinated proteins in gingival biopsies 
from patients with periodontitis (Figure 3).26 
However, we have not yet determined 
whether these proteins are of bacterial or 
human origin, whether they are citrul-
linated by bacterial or human PaD, or if this 
phenomenon is specific to periodontitis. 
Despite these limitations, it is intriguing to 
speculate that the presentation of peptides 
derived from these citrullinated proteins 
(in the context of HLA-DRB1 se molecules) 
during chronic exposure to danger signals, 
such as bacterial lipo polysacharides and 
Dna, might facilitate the activation of patho-
genic t cells. P. gingivalis has been shown to 
preferentially stimulate t cells to produce 
interleukin-17, a cytokine implicated in the 
pathogenesis of ra.7 Following B-cell acti-
vation with the subsequent production of 
anti-citrullinated protein antibodies, and 
a second inflammatory event in the syno-
vium, mechanisms of epitope spreading or 
molecular mimicry, or both, could result in 
cross-reactivity with citrullinated joint pro-
teins, such as citrullinated human α-enolase, 
perpetuating the inflammatory process into 
chronic ra (Figure 1). notably, the initial 
t-cell-mediated and B-cell-mediated anti-
body response might be directed towards 
P. gingivalis-generated carboxy-terminal 
citrulline-containing epitopes, and this reac-
tivity might be lost by the time ra de velops, 
as a consequence of epitope spreading to 
epitopes containing internal citrulline, 
generat ed by human PaDs.
an association between antibody titres to 
P. gingivalis and CCP has previously been 
demonstrated in a population of patients 
with ra.27 the anti-P. gingivalis assay, which 
used a crude lysate of bacterial cells, could 
be criticized for a lack of specificity and the 
likely presence of citrullinated proteins in 
the extract. nevertheless, the test can 
differen tiate between indivi duals infected 
with P. gingivalis and those who are not.28 
By reanalyzing the data from two pub-
lished studies on ra serum samples,10,27 we 
have preliminary evidence for an associ-
ation between the presence of antibodies to 
P.  gingivalis and expression of anti-CeP-1 
anti bodies in ra (lundberg, K. et al. 
unpublished data), indicat ing an association 
between the immune response to P. gingivalis 
and citrullinated α-enolase. However, these 
a b
Human CEP-1
P. gingivalis CEP-1
Enolase:
PAD:
P. gingivalis Human
50 kDa
Anti-CEP-1
1 2 3 4
+ – + –
Figure 2 | P. gingivalis and citrullination. a | Human and P. gingivalis ceP‑1 (amino acids 5–21 of 
the full length proteins) are 82% identical at the amino acid level. Residues that differ are 
highlighted in red. b | Human anti‑ceP‑1 antibodies, affinity‑purified from a patient with RA, cross‑
react with in vitro citrullinated recombinant P. gingivalis enolase. In vitro citrullinated recombinant 
human α‑enolase serves as a positive control (cross‑reactivity of the anti‑ceP‑1 antibody with the 
native form of human α‑enolase has previously been demonstrated10). Abbreviations: ceP‑1, 
citrullinated α‑enolase peptide 1; cit, citrulline; P. gingivalis, Porphyromonas gingivalis; PAD, 
(rabbit) peptidylarginine deiminase. Panel 2b is reproduced with permission from John Wiley and 
Sons © Lundberg, K. et al. Arthritis Rheum. 58, 3009–3019 (2008).
a b
Figure 3 | citrullinated proteins are present in the gingiva of a patient with periodontitis. 
immunohistochemical staining of extracellular and intracellular proteins in the connective tissue 
of the gingiva using a | F95 igM mouse monoclonal anticitrulline antibody and b | mouse igM (as 
a control). Brown coloration indicates the presence of citrullinated proteins. images are shown 
at ×100 magnification. information regarding the development, the characterization and the use 
of the F95 antibody for immunohistochemistry is published in Nicholas et al.30
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findings could potentially be explained by 
cross-reactivity of CeP-1-specific antibodies 
with citrullinated epitopes in the P. gingivalis 
lysate used in the assay.
a study published in 2006 reported a 
somewhat higher than expected frequency of 
anti-CCP antibodies in patients with general-
ized aggressive periodontitis when compared 
with controls, though the difference was not 
statistically significant.29 this potentially 
interesting finding needs to be confirmed 
and further investigated in large-scale perio-
dontitis cohorts. on the basis of our data, we 
hypothesize that it would be beneficial to also 
analyze anti-CeP-1 and HLA-DRB1 status 
in these cohorts. likewise, the presence of 
P. gingivalis infection should be investi gated, 
using more-specific anti bacterial antibody 
assays, in well-characterized ra cohorts. we 
also propose that a similar analytical strat-
egy, as outlined in our study on the specific 
interaction between genotype, smoking, and 
autoimmunity to citrullinated α-enolase in 
the etiology of ra,12 should be used to attain 
a comprehensive picture of the genetic 
epidemiology of periodontitis- associated 
ra. implementation of this strategy would 
address the possibility that P. gingivalis might 
be driving immune reactions that con-
tribute to the development of ra in a large 
proporti on of patients.
Conclusions
no direct evidence exists of a role for P. gin-
givalis in the development of ra. However, 
P. gingivalis is known to citrullinate both 
endogenous and human proteins, and 
ra-specific anti-CeP-1 antibodies cross-
react with citrullinated P. gingivalis enolase. 
Furthermore, HLA-DRB1 se alleles and 
smoking, risk factors for both ra and perio-
dontitis, are associated with the production 
of anti-CeP-1 antibodies. we also have pre-
liminary evidence that citrullinated proteins 
are present in the gingiva of patients with 
periodontitis and that there is a link between 
the presence and the levels of anti-CeP-1 
and anti-P. gingivalis antibodies in patients 
with ra. therefore, we believe that further 
studies into the relationship between ra and 
periodontitis, with a focus on the molecular 
mechanisms linking P. gingivalis and citrul-
line immunity, are warranted and might 
reveal that the old hypothesis—that ra is 
precipitated by infection—is true, at least for 
a subgroup of patients.
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